ArticleId,PMCid,TableName,SpecPragmatics,CellContent,Header,Stub,SuperRow,rowN,columnN,function,hasGender
352,1764757,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no
352,1764757,Table 1,BaselineCharacteristic,,,,None,0,1,1,no
352,1764757,Table 1,BaselineCharacteristic,Cilengitide + Gemcitabine n = xx,,,None,0,2,1,no
352,1764757,Table 1,BaselineCharacteristic,Gemcitabine n = xx,,,None,0,3,1,no
352,1764757,Table 1,BaselineCharacteristic,Total n = xx,,,None,0,4,1,no
352,1764757,Table 1,BaselineCharacteristic,"Age, years", ; ,"Age, years",,1,0,24,no
352,1764757,Table 1,BaselineCharacteristic,Median, ; ,"Age, years",,1,1,43,no
352,1764757,Table 1,BaselineCharacteristic,xx,Cilengitide + Gemcitabine n = xx ; ,"Age, years",,1,2,43,no
352,1764757,Table 1,BaselineCharacteristic,xx,Gemcitabine n = xx ; ,"Age, years",,1,3,43,no
352,1764757,Table 1,BaselineCharacteristic,xx,Total n = xx ; ,"Age, years",,1,4,43,no
352,1764757,Table 1,BaselineCharacteristic,, ; ,,,2,0,2,no
352,1764757,Table 1,BaselineCharacteristic,Range, ; ,,,2,1,3,no
352,1764757,Table 1,BaselineCharacteristic,"Gender (n, %)", ; ,"Gender (n, %)",,3,0,24,no
352,1764757,Table 1,BaselineCharacteristic,Male, ; ,"Gender (n, %)",,3,1,43,no
352,1764757,Table 1,BaselineCharacteristic,xx (xx%),Cilengitide + Gemcitabine n = xx ; ,"Gender (n, %)",,3,2,43,yes
352,1764757,Table 1,BaselineCharacteristic,xx (xx%),Gemcitabine n = xx ; ,"Gender (n, %)",,3,3,43,yes
352,1764757,Table 1,BaselineCharacteristic,xx (xx%),Total n = xx ; ,"Gender (n, %)",,3,4,43,yes
352,1764757,Table 1,BaselineCharacteristic,, ; ,,,4,0,2,no
352,1764757,Table 1,BaselineCharacteristic,Female, ; ,,,4,1,3,no
352,1764757,Table 1,BaselineCharacteristic,xx (xx%),Cilengitide + Gemcitabine n = xx ; ,,,4,2,3,no
352,1764757,Table 1,BaselineCharacteristic,xx (xx%),Gemcitabine n = xx ; ,,,4,3,3,no
352,1764757,Table 1,BaselineCharacteristic,xx (xx%),Total n = xx ; ,,,4,4,3,no
352,1764757,Table 1,BaselineCharacteristic,Stage, ; ,Stage,,5,0,24,no
352,1764757,Table 1,BaselineCharacteristic,III, ; ,Stage,,5,1,43,no
352,1764757,Table 1,BaselineCharacteristic,x (x%),Cilengitide + Gemcitabine n = xx ; ,Stage,,5,2,43,no
352,1764757,Table 1,BaselineCharacteristic,x (x%),Gemcitabine n = xx ; ,Stage,,5,3,43,no
352,1764757,Table 1,BaselineCharacteristic,x (x%),Total n = xx ; ,Stage,,5,4,43,no
352,1764757,Table 1,BaselineCharacteristic,, ; ,,,6,0,2,no
352,1764757,Table 1,BaselineCharacteristic,IV, ; ,,,6,1,3,no
352,1764757,Table 1,BaselineCharacteristic,x (x%),Cilengitide + Gemcitabine n = xx ; ,,,6,2,3,no
352,1764757,Table 1,BaselineCharacteristic,x (x%),Gemcitabine n = xx ; ,,,6,3,3,no
352,1764757,Table 1,BaselineCharacteristic,x (x%),Total n = xx ; ,,,6,4,3,no
352,1764757,Table 1,BaselineCharacteristic,, ; ,,,7,0,2,no
352,1764757,Table 1,BaselineCharacteristic,IVa, ; ,,,7,1,3,no
352,1764757,Table 1,BaselineCharacteristic,x (x%),Cilengitide + Gemcitabine n = xx ; ,,,7,2,3,no
352,1764757,Table 1,BaselineCharacteristic,x (x%),Gemcitabine n = xx ; ,,,7,3,3,no
352,1764757,Table 1,BaselineCharacteristic,x (x%),Total n = xx ; ,,,7,4,3,no
352,1764757,Table 1,BaselineCharacteristic,, ; ,,,8,0,2,no
352,1764757,Table 1,BaselineCharacteristic,IVb, ; ,,,8,1,3,no
352,1764757,Table 1,BaselineCharacteristic,xx (xx%),Cilengitide + Gemcitabine n = xx ; ,,,8,2,3,no
352,1764757,Table 1,BaselineCharacteristic,xx (xx%),Gemcitabine n = xx ; ,,,8,3,3,no
352,1764757,Table 1,BaselineCharacteristic,xx (xx%),Total n = xx ; ,,,8,4,3,no
352,1764757,Table 1,BaselineCharacteristic,KP score at screening, ; ,KP score at screening,,9,0,24,no
352,1764757,Table 1,BaselineCharacteristic,xx, ; ,KP score at screening,,9,1,43,no
352,1764757,Table 1,BaselineCharacteristic,x (x%),Cilengitide + Gemcitabine n = xx ; ,KP score at screening,,9,2,43,no
352,1764757,Table 1,BaselineCharacteristic,x (x%),Gemcitabine n = xx ; ,KP score at screening,,9,3,43,no
352,1764757,Table 1,BaselineCharacteristic,x (x%),Total n = xx ; ,KP score at screening,,9,4,43,no
352,1764757,Table 1,BaselineCharacteristic,, ; ,,,10,0,2,no
352,1764757,Table 1,BaselineCharacteristic,xx, ; ,,,10,1,3,no
352,1764757,Table 1,BaselineCharacteristic,xx (xx%),Cilengitide + Gemcitabine n = xx ; ,,,10,2,3,no
352,1764757,Table 1,BaselineCharacteristic,xx (xx%),Gemcitabine n = xx ; ,,,10,3,3,no
352,1764757,Table 1,BaselineCharacteristic,xx (xx%),Total n = xx ; ,,,10,4,3,no
352,1764757,Table 1,BaselineCharacteristic,, ; ,,,11,0,2,no
352,1764757,Table 1,BaselineCharacteristic,xx, ; ,,,11,1,3,no
352,1764757,Table 1,BaselineCharacteristic,xx (xx%),Cilengitide + Gemcitabine n = xx ; ,,,11,2,3,no
352,1764757,Table 1,BaselineCharacteristic,xx (xx%),Gemcitabine n = xx ; ,,,11,3,3,no
352,1764757,Table 1,BaselineCharacteristic,xx (xx%),Total n = xx ; ,,,11,4,3,no
352,1764757,Table 1,BaselineCharacteristic,, ; ,,,12,0,2,no
352,1764757,Table 1,BaselineCharacteristic,xxx, ; ,,,12,1,3,no
352,1764757,Table 1,BaselineCharacteristic,x (xx%),Cilengitide + Gemcitabine n = xx ; ,,,12,2,3,no
352,1764757,Table 1,BaselineCharacteristic,x (xx%),Gemcitabine n = xx ; ,,,12,3,3,no
352,1764757,Table 1,BaselineCharacteristic,xx (xx%),Total n = xx ; ,,,12,4,3,no
1134,2217514,Table 1,BaselineCharacteristic,Characteristics,,None,None,0,0,12,no
1134,2217514,Table 1,BaselineCharacteristic,N = xx,,Characteristics,None,0,1,1,no
1134,2217514,Table 1,BaselineCharacteristic,"Mean (range) age, years",Characteristics ; ,"Mean (range) age, years",,1,0,2,no
1134,2217514,Table 1,BaselineCharacteristic,"Performance status*, n (%)",Characteristics ; ,None,None,2,0,24,no
1134,2217514,Table 1,BaselineCharacteristic,,N = xx ; ,"Performance status*, n (%)",None,2,1,43,no
1134,2217514,Table 1,BaselineCharacteristic,?xx%,Characteristics ; ,?xx%," Performance status*, n (%)",3,0,2,no
1134,2217514,Table 1,BaselineCharacteristic,x (xx),N = xx ; ,?xx%," Performance status*, n (%)",3,1,3,no
1134,2217514,Table 1,BaselineCharacteristic,?xx%,Characteristics ; ,?xx%," Performance status*, n (%)",4,0,2,no
1134,2217514,Table 1,BaselineCharacteristic,x (xx),N = xx ; ,?xx%," Performance status*, n (%)",4,1,3,no
1134,2217514,Table 1,BaselineCharacteristic,?xxx%,Characteristics ; ,?xxx%," Performance status*, n (%)",5,0,2,no
1134,2217514,Table 1,BaselineCharacteristic,x (xx),N = xx ; ,?xxx%," Performance status*, n (%)",5,1,3,no
1134,2217514,Table 1,BaselineCharacteristic,"Sex, n (%)",Characteristics ; ,None,None,6,0,24,no
1134,2217514,Table 1,BaselineCharacteristic,,N = xx ; ,"Sex, n (%)",None,6,1,43,no
1134,2217514,Table 1,BaselineCharacteristic,?Male,Characteristics ; ,?Male," Sex, n (%)",7,0,2,no
1134,2217514,Table 1,BaselineCharacteristic,x (xx),N = xx ; ,?Male," Sex, n (%)",7,1,3,yes
1134,2217514,Table 1,BaselineCharacteristic,?Female,Characteristics ; ,?Female," Sex, n (%)",8,0,2,no
1134,2217514,Table 1,BaselineCharacteristic,x (xx),N = xx ; ,?Female," Sex, n (%)",8,1,3,yes
1134,2217514,Table 1,BaselineCharacteristic,"Race, n (%)",Characteristics ; ,None,None,9,0,24,no
1134,2217514,Table 1,BaselineCharacteristic,,N = xx ; ,"Race, n (%)",None,9,1,43,no
1134,2217514,Table 1,BaselineCharacteristic,?Caucasian,Characteristics ; ,?Caucasian," Race, n (%)",10,0,2,no
1134,2217514,Table 1,BaselineCharacteristic,x (xx),N = xx ; ,?Caucasian," Race, n (%)",10,1,3,no
1134,2217514,Table 1,BaselineCharacteristic,?Blacks/Asians,Characteristics ; ,?Blacks/Asians," Race, n (%)",11,0,2,no
1134,2217514,Table 1,BaselineCharacteristic,x (xx),N = xx ; ,?Blacks/Asians," Race, n (%)",11,1,3,no
1134,2217514,Table 1,BaselineCharacteristic,"Prior therapy, n (%)",Characteristics ; ,None,None,12,0,24,no
1134,2217514,Table 1,BaselineCharacteristic,,N = xx ; ,"Prior therapy, n (%)",None,12,1,43,no
1134,2217514,Table 1,BaselineCharacteristic,?Chemotherapy,Characteristics ; ,None,None,13,0,24,no
1134,2217514,Table 1,BaselineCharacteristic,,N = xx ; ,?Chemotherapy,None,13,1,43,no
1134,2217514,Table 1,BaselineCharacteristic,??x prior regimen,Characteristics ; ,??x prior regimen," Prior therapy, n (%) Prior therapy, n (%) ?Chemotherapy",14,0,2,no
1134,2217514,Table 1,BaselineCharacteristic,x (xx),N = xx ; ,??x prior regimen," Prior therapy, n (%) Prior therapy, n (%) ?Chemotherapy",14,1,3,no
1134,2217514,Table 1,BaselineCharacteristic,???x prior regimens,Characteristics ; ,???x prior regimens," Prior therapy, n (%) Prior therapy, n (%) ?Chemotherapy",15,0,2,no
1134,2217514,Table 1,BaselineCharacteristic,x (xx),N = xx ; ,???x prior regimens," Prior therapy, n (%) Prior therapy, n (%) ?Chemotherapy",15,1,3,no
1134,2217514,Table 1,BaselineCharacteristic,?Radiotherapy,Characteristics ; ,?Radiotherapy," Prior therapy, n (%) Prior therapy, n (%)",16,0,2,no
1134,2217514,Table 1,BaselineCharacteristic,x (xx),N = xx ; ,?Radiotherapy," Prior therapy, n (%) Prior therapy, n (%)",16,1,3,no
1134,2217514,Table 1,BaselineCharacteristic,?Immunotherapy,Characteristics ; ,?Immunotherapy," Prior therapy, n (%) Prior therapy, n (%)",17,0,2,no
1134,2217514,Table 1,BaselineCharacteristic,x (x),N = xx ; ,?Immunotherapy," Prior therapy, n (%) Prior therapy, n (%)",17,1,3,no
1134,2217514,Table 1,BaselineCharacteristic,?Other,Characteristics ; ,?Other," Prior therapy, n (%) Prior therapy, n (%)",18,0,2,no
1134,2217514,Table 1,BaselineCharacteristic,x (xx),N = xx ; ,?Other," Prior therapy, n (%) Prior therapy, n (%)",18,1,3,no
1176,2228375,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,0,12,no
1176,2228375,Table 1,BaselineCharacteristic,Budesonide pMDI (n = xxx),,Characteristic,None,0,1,1,no
1176,2228375,Table 1,BaselineCharacteristic,Budesonide/formoterol DPI (n = xxx),,Characteristic,None,0,2,1,no
1176,2228375,Table 1,BaselineCharacteristic,Budesonide/formoterol pMDI (n = xxx),,Characteristic,None,0,3,1,no
1176,2228375,Table 1,BaselineCharacteristic,"Males/females, n",Characteristic ; ,"Males/females, n",,1,0,2,no
1176,2228375,Table 1,BaselineCharacteristic,xx/xxx,Budesonide pMDI (n = xxx) ; ,"Males/females, n",,1,1,3,yes
1176,2228375,Table 1,BaselineCharacteristic,xx/xxx,Budesonide/formoterol DPI (n = xxx) ; ,"Males/females, n",,1,2,3,yes
1176,2228375,Table 1,BaselineCharacteristic,xx/xxx,Budesonide/formoterol pMDI (n = xxx) ; ,"Males/females, n",,1,3,3,yes
1176,2228375,Table 1,BaselineCharacteristic,"Mean age (range), years",Characteristic ; ,"Mean age (range), years",,2,0,2,no
1176,2228375,Table 1,BaselineCharacteristic,"Smokers, n (%)",Characteristic ; ,"Smokers, n (%)",,3,0,2,no
1176,2228375,Table 1,BaselineCharacteristic,xx (x),Budesonide pMDI (n = xxx) ; ,"Smokers, n (%)",,3,1,3,no
1176,2228375,Table 1,BaselineCharacteristic,xx (x),Budesonide/formoterol DPI (n = xxx) ; ,"Smokers, n (%)",,3,2,3,no
1176,2228375,Table 1,BaselineCharacteristic,xx (x),Budesonide/formoterol pMDI (n = xxx) ; ,"Smokers, n (%)",,3,3,3,no
1176,2228375,Table 1,BaselineCharacteristic,"Mean morning PEF (range), l/min",Characteristic ; ,"Mean morning PEF (range), l/min",,5,0,2,no
1176,2228375,Table 1,BaselineCharacteristic,Mean FEVx(range),Characteristic ; ,None,None,6,0,24,no
1176,2228375,Table 1,BaselineCharacteristic,Mean FEVx(range),Budesonide pMDI (n = xxx) ; ,Mean FEVx(range),None,6,1,43,no
1176,2228375,Table 1,BaselineCharacteristic,Mean FEVx(range),Budesonide/formoterol DPI (n = xxx) ; ,Mean FEVx(range),None,6,2,43,no
1176,2228375,Table 1,BaselineCharacteristic,Mean FEVx(range),Budesonide/formoterol pMDI (n = xxx) ; ,Mean FEVx(range),None,6,3,43,no
1176,2228375,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, Mean FEVx(range),8,0,2,no
1176,2228375,Table 1,BaselineCharacteristic,"LABA use at entry, n (%)",Characteristic ; ,"LABA use at entry, n (%)",,10,0,2,no
1176,2228375,Table 1,BaselineCharacteristic,xx (xx),Budesonide pMDI (n = xxx) ; ,"LABA use at entry, n (%)",,10,1,3,no
1176,2228375,Table 1,BaselineCharacteristic,xx (xx),Budesonide/formoterol DPI (n = xxx) ; ,"LABA use at entry, n (%)",,10,2,3,no
1176,2228375,Table 1,BaselineCharacteristic,xx (xx),Budesonide/formoterol pMDI (n = xxx) ; ,"LABA use at entry, n (%)",,10,3,3,no
1176,2228375,Table 1,BaselineCharacteristic,"Reliever medication use (range), inhalations/day",Characteristic ; ,"Reliever medication use (range), inhalations/day",,11,0,2,no
1176,2228375,Table 1,BaselineCharacteristic,"Reliever medication-free days (range), %",Characteristic ; ,"Reliever medication-free days (range), %",,12,0,2,no
1176,2228375,Table 1,BaselineCharacteristic,"Nights with awakenings (range), %",Characteristic ; ,"Nights with awakenings (range), %",,14,0,2,no
1176,2228375,Table 1,BaselineCharacteristic,"Symptom-free days (range), %",Characteristic ; ,"Symptom-free days (range), %",,15,0,2,no
1176,2228375,Table 1,BaselineCharacteristic,"Asthma-control days (range), %",Characteristic ; ,"Asthma-control days (range), %",,16,0,2,no
1269,2359662,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no
1269,2359662,Table 1,BaselineCharacteristic,No. of patients,,,None,0,1,1,no
1269,2359662,Table 1,BaselineCharacteristic,(%),,,None,0,2,1,no
1269,2359662,Table 1,BaselineCharacteristic,Patients enrolled, ; ,Patients enrolled,,1,0,2,no
1269,2359662,Table 1,BaselineCharacteristic,xx,No. of patients ; ,Patients enrolled,,1,1,3,no
1269,2359662,Table 1,BaselineCharacteristic,,(%) ; ,Patients enrolled,,1,2,3,no
1269,2359662,Table 1,BaselineCharacteristic,Evaluable for toxicity, ; ,Evaluable for toxicity,,2,0,2,no
1269,2359662,Table 1,BaselineCharacteristic,xx,No. of patients ; ,Evaluable for toxicity,,2,1,3,no
1269,2359662,Table 1,BaselineCharacteristic,,(%) ; ,Evaluable for toxicity,,2,2,3,no
1269,2359662,Table 1,BaselineCharacteristic,Evaluable for response, ; ,Evaluable for response,,3,0,2,no
1269,2359662,Table 1,BaselineCharacteristic,xx,No. of patients ; ,Evaluable for response,,3,1,3,no
1269,2359662,Table 1,BaselineCharacteristic,,(%) ; ,Evaluable for response,,3,2,3,no
1269,2359662,Table 1,BaselineCharacteristic,, ; ,None,None,4,0,2,no
1269,2359662,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,4,1,3,no
1269,2359662,Table 1,BaselineCharacteristic,,(%) ; ,None,None,4,2,3,no
1269,2359662,Table 1,BaselineCharacteristic,Age (years), ; ,None,None,5,0,24,no
1269,2359662,Table 1,BaselineCharacteristic,Age (years),No. of patients ; ,Age (years),None,5,1,43,no
1269,2359662,Table 1,BaselineCharacteristic,Age (years),(%) ; ,Age (years),None,5,2,43,no
1269,2359662,Table 1,BaselineCharacteristic,?Median (range), ; ,?Median (range), Age (years),6,0,2,no
1269,2359662,Table 1,BaselineCharacteristic,,(%) ; ,?Median (range), Age (years),6,2,3,no
1269,2359662,Table 1,BaselineCharacteristic,, ; ,None,None,7,0,2,no
1269,2359662,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,7,1,3,no
1269,2359662,Table 1,BaselineCharacteristic,,(%) ; ,None,None,7,2,3,no
1269,2359662,Table 1,BaselineCharacteristic,Gender, ; ,None,None,8,0,24,no
1269,2359662,Table 1,BaselineCharacteristic,Gender,No. of patients ; ,Gender,None,8,1,43,no
1269,2359662,Table 1,BaselineCharacteristic,Gender,(%) ; ,Gender,None,8,2,43,no
1269,2359662,Table 1,BaselineCharacteristic,?Male/female, ; ,?Male/female, Gender,9,0,2,no
1269,2359662,Table 1,BaselineCharacteristic,x/xx,No. of patients ; ,?Male/female, Gender,9,1,3,yes
1269,2359662,Table 1,BaselineCharacteristic,xx/xx,(%) ; ,?Male/female, Gender,9,2,3,yes
1269,2359662,Table 1,BaselineCharacteristic,, ; ,None,None,10,0,2,no
1269,2359662,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,10,1,3,no
1269,2359662,Table 1,BaselineCharacteristic,,(%) ; ,None,None,10,2,3,no
1269,2359662,Table 1,BaselineCharacteristic,Performance status (WHO), ; ,None,None,11,0,24,no
1269,2359662,Table 1,BaselineCharacteristic,Performance status (WHO),No. of patients ; ,Performance status (WHO),None,11,1,43,no
1269,2359662,Table 1,BaselineCharacteristic,Performance status (WHO),(%) ; ,Performance status (WHO),None,11,2,43,no
1269,2359662,Table 1,BaselineCharacteristic,?x, ; ,?x, Performance status (WHO),12,0,2,no
1269,2359662,Table 1,BaselineCharacteristic,x,No. of patients ; ,?x, Performance status (WHO),12,1,3,no
1269,2359662,Table 1,BaselineCharacteristic,xx,(%) ; ,?x, Performance status (WHO),12,2,3,no
1269,2359662,Table 1,BaselineCharacteristic,?x, ; ,?x, Performance status (WHO),13,0,2,no
1269,2359662,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?x, Performance status (WHO),13,1,3,no
1269,2359662,Table 1,BaselineCharacteristic,xx,(%) ; ,?x, Performance status (WHO),13,2,3,no
1269,2359662,Table 1,BaselineCharacteristic,?x, ; ,?x, Performance status (WHO),14,0,2,no
1269,2359662,Table 1,BaselineCharacteristic,x,No. of patients ; ,?x, Performance status (WHO),14,1,3,no
1269,2359662,Table 1,BaselineCharacteristic,x,(%) ; ,?x, Performance status (WHO),14,2,3,no
1269,2359662,Table 1,BaselineCharacteristic,, ; ,None,None,15,0,2,no
1269,2359662,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,15,1,3,no
1269,2359662,Table 1,BaselineCharacteristic,,(%) ; ,None,None,15,2,3,no
1269,2359662,Table 1,BaselineCharacteristic,Previous chemotherapy regimens, ; ,None,None,16,0,24,no
1269,2359662,Table 1,BaselineCharacteristic,Previous chemotherapy regimens,No. of patients ; ,Previous chemotherapy regimens,None,16,1,43,no
1269,2359662,Table 1,BaselineCharacteristic,Previous chemotherapy regimens,(%) ; ,Previous chemotherapy regimens,None,16,2,43,no
1269,2359662,Table 1,BaselineCharacteristic,?x, ; ,?x, Previous chemotherapy regimens,17,0,2,no
1269,2359662,Table 1,BaselineCharacteristic,x,No. of patients ; ,?x, Previous chemotherapy regimens,17,1,3,no
1269,2359662,Table 1,BaselineCharacteristic,xx,(%) ; ,?x, Previous chemotherapy regimens,17,2,3,no
1269,2359662,Table 1,BaselineCharacteristic,?x, ; ,?x, Previous chemotherapy regimens,18,0,2,no
1269,2359662,Table 1,BaselineCharacteristic,x,No. of patients ; ,?x, Previous chemotherapy regimens,18,1,3,no
1269,2359662,Table 1,BaselineCharacteristic,xx,(%) ; ,?x, Previous chemotherapy regimens,18,2,3,no
1269,2359662,Table 1,BaselineCharacteristic,?x, ; ,?x, Previous chemotherapy regimens,19,0,2,no
1269,2359662,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?x, Previous chemotherapy regimens,19,1,3,no
1269,2359662,Table 1,BaselineCharacteristic,xx,(%) ; ,?x, Previous chemotherapy regimens,19,2,3,no
1269,2359662,Table 1,BaselineCharacteristic,, ; ,None,None,20,0,2,no
1269,2359662,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,20,1,3,no
1269,2359662,Table 1,BaselineCharacteristic,,(%) ; ,None,None,20,2,3,no
1269,2359662,Table 1,BaselineCharacteristic,Previous treatment, ; ,None,None,21,0,24,no
1269,2359662,Table 1,BaselineCharacteristic,Previous treatment,No. of patients ; ,Previous treatment,None,21,1,43,no
1269,2359662,Table 1,BaselineCharacteristic,Previous treatment,(%) ; ,Previous treatment,None,21,2,43,no
1269,2359662,Table 1,BaselineCharacteristic,?Surgery, ; ,?Surgery, Previous treatment,22,0,2,no
1269,2359662,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Surgery, Previous treatment,22,1,3,no
1269,2359662,Table 1,BaselineCharacteristic,xx,(%) ; ,?Surgery, Previous treatment,22,2,3,no
1269,2359662,Table 1,BaselineCharacteristic,?Adjuvant chemotherapy, ; ,?Adjuvant chemotherapy, Previous treatment,23,0,2,no
1269,2359662,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Adjuvant chemotherapy, Previous treatment,23,1,3,no
1269,2359662,Table 1,BaselineCharacteristic,xx,(%) ; ,?Adjuvant chemotherapy, Previous treatment,23,2,3,no
1269,2359662,Table 1,BaselineCharacteristic,?Neo-adjuvant chemotherapy, ; ,?Neo-adjuvant chemotherapy, Previous treatment,24,0,2,no
1269,2359662,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Neo-adjuvant chemotherapy, Previous treatment,24,1,3,no
1269,2359662,Table 1,BaselineCharacteristic,x,(%) ; ,?Neo-adjuvant chemotherapy, Previous treatment,24,2,3,no
1269,2359662,Table 1,BaselineCharacteristic,?Chemotherapy for metastatic disease, ; ,?Chemotherapy for metastatic disease, Previous treatment,25,0,2,no
1269,2359662,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Chemotherapy for metastatic disease, Previous treatment,25,1,3,no
1269,2359662,Table 1,BaselineCharacteristic,xx,(%) ; ,?Chemotherapy for metastatic disease, Previous treatment,25,2,3,no
1269,2359662,Table 1,BaselineCharacteristic,?Adjuvant radiotherapy, ; ,?Adjuvant radiotherapy, Previous treatment,26,0,2,no
1269,2359662,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Adjuvant radiotherapy, Previous treatment,26,1,3,no
1269,2359662,Table 1,BaselineCharacteristic,xx,(%) ; ,?Adjuvant radiotherapy, Previous treatment,26,2,3,no
1269,2359662,Table 1,BaselineCharacteristic,?Radiotherapy for metastatic disease, ; ,?Radiotherapy for metastatic disease, Previous treatment,27,0,2,no
1269,2359662,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Radiotherapy for metastatic disease, Previous treatment,27,1,3,no
1269,2359662,Table 1,BaselineCharacteristic,xx,(%) ; ,?Radiotherapy for metastatic disease, Previous treatment,27,2,3,no
1269,2359662,Table 1,BaselineCharacteristic,?None, ; ,?None, Previous treatment,28,0,2,no
1269,2359662,Table 1,BaselineCharacteristic,x,No. of patients ; ,?None, Previous treatment,28,1,3,no
1269,2359662,Table 1,BaselineCharacteristic,x,(%) ; ,?None, Previous treatment,28,2,3,no
1269,2359662,Table 1,BaselineCharacteristic,, ; ,None,None,29,0,2,no
1269,2359662,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,29,1,3,no
1269,2359662,Table 1,BaselineCharacteristic,,(%) ; ,None,None,29,2,3,no
1269,2359662,Table 1,BaselineCharacteristic,Type of tumour, ; ,None,None,30,0,24,no
1269,2359662,Table 1,BaselineCharacteristic,Type of tumour,No. of patients ; ,Type of tumour,None,30,1,43,no
1269,2359662,Table 1,BaselineCharacteristic,Type of tumour,(%) ; ,Type of tumour,None,30,2,43,no
1269,2359662,Table 1,BaselineCharacteristic,?Breast cancer, ; ,?Breast cancer, Type of tumour,31,0,2,no
1269,2359662,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Breast cancer, Type of tumour,31,1,3,no
1269,2359662,Table 1,BaselineCharacteristic,xx,(%) ; ,?Breast cancer, Type of tumour,31,2,3,no
1269,2359662,Table 1,BaselineCharacteristic,?Lung cancer, ; ,?Lung cancer, Type of tumour,32,0,2,no
1269,2359662,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Lung cancer, Type of tumour,32,1,3,no
1269,2359662,Table 1,BaselineCharacteristic,x,(%) ; ,?Lung cancer, Type of tumour,32,2,3,no
1269,2359662,Table 1,BaselineCharacteristic,?Bladder cancer, ; ,?Bladder cancer, Type of tumour,33,0,2,no
1269,2359662,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Bladder cancer, Type of tumour,33,1,3,no
1269,2359662,Table 1,BaselineCharacteristic,xx,(%) ; ,?Bladder cancer, Type of tumour,33,2,3,no
1269,2359662,Table 1,BaselineCharacteristic,?Ovarian cancer, ; ,?Ovarian cancer, Type of tumour,34,0,2,no
1269,2359662,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Ovarian cancer, Type of tumour,34,1,3,no
1269,2359662,Table 1,BaselineCharacteristic,x,(%) ; ,?Ovarian cancer, Type of tumour,34,2,3,no
1269,2359662,Table 1,BaselineCharacteristic,?Cancer of unknown primary, ; ,?Cancer of unknown primary, Type of tumour,35,0,2,no
1269,2359662,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Cancer of unknown primary, Type of tumour,35,1,3,no
1269,2359662,Table 1,BaselineCharacteristic,x,(%) ; ,?Cancer of unknown primary, Type of tumour,35,2,3,no
1269,2359662,Table 1,BaselineCharacteristic,?Other, ; ,?Other, Type of tumour,36,0,2,no
1269,2359662,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Other, Type of tumour,36,1,3,no
1269,2359662,Table 1,BaselineCharacteristic,xx,(%) ; ,?Other, Type of tumour,36,2,3,no
1318,2360329,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no
1318,2360329,Table 1,BaselineCharacteristic,VIN/CARBO,,,None,0,1,1,no
1318,2360329,Table 1,BaselineCharacteristic,VIN/CARBO,,,None,0,2,1,no
1318,2360329,Table 1,BaselineCharacteristic,GEM/CARBO,,,None,0,3,1,no
1318,2360329,Table 1,BaselineCharacteristic,GEM/CARBO,,,None,0,4,1,no
1318,2360329,Table 1,BaselineCharacteristic,,,,None,0,5,1,no
1318,2360329,Table 1,BaselineCharacteristic,, ; ,None,None,1,0,12,no
1318,2360329,Table 1,BaselineCharacteristic,(n=xxx),VIN/CARBO ; ,,None,1,1,1,no
1318,2360329,Table 1,BaselineCharacteristic,(n=xxx),VIN/CARBO ; ,,None,1,2,1,no
1318,2360329,Table 1,BaselineCharacteristic,(n=xxx),GEM/CARBO ; ,,None,1,3,1,no
1318,2360329,Table 1,BaselineCharacteristic,(n=xxx),GEM/CARBO ; ,,None,1,4,1,no
1318,2360329,Table 1,BaselineCharacteristic,, ; ,,None,1,5,1,no
1318,2360329,Table 1,BaselineCharacteristic,Characteristics, ;  ; ,None,None,2,0,12,no
1318,2360329,Table 1,BaselineCharacteristic,n,VIN/CARBO ; (n=xxx) ; ,Characteristics,None,2,1,1,no
1318,2360329,Table 1,BaselineCharacteristic,%,VIN/CARBO ; (n=xxx) ; ,Characteristics,None,2,2,1,no
1318,2360329,Table 1,BaselineCharacteristic,n,GEM/CARBO ; (n=xxx) ; ,Characteristics,None,2,3,1,no
1318,2360329,Table 1,BaselineCharacteristic,%,GEM/CARBO ; (n=xxx) ; ,Characteristics,None,2,4,1,no
1318,2360329,Table 1,BaselineCharacteristic,P, ;  ; ,Characteristics,None,2,5,1,no
1318,2360329,Table 1,BaselineCharacteristic,Age (years), ;  ; Characteristics ; ,None,None,3,0,24,no
1318,2360329,Table 1,BaselineCharacteristic,Age (years),VIN/CARBO ; (n=xxx) ; n ; ,Age (years),None,3,1,43,no
1318,2360329,Table 1,BaselineCharacteristic,Age (years),VIN/CARBO ; (n=xxx) ; % ; ,Age (years),None,3,2,43,no
1318,2360329,Table 1,BaselineCharacteristic,Age (years),GEM/CARBO ; (n=xxx) ; n ; ,Age (years),None,3,3,43,no
1318,2360329,Table 1,BaselineCharacteristic,Age (years),GEM/CARBO ; (n=xxx) ; % ; ,Age (years),None,3,4,43,no
1318,2360329,Table 1,BaselineCharacteristic,Age (years), ;  ; P ; ,Age (years),None,3,5,43,no
1318,2360329,Table 1,BaselineCharacteristic,?Median, ;  ; Characteristics ; ,?Median, Age (years),4,0,2,no
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; n ; ,?Median, Age (years),4,1,3,no
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; % ; ,?Median, Age (years),4,2,3,no
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; n ; ,?Median, Age (years),4,3,3,no
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; % ; ,?Median, Age (years),4,4,3,no
1318,2360329,Table 1,BaselineCharacteristic,x.xx, ;  ; P ; ,?Median, Age (years),4,5,3,no
1318,2360329,Table 1,BaselineCharacteristic,?Range, ;  ; Characteristics ; ,?Range, Age (years),5,0,2,no
1318,2360329,Table 1,BaselineCharacteristic,, ;  ; P ; ,?Range, Age (years),5,5,3,no
1318,2360329,Table 1,BaselineCharacteristic,, ;  ; Characteristics ; ,None,None,6,0,2,no
1318,2360329,Table 1,BaselineCharacteristic,,VIN/CARBO ; (n=xxx) ; n ; ,None,None,6,1,3,no
1318,2360329,Table 1,BaselineCharacteristic,,VIN/CARBO ; (n=xxx) ; % ; ,None,None,6,2,3,no
1318,2360329,Table 1,BaselineCharacteristic,,GEM/CARBO ; (n=xxx) ; n ; ,None,None,6,3,3,no
1318,2360329,Table 1,BaselineCharacteristic,,GEM/CARBO ; (n=xxx) ; % ; ,None,None,6,4,3,no
1318,2360329,Table 1,BaselineCharacteristic,, ;  ; P ; ,None,None,6,5,3,no
1318,2360329,Table 1,BaselineCharacteristic,Sex, ;  ; Characteristics ; ,None,None,7,0,24,no
1318,2360329,Table 1,BaselineCharacteristic,Sex,VIN/CARBO ; (n=xxx) ; n ; ,Sex,None,7,1,43,no
1318,2360329,Table 1,BaselineCharacteristic,Sex,VIN/CARBO ; (n=xxx) ; % ; ,Sex,None,7,2,43,no
1318,2360329,Table 1,BaselineCharacteristic,Sex,GEM/CARBO ; (n=xxx) ; n ; ,Sex,None,7,3,43,no
1318,2360329,Table 1,BaselineCharacteristic,Sex,GEM/CARBO ; (n=xxx) ; % ; ,Sex,None,7,4,43,no
1318,2360329,Table 1,BaselineCharacteristic,Sex, ;  ; P ; ,Sex,None,7,5,43,no
1318,2360329,Table 1,BaselineCharacteristic,?Female, ;  ; Characteristics ; ,?Female, Sex,8,0,2,no
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; n ; ,?Female, Sex,8,1,3,yes
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; % ; ,?Female, Sex,8,2,3,yes
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; n ; ,?Female, Sex,8,3,3,yes
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; % ; ,?Female, Sex,8,4,3,yes
1318,2360329,Table 1,BaselineCharacteristic,x.xx, ;  ; P ; ,?Female, Sex,8,5,3,no
1318,2360329,Table 1,BaselineCharacteristic,?Male, ;  ; Characteristics ; ,?Male, Sex,9,0,2,no
1318,2360329,Table 1,BaselineCharacteristic,xxx,VIN/CARBO ; (n=xxx) ; n ; ,?Male, Sex,9,1,3,yes
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; % ; ,?Male, Sex,9,2,3,yes
1318,2360329,Table 1,BaselineCharacteristic,xxx,GEM/CARBO ; (n=xxx) ; n ; ,?Male, Sex,9,3,3,yes
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; % ; ,?Male, Sex,9,4,3,yes
1318,2360329,Table 1,BaselineCharacteristic,, ;  ; P ; ,?Male, Sex,9,5,3,no
1318,2360329,Table 1,BaselineCharacteristic,, ;  ; Characteristics ; ,None,None,10,0,2,no
1318,2360329,Table 1,BaselineCharacteristic,,VIN/CARBO ; (n=xxx) ; n ; ,None,None,10,1,3,no
1318,2360329,Table 1,BaselineCharacteristic,,VIN/CARBO ; (n=xxx) ; % ; ,None,None,10,2,3,no
1318,2360329,Table 1,BaselineCharacteristic,,GEM/CARBO ; (n=xxx) ; n ; ,None,None,10,3,3,no
1318,2360329,Table 1,BaselineCharacteristic,,GEM/CARBO ; (n=xxx) ; % ; ,None,None,10,4,3,no
1318,2360329,Table 1,BaselineCharacteristic,, ;  ; P ; ,None,None,10,5,3,no
1318,2360329,Table 1,BaselineCharacteristic,Performance status, ;  ; Characteristics ; ,None,None,11,0,24,no
1318,2360329,Table 1,BaselineCharacteristic,Performance status,VIN/CARBO ; (n=xxx) ; n ; ,Performance status,None,11,1,43,no
1318,2360329,Table 1,BaselineCharacteristic,Performance status,VIN/CARBO ; (n=xxx) ; % ; ,Performance status,None,11,2,43,no
1318,2360329,Table 1,BaselineCharacteristic,Performance status,GEM/CARBO ; (n=xxx) ; n ; ,Performance status,None,11,3,43,no
1318,2360329,Table 1,BaselineCharacteristic,Performance status,GEM/CARBO ; (n=xxx) ; % ; ,Performance status,None,11,4,43,no
1318,2360329,Table 1,BaselineCharacteristic,Performance status, ;  ; P ; ,Performance status,None,11,5,43,no
1318,2360329,Table 1,BaselineCharacteristic,?x/x, ;  ; Characteristics ; ,?x/x, Performance status,12,0,2,no
1318,2360329,Table 1,BaselineCharacteristic,xxx,VIN/CARBO ; (n=xxx) ; n ; ,?x/x, Performance status,12,1,3,no
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; % ; ,?x/x, Performance status,12,2,3,no
1318,2360329,Table 1,BaselineCharacteristic,xxx,GEM/CARBO ; (n=xxx) ; n ; ,?x/x, Performance status,12,3,3,no
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; % ; ,?x/x, Performance status,12,4,3,no
1318,2360329,Table 1,BaselineCharacteristic,x.xx, ;  ; P ; ,?x/x, Performance status,12,5,3,no
1318,2360329,Table 1,BaselineCharacteristic,?x, ;  ; Characteristics ; ,?x, Performance status,13,0,2,no
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; n ; ,?x, Performance status,13,1,3,no
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; % ; ,?x, Performance status,13,2,3,no
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; n ; ,?x, Performance status,13,3,3,no
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; % ; ,?x, Performance status,13,4,3,no
1318,2360329,Table 1,BaselineCharacteristic,, ;  ; P ; ,?x, Performance status,13,5,3,no
1318,2360329,Table 1,BaselineCharacteristic,, ;  ; Characteristics ; ,None,None,14,0,2,no
1318,2360329,Table 1,BaselineCharacteristic,,VIN/CARBO ; (n=xxx) ; n ; ,None,None,14,1,3,no
1318,2360329,Table 1,BaselineCharacteristic,,VIN/CARBO ; (n=xxx) ; % ; ,None,None,14,2,3,no
1318,2360329,Table 1,BaselineCharacteristic,,GEM/CARBO ; (n=xxx) ; n ; ,None,None,14,3,3,no
1318,2360329,Table 1,BaselineCharacteristic,,GEM/CARBO ; (n=xxx) ; % ; ,None,None,14,4,3,no
1318,2360329,Table 1,BaselineCharacteristic,, ;  ; P ; ,None,None,14,5,3,no
1318,2360329,Table 1,BaselineCharacteristic,Extent of disease, ;  ; Characteristics ; ,None,None,15,0,24,no
1318,2360329,Table 1,BaselineCharacteristic,Extent of disease,VIN/CARBO ; (n=xxx) ; n ; ,Extent of disease,None,15,1,43,no
1318,2360329,Table 1,BaselineCharacteristic,Extent of disease,VIN/CARBO ; (n=xxx) ; % ; ,Extent of disease,None,15,2,43,no
1318,2360329,Table 1,BaselineCharacteristic,Extent of disease,GEM/CARBO ; (n=xxx) ; n ; ,Extent of disease,None,15,3,43,no
1318,2360329,Table 1,BaselineCharacteristic,Extent of disease,GEM/CARBO ; (n=xxx) ; % ; ,Extent of disease,None,15,4,43,no
1318,2360329,Table 1,BaselineCharacteristic,Extent of disease, ;  ; P ; ,Extent of disease,None,15,5,43,no
1318,2360329,Table 1,BaselineCharacteristic,?Stage IIIB, ;  ; Characteristics ; ,?Stage IIIB, Extent of disease,16,0,2,no
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; n ; ,?Stage IIIB, Extent of disease,16,1,3,no
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; % ; ,?Stage IIIB, Extent of disease,16,2,3,no
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; n ; ,?Stage IIIB, Extent of disease,16,3,3,no
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; % ; ,?Stage IIIB, Extent of disease,16,4,3,no
1318,2360329,Table 1,BaselineCharacteristic,x.xx, ;  ; P ; ,?Stage IIIB, Extent of disease,16,5,3,no
1318,2360329,Table 1,BaselineCharacteristic,?Stage IV, ;  ; Characteristics ; ,?Stage IV, Extent of disease,17,0,2,no
1318,2360329,Table 1,BaselineCharacteristic,xxx,VIN/CARBO ; (n=xxx) ; n ; ,?Stage IV, Extent of disease,17,1,3,no
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; % ; ,?Stage IV, Extent of disease,17,2,3,no
1318,2360329,Table 1,BaselineCharacteristic,xxx,GEM/CARBO ; (n=xxx) ; n ; ,?Stage IV, Extent of disease,17,3,3,no
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; % ; ,?Stage IV, Extent of disease,17,4,3,no
1318,2360329,Table 1,BaselineCharacteristic,, ;  ; P ; ,?Stage IV, Extent of disease,17,5,3,no
1318,2360329,Table 1,BaselineCharacteristic,, ;  ; Characteristics ; ,None,None,18,0,2,no
1318,2360329,Table 1,BaselineCharacteristic,,VIN/CARBO ; (n=xxx) ; n ; ,None,None,18,1,3,no
1318,2360329,Table 1,BaselineCharacteristic,,VIN/CARBO ; (n=xxx) ; % ; ,None,None,18,2,3,no
1318,2360329,Table 1,BaselineCharacteristic,,GEM/CARBO ; (n=xxx) ; n ; ,None,None,18,3,3,no
1318,2360329,Table 1,BaselineCharacteristic,,GEM/CARBO ; (n=xxx) ; % ; ,None,None,18,4,3,no
1318,2360329,Table 1,BaselineCharacteristic,, ;  ; P ; ,None,None,18,5,3,no
1318,2360329,Table 1,BaselineCharacteristic,Histology, ;  ; Characteristics ; ,None,None,19,0,24,no
1318,2360329,Table 1,BaselineCharacteristic,Histology,VIN/CARBO ; (n=xxx) ; n ; ,Histology,None,19,1,43,no
1318,2360329,Table 1,BaselineCharacteristic,Histology,VIN/CARBO ; (n=xxx) ; % ; ,Histology,None,19,2,43,no
1318,2360329,Table 1,BaselineCharacteristic,Histology,GEM/CARBO ; (n=xxx) ; n ; ,Histology,None,19,3,43,no
1318,2360329,Table 1,BaselineCharacteristic,Histology,GEM/CARBO ; (n=xxx) ; % ; ,Histology,None,19,4,43,no
1318,2360329,Table 1,BaselineCharacteristic,Histology, ;  ; P ; ,Histology,None,19,5,43,no
1318,2360329,Table 1,BaselineCharacteristic,?Squamous cell carcinoma, ;  ; Characteristics ; ,?Squamous cell carcinoma, Histology,20,0,2,no
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; n ; ,?Squamous cell carcinoma, Histology,20,1,3,no
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; % ; ,?Squamous cell carcinoma, Histology,20,2,3,no
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; n ; ,?Squamous cell carcinoma, Histology,20,3,3,no
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; % ; ,?Squamous cell carcinoma, Histology,20,4,3,no
1318,2360329,Table 1,BaselineCharacteristic,x.xx, ;  ; P ; ,?Squamous cell carcinoma, Histology,20,5,3,no
1318,2360329,Table 1,BaselineCharacteristic,?Adenocarcinoma, ;  ; Characteristics ; ,?Adenocarcinoma, Histology,21,0,2,no
1318,2360329,Table 1,BaselineCharacteristic,xxx,VIN/CARBO ; (n=xxx) ; n ; ,?Adenocarcinoma, Histology,21,1,3,no
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; % ; ,?Adenocarcinoma, Histology,21,2,3,no
1318,2360329,Table 1,BaselineCharacteristic,xxx,GEM/CARBO ; (n=xxx) ; n ; ,?Adenocarcinoma, Histology,21,3,3,no
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; % ; ,?Adenocarcinoma, Histology,21,4,3,no
1318,2360329,Table 1,BaselineCharacteristic,, ;  ; P ; ,?Adenocarcinoma, Histology,21,5,3,no
1318,2360329,Table 1,BaselineCharacteristic,?Large cell carcinoma, ;  ; Characteristics ; ,?Large cell carcinoma, Histology,22,0,2,no
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; n ; ,?Large cell carcinoma, Histology,22,1,3,no
1318,2360329,Table 1,BaselineCharacteristic,x,VIN/CARBO ; (n=xxx) ; % ; ,?Large cell carcinoma, Histology,22,2,3,no
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; n ; ,?Large cell carcinoma, Histology,22,3,3,no
1318,2360329,Table 1,BaselineCharacteristic,x,GEM/CARBO ; (n=xxx) ; % ; ,?Large cell carcinoma, Histology,22,4,3,no
1318,2360329,Table 1,BaselineCharacteristic,, ;  ; P ; ,?Large cell carcinoma, Histology,22,5,3,no
1318,2360329,Table 1,BaselineCharacteristic,?Other, ;  ; Characteristics ; ,?Other, Histology,23,0,2,no
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; n ; ,?Other, Histology,23,1,3,no
1318,2360329,Table 1,BaselineCharacteristic,xx,VIN/CARBO ; (n=xxx) ; % ; ,?Other, Histology,23,2,3,no
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; n ; ,?Other, Histology,23,3,3,no
1318,2360329,Table 1,BaselineCharacteristic,xx,GEM/CARBO ; (n=xxx) ; % ; ,?Other, Histology,23,4,3,no
1318,2360329,Table 1,BaselineCharacteristic,, ;  ; P ; ,?Other, Histology,23,5,3,no
1345,2360517,Table 2,BaselineCharacteristic,N=xx,,None,None,0,0,12,no
1345,2360517,Table 2,BaselineCharacteristic,,,N=xx,None,0,1,1,no
1345,2360517,Table 2,BaselineCharacteristic,Age in years (mean),N=xx ; ,Age in years (mean),,1,0,2,no
1345,2360517,Table 2,BaselineCharacteristic,xx.x?yrs (xx.x?yrs), ; ,Age in years (mean),,1,1,3,no
1345,2360517,Table 2,BaselineCharacteristic,Sex ratio,N=xx ; ,Sex ratio,,2,0,2,no
1345,2360517,Table 2,BaselineCharacteristic,xx males/x females, ; ,Sex ratio,,2,1,3,yes
1345,2360517,Table 2,BaselineCharacteristic,,N=xx ; ,None,None,3,0,2,no
1345,2360517,Table 2,BaselineCharacteristic,, ; ,None,None,3,1,3,no
1345,2360517,Table 2,BaselineCharacteristic,Histology n (%),N=xx ; ,None,None,4,0,24,no
1345,2360517,Table 2,BaselineCharacteristic,, ; ,Histology n (%),None,4,1,43,no
1345,2360517,Table 2,BaselineCharacteristic,?Squamous cell carcinoma,N=xx ; ,?Squamous cell carcinoma, Histology n (%),5,0,2,no
1345,2360517,Table 2,BaselineCharacteristic,xx (xx.x%), ; ,?Squamous cell carcinoma, Histology n (%),5,1,3,no
1345,2360517,Table 2,BaselineCharacteristic,?Adenocarcinoma,N=xx ; ,?Adenocarcinoma, Histology n (%),6,0,2,no
1345,2360517,Table 2,BaselineCharacteristic,x (x.x%), ; ,?Adenocarcinoma, Histology n (%),6,1,3,no
1345,2360517,Table 2,BaselineCharacteristic,?Poor differenced,N=xx ; ,?Poor differenced, Histology n (%),7,0,2,no
1345,2360517,Table 2,BaselineCharacteristic,x (x.x%), ; ,?Poor differenced, Histology n (%),7,1,3,no
1345,2360517,Table 2,BaselineCharacteristic,,N=xx ; ,None,None,8,0,2,no
1345,2360517,Table 2,BaselineCharacteristic,, ; ,None,None,8,1,3,no
1345,2360517,Table 2,BaselineCharacteristic,Tumour n (%),N=xx ; ,None,None,9,0,24,no
1345,2360517,Table 2,BaselineCharacteristic,, ; ,Tumour n (%),None,9,1,43,no
1345,2360517,Table 2,BaselineCharacteristic,?Proximal,N=xx ; ,?Proximal, Tumour n (%),10,0,2,no
1345,2360517,Table 2,BaselineCharacteristic,xx (xx.x%), ; ,?Proximal, Tumour n (%),10,1,3,no
1345,2360517,Table 2,BaselineCharacteristic,?Middle,N=xx ; ,?Middle, Tumour n (%),11,0,2,no
1345,2360517,Table 2,BaselineCharacteristic,xx (xx.x%), ; ,?Middle, Tumour n (%),11,1,3,no
1345,2360517,Table 2,BaselineCharacteristic,?Distal,N=xx ; ,?Distal, Tumour n (%),12,0,2,no
1345,2360517,Table 2,BaselineCharacteristic,x (xx.x%), ; ,?Distal, Tumour n (%),12,1,3,no
1345,2360517,Table 2,BaselineCharacteristic,,N=xx ; ,None,None,13,0,2,no
1345,2360517,Table 2,BaselineCharacteristic,, ; ,None,None,13,1,3,no
1345,2360517,Table 2,BaselineCharacteristic,Dysphagia (Atkinson score): n (%),N=xx ; ,None,None,14,0,24,no
1345,2360517,Table 2,BaselineCharacteristic,, ; ,Dysphagia (Atkinson score): n (%),None,14,1,43,no
1345,2360517,Table 2,BaselineCharacteristic,?Grade>x,N=xx ; ,?Grade>x, Dysphagia (Atkinson score): n (%),15,0,2,no
1345,2360517,Table 2,BaselineCharacteristic,xx (xx.x%), ; ,?Grade>x, Dysphagia (Atkinson score): n (%),15,1,3,no
1345,2360517,Table 2,BaselineCharacteristic,,N=xx ; ,None,None,16,0,2,no
1345,2360517,Table 2,BaselineCharacteristic,, ; ,None,None,16,1,3,no
1345,2360517,Table 2,BaselineCharacteristic,Performance status ECOG: n (%),N=xx ; ,None,None,17,0,24,no
1345,2360517,Table 2,BaselineCharacteristic,, ; ,Performance status ECOG: n (%),None,17,1,43,no
1345,2360517,Table 2,BaselineCharacteristic,?x,N=xx ; ,?x, Performance status ECOG: n (%),18,0,2,no
1345,2360517,Table 2,BaselineCharacteristic,xx (xx.x%), ; ,?x, Performance status ECOG: n (%),18,1,3,no
1345,2360517,Table 2,BaselineCharacteristic,,N=xx ; ,None,None,20,0,2,no
1345,2360517,Table 2,BaselineCharacteristic,, ; ,None,None,20,1,3,no
1345,2360517,Table 2,BaselineCharacteristic,Weight loss n (%),N=xx ; ,None,None,21,0,24,no
1345,2360517,Table 2,BaselineCharacteristic,, ; ,Weight loss n (%),None,21,1,43,no
1345,2360517,Table 2,BaselineCharacteristic,?<xx%,N=xx ; ,?<xx%, Weight loss n (%),22,0,2,no
1345,2360517,Table 2,BaselineCharacteristic,xx (xx.x%), ; ,?<xx%, Weight loss n (%),22,1,3,no
1345,2360517,Table 2,BaselineCharacteristic,?>xx%,N=xx ; ,?>xx%, Weight loss n (%),23,0,2,no
1345,2360517,Table 2,BaselineCharacteristic,xx (xx.x%), ; ,?>xx%, Weight loss n (%),23,1,3,no
1345,2360517,Table 2,BaselineCharacteristic,,N=xx ; ,None,None,24,0,2,no
1345,2360517,Table 2,BaselineCharacteristic,, ; ,None,None,24,1,3,no
1345,2360517,Table 2,BaselineCharacteristic,"Tumour stage, UICC xxxx: n (%)",N=xx ; ,None,None,25,0,24,no
1345,2360517,Table 2,BaselineCharacteristic,, ; ,"Tumour stage, UICC xxxx: n (%)",None,25,1,43,no
1345,2360517,Table 2,BaselineCharacteristic,?Stage I,N=xx ; ,?Stage I," Tumour stage, UICC xxxx: n (%)",26,0,2,no
1345,2360517,Table 2,BaselineCharacteristic,xx (xx.x%), ; ,?Stage I," Tumour stage, UICC xxxx: n (%)",26,1,3,no
1345,2360517,Table 2,BaselineCharacteristic,?Stage II,N=xx ; ,?Stage II," Tumour stage, UICC xxxx: n (%)",27,0,2,no
1345,2360517,Table 2,BaselineCharacteristic,xx (xx.x%), ; ,?Stage II," Tumour stage, UICC xxxx: n (%)",27,1,3,no
1345,2360517,Table 2,BaselineCharacteristic,?Stage III,N=xx ; ,?Stage III," Tumour stage, UICC xxxx: n (%)",28,0,2,no
1345,2360517,Table 2,BaselineCharacteristic,xx (xx.x%), ; ,?Stage III," Tumour stage, UICC xxxx: n (%)",28,1,3,no
1345,2360517,Table 2,BaselineCharacteristic,?Serum albumin (mean in g?l?x),N=xx ; ,?Serum albumin (mean in g?l?x)," Tumour stage, UICC xxxx: n (%)",29,0,2,no
1345,2360517,Table 2,BaselineCharacteristic,xx.x?g?l?x, ; ,?Serum albumin (mean in g?l?x)," Tumour stage, UICC xxxx: n (%)",29,1,3,no
1345,2360517,Table 2,BaselineCharacteristic,"?Tumour diameter (CT scan, median in mm)",N=xx ; ,"?Tumour diameter (CT scan, median in mm)"," Tumour stage, UICC xxxx: n (%)",30,0,2,no
1345,2360517,Table 2,BaselineCharacteristic,xx.x?mm, ; ,"?Tumour diameter (CT scan, median in mm)"," Tumour stage, UICC xxxx: n (%)",30,1,3,no
1345,2360517,Table 2,BaselineCharacteristic,,N=xx ; ,None,None,31,0,2,no
1345,2360517,Table 2,BaselineCharacteristic,, ; ,None,None,31,1,3,no
1345,2360517,Table 2,BaselineCharacteristic,Endoscopic Ultrasonography (n=xx),N=xx ; ,None,None,32,0,24,no
1345,2360517,Table 2,BaselineCharacteristic,, ; ,Endoscopic Ultrasonography (n=xx),None,32,1,43,no
1345,2360517,Table 2,BaselineCharacteristic,?Tx,N=xx ; ,?Tx, Endoscopic Ultrasonography (n=xx),33,0,2,no
1345,2360517,Table 2,BaselineCharacteristic,x (xx%), ; ,?Tx, Endoscopic Ultrasonography (n=xx),33,1,3,no
1345,2360517,Table 2,BaselineCharacteristic,?N+,N=xx ; ,?N+, Endoscopic Ultrasonography (n=xx),34,0,2,no
1345,2360517,Table 2,BaselineCharacteristic,x (xx%), ; ,?N+, Endoscopic Ultrasonography (n=xx),34,1,3,no
1345,2360517,Table 2,BaselineCharacteristic,?Mxa (celiac node),N=xx ; ,?Mxa (celiac node), Endoscopic Ultrasonography (n=xx),35,0,2,no
1345,2360517,Table 2,BaselineCharacteristic,x (x.x%), ; ,?Mxa (celiac node), Endoscopic Ultrasonography (n=xx),35,1,3,no
1347,2360530,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,0,12,no
1347,2360530,Table 1,BaselineCharacteristic,N,,Characteristic,None,0,1,1,no
1347,2360530,Table 1,BaselineCharacteristic,(%),,Characteristic,None,0,2,1,no
1347,2360530,Table 1,BaselineCharacteristic,Included,Characteristic ; ,Included,,1,0,2,no
1347,2360530,Table 1,BaselineCharacteristic,xx,N ; ,Included,,1,1,3,no
1347,2360530,Table 1,BaselineCharacteristic,,(%) ; ,Included,,1,2,3,no
1347,2360530,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,2,0,2,no
1347,2360530,Table 1,BaselineCharacteristic,,N ; ,None,None,2,1,3,no
1347,2360530,Table 1,BaselineCharacteristic,,(%) ; ,None,None,2,2,3,no
1347,2360530,Table 1,BaselineCharacteristic,Age (years),Characteristic ; ,None,None,3,0,24,no
1347,2360530,Table 1,BaselineCharacteristic,,N ; ,Age (years),None,3,1,43,no
1347,2360530,Table 1,BaselineCharacteristic,,(%) ; ,Age (years),None,3,2,43,no
1347,2360530,Table 1,BaselineCharacteristic,?Median,Characteristic ; ,?Median, Age (years),4,0,2,no
1347,2360530,Table 1,BaselineCharacteristic,xx,N ; ,?Median, Age (years),4,1,3,no
1347,2360530,Table 1,BaselineCharacteristic,,(%) ; ,?Median, Age (years),4,2,3,no
1347,2360530,Table 1,BaselineCharacteristic,?Range,Characteristic ; ,?Range, Age (years),5,0,2,no
1347,2360530,Table 1,BaselineCharacteristic,,(%) ; ,?Range, Age (years),5,2,3,no
1347,2360530,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,6,0,2,no
1347,2360530,Table 1,BaselineCharacteristic,,N ; ,None,None,6,1,3,no
1347,2360530,Table 1,BaselineCharacteristic,,(%) ; ,None,None,6,2,3,no
1347,2360530,Table 1,BaselineCharacteristic,KPS ?xx%,Characteristic ; ,KPS ?xx%,,7,0,2,no
1347,2360530,Table 1,BaselineCharacteristic,xx,N ; ,KPS ?xx%,,7,1,3,no
1347,2360530,Table 1,BaselineCharacteristic,xxx,(%) ; ,KPS ?xx%,,7,2,3,no
1347,2360530,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,8,0,2,no
1347,2360530,Table 1,BaselineCharacteristic,,N ; ,None,None,8,1,3,no
1347,2360530,Table 1,BaselineCharacteristic,,(%) ; ,None,None,8,2,3,no
1347,2360530,Table 1,BaselineCharacteristic,HER x testing,Characteristic ; ,None,None,9,0,24,no
1347,2360530,Table 1,BaselineCharacteristic,HER x testing,N ; ,HER x testing,None,9,1,43,no
1347,2360530,Table 1,BaselineCharacteristic,HER x testing,(%) ; ,HER x testing,None,9,2,43,no
1347,2360530,Table 1,BaselineCharacteristic,?IHC x+,Characteristic ; ,?IHC x+, HER x testing,10,0,2,no
1347,2360530,Table 1,BaselineCharacteristic,xx,N ; ,?IHC x+, HER x testing,10,1,3,no
1347,2360530,Table 1,BaselineCharacteristic,xx.x,(%) ; ,?IHC x+, HER x testing,10,2,3,no
1347,2360530,Table 1,BaselineCharacteristic,?IHC x+/FISH+,Characteristic ; ,?IHC x+/FISH+, HER x testing,11,0,2,no
1347,2360530,Table 1,BaselineCharacteristic,x,N ; ,?IHC x+/FISH+, HER x testing,11,1,3,no
1347,2360530,Table 1,BaselineCharacteristic,x.x,(%) ; ,?IHC x+/FISH+, HER x testing,11,2,3,no
1347,2360530,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,12,0,2,no
1347,2360530,Table 1,BaselineCharacteristic,,N ; ,None,None,12,1,3,no
1347,2360530,Table 1,BaselineCharacteristic,,(%) ; ,None,None,12,2,3,no
1347,2360530,Table 1,BaselineCharacteristic,Prior hormonotherapy,Characteristic ; ,Prior hormonotherapy,,13,0,2,no
1347,2360530,Table 1,BaselineCharacteristic,xx,N ; ,Prior hormonotherapy,,13,1,3,no
1347,2360530,Table 1,BaselineCharacteristic,xx.x,(%) ; ,Prior hormonotherapy,,13,2,3,no
1347,2360530,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,14,0,2,no
1347,2360530,Table 1,BaselineCharacteristic,,N ; ,None,None,14,1,3,no
1347,2360530,Table 1,BaselineCharacteristic,,(%) ; ,None,None,14,2,3,no
1347,2360530,Table 1,BaselineCharacteristic,Prior chemotherapy,Characteristic ; ,Prior chemotherapy,,15,0,24,no
1347,2360530,Table 1,BaselineCharacteristic,xx,N ; ,Prior chemotherapy,,15,1,43,no
1347,2360530,Table 1,BaselineCharacteristic,xx.x,(%) ; ,Prior chemotherapy,,15,2,43,no
1347,2360530,Table 1,BaselineCharacteristic,?Neoadjuvant,Characteristic ; ,?Neoadjuvant, Prior chemotherapy,16,0,2,no
1347,2360530,Table 1,BaselineCharacteristic,x,N ; ,?Neoadjuvant, Prior chemotherapy,16,1,3,no
1347,2360530,Table 1,BaselineCharacteristic,x.x,(%) ; ,?Neoadjuvant, Prior chemotherapy,16,2,3,no
1347,2360530,Table 1,BaselineCharacteristic,?Adjuvant,Characteristic ; ,?Adjuvant, Prior chemotherapy,17,0,2,no
1347,2360530,Table 1,BaselineCharacteristic,xx,N ; ,?Adjuvant, Prior chemotherapy,17,1,3,no
1347,2360530,Table 1,BaselineCharacteristic,xx.x,(%) ; ,?Adjuvant, Prior chemotherapy,17,2,3,no
1347,2360530,Table 1,BaselineCharacteristic,?Both,Characteristic ; ,?Both, Prior chemotherapy,18,0,2,no
1347,2360530,Table 1,BaselineCharacteristic,xx,N ; ,?Both, Prior chemotherapy,18,1,3,no
1347,2360530,Table 1,BaselineCharacteristic,xx.x,(%) ; ,?Both, Prior chemotherapy,18,2,3,no
1347,2360530,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,19,0,2,no
1347,2360530,Table 1,BaselineCharacteristic,,N ; ,None,None,19,1,3,no
1347,2360530,Table 1,BaselineCharacteristic,,(%) ; ,None,None,19,2,3,no
1347,2360530,Table 1,BaselineCharacteristic,Chemotherapy regimen,Characteristic ; ,None,None,20,0,24,no
1347,2360530,Table 1,BaselineCharacteristic,,N ; ,Chemotherapy regimen,None,20,1,43,no
1347,2360530,Table 1,BaselineCharacteristic,,(%) ; ,Chemotherapy regimen,None,20,2,43,no
1347,2360530,Table 1,BaselineCharacteristic,?Anthracycline based,Characteristic ; ,?Anthracycline based, Chemotherapy regimen,21,0,2,no
1347,2360530,Table 1,BaselineCharacteristic,xx,N ; ,?Anthracycline based, Chemotherapy regimen,21,1,3,no
1347,2360530,Table 1,BaselineCharacteristic,xx.x,(%) ; ,?Anthracycline based, Chemotherapy regimen,21,2,3,no
1347,2360530,Table 1,BaselineCharacteristic,?Anthracycline+taxane,Characteristic ; ,?Anthracycline+taxane, Chemotherapy regimen,22,0,2,no
1347,2360530,Table 1,BaselineCharacteristic,xx,N ; ,?Anthracycline+taxane, Chemotherapy regimen,22,1,3,no
1347,2360530,Table 1,BaselineCharacteristic,xx.x,(%) ; ,?Anthracycline+taxane, Chemotherapy regimen,22,2,3,no
1347,2360530,Table 1,BaselineCharacteristic,?CMF,Characteristic ; ,?CMF, Chemotherapy regimen,23,0,2,no
1347,2360530,Table 1,BaselineCharacteristic,x,N ; ,?CMF, Chemotherapy regimen,23,1,3,no
1347,2360530,Table 1,BaselineCharacteristic,xx.x,(%) ; ,?CMF, Chemotherapy regimen,23,2,3,no
1347,2360530,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,24,0,2,no
1347,2360530,Table 1,BaselineCharacteristic,,N ; ,None,None,24,1,3,no
1347,2360530,Table 1,BaselineCharacteristic,,(%) ; ,None,None,24,2,3,no
1347,2360530,Table 1,BaselineCharacteristic,Metastatic sites ?x,Characteristic ; ,Metastatic sites ?x,,25,0,24,no
1347,2360530,Table 1,BaselineCharacteristic,xx,N ; ,Metastatic sites ?x,,25,1,43,no
1347,2360530,Table 1,BaselineCharacteristic,xx.x,(%) ; ,Metastatic sites ?x,,25,2,43,no
1347,2360530,Table 1,BaselineCharacteristic,?Lymph nodes,Characteristic ; ,?Lymph nodes, Metastatic sites ?x,26,0,2,no
1347,2360530,Table 1,BaselineCharacteristic,xx,N ; ,?Lymph nodes, Metastatic sites ?x,26,1,3,no
1347,2360530,Table 1,BaselineCharacteristic,xx.x,(%) ; ,?Lymph nodes, Metastatic sites ?x,26,2,3,no
1347,2360530,Table 1,BaselineCharacteristic,?Visceral (lung/liver),Characteristic ; ,?Visceral (lung/liver), Metastatic sites ?x,27,0,2,no
1347,2360530,Table 1,BaselineCharacteristic,xx,N ; ,?Visceral (lung/liver), Metastatic sites ?x,27,1,3,no
1347,2360530,Table 1,BaselineCharacteristic,xx.x,(%) ; ,?Visceral (lung/liver), Metastatic sites ?x,27,2,3,no
1347,2360530,Table 1,BaselineCharacteristic,?Liver,Characteristic ; ,?Liver, Metastatic sites ?x,28,0,2,no
1347,2360530,Table 1,BaselineCharacteristic,xx,N ; ,?Liver, Metastatic sites ?x,28,1,3,no
1347,2360530,Table 1,BaselineCharacteristic,xx.x,(%) ; ,?Liver, Metastatic sites ?x,28,2,3,no
1347,2360530,Table 1,BaselineCharacteristic,?Lung,Characteristic ; ,?Lung, Metastatic sites ?x,29,0,2,no
1347,2360530,Table 1,BaselineCharacteristic,xx,N ; ,?Lung, Metastatic sites ?x,29,1,3,no
1347,2360530,Table 1,BaselineCharacteristic,xx.x,(%) ; ,?Lung, Metastatic sites ?x,29,2,3,no
1347,2360530,Table 1,BaselineCharacteristic,?Bone,Characteristic ; ,?Bone, Metastatic sites ?x,30,0,2,no
1347,2360530,Table 1,BaselineCharacteristic,xx,N ; ,?Bone, Metastatic sites ?x,30,1,3,no
1347,2360530,Table 1,BaselineCharacteristic,xx.x,(%) ; ,?Bone, Metastatic sites ?x,30,2,3,no
1347,2360530,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,31,0,2,no
1347,2360530,Table 1,BaselineCharacteristic,,N ; ,None,None,31,1,3,no
1347,2360530,Table 1,BaselineCharacteristic,,(%) ; ,None,None,31,2,3,no
1347,2360530,Table 1,BaselineCharacteristic,Disease-free interval from diagnosis to first relapse (months),Characteristic ; ,None,None,32,0,24,no
1347,2360530,Table 1,BaselineCharacteristic,Disease-free interval from diagnosis to first relapse (months),N ; ,Disease-free interval from diagnosis to first relapse (months),None,32,1,43,no
1347,2360530,Table 1,BaselineCharacteristic,Disease-free interval from diagnosis to first relapse (months),(%) ; ,Disease-free interval from diagnosis to first relapse (months),None,32,2,43,no
1347,2360530,Table 1,BaselineCharacteristic,?Median,Characteristic ; ,?Median, Disease-free interval from diagnosis to first relapse (months),33,0,2,no
1347,2360530,Table 1,BaselineCharacteristic,xx.x,N ; ,?Median, Disease-free interval from diagnosis to first relapse (months),33,1,3,no
1347,2360530,Table 1,BaselineCharacteristic,,(%) ; ,?Median, Disease-free interval from diagnosis to first relapse (months),33,2,3,no
1347,2360530,Table 1,BaselineCharacteristic,?Range,Characteristic ; ,?Range, Disease-free interval from diagnosis to first relapse (months),34,0,2,no
1347,2360530,Table 1,BaselineCharacteristic,,(%) ; ,?Range, Disease-free interval from diagnosis to first relapse (months),34,2,3,no
1348,2360532,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,0,12,no
1348,2360532,Table 1,BaselineCharacteristic,n,,Characteristic,None,0,1,1,no
1348,2360532,Table 1,BaselineCharacteristic,%,,Characteristic,None,0,2,1,no
1348,2360532,Table 1,BaselineCharacteristic,Sex,Characteristic ; ,None,None,1,0,24,no
1348,2360532,Table 1,BaselineCharacteristic,,n ; ,Sex,None,1,1,43,no
1348,2360532,Table 1,BaselineCharacteristic,,% ; ,Sex,None,1,2,43,no
1348,2360532,Table 1,BaselineCharacteristic,?Male,Characteristic ; ,?Male, Sex,2,0,2,no
1348,2360532,Table 1,BaselineCharacteristic,xx,n ; ,?Male, Sex,2,1,3,yes
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,?Male, Sex,2,2,3,yes
1348,2360532,Table 1,BaselineCharacteristic,?Female,Characteristic ; ,?Female, Sex,3,0,2,no
1348,2360532,Table 1,BaselineCharacteristic,xx,n ; ,?Female, Sex,3,1,3,yes
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,?Female, Sex,3,2,3,yes
1348,2360532,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,4,0,2,no
1348,2360532,Table 1,BaselineCharacteristic,,n ; ,None,None,4,1,3,no
1348,2360532,Table 1,BaselineCharacteristic,,% ; ,None,None,4,2,3,no
1348,2360532,Table 1,BaselineCharacteristic,WHO performance status,Characteristic ; ,None,None,5,0,24,no
1348,2360532,Table 1,BaselineCharacteristic,WHO performance status,n ; ,WHO performance status,None,5,1,43,no
1348,2360532,Table 1,BaselineCharacteristic,WHO performance status,% ; ,WHO performance status,None,5,2,43,no
1348,2360532,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, WHO performance status,6,0,2,no
1348,2360532,Table 1,BaselineCharacteristic,xx,n ; ,?x, WHO performance status,6,1,3,no
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,?x, WHO performance status,6,2,3,no
1348,2360532,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, WHO performance status,7,0,2,no
1348,2360532,Table 1,BaselineCharacteristic,xx,n ; ,?x, WHO performance status,7,1,3,no
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,?x, WHO performance status,7,2,3,no
1348,2360532,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, WHO performance status,8,0,2,no
1348,2360532,Table 1,BaselineCharacteristic,xx,n ; ,?x, WHO performance status,8,1,3,no
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,?x, WHO performance status,8,2,3,no
1348,2360532,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,9,0,2,no
1348,2360532,Table 1,BaselineCharacteristic,,n ; ,None,None,9,1,3,no
1348,2360532,Table 1,BaselineCharacteristic,,% ; ,None,None,9,2,3,no
1348,2360532,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,13,0,2,no
1348,2360532,Table 1,BaselineCharacteristic,,n ; ,None,None,13,1,3,no
1348,2360532,Table 1,BaselineCharacteristic,,% ; ,None,None,13,2,3,no
1348,2360532,Table 1,BaselineCharacteristic,Raised AFP,Characteristic ; ,Raised AFP,,14,0,2,no
1348,2360532,Table 1,BaselineCharacteristic,xx,n ; ,Raised AFP,,14,1,3,no
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,Raised AFP,,14,2,3,no
1348,2360532,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,15,0,2,no
1348,2360532,Table 1,BaselineCharacteristic,,n ; ,None,None,15,1,3,no
1348,2360532,Table 1,BaselineCharacteristic,,% ; ,None,None,15,2,3,no
1348,2360532,Table 1,BaselineCharacteristic,Race,Characteristic ; ,None,None,16,0,24,no
1348,2360532,Table 1,BaselineCharacteristic,Race,n ; ,Race,None,16,1,43,no
1348,2360532,Table 1,BaselineCharacteristic,Race,% ; ,Race,None,16,2,43,no
1348,2360532,Table 1,BaselineCharacteristic,?Caucasian,Characteristic ; ,?Caucasian, Race,17,0,2,no
1348,2360532,Table 1,BaselineCharacteristic,xx,n ; ,?Caucasian, Race,17,1,3,no
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,?Caucasian, Race,17,2,3,no
1348,2360532,Table 1,BaselineCharacteristic,?Asian,Characteristic ; ,?Asian, Race,18,0,2,no
1348,2360532,Table 1,BaselineCharacteristic,xx,n ; ,?Asian, Race,18,1,3,no
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,?Asian, Race,18,2,3,no
1348,2360532,Table 1,BaselineCharacteristic,?African,Characteristic ; ,?African, Race,19,0,2,no
1348,2360532,Table 1,BaselineCharacteristic,x,n ; ,?African, Race,19,1,3,no
1348,2360532,Table 1,BaselineCharacteristic,x,% ; ,?African, Race,19,2,3,no
1348,2360532,Table 1,BaselineCharacteristic,?Polynesian or Melanesian,Characteristic ; ,?Polynesian or Melanesian, Race,20,0,2,no
1348,2360532,Table 1,BaselineCharacteristic,x,n ; ,?Polynesian or Melanesian, Race,20,1,3,no
1348,2360532,Table 1,BaselineCharacteristic,x,% ; ,?Polynesian or Melanesian, Race,20,2,3,no
1348,2360532,Table 1,BaselineCharacteristic,?Other,Characteristic ; ,?Other, Race,21,0,2,no
1348,2360532,Table 1,BaselineCharacteristic,x,n ; ,?Other, Race,21,1,3,no
1348,2360532,Table 1,BaselineCharacteristic,x,% ; ,?Other, Race,21,2,3,no
1348,2360532,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,22,0,2,no
1348,2360532,Table 1,BaselineCharacteristic,,n ; ,None,None,22,1,3,no
1348,2360532,Table 1,BaselineCharacteristic,,% ; ,None,None,22,2,3,no
1348,2360532,Table 1,BaselineCharacteristic,Possible causes of HCCa,Characteristic ; ,None,None,23,0,24,no
1348,2360532,Table 1,BaselineCharacteristic,Possible causes of HCCa,n ; ,Possible causes of HCCa,None,23,1,43,no
1348,2360532,Table 1,BaselineCharacteristic,Possible causes of HCCa,% ; ,Possible causes of HCCa,None,23,2,43,no
1348,2360532,Table 1,BaselineCharacteristic,?Alcoholic liver disease,Characteristic ; ,?Alcoholic liver disease, Possible causes of HCCa,24,0,2,no
1348,2360532,Table 1,BaselineCharacteristic,xx,n ; ,?Alcoholic liver disease, Possible causes of HCCa,24,1,3,no
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,?Alcoholic liver disease, Possible causes of HCCa,24,2,3,no
1348,2360532,Table 1,BaselineCharacteristic,?Hepatitis,Characteristic ; ,?Hepatitis, Possible causes of HCCa,25,0,24,no
1348,2360532,Table 1,BaselineCharacteristic,xx,n ; ,?Hepatitis, Possible causes of HCCa,25,1,43,no
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,?Hepatitis, Possible causes of HCCa,25,2,43,no
1348,2360532,Table 1,BaselineCharacteristic,??HBsAg and no antibody to HCV,Characteristic ; ,??HBsAg and no antibody to HCV, Possible causes of HCCa ?Hepatitis,26,0,2,no
1348,2360532,Table 1,BaselineCharacteristic,xx,n ; ,??HBsAg and no antibody to HCV, Possible causes of HCCa ?Hepatitis,26,1,3,no
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,??HBsAg and no antibody to HCV, Possible causes of HCCa ?Hepatitis,26,2,3,no
1348,2360532,Table 1,BaselineCharacteristic,??Antibody to HCV and no HBsAg,Characteristic ; ,??Antibody to HCV and no HBsAg, Possible causes of HCCa ?Hepatitis,27,0,2,no
1348,2360532,Table 1,BaselineCharacteristic,x,n ; ,??Antibody to HCV and no HBsAg, Possible causes of HCCa ?Hepatitis,27,1,3,no
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,??Antibody to HCV and no HBsAg, Possible causes of HCCa ?Hepatitis,27,2,3,no
1348,2360532,Table 1,BaselineCharacteristic,??HBsAg and antibody to HCV,Characteristic ; ,??HBsAg and antibody to HCV, Possible causes of HCCa ?Hepatitis,28,0,2,no
1348,2360532,Table 1,BaselineCharacteristic,x,n ; ,??HBsAg and antibody to HCV, Possible causes of HCCa ?Hepatitis,28,1,3,no
1348,2360532,Table 1,BaselineCharacteristic,x,% ; ,??HBsAg and antibody to HCV, Possible causes of HCCa ?Hepatitis,28,2,3,no
1348,2360532,Table 1,BaselineCharacteristic,??No HBsAg or antibody to HCV,Characteristic ; ,??No HBsAg or antibody to HCV, Possible causes of HCCa ?Hepatitis,29,0,2,no
1348,2360532,Table 1,BaselineCharacteristic,x,n ; ,??No HBsAg or antibody to HCV, Possible causes of HCCa ?Hepatitis,29,1,3,no
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,??No HBsAg or antibody to HCV, Possible causes of HCCa ?Hepatitis,29,2,3,no
1348,2360532,Table 1,BaselineCharacteristic,??Unclassified,Characteristic ; ,??Unclassified, Possible causes of HCCa ?Hepatitis,30,0,2,no
1348,2360532,Table 1,BaselineCharacteristic,x,n ; ,??Unclassified, Possible causes of HCCa ?Hepatitis,30,1,3,no
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,??Unclassified, Possible causes of HCCa ?Hepatitis,30,2,3,no
1348,2360532,Table 1,BaselineCharacteristic,?Haemochromatosis,Characteristic ; ,?Haemochromatosis, Possible causes of HCCa,31,0,2,no
1348,2360532,Table 1,BaselineCharacteristic,x,n ; ,?Haemochromatosis, Possible causes of HCCa,31,1,3,no
1348,2360532,Table 1,BaselineCharacteristic,x,% ; ,?Haemochromatosis, Possible causes of HCCa,31,2,3,no
1348,2360532,Table 1,BaselineCharacteristic,?Other,Characteristic ; ,?Other, Possible causes of HCCa,32,0,2,no
1348,2360532,Table 1,BaselineCharacteristic,x,n ; ,?Other, Possible causes of HCCa,32,1,3,no
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,?Other, Possible causes of HCCa,32,2,3,no
1348,2360532,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,33,0,2,no
1348,2360532,Table 1,BaselineCharacteristic,,n ; ,None,None,33,1,3,no
1348,2360532,Table 1,BaselineCharacteristic,,% ; ,None,None,33,2,3,no
1348,2360532,Table 1,BaselineCharacteristic,Most recent treatment for HCC,Characteristic ; ,None,None,34,0,24,no
1348,2360532,Table 1,BaselineCharacteristic,Most recent treatment for HCC,n ; ,Most recent treatment for HCC,None,34,1,43,no
1348,2360532,Table 1,BaselineCharacteristic,Most recent treatment for HCC,% ; ,Most recent treatment for HCC,None,34,2,43,no
1348,2360532,Table 1,BaselineCharacteristic,?No previous therapy,Characteristic ; ,?No previous therapy, Most recent treatment for HCC,35,0,2,no
1348,2360532,Table 1,BaselineCharacteristic,xx,n ; ,?No previous therapy, Most recent treatment for HCC,35,1,3,no
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,?No previous therapy, Most recent treatment for HCC,35,2,3,no
1348,2360532,Table 1,BaselineCharacteristic,?Surgery,Characteristic ; ,?Surgery, Most recent treatment for HCC,36,0,2,no
1348,2360532,Table 1,BaselineCharacteristic,x,n ; ,?Surgery, Most recent treatment for HCC,36,1,3,no
1348,2360532,Table 1,BaselineCharacteristic,x,% ; ,?Surgery, Most recent treatment for HCC,36,2,3,no
1348,2360532,Table 1,BaselineCharacteristic,?Chemotherapy,Characteristic ; ,?Chemotherapy, Most recent treatment for HCC,37,0,2,no
1348,2360532,Table 1,BaselineCharacteristic,x,n ; ,?Chemotherapy, Most recent treatment for HCC,37,1,3,no
1348,2360532,Table 1,BaselineCharacteristic,x,% ; ,?Chemotherapy, Most recent treatment for HCC,37,2,3,no
1348,2360532,Table 1,BaselineCharacteristic,?Local ablation,Characteristic ; ,?Local ablation, Most recent treatment for HCC,38,0,2,no
1348,2360532,Table 1,BaselineCharacteristic,x,n ; ,?Local ablation, Most recent treatment for HCC,38,1,3,no
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,?Local ablation, Most recent treatment for HCC,38,2,3,no
1348,2360532,Table 1,BaselineCharacteristic,?Chemoembolisation,Characteristic ; ,?Chemoembolisation, Most recent treatment for HCC,39,0,2,no
1348,2360532,Table 1,BaselineCharacteristic,x,n ; ,?Chemoembolisation, Most recent treatment for HCC,39,1,3,no
1348,2360532,Table 1,BaselineCharacteristic,x,% ; ,?Chemoembolisation, Most recent treatment for HCC,39,2,3,no
1348,2360532,Table 1,BaselineCharacteristic,?Other,Characteristic ; ,?Other, Most recent treatment for HCC,40,0,2,no
1348,2360532,Table 1,BaselineCharacteristic,xx,n ; ,?Other, Most recent treatment for HCC,40,1,3,no
1348,2360532,Table 1,BaselineCharacteristic,xx,% ; ,?Other, Most recent treatment for HCC,40,2,3,no
1351,2360546,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no
1351,2360546,Table 1,BaselineCharacteristic,No.,,,None,0,1,1,no
1351,2360546,Table 1,BaselineCharacteristic,%,,,None,0,2,1,no
1351,2360546,Table 1,BaselineCharacteristic,Total, ; ,Total,,1,0,2,no
1351,2360546,Table 1,BaselineCharacteristic,xx,No. ; ,Total,,1,1,3,no
1351,2360546,Table 1,BaselineCharacteristic,,% ; ,Total,,1,2,3,no
1351,2360546,Table 1,BaselineCharacteristic,, ; ,None,None,2,0,2,no
1351,2360546,Table 1,BaselineCharacteristic,,No. ; ,None,None,2,1,3,no
1351,2360546,Table 1,BaselineCharacteristic,,% ; ,None,None,2,2,3,no
1351,2360546,Table 1,BaselineCharacteristic,Sex, ; ,None,None,3,0,24,no
1351,2360546,Table 1,BaselineCharacteristic,,No. ; ,Sex,None,3,1,43,no
1351,2360546,Table 1,BaselineCharacteristic,,% ; ,Sex,None,3,2,43,no
1351,2360546,Table 1,BaselineCharacteristic,?Male, ; ,?Male, Sex,4,0,2,no
1351,2360546,Table 1,BaselineCharacteristic,xx,No. ; ,?Male, Sex,4,1,3,yes
1351,2360546,Table 1,BaselineCharacteristic,xx.x,% ; ,?Male, Sex,4,2,3,yes
1351,2360546,Table 1,BaselineCharacteristic,?Female, ; ,?Female, Sex,5,0,2,no
1351,2360546,Table 1,BaselineCharacteristic,xx,No. ; ,?Female, Sex,5,1,3,yes
1351,2360546,Table 1,BaselineCharacteristic,xx.x,% ; ,?Female, Sex,5,2,3,yes
1351,2360546,Table 1,BaselineCharacteristic,, ; ,None,None,6,0,2,no
1351,2360546,Table 1,BaselineCharacteristic,,No. ; ,None,None,6,1,3,no
1351,2360546,Table 1,BaselineCharacteristic,,% ; ,None,None,6,2,3,no
1351,2360546,Table 1,BaselineCharacteristic,Age (years), ; ,None,None,7,0,24,no
1351,2360546,Table 1,BaselineCharacteristic,,No. ; ,Age (years),None,7,1,43,no
1351,2360546,Table 1,BaselineCharacteristic,,% ; ,Age (years),None,7,2,43,no
1351,2360546,Table 1,BaselineCharacteristic,?Median, ; ,?Median, Age (years),8,0,2,no
1351,2360546,Table 1,BaselineCharacteristic,xx.x,No. ; ,?Median, Age (years),8,1,3,no
1351,2360546,Table 1,BaselineCharacteristic,,% ; ,?Median, Age (years),8,2,3,no
1351,2360546,Table 1,BaselineCharacteristic,?Range, ; ,?Range, Age (years),9,0,2,no
1351,2360546,Table 1,BaselineCharacteristic,,% ; ,?Range, Age (years),9,2,3,no
1351,2360546,Table 1,BaselineCharacteristic,, ; ,None,None,10,0,2,no
1351,2360546,Table 1,BaselineCharacteristic,,No. ; ,None,None,10,1,3,no
1351,2360546,Table 1,BaselineCharacteristic,,% ; ,None,None,10,2,3,no
1351,2360546,Table 1,BaselineCharacteristic,Histology, ; ,None,None,11,0,24,no
1351,2360546,Table 1,BaselineCharacteristic,,No. ; ,Histology,None,11,1,43,no
1351,2360546,Table 1,BaselineCharacteristic,,% ; ,Histology,None,11,2,43,no
1351,2360546,Table 1,BaselineCharacteristic,?Adeno, ; ,?Adeno, Histology,12,0,2,no
1351,2360546,Table 1,BaselineCharacteristic,x,No. ; ,?Adeno, Histology,12,1,3,no
1351,2360546,Table 1,BaselineCharacteristic,xx,% ; ,?Adeno, Histology,12,2,3,no
1351,2360546,Table 1,BaselineCharacteristic,?Squamous, ; ,?Squamous, Histology,13,0,2,no
1351,2360546,Table 1,BaselineCharacteristic,xx,No. ; ,?Squamous, Histology,13,1,3,no
1351,2360546,Table 1,BaselineCharacteristic,xx,% ; ,?Squamous, Histology,13,2,3,no
1351,2360546,Table 1,BaselineCharacteristic,?Large, ; ,?Large, Histology,14,0,2,no
1351,2360546,Table 1,BaselineCharacteristic,x,No. ; ,?Large, Histology,14,1,3,no
1351,2360546,Table 1,BaselineCharacteristic,xx,% ; ,?Large, Histology,14,2,3,no
1351,2360546,Table 1,BaselineCharacteristic,?Other, ; ,?Other, Histology,15,0,2,no
1351,2360546,Table 1,BaselineCharacteristic,x,No. ; ,?Other, Histology,15,1,3,no
1351,2360546,Table 1,BaselineCharacteristic,xx,% ; ,?Other, Histology,15,2,3,no
1351,2360546,Table 1,BaselineCharacteristic,, ; ,None,None,16,0,2,no
1351,2360546,Table 1,BaselineCharacteristic,,No. ; ,None,None,16,1,3,no
1351,2360546,Table 1,BaselineCharacteristic,,% ; ,None,None,16,2,3,no
1351,2360546,Table 1,BaselineCharacteristic,Performance status (ECOG), ; ,None,None,17,0,24,no
1351,2360546,Table 1,BaselineCharacteristic,Performance status (ECOG),No. ; ,Performance status (ECOG),None,17,1,43,no
1351,2360546,Table 1,BaselineCharacteristic,Performance status (ECOG),% ; ,Performance status (ECOG),None,17,2,43,no
1351,2360546,Table 1,BaselineCharacteristic,?x, ; ,?x, Performance status (ECOG),18,0,2,no
1351,2360546,Table 1,BaselineCharacteristic,x,No. ; ,?x, Performance status (ECOG),18,1,3,no
1351,2360546,Table 1,BaselineCharacteristic,x,% ; ,?x, Performance status (ECOG),18,2,3,no
1351,2360546,Table 1,BaselineCharacteristic,?x, ; ,?x, Performance status (ECOG),19,0,2,no
1351,2360546,Table 1,BaselineCharacteristic,xx,No. ; ,?x, Performance status (ECOG),19,1,3,no
1351,2360546,Table 1,BaselineCharacteristic,xx.x,% ; ,?x, Performance status (ECOG),19,2,3,no
1351,2360546,Table 1,BaselineCharacteristic,?x, ; ,?x, Performance status (ECOG),20,0,2,no
1351,2360546,Table 1,BaselineCharacteristic,x,No. ; ,?x, Performance status (ECOG),20,1,3,no
1351,2360546,Table 1,BaselineCharacteristic,xx.x,% ; ,?x, Performance status (ECOG),20,2,3,no
1351,2360546,Table 1,BaselineCharacteristic,, ; ,None,None,21,0,2,no
1351,2360546,Table 1,BaselineCharacteristic,,No. ; ,None,None,21,1,3,no
1351,2360546,Table 1,BaselineCharacteristic,,% ; ,None,None,21,2,3,no
1351,2360546,Table 1,BaselineCharacteristic,Disease stage, ; ,None,None,22,0,24,no
1351,2360546,Table 1,BaselineCharacteristic,Disease stage,No. ; ,Disease stage,None,22,1,43,no
1351,2360546,Table 1,BaselineCharacteristic,Disease stage,% ; ,Disease stage,None,22,2,43,no
1351,2360546,Table 1,BaselineCharacteristic,?IIIA, ; ,?IIIA, Disease stage,23,0,2,no
1351,2360546,Table 1,BaselineCharacteristic,x,No. ; ,?IIIA, Disease stage,23,1,3,no
1351,2360546,Table 1,BaselineCharacteristic,x.x,% ; ,?IIIA, Disease stage,23,2,3,no
1351,2360546,Table 1,BaselineCharacteristic,?IIIB, ; ,?IIIB, Disease stage,24,0,2,no
1351,2360546,Table 1,BaselineCharacteristic,xx,No. ; ,?IIIB, Disease stage,24,1,3,no
1351,2360546,Table 1,BaselineCharacteristic,xx.x,% ; ,?IIIB, Disease stage,24,2,3,no
1351,2360546,Table 1,BaselineCharacteristic,?IV, ; ,?IV, Disease stage,25,0,2,no
1351,2360546,Table 1,BaselineCharacteristic,x,No. ; ,?IV, Disease stage,25,1,3,no
1351,2360546,Table 1,BaselineCharacteristic,xx.x,% ; ,?IV, Disease stage,25,2,3,no
1355,2360560,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no
1355,2360560,Table 1,BaselineCharacteristic,No. of patients (%),,,None,0,1,1,no
1355,2360560,Table 1,BaselineCharacteristic,Gender, ; ,None,None,1,0,24,no
1355,2360560,Table 1,BaselineCharacteristic,Gender,No. of patients (%) ; ,Gender,None,1,1,43,no
1355,2360560,Table 1,BaselineCharacteristic,?Female, ; ,?Female, Gender,2,0,2,no
1355,2360560,Table 1,BaselineCharacteristic,xx (xx),No. of patients (%) ; ,?Female, Gender,2,1,3,no
1355,2360560,Table 1,BaselineCharacteristic,?Male, ; ,?Male, Gender,3,0,2,no
1355,2360560,Table 1,BaselineCharacteristic,xx (xx),No. of patients (%) ; ,?Male, Gender,3,1,3,no
1355,2360560,Table 1,BaselineCharacteristic,, ; ,None,None,4,0,2,no
1355,2360560,Table 1,BaselineCharacteristic,,No. of patients (%) ; ,None,None,4,1,3,no
1355,2360560,Table 1,BaselineCharacteristic,Age (years), ; ,None,None,5,0,24,no
1355,2360560,Table 1,BaselineCharacteristic,Age (years),No. of patients (%) ; ,Age (years),None,5,1,43,no
1355,2360560,Table 1,BaselineCharacteristic,?Median, ; ,?Median, Age (years),6,0,2,no
1355,2360560,Table 1,BaselineCharacteristic,xx,No. of patients (%) ; ,?Median, Age (years),6,1,3,no
1355,2360560,Table 1,BaselineCharacteristic,?Range, ; ,?Range, Age (years),7,0,2,no
1355,2360560,Table 1,BaselineCharacteristic,, ; ,None,None,8,0,2,no
1355,2360560,Table 1,BaselineCharacteristic,,No. of patients (%) ; ,None,None,8,1,3,no
1355,2360560,Table 1,BaselineCharacteristic,KPS, ; ,None,None,9,0,24,no
1355,2360560,Table 1,BaselineCharacteristic,KPS,No. of patients (%) ; ,KPS,None,9,1,43,no
1355,2360560,Table 1,BaselineCharacteristic,?Median, ; ,?Median, KPS,10,0,2,no
1355,2360560,Table 1,BaselineCharacteristic,xx,No. of patients (%) ; ,?Median, KPS,10,1,3,no
1355,2360560,Table 1,BaselineCharacteristic,?Range, ; ,?Range, KPS,11,0,2,no
1355,2360560,Table 1,BaselineCharacteristic,, ; ,None,None,12,0,2,no
1355,2360560,Table 1,BaselineCharacteristic,,No. of patients (%) ; ,None,None,12,1,3,no
1355,2360560,Table 1,BaselineCharacteristic,Extent of resection, ; ,None,None,13,0,24,no
1355,2360560,Table 1,BaselineCharacteristic,Extent of resection,No. of patients (%) ; ,Extent of resection,None,13,1,43,no
1355,2360560,Table 1,BaselineCharacteristic,?Gross total resection, ; ,?Gross total resection, Extent of resection,14,0,2,no
1355,2360560,Table 1,BaselineCharacteristic,xx (xx),No. of patients (%) ; ,?Gross total resection, Extent of resection,14,1,3,no
1355,2360560,Table 1,BaselineCharacteristic,?Partial resection or biopsy, ; ,?Partial resection or biopsy, Extent of resection,15,0,2,no
1355,2360560,Table 1,BaselineCharacteristic,xx (xx),No. of patients (%) ; ,?Partial resection or biopsy, Extent of resection,15,1,3,no
1355,2360560,Table 1,BaselineCharacteristic,, ; ,None,None,16,0,2,no
1355,2360560,Table 1,BaselineCharacteristic,,No. of patients (%) ; ,None,None,16,1,3,no
1355,2360560,Table 1,BaselineCharacteristic,Previous treatment, ; ,None,None,17,0,24,no
1355,2360560,Table 1,BaselineCharacteristic,Previous treatment,No. of patients (%) ; ,Previous treatment,None,17,1,43,no
1355,2360560,Table 1,BaselineCharacteristic,?Primary resection, ; ,?Primary resection, Previous treatment,18,0,2,no
1355,2360560,Table 1,BaselineCharacteristic,xx (xxx),No. of patients (%) ; ,?Primary resection, Previous treatment,18,1,3,no
1355,2360560,Table 1,BaselineCharacteristic,?Radiotherapy, ; ,?Radiotherapy, Previous treatment,19,0,2,no
1355,2360560,Table 1,BaselineCharacteristic,xx (xxx),No. of patients (%) ; ,?Radiotherapy, Previous treatment,19,1,3,no
1355,2360560,Table 1,BaselineCharacteristic,?Chemotherapy, ; ,?Chemotherapy, Previous treatment,20,0,2,no
1355,2360560,Table 1,BaselineCharacteristic,x,No. of patients (%) ; ,?Chemotherapy, Previous treatment,20,1,3,no
1355,2360560,Table 1,BaselineCharacteristic,?Repeat surgery for recurrence, ; ,?Repeat surgery for recurrence, Previous treatment,21,0,2,no
1355,2360560,Table 1,BaselineCharacteristic,x,No. of patients (%) ; ,?Repeat surgery for recurrence, Previous treatment,21,1,3,no
1355,2360560,Table 1,BaselineCharacteristic,, ; ,None,None,22,0,2,no
1355,2360560,Table 1,BaselineCharacteristic,,No. of patients (%) ; ,None,None,22,1,3,no
1355,2360560,Table 1,BaselineCharacteristic,Cycles of temozolomide, ; ,None,None,23,0,24,no
1355,2360560,Table 1,BaselineCharacteristic,Cycles of temozolomide,No. of patients (%) ; ,Cycles of temozolomide,None,23,1,43,no
1355,2360560,Table 1,BaselineCharacteristic,??x, ; ,??x, Cycles of temozolomide,24,0,2,no
1355,2360560,Table 1,BaselineCharacteristic,xx,No. of patients (%) ; ,??x, Cycles of temozolomide,24,1,3,no
1355,2360560,Table 1,BaselineCharacteristic,?>xx, ; ,?>xx, Cycles of temozolomide,27,0,2,no
1355,2360560,Table 1,BaselineCharacteristic,x,No. of patients (%) ; ,?>xx, Cycles of temozolomide,27,1,3,no
1377,2360766,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no
1377,2360766,Table 1,BaselineCharacteristic,Phase I (n=xx),,,None,0,1,1,no
1377,2360766,Table 1,BaselineCharacteristic,Phase II (n=xx),,,None,0,2,1,no
1377,2360766,Table 1,BaselineCharacteristic,"Median age, years (range)", ; ,"Median age, years (range)",,1,0,2,no
1377,2360766,Table 1,BaselineCharacteristic,Male/female, ; ,Male/female,,2,0,2,no
1377,2360766,Table 1,BaselineCharacteristic,xx/x,Phase I (n=xx) ; ,Male/female,,2,1,3,yes
1377,2360766,Table 1,BaselineCharacteristic,xx/x,Phase II (n=xx) ; ,Male/female,,2,2,3,yes
1377,2360766,Table 1,BaselineCharacteristic,, ; ,None,None,3,0,2,no
1377,2360766,Table 1,BaselineCharacteristic,,Phase I (n=xx) ; ,None,None,3,1,3,no
1377,2360766,Table 1,BaselineCharacteristic,,Phase II (n=xx) ; ,None,None,3,2,3,no
1377,2360766,Table 1,BaselineCharacteristic,Performance status, ; ,None,None,4,0,24,no
1377,2360766,Table 1,BaselineCharacteristic,Performance status,Phase I (n=xx) ; ,Performance status,None,4,1,43,no
1377,2360766,Table 1,BaselineCharacteristic,Performance status,Phase II (n=xx) ; ,Performance status,None,4,2,43,no
1377,2360766,Table 1,BaselineCharacteristic,?x, ; ,?x, Performance status,5,0,2,no
1377,2360766,Table 1,BaselineCharacteristic,xx,Phase I (n=xx) ; ,?x, Performance status,5,1,3,no
1377,2360766,Table 1,BaselineCharacteristic,xx,Phase II (n=xx) ; ,?x, Performance status,5,2,3,no
1377,2360766,Table 1,BaselineCharacteristic,?x, ; ,?x, Performance status,6,0,2,no
1377,2360766,Table 1,BaselineCharacteristic,x,Phase I (n=xx) ; ,?x, Performance status,6,1,3,no
1377,2360766,Table 1,BaselineCharacteristic,x,Phase II (n=xx) ; ,?x, Performance status,6,2,3,no
1377,2360766,Table 1,BaselineCharacteristic,, ; ,None,None,7,0,2,no
1377,2360766,Table 1,BaselineCharacteristic,,Phase I (n=xx) ; ,None,None,7,1,3,no
1377,2360766,Table 1,BaselineCharacteristic,,Phase II (n=xx) ; ,None,None,7,2,3,no
1377,2360766,Table 1,BaselineCharacteristic,Histological type, ; ,None,None,8,0,24,no
1377,2360766,Table 1,BaselineCharacteristic,Histological type,Phase I (n=xx) ; ,Histological type,None,8,1,43,no
1377,2360766,Table 1,BaselineCharacteristic,Histological type,Phase II (n=xx) ; ,Histological type,None,8,2,43,no
1377,2360766,Table 1,BaselineCharacteristic,?Intestinal, ; ,?Intestinal, Histological type,9,0,2,no
1377,2360766,Table 1,BaselineCharacteristic,xx,Phase I (n=xx) ; ,?Intestinal, Histological type,9,1,3,no
1377,2360766,Table 1,BaselineCharacteristic,xx,Phase II (n=xx) ; ,?Intestinal, Histological type,9,2,3,no
1377,2360766,Table 1,BaselineCharacteristic,?Diffuse, ; ,?Diffuse, Histological type,10,0,2,no
1377,2360766,Table 1,BaselineCharacteristic,x,Phase I (n=xx) ; ,?Diffuse, Histological type,10,1,3,no
1377,2360766,Table 1,BaselineCharacteristic,x,Phase II (n=xx) ; ,?Diffuse, Histological type,10,2,3,no
1377,2360766,Table 1,BaselineCharacteristic,, ; ,None,None,11,0,2,no
1377,2360766,Table 1,BaselineCharacteristic,,Phase I (n=xx) ; ,None,None,11,1,3,no
1377,2360766,Table 1,BaselineCharacteristic,,Phase II (n=xx) ; ,None,None,11,2,3,no
1377,2360766,Table 1,BaselineCharacteristic,Prior therapy, ; ,None,None,12,0,24,no
1377,2360766,Table 1,BaselineCharacteristic,Prior therapy,Phase I (n=xx) ; ,Prior therapy,None,12,1,43,no
1377,2360766,Table 1,BaselineCharacteristic,Prior therapy,Phase II (n=xx) ; ,Prior therapy,None,12,2,43,no
1377,2360766,Table 1,BaselineCharacteristic,?None, ; ,?None, Prior therapy,13,0,2,no
1377,2360766,Table 1,BaselineCharacteristic,xx,Phase I (n=xx) ; ,?None, Prior therapy,13,1,3,no
1377,2360766,Table 1,BaselineCharacteristic,xx,Phase II (n=xx) ; ,?None, Prior therapy,13,2,3,no
1377,2360766,Table 1,BaselineCharacteristic,?Gastrectomy, ; ,?Gastrectomy, Prior therapy,14,0,2,no
1377,2360766,Table 1,BaselineCharacteristic,x,Phase I (n=xx) ; ,?Gastrectomy, Prior therapy,14,1,3,no
1377,2360766,Table 1,BaselineCharacteristic,x,Phase II (n=xx) ; ,?Gastrectomy, Prior therapy,14,2,3,no
1377,2360766,Table 1,BaselineCharacteristic,?Gastrectomy+chemotherapy, ; ,?Gastrectomy+chemotherapy, Prior therapy,15,0,2,no
1377,2360766,Table 1,BaselineCharacteristic,x,Phase I (n=xx) ; ,?Gastrectomy+chemotherapy, Prior therapy,15,1,3,no
1377,2360766,Table 1,BaselineCharacteristic,x,Phase II (n=xx) ; ,?Gastrectomy+chemotherapy, Prior therapy,15,2,3,no
1377,2360766,Table 1,BaselineCharacteristic,, ; ,None,None,16,0,2,no
1377,2360766,Table 1,BaselineCharacteristic,,Phase I (n=xx) ; ,None,None,16,1,3,no
1377,2360766,Table 1,BaselineCharacteristic,,Phase II (n=xx) ; ,None,None,16,2,3,no
1377,2360766,Table 1,BaselineCharacteristic,Site of metastasis, ; ,None,None,17,0,24,no
1377,2360766,Table 1,BaselineCharacteristic,Site of metastasis,Phase I (n=xx) ; ,Site of metastasis,None,17,1,43,no
1377,2360766,Table 1,BaselineCharacteristic,Site of metastasis,Phase II (n=xx) ; ,Site of metastasis,None,17,2,43,no
1377,2360766,Table 1,BaselineCharacteristic,?Liver, ; ,?Liver, Site of metastasis,18,0,2,no
1377,2360766,Table 1,BaselineCharacteristic,x,Phase I (n=xx) ; ,?Liver, Site of metastasis,18,1,3,no
1377,2360766,Table 1,BaselineCharacteristic,x,Phase II (n=xx) ; ,?Liver, Site of metastasis,18,2,3,no
1377,2360766,Table 1,BaselineCharacteristic,?Lymph nodes, ; ,?Lymph nodes, Site of metastasis,19,0,2,no
1377,2360766,Table 1,BaselineCharacteristic,xx,Phase I (n=xx) ; ,?Lymph nodes, Site of metastasis,19,1,3,no
1377,2360766,Table 1,BaselineCharacteristic,xx,Phase II (n=xx) ; ,?Lymph nodes, Site of metastasis,19,2,3,no
1377,2360766,Table 1,BaselineCharacteristic,?Peritoneum, ; ,?Peritoneum, Site of metastasis,20,0,2,no
1377,2360766,Table 1,BaselineCharacteristic,x,Phase I (n=xx) ; ,?Peritoneum, Site of metastasis,20,1,3,no
1377,2360766,Table 1,BaselineCharacteristic,x,Phase II (n=xx) ; ,?Peritoneum, Site of metastasis,20,2,3,no
1386,2361170,Table 2,BaselineCharacteristic,Characteristics,,None,None,0,0,12,no
1386,2361170,Table 2,BaselineCharacteristic,n,,Characteristics,None,0,1,1,no
1386,2361170,Table 2,BaselineCharacteristic,Men/women,Characteristics ; ,Men/women,,1,0,2,no
1386,2361170,Table 2,BaselineCharacteristic,xx/xx,n ; ,Men/women,,1,1,3,yes
1386,2361170,Table 2,BaselineCharacteristic,PS x/x/x,Characteristics ; ,PS x/x/x,,2,0,2,no
1386,2361170,Table 2,BaselineCharacteristic,xx/xx/x,n ; ,PS x/x/x,,2,1,3,no
1386,2361170,Table 2,BaselineCharacteristic,LAD/MET,Characteristics ; ,LAD/MET,,3,0,2,no
1386,2361170,Table 2,BaselineCharacteristic,xx/xx,n ; ,LAD/MET,,3,1,3,no
1386,2361170,Table 2,BaselineCharacteristic,Adjuvant RT-CT,Characteristics ; ,Adjuvant RT-CT,,4,0,2,no
1386,2361170,Table 2,BaselineCharacteristic,x,n ; ,Adjuvant RT-CT,,4,1,3,no
1386,2361170,Table 2,BaselineCharacteristic,,Characteristics ; ,None,None,5,0,2,no
1386,2361170,Table 2,BaselineCharacteristic,,n ; ,None,None,5,1,3,no
1386,2361170,Table 2,BaselineCharacteristic,Prior therapy,Characteristics ; ,None,None,6,0,24,no
1386,2361170,Table 2,BaselineCharacteristic,Prior therapy,n ; ,Prior therapy,None,6,1,43,no
1386,2361170,Table 2,BaselineCharacteristic,?RT-CT,Characteristics ; ,?RT-CT, Prior therapy,7,0,2,no
1386,2361170,Table 2,BaselineCharacteristic,x,n ; ,?RT-CT, Prior therapy,7,1,3,no
1386,2361170,Table 2,BaselineCharacteristic,?GEM,Characteristics ; ,?GEM, Prior therapy,8,0,2,no
1386,2361170,Table 2,BaselineCharacteristic,xx,n ; ,?GEM, Prior therapy,8,1,3,no
1386,2361170,Table 2,BaselineCharacteristic,?GEM-PX,Characteristics ; ,?GEM-PX, Prior therapy,9,0,2,no
1386,2361170,Table 2,BaselineCharacteristic,x,n ; ,?GEM-PX, Prior therapy,9,1,3,no
1386,2361170,Table 2,BaselineCharacteristic,?GEM-CDDP,Characteristics ; ,?GEM-CDDP, Prior therapy,10,0,2,no
1386,2361170,Table 2,BaselineCharacteristic,x,n ; ,?GEM-CDDP, Prior therapy,10,1,3,no
1386,2361170,Table 2,BaselineCharacteristic,?Ralitrexed-GEM,Characteristics ; ,?Ralitrexed-GEM, Prior therapy,11,0,2,no
1386,2361170,Table 2,BaselineCharacteristic,x,n ; ,?Ralitrexed-GEM, Prior therapy,11,1,3,no
1388,2361202,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no
1388,2361202,Table 1,BaselineCharacteristic,Patients,,,None,0,1,1,no
1388,2361202,Table 1,BaselineCharacteristic,Patients,,,None,0,2,1,no
1388,2361202,Table 1,BaselineCharacteristic,Characteristic, ; ,None,None,1,0,12,no
1388,2361202,Table 1,BaselineCharacteristic,No.,Patients ; ,Characteristic,None,1,1,1,no
1388,2361202,Table 1,BaselineCharacteristic,%,Patients ; ,Characteristic,None,1,2,1,no
1388,2361202,Table 1,BaselineCharacteristic,Total, ; Characteristic ; ,Total,,2,0,2,no
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; No. ; ,Total,,2,1,3,no
1388,2361202,Table 1,BaselineCharacteristic,xxx,Patients ; % ; ,Total,,2,2,3,no
1388,2361202,Table 1,BaselineCharacteristic,Male, ; Characteristic ; ,Male,,3,0,2,no
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; No. ; ,Male,,3,1,3,yes
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; % ; ,Male,,3,2,3,yes
1388,2361202,Table 1,BaselineCharacteristic,Female, ; Characteristic ; ,Female,,4,0,2,no
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; No. ; ,Female,,4,1,3,yes
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; % ; ,Female,,4,2,3,yes
1388,2361202,Table 1,BaselineCharacteristic,, ; Characteristic ; ,None,None,5,0,2,no
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; No. ; ,None,None,5,1,3,no
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; % ; ,None,None,5,2,3,no
1388,2361202,Table 1,BaselineCharacteristic,Age (years), ; Characteristic ; ,None,None,6,0,24,no
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; No. ; ,Age (years),None,6,1,43,no
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; % ; ,Age (years),None,6,2,43,no
1388,2361202,Table 1,BaselineCharacteristic,?Median, ; Characteristic ; ,?Median, Age (years),7,0,2,no
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; No. ; ,?Median, Age (years),7,1,3,no
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; % ; ,?Median, Age (years),7,2,3,no
1388,2361202,Table 1,BaselineCharacteristic,?Range, ; Characteristic ; ,?Range, Age (years),8,0,2,no
1388,2361202,Table 1,BaselineCharacteristic,, ; Characteristic ; ,None,None,9,0,2,no
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; No. ; ,None,None,9,1,3,no
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; % ; ,None,None,9,2,3,no
1388,2361202,Table 1,BaselineCharacteristic,Disease at time of commencing IRESSA, ; Characteristic ; ,None,None,10,0,24,no
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; No. ; ,Disease at time of commencing IRESSA,None,10,1,43,no
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; % ; ,Disease at time of commencing IRESSA,None,10,2,43,no
1388,2361202,Table 1,BaselineCharacteristic,?Locally recurrent, ; Characteristic ; ,?Locally recurrent, Disease at time of commencing IRESSA,11,0,2,no
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; No. ; ,?Locally recurrent, Disease at time of commencing IRESSA,11,1,3,no
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; % ; ,?Locally recurrent, Disease at time of commencing IRESSA,11,2,3,no
1388,2361202,Table 1,BaselineCharacteristic,?Metastatica, ; Characteristic ; ,?Metastatica, Disease at time of commencing IRESSA,12,0,2,no
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; No. ; ,?Metastatica, Disease at time of commencing IRESSA,12,1,3,no
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; % ; ,?Metastatica, Disease at time of commencing IRESSA,12,2,3,no
1388,2361202,Table 1,BaselineCharacteristic,, ; Characteristic ; ,None,None,13,0,2,no
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; No. ; ,None,None,13,1,3,no
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; % ; ,None,None,13,2,3,no
1388,2361202,Table 1,BaselineCharacteristic,Histology, ; Characteristic ; ,None,None,14,0,24,no
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; No. ; ,Histology,None,14,1,43,no
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; % ; ,Histology,None,14,2,43,no
1388,2361202,Table 1,BaselineCharacteristic,?Squamous cell carcinoma, ; Characteristic ; ,?Squamous cell carcinoma, Histology,15,0,2,no
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; No. ; ,?Squamous cell carcinoma, Histology,15,1,3,no
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; % ; ,?Squamous cell carcinoma, Histology,15,2,3,no
1388,2361202,Table 1,BaselineCharacteristic,?UCNTb, ; Characteristic ; ,?UCNTb, Histology,16,0,2,no
1388,2361202,Table 1,BaselineCharacteristic,x,Patients ; No. ; ,?UCNTb, Histology,16,1,3,no
1388,2361202,Table 1,BaselineCharacteristic,x,Patients ; % ; ,?UCNTb, Histology,16,2,3,no
1388,2361202,Table 1,BaselineCharacteristic,?Carcinosarcoma, ; Characteristic ; ,?Carcinosarcoma, Histology,17,0,2,no
1388,2361202,Table 1,BaselineCharacteristic,x,Patients ; No. ; ,?Carcinosarcoma, Histology,17,1,3,no
1388,2361202,Table 1,BaselineCharacteristic,x,Patients ; % ; ,?Carcinosarcoma, Histology,17,2,3,no
1388,2361202,Table 1,BaselineCharacteristic,, ; Characteristic ; ,None,None,18,0,2,no
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; No. ; ,None,None,18,1,3,no
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; % ; ,None,None,18,2,3,no
1388,2361202,Table 1,BaselineCharacteristic,ECOG performance status, ; Characteristic ; ,None,None,19,0,24,no
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; No. ; ,ECOG performance status,None,19,1,43,no
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; % ; ,ECOG performance status,None,19,2,43,no
1388,2361202,Table 1,BaselineCharacteristic,?x, ; Characteristic ; ,?x, ECOG performance status,20,0,2,no
1388,2361202,Table 1,BaselineCharacteristic,x,Patients ; No. ; ,?x, ECOG performance status,20,1,3,no
1388,2361202,Table 1,BaselineCharacteristic,x,Patients ; % ; ,?x, ECOG performance status,20,2,3,no
1388,2361202,Table 1,BaselineCharacteristic,?x, ; Characteristic ; ,?x, ECOG performance status,21,0,2,no
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; No. ; ,?x, ECOG performance status,21,1,3,no
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; % ; ,?x, ECOG performance status,21,2,3,no
1388,2361202,Table 1,BaselineCharacteristic,?x, ; Characteristic ; ,?x, ECOG performance status,22,0,2,no
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; No. ; ,?x, ECOG performance status,22,1,3,no
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; % ; ,?x, ECOG performance status,22,2,3,no
1388,2361202,Table 1,BaselineCharacteristic,?x, ; Characteristic ; ,?x, ECOG performance status,23,0,2,no
1388,2361202,Table 1,BaselineCharacteristic,x,Patients ; No. ; ,?x, ECOG performance status,23,1,3,no
1388,2361202,Table 1,BaselineCharacteristic,x,Patients ; % ; ,?x, ECOG performance status,23,2,3,no
1388,2361202,Table 1,BaselineCharacteristic,, ; Characteristic ; ,None,None,24,0,2,no
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; No. ; ,None,None,24,1,3,no
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; % ; ,None,None,24,2,3,no
1388,2361202,Table 1,BaselineCharacteristic,Prior therapy (n=xx), ; Characteristic ; ,None,None,25,0,24,no
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; No. ; ,Prior therapy (n=xx),None,25,1,43,no
1388,2361202,Table 1,BaselineCharacteristic,,Patients ; % ; ,Prior therapy (n=xx),None,25,2,43,no
1388,2361202,Table 1,BaselineCharacteristic,?Surgery, ; Characteristic ; ,?Surgery, Prior therapy (n=xx),26,0,2,no
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; No. ; ,?Surgery, Prior therapy (n=xx),26,1,3,no
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; % ; ,?Surgery, Prior therapy (n=xx),26,2,3,no
1388,2361202,Table 1,BaselineCharacteristic,?Radiotherapy, ; Characteristic ; ,?Radiotherapy, Prior therapy (n=xx),27,0,24,no
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; No. ; ,?Radiotherapy, Prior therapy (n=xx),27,1,43,no
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; % ; ,?Radiotherapy, Prior therapy (n=xx),27,2,43,no
1388,2361202,Table 1,BaselineCharacteristic,??With chemotherapy, ; Characteristic ; ,??With chemotherapy, Prior therapy (n=xx) ?Radiotherapy,28,0,2,no
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; No. ; ,??With chemotherapy, Prior therapy (n=xx) ?Radiotherapy,28,1,3,no
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; % ; ,??With chemotherapy, Prior therapy (n=xx) ?Radiotherapy,28,2,3,no
1388,2361202,Table 1,BaselineCharacteristic,??Alone (radical or palliative), ; Characteristic ; ,??Alone (radical or palliative), Prior therapy (n=xx) ?Radiotherapy,29,0,2,no
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; No. ; ,??Alone (radical or palliative), Prior therapy (n=xx) ?Radiotherapy,29,1,3,no
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; % ; ,??Alone (radical or palliative), Prior therapy (n=xx) ?Radiotherapy,29,2,3,no
1388,2361202,Table 1,BaselineCharacteristic,?Chemotherapy, ; Characteristic ; ,?Chemotherapy, Prior therapy (n=xx),30,0,24,no
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; No. ; ,?Chemotherapy, Prior therapy (n=xx),30,1,43,no
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; % ; ,?Chemotherapy, Prior therapy (n=xx),30,2,43,no
1388,2361202,Table 1,BaselineCharacteristic,??Radical chemoradiation only, ; Characteristic ; ,??Radical chemoradiation only, Prior therapy (n=xx) ?Chemotherapy,31,0,2,no
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; No. ; ,??Radical chemoradiation only, Prior therapy (n=xx) ?Chemotherapy,31,1,3,no
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; % ; ,??Radical chemoradiation only, Prior therapy (n=xx) ?Chemotherapy,31,2,3,no
1388,2361202,Table 1,BaselineCharacteristic,??Radical chemoradiation and then for recurrence or metastases, ; Characteristic ; ,??Radical chemoradiation and then for recurrence or metastases, Prior therapy (n=xx) ?Chemotherapy,32,0,2,no
1388,2361202,Table 1,BaselineCharacteristic,x,Patients ; No. ; ,??Radical chemoradiation and then for recurrence or metastases, Prior therapy (n=xx) ?Chemotherapy,32,1,3,no
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; % ; ,??Radical chemoradiation and then for recurrence or metastases, Prior therapy (n=xx) ?Chemotherapy,32,2,3,no
1388,2361202,Table 1,BaselineCharacteristic,??Only for recurrent disease or metastases, ; Characteristic ; ,??Only for recurrent disease or metastases, Prior therapy (n=xx) ?Chemotherapy,33,0,2,no
1388,2361202,Table 1,BaselineCharacteristic,x,Patients ; No. ; ,??Only for recurrent disease or metastases, Prior therapy (n=xx) ?Chemotherapy,33,1,3,no
1388,2361202,Table 1,BaselineCharacteristic,xx,Patients ; % ; ,??Only for recurrent disease or metastases, Prior therapy (n=xx) ?Chemotherapy,33,2,3,no
1424,2361402,Table 2,BaselineCharacteristic,,,None,None,0,0,12,no
1424,2361402,Table 2,BaselineCharacteristic,Phase I,,,None,0,1,1,no
1424,2361402,Table 2,BaselineCharacteristic,Phase II,,,None,0,2,1,no
1424,2361402,Table 2,BaselineCharacteristic,Total,,,None,0,3,1,no
1424,2361402,Table 2,BaselineCharacteristic,No. patients entered, ; ,No. patients entered,,1,0,2,no
1424,2361402,Table 2,BaselineCharacteristic,xx,Phase I ; ,No. patients entered,,1,1,3,no
1424,2361402,Table 2,BaselineCharacteristic,xx,Phase II ; ,No. patients entered,,1,2,3,no
1424,2361402,Table 2,BaselineCharacteristic,xx,Total ; ,No. patients entered,,1,3,3,no
1424,2361402,Table 2,BaselineCharacteristic,Median age (years) (range), ; ,Median age (years) (range),,2,0,2,no
1424,2361402,Table 2,BaselineCharacteristic,, ; ,None,None,3,0,2,no
1424,2361402,Table 2,BaselineCharacteristic,,Phase I ; ,None,None,3,1,3,no
1424,2361402,Table 2,BaselineCharacteristic,,Phase II ; ,None,None,3,2,3,no
1424,2361402,Table 2,BaselineCharacteristic,,Total ; ,None,None,3,3,3,no
1424,2361402,Table 2,BaselineCharacteristic,Gender, ; ,None,None,4,0,24,no
1424,2361402,Table 2,BaselineCharacteristic,Gender,Phase I ; ,Gender,None,4,1,43,no
1424,2361402,Table 2,BaselineCharacteristic,Gender,Phase II ; ,Gender,None,4,2,43,no
1424,2361402,Table 2,BaselineCharacteristic,Gender,Total ; ,Gender,None,4,3,43,no
1424,2361402,Table 2,BaselineCharacteristic,?Male, ; ,?Male, Gender,5,0,2,no
1424,2361402,Table 2,BaselineCharacteristic,xx,Phase I ; ,?Male, Gender,5,1,3,yes
1424,2361402,Table 2,BaselineCharacteristic,xx,Phase II ; ,?Male, Gender,5,2,3,yes
1424,2361402,Table 2,BaselineCharacteristic,xx,Total ; ,?Male, Gender,5,3,3,yes
1424,2361402,Table 2,BaselineCharacteristic,?Female, ; ,?Female, Gender,6,0,2,no
1424,2361402,Table 2,BaselineCharacteristic,x,Phase I ; ,?Female, Gender,6,1,3,yes
1424,2361402,Table 2,BaselineCharacteristic,x,Phase II ; ,?Female, Gender,6,2,3,yes
1424,2361402,Table 2,BaselineCharacteristic,x,Total ; ,?Female, Gender,6,3,3,yes
1424,2361402,Table 2,BaselineCharacteristic,, ; ,None,None,7,0,2,no
1424,2361402,Table 2,BaselineCharacteristic,,Phase I ; ,None,None,7,1,3,no
1424,2361402,Table 2,BaselineCharacteristic,,Phase II ; ,None,None,7,2,3,no
1424,2361402,Table 2,BaselineCharacteristic,,Total ; ,None,None,7,3,3,no
1424,2361402,Table 2,BaselineCharacteristic,ECOG PS, ; ,None,None,8,0,24,no
1424,2361402,Table 2,BaselineCharacteristic,ECOG PS,Phase I ; ,ECOG PS,None,8,1,43,no
1424,2361402,Table 2,BaselineCharacteristic,ECOG PS,Phase II ; ,ECOG PS,None,8,2,43,no
1424,2361402,Table 2,BaselineCharacteristic,ECOG PS,Total ; ,ECOG PS,None,8,3,43,no
1424,2361402,Table 2,BaselineCharacteristic,?x, ; ,?x, ECOG PS,9,0,2,no
1424,2361402,Table 2,BaselineCharacteristic,x,Phase I ; ,?x, ECOG PS,9,1,3,no
1424,2361402,Table 2,BaselineCharacteristic,xx,Phase II ; ,?x, ECOG PS,9,2,3,no
1424,2361402,Table 2,BaselineCharacteristic,xx,Total ; ,?x, ECOG PS,9,3,3,no
1424,2361402,Table 2,BaselineCharacteristic,?x, ; ,?x, ECOG PS,10,0,2,no
1424,2361402,Table 2,BaselineCharacteristic,x,Phase I ; ,?x, ECOG PS,10,1,3,no
1424,2361402,Table 2,BaselineCharacteristic,x,Phase II ; ,?x, ECOG PS,10,2,3,no
1424,2361402,Table 2,BaselineCharacteristic,x,Total ; ,?x, ECOG PS,10,3,3,no
1424,2361402,Table 2,BaselineCharacteristic,?x, ; ,?x, ECOG PS,11,0,2,no
1424,2361402,Table 2,BaselineCharacteristic,x,Phase I ; ,?x, ECOG PS,11,1,3,no
1424,2361402,Table 2,BaselineCharacteristic,x,Phase II ; ,?x, ECOG PS,11,2,3,no
1424,2361402,Table 2,BaselineCharacteristic,x,Total ; ,?x, ECOG PS,11,3,3,no
1424,2361402,Table 2,BaselineCharacteristic,Baseline LVEF (median), ; ,Baseline LVEF (median),,12,0,2,no
1424,2361402,Table 2,BaselineCharacteristic,,Total ; ,Baseline LVEF (median),,12,3,3,no
1424,2361402,Table 2,BaselineCharacteristic,, ; ,None,None,13,0,2,no
1424,2361402,Table 2,BaselineCharacteristic,,Phase I ; ,None,None,13,1,3,no
1424,2361402,Table 2,BaselineCharacteristic,,Phase II ; ,None,None,13,2,3,no
1424,2361402,Table 2,BaselineCharacteristic,,Total ; ,None,None,13,3,3,no
1424,2361402,Table 2,BaselineCharacteristic,Dominant site of disease, ; ,None,None,14,0,24,no
1424,2361402,Table 2,BaselineCharacteristic,Dominant site of disease,Phase I ; ,Dominant site of disease,None,14,1,43,no
1424,2361402,Table 2,BaselineCharacteristic,Dominant site of disease,Phase II ; ,Dominant site of disease,None,14,2,43,no
1424,2361402,Table 2,BaselineCharacteristic,Dominant site of disease,Total ; ,Dominant site of disease,None,14,3,43,no
1424,2361402,Table 2,BaselineCharacteristic,?Viscera, ; ,?Viscera, Dominant site of disease,15,0,2,no
1424,2361402,Table 2,BaselineCharacteristic,xx,Phase I ; ,?Viscera, Dominant site of disease,15,1,3,no
1424,2361402,Table 2,BaselineCharacteristic,x,Phase II ; ,?Viscera, Dominant site of disease,15,2,3,no
1424,2361402,Table 2,BaselineCharacteristic,xx,Total ; ,?Viscera, Dominant site of disease,15,3,3,no
1424,2361402,Table 2,BaselineCharacteristic,?Soft tissue/bone, ; ,?Soft tissue/bone, Dominant site of disease,16,0,2,no
1424,2361402,Table 2,BaselineCharacteristic,x,Phase I ; ,?Soft tissue/bone, Dominant site of disease,16,1,3,no
1424,2361402,Table 2,BaselineCharacteristic,xx,Phase II ; ,?Soft tissue/bone, Dominant site of disease,16,2,3,no
1424,2361402,Table 2,BaselineCharacteristic,xx,Total ; ,?Soft tissue/bone, Dominant site of disease,16,3,3,no
1424,2361402,Table 2,BaselineCharacteristic,, ; ,None,None,17,0,2,no
1424,2361402,Table 2,BaselineCharacteristic,,Phase I ; ,None,None,17,1,3,no
1424,2361402,Table 2,BaselineCharacteristic,,Phase II ; ,None,None,17,2,3,no
1424,2361402,Table 2,BaselineCharacteristic,,Total ; ,None,None,17,3,3,no
1424,2361402,Table 2,BaselineCharacteristic,Number of metastatic sites, ; ,None,None,18,0,24,no
1424,2361402,Table 2,BaselineCharacteristic,Number of metastatic sites,Phase I ; ,Number of metastatic sites,None,18,1,43,no
1424,2361402,Table 2,BaselineCharacteristic,Number of metastatic sites,Phase II ; ,Number of metastatic sites,None,18,2,43,no
1424,2361402,Table 2,BaselineCharacteristic,Number of metastatic sites,Total ; ,Number of metastatic sites,None,18,3,43,no
1424,2361402,Table 2,BaselineCharacteristic,?x, ; ,?x, Number of metastatic sites,19,0,2,no
1424,2361402,Table 2,BaselineCharacteristic,x,Phase I ; ,?x, Number of metastatic sites,19,1,3,no
1424,2361402,Table 2,BaselineCharacteristic,x,Phase II ; ,?x, Number of metastatic sites,19,2,3,no
1424,2361402,Table 2,BaselineCharacteristic,x,Total ; ,?x, Number of metastatic sites,19,3,3,no
1424,2361402,Table 2,BaselineCharacteristic,??x, ; ,??x, Number of metastatic sites,20,0,2,no
1424,2361402,Table 2,BaselineCharacteristic,x,Phase I ; ,??x, Number of metastatic sites,20,1,3,no
1424,2361402,Table 2,BaselineCharacteristic,xx,Phase II ; ,??x, Number of metastatic sites,20,2,3,no
1424,2361402,Table 2,BaselineCharacteristic,xx,Total ; ,??x, Number of metastatic sites,20,3,3,no
1433,2361449,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,0,12,no
1433,2361449,Table 1,BaselineCharacteristic,No.,,Characteristic,None,0,1,1,no
1433,2361449,Table 1,BaselineCharacteristic,%,,Characteristic,None,0,2,1,no
1433,2361449,Table 1,BaselineCharacteristic,Age (years),Characteristic ; ,None,None,1,0,24,no
1433,2361449,Table 1,BaselineCharacteristic,Age (years),No. ; ,Age (years),None,1,1,43,no
1433,2361449,Table 1,BaselineCharacteristic,Age (years),% ; ,Age (years),None,1,2,43,no
1433,2361449,Table 1,BaselineCharacteristic,?Median,Characteristic ; ,?Median, Age (years),2,0,2,no
1433,2361449,Table 1,BaselineCharacteristic,xx,No. ; ,?Median, Age (years),2,1,3,no
1433,2361449,Table 1,BaselineCharacteristic,,% ; ,?Median, Age (years),2,2,3,no
1433,2361449,Table 1,BaselineCharacteristic,?Range,Characteristic ; ,?Range, Age (years),3,0,2,no
1433,2361449,Table 1,BaselineCharacteristic,,% ; ,?Range, Age (years),3,2,3,no
1433,2361449,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,4,0,2,no
1433,2361449,Table 1,BaselineCharacteristic,,No. ; ,None,None,4,1,3,no
1433,2361449,Table 1,BaselineCharacteristic,,% ; ,None,None,4,2,3,no
1433,2361449,Table 1,BaselineCharacteristic,Sex,Characteristic ; ,None,None,5,0,24,no
1433,2361449,Table 1,BaselineCharacteristic,Sex,No. ; ,Sex,None,5,1,43,no
1433,2361449,Table 1,BaselineCharacteristic,Sex,% ; ,Sex,None,5,2,43,no
1433,2361449,Table 1,BaselineCharacteristic,?Male,Characteristic ; ,?Male, Sex,6,0,2,no
1433,2361449,Table 1,BaselineCharacteristic,xx,No. ; ,?Male, Sex,6,1,3,yes
1433,2361449,Table 1,BaselineCharacteristic,xx.x,% ; ,?Male, Sex,6,2,3,yes
1433,2361449,Table 1,BaselineCharacteristic,?Female,Characteristic ; ,?Female, Sex,7,0,2,no
1433,2361449,Table 1,BaselineCharacteristic,xx,No. ; ,?Female, Sex,7,1,3,yes
1433,2361449,Table 1,BaselineCharacteristic,xx.x,% ; ,?Female, Sex,7,2,3,yes
1433,2361449,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,8,0,2,no
1433,2361449,Table 1,BaselineCharacteristic,,No. ; ,None,None,8,1,3,no
1433,2361449,Table 1,BaselineCharacteristic,,% ; ,None,None,8,2,3,no
1433,2361449,Table 1,BaselineCharacteristic,ECOG performance status,Characteristic ; ,None,None,9,0,24,no
1433,2361449,Table 1,BaselineCharacteristic,ECOG performance status,No. ; ,ECOG performance status,None,9,1,43,no
1433,2361449,Table 1,BaselineCharacteristic,ECOG performance status,% ; ,ECOG performance status,None,9,2,43,no
1433,2361449,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, ECOG performance status,10,0,2,no
1433,2361449,Table 1,BaselineCharacteristic,x,No. ; ,?x, ECOG performance status,10,1,3,no
1433,2361449,Table 1,BaselineCharacteristic,xx.x,% ; ,?x, ECOG performance status,10,2,3,no
1433,2361449,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, ECOG performance status,11,0,2,no
1433,2361449,Table 1,BaselineCharacteristic,xx,No. ; ,?x, ECOG performance status,11,1,3,no
1433,2361449,Table 1,BaselineCharacteristic,xx.x,% ; ,?x, ECOG performance status,11,2,3,no
1433,2361449,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, ECOG performance status,12,0,2,no
1433,2361449,Table 1,BaselineCharacteristic,x,No. ; ,?x, ECOG performance status,12,1,3,no
1433,2361449,Table 1,BaselineCharacteristic,x.x,% ; ,?x, ECOG performance status,12,2,3,no
1433,2361449,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,13,0,2,no
1433,2361449,Table 1,BaselineCharacteristic,,No. ; ,None,None,13,1,3,no
1433,2361449,Table 1,BaselineCharacteristic,,% ; ,None,None,13,2,3,no
1433,2361449,Table 1,BaselineCharacteristic,Extent of disease,Characteristic ; ,None,None,14,0,24,no
1433,2361449,Table 1,BaselineCharacteristic,Extent of disease,No. ; ,Extent of disease,None,14,1,43,no
1433,2361449,Table 1,BaselineCharacteristic,Extent of disease,% ; ,Extent of disease,None,14,2,43,no
1433,2361449,Table 1,BaselineCharacteristic,?Relapsed,Characteristic ; ,?Relapsed, Extent of disease,15,0,2,no
1433,2361449,Table 1,BaselineCharacteristic,xx,No. ; ,?Relapsed, Extent of disease,15,1,3,no
1433,2361449,Table 1,BaselineCharacteristic,xx.x,% ; ,?Relapsed, Extent of disease,15,2,3,no
1433,2361449,Table 1,BaselineCharacteristic,?Initially metastatic,Characteristic ; ,?Initially metastatic, Extent of disease,16,0,2,no
1433,2361449,Table 1,BaselineCharacteristic,xx,No. ; ,?Initially metastatic, Extent of disease,16,1,3,no
1433,2361449,Table 1,BaselineCharacteristic,xx.x,% ; ,?Initially metastatic, Extent of disease,16,2,3,no
1433,2361449,Table 1,BaselineCharacteristic,?Initially locally advanced,Characteristic ; ,?Initially locally advanced, Extent of disease,17,0,2,no
1433,2361449,Table 1,BaselineCharacteristic,x,No. ; ,?Initially locally advanced, Extent of disease,17,1,3,no
1433,2361449,Table 1,BaselineCharacteristic,x.x,% ; ,?Initially locally advanced, Extent of disease,17,2,3,no
1433,2361449,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,18,0,2,no
1433,2361449,Table 1,BaselineCharacteristic,,No. ; ,None,None,18,1,3,no
1433,2361449,Table 1,BaselineCharacteristic,,% ; ,None,None,18,2,3,no
1433,2361449,Table 1,BaselineCharacteristic,Prior adjuvant chemotherapy,Characteristic ; ,None,None,19,0,24,no
1433,2361449,Table 1,BaselineCharacteristic,Prior adjuvant chemotherapy,No. ; ,Prior adjuvant chemotherapy,None,19,1,43,no
1433,2361449,Table 1,BaselineCharacteristic,Prior adjuvant chemotherapy,% ; ,Prior adjuvant chemotherapy,None,19,2,43,no
1433,2361449,Table 1,BaselineCharacteristic,?Yes,Characteristic ; ,?Yes, Prior adjuvant chemotherapy,20,0,24,no
1433,2361449,Table 1,BaselineCharacteristic,x,No. ; ,?Yes, Prior adjuvant chemotherapy,20,1,43,no
1433,2361449,Table 1,BaselineCharacteristic,xx,% ; ,?Yes, Prior adjuvant chemotherapy,20,2,43,no
1433,2361449,Table 1,BaselineCharacteristic,??x-FU+doxorubicin+mitomycin-C,Characteristic ; ,??x-FU+doxorubicin+mitomycin-C, Prior adjuvant chemotherapy ?Yes,21,0,2,no
1433,2361449,Table 1,BaselineCharacteristic,?x,No. ; ,??x-FU+doxorubicin+mitomycin-C, Prior adjuvant chemotherapy ?Yes,21,1,3,no
1433,2361449,Table 1,BaselineCharacteristic,,% ; ,??x-FU+doxorubicin+mitomycin-C, Prior adjuvant chemotherapy ?Yes,21,2,3,no
1433,2361449,Table 1,BaselineCharacteristic,??x-FU or doxifluridine+cisplatin,Characteristic ; ,??x-FU or doxifluridine+cisplatin, Prior adjuvant chemotherapy ?Yes,22,0,2,no
1433,2361449,Table 1,BaselineCharacteristic,?x,No. ; ,??x-FU or doxifluridine+cisplatin, Prior adjuvant chemotherapy ?Yes,22,1,3,no
1433,2361449,Table 1,BaselineCharacteristic,,% ; ,??x-FU or doxifluridine+cisplatin, Prior adjuvant chemotherapy ?Yes,22,2,3,no
1433,2361449,Table 1,BaselineCharacteristic,??Doxifluridine+mitomycin-C,Characteristic ; ,??Doxifluridine+mitomycin-C, Prior adjuvant chemotherapy ?Yes,23,0,2,no
1433,2361449,Table 1,BaselineCharacteristic,?x,No. ; ,??Doxifluridine+mitomycin-C, Prior adjuvant chemotherapy ?Yes,23,1,3,no
1433,2361449,Table 1,BaselineCharacteristic,,% ; ,??Doxifluridine+mitomycin-C, Prior adjuvant chemotherapy ?Yes,23,2,3,no
1433,2361449,Table 1,BaselineCharacteristic,?No,Characteristic ; ,?No, Prior adjuvant chemotherapy,24,0,2,no
1433,2361449,Table 1,BaselineCharacteristic,xx,No. ; ,?No, Prior adjuvant chemotherapy,24,1,3,no
1433,2361449,Table 1,BaselineCharacteristic,xx,% ; ,?No, Prior adjuvant chemotherapy,24,2,3,no
1433,2361449,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,25,0,2,no
1433,2361449,Table 1,BaselineCharacteristic,,No. ; ,None,None,25,1,3,no
1433,2361449,Table 1,BaselineCharacteristic,,% ; ,None,None,25,2,3,no
1433,2361449,Table 1,BaselineCharacteristic,Metastatic sites,Characteristic ; ,None,None,26,0,24,no
1433,2361449,Table 1,BaselineCharacteristic,Metastatic sites,No. ; ,Metastatic sites,None,26,1,43,no
1433,2361449,Table 1,BaselineCharacteristic,Metastatic sites,% ; ,Metastatic sites,None,26,2,43,no
1433,2361449,Table 1,BaselineCharacteristic,?Abdominal lymph node,Characteristic ; ,?Abdominal lymph node, Metastatic sites,27,0,2,no
1433,2361449,Table 1,BaselineCharacteristic,xx,No. ; ,?Abdominal lymph node, Metastatic sites,27,1,3,no
1433,2361449,Table 1,BaselineCharacteristic,xx.x,% ; ,?Abdominal lymph node, Metastatic sites,27,2,3,no
1433,2361449,Table 1,BaselineCharacteristic,?Liver,Characteristic ; ,?Liver, Metastatic sites,28,0,2,no
1433,2361449,Table 1,BaselineCharacteristic,xx,No. ; ,?Liver, Metastatic sites,28,1,3,no
1433,2361449,Table 1,BaselineCharacteristic,xx.x,% ; ,?Liver, Metastatic sites,28,2,3,no
1433,2361449,Table 1,BaselineCharacteristic,?Peritoneum,Characteristic ; ,?Peritoneum, Metastatic sites,29,0,2,no
1433,2361449,Table 1,BaselineCharacteristic,xx,No. ; ,?Peritoneum, Metastatic sites,29,1,3,no
1433,2361449,Table 1,BaselineCharacteristic,xx.x,% ; ,?Peritoneum, Metastatic sites,29,2,3,no
1433,2361449,Table 1,BaselineCharacteristic,?Lung,Characteristic ; ,?Lung, Metastatic sites,30,0,2,no
1433,2361449,Table 1,BaselineCharacteristic,x,No. ; ,?Lung, Metastatic sites,30,1,3,no
1433,2361449,Table 1,BaselineCharacteristic,xx.x,% ; ,?Lung, Metastatic sites,30,2,3,no
1433,2361449,Table 1,BaselineCharacteristic,?Cervical lymph node,Characteristic ; ,?Cervical lymph node, Metastatic sites,31,0,2,no
1433,2361449,Table 1,BaselineCharacteristic,x,No. ; ,?Cervical lymph node, Metastatic sites,31,1,3,no
1433,2361449,Table 1,BaselineCharacteristic,xx.x,% ; ,?Cervical lymph node, Metastatic sites,31,2,3,no
1433,2361449,Table 1,BaselineCharacteristic,?Ovary,Characteristic ; ,?Ovary, Metastatic sites,32,0,2,no
1433,2361449,Table 1,BaselineCharacteristic,x,No. ; ,?Ovary, Metastatic sites,32,1,3,no
1433,2361449,Table 1,BaselineCharacteristic,x.x,% ; ,?Ovary, Metastatic sites,32,2,3,no
1433,2361449,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,33,0,2,no
1433,2361449,Table 1,BaselineCharacteristic,,No. ; ,None,None,33,1,3,no
1433,2361449,Table 1,BaselineCharacteristic,,% ; ,None,None,33,2,3,no
1433,2361449,Table 1,BaselineCharacteristic,No. of metastases,Characteristic ; ,None,None,34,0,24,no
1433,2361449,Table 1,BaselineCharacteristic,No. of metastases,No. ; ,No. of metastases,None,34,1,43,no
1433,2361449,Table 1,BaselineCharacteristic,No. of metastases,% ; ,No. of metastases,None,34,2,43,no
1433,2361449,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, No. of metastases,35,0,2,no
1433,2361449,Table 1,BaselineCharacteristic,xx,No. ; ,?x, No. of metastases,35,1,3,no
1433,2361449,Table 1,BaselineCharacteristic,xx.x,% ; ,?x, No. of metastases,35,2,3,no
1433,2361449,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, No. of metastases,36,0,2,no
1433,2361449,Table 1,BaselineCharacteristic,xx,No. ; ,?x, No. of metastases,36,1,3,no
1433,2361449,Table 1,BaselineCharacteristic,xx.x,% ; ,?x, No. of metastases,36,2,3,no
1433,2361449,Table 1,BaselineCharacteristic,??x,Characteristic ; ,??x, No. of metastases,37,0,2,no
1433,2361449,Table 1,BaselineCharacteristic,xx,No. ; ,??x, No. of metastases,37,1,3,no
1433,2361449,Table 1,BaselineCharacteristic,xx.x,% ; ,??x, No. of metastases,37,2,3,no
1437,2361475,Table 1,BaselineCharacteristic,Characteristics,,None,None,0,0,12,no
1437,2361475,Table 1,BaselineCharacteristic,No. of patients,,Characteristics,None,0,1,1,no
1437,2361475,Table 1,BaselineCharacteristic,"Median age (range), years",Characteristics ; ,"Median age (range), years",,1,0,2,no
1437,2361475,Table 1,BaselineCharacteristic,Male/female (%),Characteristics ; ,Male/female (%),,2,0,2,no
1437,2361475,Table 1,BaselineCharacteristic,xx (xx.x)/xx (xx.x),No. of patients ; ,Male/female (%),,2,1,3,yes
1437,2361475,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,3,0,2,no
1437,2361475,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,3,1,3,no
1437,2361475,Table 1,BaselineCharacteristic,KPS (%),Characteristics ; ,None,None,4,0,24,no
1437,2361475,Table 1,BaselineCharacteristic,,No. of patients ; ,KPS (%),None,4,1,43,no
1437,2361475,Table 1,BaselineCharacteristic,?xxx,Characteristics ; ,?xxx, KPS (%),5,0,2,no
1437,2361475,Table 1,BaselineCharacteristic,xx (xx.x),No. of patients ; ,?xxx, KPS (%),5,1,3,no
1437,2361475,Table 1,BaselineCharacteristic,?xx,Characteristics ; ,?xx, KPS (%),7,0,2,no
1437,2361475,Table 1,BaselineCharacteristic,x (x.x),No. of patients ; ,?xx, KPS (%),7,1,3,no
1437,2361475,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,8,0,2,no
1437,2361475,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,8,1,3,no
1437,2361475,Table 1,BaselineCharacteristic,Stage IIIB/IV (%),Characteristics ; ,Stage IIIB/IV (%),,9,0,2,no
1437,2361475,Table 1,BaselineCharacteristic,x (xx.x)/xx (xx.x),No. of patients ; ,Stage IIIB/IV (%),,9,1,3,no
1437,2361475,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,10,0,2,no
1437,2361475,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,10,1,3,no
1437,2361475,Table 1,BaselineCharacteristic,Sites of metastasis,Characteristics ; ,None,None,11,0,24,no
1437,2361475,Table 1,BaselineCharacteristic,Sites of metastasis,No. of patients ; ,Sites of metastasis,None,11,1,43,no
1437,2361475,Table 1,BaselineCharacteristic,?Liver,Characteristics ; ,?Liver, Sites of metastasis,12,0,2,no
1437,2361475,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Liver, Sites of metastasis,12,1,3,no
1437,2361475,Table 1,BaselineCharacteristic,?Brain,Characteristics ; ,?Brain, Sites of metastasis,13,0,2,no
1437,2361475,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Brain, Sites of metastasis,13,1,3,no
1437,2361475,Table 1,BaselineCharacteristic,?Bone,Characteristics ; ,?Bone, Sites of metastasis,14,0,2,no
1437,2361475,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Bone, Sites of metastasis,14,1,3,no
1437,2361475,Table 1,BaselineCharacteristic,?Nodes,Characteristics ; ,?Nodes, Sites of metastasis,15,0,2,no
1437,2361475,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Nodes, Sites of metastasis,15,1,3,no
1437,2361475,Table 1,BaselineCharacteristic,?Others,Characteristics ; ,?Others, Sites of metastasis,16,0,2,no
1437,2361475,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Others, Sites of metastasis,16,1,3,no
1437,2361475,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,17,0,2,no
1437,2361475,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,17,1,3,no
1437,2361475,Table 1,BaselineCharacteristic,No. of metastatic sites,Characteristics ; ,None,None,18,0,24,no
1437,2361475,Table 1,BaselineCharacteristic,No. of metastatic sites,No. of patients ; ,No. of metastatic sites,None,18,1,43,no
1437,2361475,Table 1,BaselineCharacteristic,?x,Characteristics ; ,?x, No. of metastatic sites,19,0,2,no
1437,2361475,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?x, No. of metastatic sites,19,1,3,no
1437,2361475,Table 1,BaselineCharacteristic,??x,Characteristics ; ,??x, No. of metastatic sites,20,0,2,no
1437,2361475,Table 1,BaselineCharacteristic,xx,No. of patients ; ,??x, No. of metastatic sites,20,1,3,no
1437,2361475,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,21,0,2,no
1437,2361475,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,21,1,3,no
1437,2361475,Table 1,BaselineCharacteristic,Histology (%),Characteristics ; ,None,None,22,0,24,no
1437,2361475,Table 1,BaselineCharacteristic,Histology (%),No. of patients ; ,Histology (%),None,22,1,43,no
1437,2361475,Table 1,BaselineCharacteristic,?Adenocarcinoma,Characteristics ; ,?Adenocarcinoma, Histology (%),23,0,2,no
1437,2361475,Table 1,BaselineCharacteristic,xx (xx.x),No. of patients ; ,?Adenocarcinoma, Histology (%),23,1,3,no
1437,2361475,Table 1,BaselineCharacteristic,?Squamous,Characteristics ; ,?Squamous, Histology (%),24,0,2,no
1437,2361475,Table 1,BaselineCharacteristic,xx (xx.x),No. of patients ; ,?Squamous, Histology (%),24,1,3,no
1437,2361475,Table 1,BaselineCharacteristic,?Bronchioloalveolar,Characteristics ; ,?Bronchioloalveolar, Histology (%),25,0,2,no
1437,2361475,Table 1,BaselineCharacteristic,x (x.x),No. of patients ; ,?Bronchioloalveolar, Histology (%),25,1,3,no
1437,2361475,Table 1,BaselineCharacteristic,?Undifferentiated,Characteristics ; ,?Undifferentiated, Histology (%),26,0,2,no
1437,2361475,Table 1,BaselineCharacteristic,x (x.x),No. of patients ; ,?Undifferentiated, Histology (%),26,1,3,no
1437,2361475,Table 1,BaselineCharacteristic,?Other NSCLC,Characteristics ; ,?Other NSCLC, Histology (%),27,0,2,no
1437,2361475,Table 1,BaselineCharacteristic,x (x.x),No. of patients ; ,?Other NSCLC, Histology (%),27,1,3,no
1437,2361475,Table 1,BaselineCharacteristic,?Unknown,Characteristics ; ,?Unknown, Histology (%),28,0,2,no
1437,2361475,Table 1,BaselineCharacteristic,x (x.x),No. of patients ; ,?Unknown, Histology (%),28,1,3,no
1443,2361496,Table 2,BaselineCharacteristic,Median age (range),,None,None,0,0,12,no
1443,2361496,Table 2,BaselineCharacteristic,Male?:?female,,None,None,1,0,12,no
1443,2361496,Table 2,BaselineCharacteristic,xx?:?x,,Male?:?female,None,1,1,1,yes
1443,2361496,Table 2,BaselineCharacteristic,,,None,None,2,0,2,no
1443,2361496,Table 2,BaselineCharacteristic,,,None,None,2,1,3,no
1443,2361496,Table 2,BaselineCharacteristic,Performance status,,None,None,3,0,24,no
1443,2361496,Table 2,BaselineCharacteristic,Performance status,,Performance status,None,3,1,43,no
1443,2361496,Table 2,BaselineCharacteristic,?x,,?x, Performance status,4,0,2,no
1443,2361496,Table 2,BaselineCharacteristic,xx,,?x, Performance status,4,1,3,no
1443,2361496,Table 2,BaselineCharacteristic,?x,,?x, Performance status,5,0,2,no
1443,2361496,Table 2,BaselineCharacteristic,xx,,?x, Performance status,5,1,3,no
1443,2361496,Table 2,BaselineCharacteristic,?x,,?x, Performance status,6,0,2,no
1443,2361496,Table 2,BaselineCharacteristic,x,,?x, Performance status,6,1,3,no
1443,2361496,Table 2,BaselineCharacteristic,?Unrecorded,,?Unrecorded, Performance status,7,0,2,no
1443,2361496,Table 2,BaselineCharacteristic,x,,?Unrecorded, Performance status,7,1,3,no
1443,2361496,Table 2,BaselineCharacteristic,,,None,None,8,0,2,no
1443,2361496,Table 2,BaselineCharacteristic,,,None,None,8,1,3,no
1443,2361496,Table 2,BaselineCharacteristic,Histology,,None,None,9,0,24,no
1443,2361496,Table 2,BaselineCharacteristic,Histology,,Histology,None,9,1,43,no
1443,2361496,Table 2,BaselineCharacteristic,?Squamous,,?Squamous, Histology,10,0,2,no
1443,2361496,Table 2,BaselineCharacteristic,xx,,?Squamous, Histology,10,1,3,no
1443,2361496,Table 2,BaselineCharacteristic,?Adeno,,?Adeno, Histology,11,0,2,no
1443,2361496,Table 2,BaselineCharacteristic,xx,,?Adeno, Histology,11,1,3,no
1443,2361496,Table 2,BaselineCharacteristic,?Mixed,,?Mixed, Histology,12,0,2,no
1443,2361496,Table 2,BaselineCharacteristic,x,,?Mixed, Histology,12,1,3,no
1443,2361496,Table 2,BaselineCharacteristic,,,None,None,13,0,2,no
1443,2361496,Table 2,BaselineCharacteristic,,,None,None,13,1,3,no
1443,2361496,Table 2,BaselineCharacteristic,Stage,,None,None,14,0,24,no
1443,2361496,Table 2,BaselineCharacteristic,Stage,,Stage,None,14,1,43,no
1443,2361496,Table 2,BaselineCharacteristic,?Locally advanced,,?Locally advanced, Stage,15,0,2,no
1443,2361496,Table 2,BaselineCharacteristic,x,,?Locally advanced, Stage,15,1,3,no
1443,2361496,Table 2,BaselineCharacteristic,?Metastatic,,?Metastatic, Stage,16,0,2,no
1443,2361496,Table 2,BaselineCharacteristic,xx,,?Metastatic, Stage,16,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no
1762,2364769,Table 1,BaselineCharacteristic,Interferon,,,None,0,1,1,no
1762,2364769,Table 1,BaselineCharacteristic,Observation,,,None,0,2,1,no
1762,2364769,Table 1,BaselineCharacteristic,, ; ,None,None,1,0,12,no
1762,2364769,Table 1,BaselineCharacteristic,(n=xxx),Interferon ; ,,None,1,1,1,no
1762,2364769,Table 1,BaselineCharacteristic,(n=xxx),Observation ; ,,None,1,2,1,no
1762,2364769,Table 1,BaselineCharacteristic,Median (range) age at diagnosis (years), ;  ; ,Median (range) age at diagnosis (years),,2,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,, ;  ; ,None,None,3,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,None,None,3,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,None,None,3,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,FIGO stage at diagnosis, ;  ; ,None,None,4,0,24,no
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,FIGO stage at diagnosis,None,4,1,43,no
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,FIGO stage at diagnosis,None,4,2,43,no
1762,2364769,Table 1,BaselineCharacteristic,?I, ;  ; ,?I, FIGO stage at diagnosis,5,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,xx (x%),Interferon ; (n=xxx) ; ,?I, FIGO stage at diagnosis,5,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,xx (x%),Observation ; (n=xxx) ; ,?I, FIGO stage at diagnosis,5,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,?II, ;  ; ,?II, FIGO stage at diagnosis,6,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?II, FIGO stage at diagnosis,6,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?II, FIGO stage at diagnosis,6,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,?III, ;  ; ,?III, FIGO stage at diagnosis,7,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?III, FIGO stage at diagnosis,7,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?III, FIGO stage at diagnosis,7,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,?IV, ;  ; ,?IV, FIGO stage at diagnosis,8,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?IV, FIGO stage at diagnosis,8,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?IV, FIGO stage at diagnosis,8,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,, ;  ; ,None,None,9,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,None,None,9,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,None,None,9,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,Residual disease following surgery (cm), ;  ; ,None,None,10,0,24,no
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,Residual disease following surgery (cm),None,10,1,43,no
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,Residual disease following surgery (cm),None,10,2,43,no
1762,2364769,Table 1,BaselineCharacteristic,?x, ;  ; ,?x, Residual disease following surgery (cm),11,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?x, Residual disease following surgery (cm),11,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?x, Residual disease following surgery (cm),11,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,?<x, ;  ; ,?<x, Residual disease following surgery (cm),12,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?<x, Residual disease following surgery (cm),12,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?<x, Residual disease following surgery (cm),12,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,?>x, ;  ; ,?>x, Residual disease following surgery (cm),14,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?>x, Residual disease following surgery (cm),14,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?>x, Residual disease following surgery (cm),14,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,, ;  ; ,None,None,15,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,None,None,15,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,None,None,15,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,Histology, ;  ; ,None,None,16,0,24,no
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,Histology,None,16,1,43,no
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,Histology,None,16,2,43,no
1762,2364769,Table 1,BaselineCharacteristic,?Serous, ;  ; ,?Serous, Histology,17,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?Serous, Histology,17,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?Serous, Histology,17,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,?Mucinous, ;  ; ,?Mucinous, Histology,18,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,xx (x%),Interferon ; (n=xxx) ; ,?Mucinous, Histology,18,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,xx (x%),Observation ; (n=xxx) ; ,?Mucinous, Histology,18,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,?Endometrioid, ;  ; ,?Endometrioid, Histology,19,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?Endometrioid, Histology,19,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?Endometrioid, Histology,19,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,?Clear cell, ;  ; ,?Clear cell, Histology,20,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,x (x%),Interferon ; (n=xxx) ; ,?Clear cell, Histology,20,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,x (x%),Observation ; (n=xxx) ; ,?Clear cell, Histology,20,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,?Other, ;  ; ,?Other, Histology,21,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?Other, Histology,21,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,xx (x%),Observation ; (n=xxx) ; ,?Other, Histology,21,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,?Undifferentiated, ;  ; ,?Undifferentiated, Histology,22,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,x (x%),Interferon ; (n=xxx) ; ,?Undifferentiated, Histology,22,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,x (x%),Observation ; (n=xxx) ; ,?Undifferentiated, Histology,22,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,?Not stated, ;  ; ,?Not stated, Histology,23,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?Not stated, Histology,23,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?Not stated, Histology,23,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,, ;  ; ,None,None,24,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,None,None,24,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,None,None,24,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,Tumour grade, ;  ; ,None,None,25,0,24,no
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,Tumour grade,None,25,1,43,no
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,Tumour grade,None,25,2,43,no
1762,2364769,Table 1,BaselineCharacteristic,?x, ;  ; ,?x, Tumour grade,26,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,xx (x%),Interferon ; (n=xxx) ; ,?x, Tumour grade,26,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?x, Tumour grade,26,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,?x, ;  ; ,?x, Tumour grade,27,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?x, Tumour grade,27,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?x, Tumour grade,27,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,?x, ;  ; ,?x, Tumour grade,28,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?x, Tumour grade,28,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?x, Tumour grade,28,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,?Not stated, ;  ; ,?Not stated, Tumour grade,29,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,xx,Interferon ; (n=xxx) ; ,?Not stated, Tumour grade,29,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,xx,Observation ; (n=xxx) ; ,?Not stated, Tumour grade,29,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,, ;  ; ,None,None,30,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,None,None,30,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,None,None,30,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,WHO performance status pre-chemotherapy, ;  ; ,None,None,31,0,24,no
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,WHO performance status pre-chemotherapy,None,31,1,43,no
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,WHO performance status pre-chemotherapy,None,31,2,43,no
1762,2364769,Table 1,BaselineCharacteristic,?x, ;  ; ,?x, WHO performance status pre-chemotherapy,32,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?x, WHO performance status pre-chemotherapy,32,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?x, WHO performance status pre-chemotherapy,32,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,?x, ;  ; ,?x, WHO performance status pre-chemotherapy,33,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?x, WHO performance status pre-chemotherapy,33,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?x, WHO performance status pre-chemotherapy,33,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,?x, ;  ; ,?x, WHO performance status pre-chemotherapy,34,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,x (x%),Interferon ; (n=xxx) ; ,?x, WHO performance status pre-chemotherapy,34,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?x, WHO performance status pre-chemotherapy,34,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,?x, ;  ; ,?x, WHO performance status pre-chemotherapy,35,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,x (x%),Interferon ; (n=xxx) ; ,?x, WHO performance status pre-chemotherapy,35,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,x (x%),Observation ; (n=xxx) ; ,?x, WHO performance status pre-chemotherapy,35,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,?x, ;  ; ,?x, WHO performance status pre-chemotherapy,36,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,x (x%),Interferon ; (n=xxx) ; ,?x, WHO performance status pre-chemotherapy,36,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,x,Observation ; (n=xxx) ; ,?x, WHO performance status pre-chemotherapy,36,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,?Not stated, ;  ; ,?Not stated, WHO performance status pre-chemotherapy,37,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,x,Interferon ; (n=xxx) ; ,?Not stated, WHO performance status pre-chemotherapy,37,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,x,Observation ; (n=xxx) ; ,?Not stated, WHO performance status pre-chemotherapy,37,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,, ;  ; ,None,None,38,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,None,None,38,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,None,None,38,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,Chemotherapy regimen, ;  ; ,None,None,39,0,24,no
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,Chemotherapy regimen,None,39,1,43,no
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,Chemotherapy regimen,None,39,2,43,no
1762,2364769,Table 1,BaselineCharacteristic,?Platinum single agent, ;  ; ,?Platinum single agent, Chemotherapy regimen,40,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?Platinum single agent, Chemotherapy regimen,40,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?Platinum single agent, Chemotherapy regimen,40,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,?Platinum combination, ;  ; ,?Platinum combination, Chemotherapy regimen,41,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?Platinum combination, Chemotherapy regimen,41,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?Platinum combination, Chemotherapy regimen,41,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,?Platinum/taxane, ;  ; ,?Platinum/taxane, Chemotherapy regimen,42,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?Platinum/taxane, Chemotherapy regimen,42,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?Platinum/taxane, Chemotherapy regimen,42,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,?Taxane single agent, ;  ; ,?Taxane single agent, Chemotherapy regimen,43,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,x,Interferon ; (n=xxx) ; ,?Taxane single agent, Chemotherapy regimen,43,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,x (x%),Observation ; (n=xxx) ; ,?Taxane single agent, Chemotherapy regimen,43,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,?Other single agent, ;  ; ,?Other single agent, Chemotherapy regimen,44,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,x (x%),Interferon ; (n=xxx) ; ,?Other single agent, Chemotherapy regimen,44,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,x (x%),Observation ; (n=xxx) ; ,?Other single agent, Chemotherapy regimen,44,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,, ;  ; ,None,None,45,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,None,None,45,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,None,None,45,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,Response to surgery and/or chemotherapy, ;  ; ,None,None,46,0,24,no
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,Response to surgery and/or chemotherapy,None,46,1,43,no
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,Response to surgery and/or chemotherapy,None,46,2,43,no
1762,2364769,Table 1,BaselineCharacteristic,?Disease free, ;  ; ,?Disease free, Response to surgery and/or chemotherapy,47,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?Disease free, Response to surgery and/or chemotherapy,47,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?Disease free, Response to surgery and/or chemotherapy,47,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,?Disease present, ;  ; ,?Disease present, Response to surgery and/or chemotherapy,48,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?Disease present, Response to surgery and/or chemotherapy,48,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?Disease present, Response to surgery and/or chemotherapy,48,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,?Not evaluable, ;  ; ,?Not evaluable, Response to surgery and/or chemotherapy,49,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,x,Interferon ; (n=xxx) ; ,?Not evaluable, Response to surgery and/or chemotherapy,49,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,x,Observation ; (n=xxx) ; ,?Not evaluable, Response to surgery and/or chemotherapy,49,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,, ;  ; ,None,None,50,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,None,None,50,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,None,None,50,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,CAxxx after surgery and/or chemotherapy, ;  ; ,None,None,51,0,24,no
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,CAxxx after surgery and/or chemotherapy,None,51,1,43,no
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,CAxxx after surgery and/or chemotherapy,None,51,2,43,no
1762,2364769,Table 1,BaselineCharacteristic,?<xx?U?ml?x, ;  ; ,?<xx?U?ml?x, CAxxx after surgery and/or chemotherapy,52,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?<xx?U?ml?x, CAxxx after surgery and/or chemotherapy,52,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?<xx?U?ml?x, CAxxx after surgery and/or chemotherapy,52,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,?>xxx, ;  ; ,?>xxx, CAxxx after surgery and/or chemotherapy,55,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,x (x%),Interferon ; (n=xxx) ; ,?>xxx, CAxxx after surgery and/or chemotherapy,55,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,x (x%),Observation ; (n=xxx) ; ,?>xxx, CAxxx after surgery and/or chemotherapy,55,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,?Not stated, ;  ; ,?Not stated, CAxxx after surgery and/or chemotherapy,56,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,xx,Interferon ; (n=xxx) ; ,?Not stated, CAxxx after surgery and/or chemotherapy,56,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,xx,Observation ; (n=xxx) ; ,?Not stated, CAxxx after surgery and/or chemotherapy,56,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,, ;  ; ,None,None,57,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,None,None,57,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,None,None,57,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,WHO performance status at randomisation, ;  ; ,None,None,58,0,24,no
1762,2364769,Table 1,BaselineCharacteristic,,Interferon ; (n=xxx) ; ,WHO performance status at randomisation,None,58,1,43,no
1762,2364769,Table 1,BaselineCharacteristic,,Observation ; (n=xxx) ; ,WHO performance status at randomisation,None,58,2,43,no
1762,2364769,Table 1,BaselineCharacteristic,?x, ;  ; ,?x, WHO performance status at randomisation,59,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,xxx (xx%),Interferon ; (n=xxx) ; ,?x, WHO performance status at randomisation,59,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,xxx (xx%),Observation ; (n=xxx) ; ,?x, WHO performance status at randomisation,59,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,?x, ;  ; ,?x, WHO performance status at randomisation,60,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Interferon ; (n=xxx) ; ,?x, WHO performance status at randomisation,60,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,xx (xx%),Observation ; (n=xxx) ; ,?x, WHO performance status at randomisation,60,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,?x, ;  ; ,?x, WHO performance status at randomisation,61,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,x (x%),Interferon ; (n=xxx) ; ,?x, WHO performance status at randomisation,61,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,x (x%),Observation ; (n=xxx) ; ,?x, WHO performance status at randomisation,61,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,?x, ;  ; ,?x, WHO performance status at randomisation,62,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,x,Interferon ; (n=xxx) ; ,?x, WHO performance status at randomisation,62,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,x,Observation ; (n=xxx) ; ,?x, WHO performance status at randomisation,62,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,?x, ;  ; ,?x, WHO performance status at randomisation,63,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,x,Interferon ; (n=xxx) ; ,?x, WHO performance status at randomisation,63,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,x,Observation ; (n=xxx) ; ,?x, WHO performance status at randomisation,63,2,3,no
1762,2364769,Table 1,BaselineCharacteristic,?Not stated, ;  ; ,?Not stated, WHO performance status at randomisation,64,0,2,no
1762,2364769,Table 1,BaselineCharacteristic,x,Interferon ; (n=xxx) ; ,?Not stated, WHO performance status at randomisation,64,1,3,no
1762,2364769,Table 1,BaselineCharacteristic,x,Observation ; (n=xxx) ; ,?Not stated, WHO performance status at randomisation,64,2,3,no
1769,2364792,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no
1769,2364792,Table 1,BaselineCharacteristic,No. (%),,,None,0,1,1,no
1769,2364792,Table 1,BaselineCharacteristic,Number of patients, ; ,Number of patients,,1,0,2,no
1769,2364792,Table 1,BaselineCharacteristic,xx (xxx),No. (%) ; ,Number of patients,,1,1,3,no
1769,2364792,Table 1,BaselineCharacteristic,Median age (years), ; ,Median age (years),,2,0,24,no
1769,2364792,Table 1,BaselineCharacteristic,xx,No. (%) ; ,Median age (years),,2,1,43,no
1769,2364792,Table 1,BaselineCharacteristic,?Range, ; ,?Range, Median age (years),3,0,2,no
1769,2364792,Table 1,BaselineCharacteristic,WHOa performance status, ; ,None,None,4,0,24,no
1769,2364792,Table 1,BaselineCharacteristic,WHOa performance status,No. (%) ; ,WHOa performance status,None,4,1,43,no
1769,2364792,Table 1,BaselineCharacteristic,?x, ; ,?x, WHOa performance status,5,0,2,no
1769,2364792,Table 1,BaselineCharacteristic,xx (xx),No. (%) ; ,?x, WHOa performance status,5,1,3,no
1769,2364792,Table 1,BaselineCharacteristic,??x, ; ,??x, WHOa performance status,6,0,2,no
1769,2364792,Table 1,BaselineCharacteristic,x (xx),No. (%) ; ,??x, WHOa performance status,6,1,3,no
1769,2364792,Table 1,BaselineCharacteristic,Adjuvant therapy, ; ,None,None,7,0,24,no
1769,2364792,Table 1,BaselineCharacteristic,Adjuvant therapy,No. (%) ; ,Adjuvant therapy,None,7,1,43,no
1769,2364792,Table 1,BaselineCharacteristic,?Chemotherapy with anthracyclines, ; ,?Chemotherapy with anthracyclines, Adjuvant therapy,8,0,2,no
1769,2364792,Table 1,BaselineCharacteristic,xx (xx),No. (%) ; ,?Chemotherapy with anthracyclines, Adjuvant therapy,8,1,3,no
1769,2364792,Table 1,BaselineCharacteristic,?Chemotherapy without anthracyclines, ; ,?Chemotherapy without anthracyclines, Adjuvant therapy,9,0,2,no
1769,2364792,Table 1,BaselineCharacteristic,x (xx),No. (%) ; ,?Chemotherapy without anthracyclines, Adjuvant therapy,9,1,3,no
1769,2364792,Table 1,BaselineCharacteristic,?Hormonal therapy, ; ,?Hormonal therapy, Adjuvant therapy,10,0,2,no
1769,2364792,Table 1,BaselineCharacteristic,xx (xx),No. (%) ; ,?Hormonal therapy, Adjuvant therapy,10,1,3,no
1769,2364792,Table 1,BaselineCharacteristic,Previous metastatic breast cancer therapy, ; ,None,None,11,0,24,no
1769,2364792,Table 1,BaselineCharacteristic,Previous metastatic breast cancer therapy,No. (%) ; ,Previous metastatic breast cancer therapy,None,11,1,43,no
1769,2364792,Table 1,BaselineCharacteristic,?Hormonal therapy, ; ,?Hormonal therapy, Previous metastatic breast cancer therapy,12,0,2,no
1769,2364792,Table 1,BaselineCharacteristic,x (x),No. (%) ; ,?Hormonal therapy, Previous metastatic breast cancer therapy,12,1,3,no
1769,2364792,Table 1,BaselineCharacteristic,Disease sites, ; ,None,None,13,0,24,no
1769,2364792,Table 1,BaselineCharacteristic,Disease sites,No. (%) ; ,Disease sites,None,13,1,43,no
1769,2364792,Table 1,BaselineCharacteristic,?Soft tissue and skin, ; ,?Soft tissue and skin, Disease sites,14,0,2,no
1769,2364792,Table 1,BaselineCharacteristic,x (xx),No. (%) ; ,?Soft tissue and skin, Disease sites,14,1,3,no
1769,2364792,Table 1,BaselineCharacteristic,?Liver, ; ,?Liver, Disease sites,15,0,2,no
1769,2364792,Table 1,BaselineCharacteristic,x (xx),No. (%) ; ,?Liver, Disease sites,15,1,3,no
1769,2364792,Table 1,BaselineCharacteristic,?Lung and pleura, ; ,?Lung and pleura, Disease sites,16,0,2,no
1769,2364792,Table 1,BaselineCharacteristic,x (xx),No. (%) ; ,?Lung and pleura, Disease sites,16,1,3,no
1769,2364792,Table 1,BaselineCharacteristic,?Bone, ; ,?Bone, Disease sites,17,0,2,no
1769,2364792,Table 1,BaselineCharacteristic,x (xx),No. (%) ; ,?Bone, Disease sites,17,1,3,no
1769,2364792,Table 1,BaselineCharacteristic,?Brain, ; ,?Brain, Disease sites,18,0,2,no
1769,2364792,Table 1,BaselineCharacteristic,x (x),No. (%) ; ,?Brain, Disease sites,18,1,3,no
1769,2364792,Table 1,BaselineCharacteristic,Number of organs involved, ; ,None,None,19,0,24,no
1769,2364792,Table 1,BaselineCharacteristic,Number of organs involved,No. (%) ; ,Number of organs involved,None,19,1,43,no
1769,2364792,Table 1,BaselineCharacteristic,?x, ; ,?x, Number of organs involved,20,0,2,no
1769,2364792,Table 1,BaselineCharacteristic,x (xx),No. (%) ; ,?x, Number of organs involved,20,1,3,no
1769,2364792,Table 1,BaselineCharacteristic,?x, ; ,?x, Number of organs involved,21,0,2,no
1769,2364792,Table 1,BaselineCharacteristic,x (xx),No. (%) ; ,?x, Number of organs involved,21,1,3,no
1888,2376376,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no
1888,2376376,Table 1,BaselineCharacteristic,Epoetin ? (n=xxx),,,None,0,1,1,no
1888,2376376,Table 1,BaselineCharacteristic,Control (n=xxx),,,None,0,2,1,no
1888,2376376,Table 1,BaselineCharacteristic,"Sex, n (%)", ; ,None,None,1,0,24,no
1888,2376376,Table 1,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,"Sex, n (%)",None,1,1,43,no
1888,2376376,Table 1,BaselineCharacteristic,,Control (n=xxx) ; ,"Sex, n (%)",None,1,2,43,no
1888,2376376,Table 1,BaselineCharacteristic,Male, ; ,Male," Sex, n (%)",2,0,2,no
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,Male," Sex, n (%)",2,1,3,yes
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,Male," Sex, n (%)",2,2,3,yes
1888,2376376,Table 1,BaselineCharacteristic,Female, ; ,Female," Sex, n (%)",3,0,2,no
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,Female," Sex, n (%)",3,1,3,yes
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,Female," Sex, n (%)",3,2,3,yes
1888,2376376,Table 1,BaselineCharacteristic,, ; ,None,None,4,0,2,no
1888,2376376,Table 1,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,None,None,4,1,3,no
1888,2376376,Table 1,BaselineCharacteristic,,Control (n=xxx) ; ,None,None,4,2,3,no
1888,2376376,Table 1,BaselineCharacteristic,Age (year), ; ,None,None,5,0,24,no
1888,2376376,Table 1,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,Age (year),None,5,1,43,no
1888,2376376,Table 1,BaselineCharacteristic,,Control (n=xxx) ; ,Age (year),None,5,2,43,no
1888,2376376,Table 1,BaselineCharacteristic,Median (range), ; ,Median (range), Age (year),6,0,2,no
1888,2376376,Table 1,BaselineCharacteristic,, ; ,None,None,7,0,2,no
1888,2376376,Table 1,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,None,None,7,1,3,no
1888,2376376,Table 1,BaselineCharacteristic,,Control (n=xxx) ; ,None,None,7,2,3,no
1888,2376376,Table 1,BaselineCharacteristic,"WHO Performance Status, N (%)", ; ,None,None,8,0,24,no
1888,2376376,Table 1,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,"WHO Performance Status, N (%)",None,8,1,43,no
1888,2376376,Table 1,BaselineCharacteristic,,Control (n=xxx) ; ,"WHO Performance Status, N (%)",None,8,2,43,no
1888,2376376,Table 1,BaselineCharacteristic,x, ; ,x," WHO Performance Status, N (%)",9,0,2,no
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,x," WHO Performance Status, N (%)",9,1,3,no
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,x," WHO Performance Status, N (%)",9,2,3,no
1888,2376376,Table 1,BaselineCharacteristic,x, ; ,x," WHO Performance Status, N (%)",10,0,2,no
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,x," WHO Performance Status, N (%)",10,1,3,no
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,x," WHO Performance Status, N (%)",10,2,3,no
1888,2376376,Table 1,BaselineCharacteristic,x, ; ,x," WHO Performance Status, N (%)",11,0,2,no
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,x," WHO Performance Status, N (%)",11,1,3,no
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,x," WHO Performance Status, N (%)",11,2,3,no
1888,2376376,Table 1,BaselineCharacteristic,, ; ,None,None,12,0,2,no
1888,2376376,Table 1,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,None,None,12,1,3,no
1888,2376376,Table 1,BaselineCharacteristic,,Control (n=xxx) ; ,None,None,12,2,3,no
1888,2376376,Table 1,BaselineCharacteristic,Time from diagnosis of anaemia of malignancy (months), ; ,None,None,13,0,24,no
1888,2376376,Table 1,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,Time from diagnosis of anaemia of malignancy (months),None,13,1,43,no
1888,2376376,Table 1,BaselineCharacteristic,,Control (n=xxx) ; ,Time from diagnosis of anaemia of malignancy (months),None,13,2,43,no
1888,2376376,Table 1,BaselineCharacteristic,Median (range), ; ,Median (range), Time from diagnosis of anaemia of malignancy (months),14,0,2,no
1888,2376376,Table 1,BaselineCharacteristic,, ; ,None,None,15,0,2,no
1888,2376376,Table 1,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,None,None,15,1,3,no
1888,2376376,Table 1,BaselineCharacteristic,,Control (n=xxx) ; ,None,None,15,2,3,no
1888,2376376,Table 1,BaselineCharacteristic,"Underlying cancer type, N (%)", ; ,None,None,16,0,24,no
1888,2376376,Table 1,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,"Underlying cancer type, N (%)",None,16,1,43,no
1888,2376376,Table 1,BaselineCharacteristic,,Control (n=xxx) ; ,"Underlying cancer type, N (%)",None,16,2,43,no
1888,2376376,Table 1,BaselineCharacteristic,Lymphoid tumour, ; ,Lymphoid tumour," Underlying cancer type, N (%)",17,0,2,no
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,Lymphoid tumour," Underlying cancer type, N (%)",17,1,3,no
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,Lymphoid tumour," Underlying cancer type, N (%)",17,2,3,no
1888,2376376,Table 1,BaselineCharacteristic,Multiple myeloma, ; ,Multiple myeloma," Underlying cancer type, N (%)",18,0,2,no
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,Multiple myeloma," Underlying cancer type, N (%)",18,1,3,no
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,Multiple myeloma," Underlying cancer type, N (%)",18,2,3,no
1888,2376376,Table 1,BaselineCharacteristic,"Non-Hodgkin\'s lymphoma", ; ,"Non-Hodgkin\'s lymphoma"," Underlying cancer type, N (%)",19,0,2,no
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,"Non-Hodgkin\'s lymphoma"," Underlying cancer type, N (%)",19,1,3,no
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,"Non-Hodgkin\'s lymphoma"," Underlying cancer type, N (%)",19,2,3,no
1888,2376376,Table 1,BaselineCharacteristic,Chronic lymphocytic leukaemia, ; ,Chronic lymphocytic leukaemia," Underlying cancer type, N (%)",20,0,2,no
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,Chronic lymphocytic leukaemia," Underlying cancer type, N (%)",20,1,3,no
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,Chronic lymphocytic leukaemia," Underlying cancer type, N (%)",20,2,3,no
1888,2376376,Table 1,BaselineCharacteristic,Other, ; ,Other," Underlying cancer type, N (%)",21,0,2,no
1888,2376376,Table 1,BaselineCharacteristic,x (x),Epoetin ? (n=xxx) ; ,Other," Underlying cancer type, N (%)",21,1,3,no
1888,2376376,Table 1,BaselineCharacteristic,x (<x),Control (n=xxx) ; ,Other," Underlying cancer type, N (%)",21,2,3,no
1888,2376376,Table 1,BaselineCharacteristic,, ; ,None,None,22,0,2,no
1888,2376376,Table 1,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,None,None,22,1,3,no
1888,2376376,Table 1,BaselineCharacteristic,,Control (n=xxx) ; ,None,None,22,2,3,no
1888,2376376,Table 1,BaselineCharacteristic,Solid tumour, ; ,Solid tumour," Underlying cancer type, N (%)",23,0,2,no
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,Solid tumour," Underlying cancer type, N (%)",23,1,3,no
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,Solid tumour," Underlying cancer type, N (%)",23,2,3,no
1888,2376376,Table 1,BaselineCharacteristic,Ovarian, ; ,Ovarian," Underlying cancer type, N (%)",24,0,2,no
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,Ovarian," Underlying cancer type, N (%)",24,1,3,no
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,Ovarian," Underlying cancer type, N (%)",24,2,3,no
1888,2376376,Table 1,BaselineCharacteristic,"Bone, connective tissue, skin and breast", ; ,"Bone, connective tissue, skin and breast"," Underlying cancer type, N (%)",25,0,2,no
1888,2376376,Table 1,BaselineCharacteristic,x (x),Epoetin ? (n=xxx) ; ,"Bone, connective tissue, skin and breast"," Underlying cancer type, N (%)",25,1,3,no
1888,2376376,Table 1,BaselineCharacteristic,xx (x),Control (n=xxx) ; ,"Bone, connective tissue, skin and breast"," Underlying cancer type, N (%)",25,2,3,no
1888,2376376,Table 1,BaselineCharacteristic,"Digestive organs, peritoneum", ; ,"Digestive organs, peritoneum"," Underlying cancer type, N (%)",26,0,2,no
1888,2376376,Table 1,BaselineCharacteristic,x (x),Epoetin ? (n=xxx) ; ,"Digestive organs, peritoneum"," Underlying cancer type, N (%)",26,1,3,no
1888,2376376,Table 1,BaselineCharacteristic,x (x),Control (n=xxx) ; ,"Digestive organs, peritoneum"," Underlying cancer type, N (%)",26,2,3,no
1888,2376376,Table 1,BaselineCharacteristic,Respiratory and intrathoracic organs, ; ,Respiratory and intrathoracic organs," Underlying cancer type, N (%)",27,0,2,no
1888,2376376,Table 1,BaselineCharacteristic,x (x),Epoetin ? (n=xxx) ; ,Respiratory and intrathoracic organs," Underlying cancer type, N (%)",27,1,3,no
1888,2376376,Table 1,BaselineCharacteristic,x (x),Control (n=xxx) ; ,Respiratory and intrathoracic organs," Underlying cancer type, N (%)",27,2,3,no
1888,2376376,Table 1,BaselineCharacteristic,Other, ; ,Other," Underlying cancer type, N (%)",28,0,2,no
1888,2376376,Table 1,BaselineCharacteristic,xx (x),Epoetin ? (n=xxx) ; ,Other," Underlying cancer type, N (%)",28,1,3,no
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,Other," Underlying cancer type, N (%)",28,2,3,no
1888,2376376,Table 1,BaselineCharacteristic,"Patients with chemotherapy before study, N (%)", ; ,"Patients with chemotherapy before study, N (%)"," Underlying cancer type, N (%)",29,0,2,no
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,"Patients with chemotherapy before study, N (%)"," Underlying cancer type, N (%)",29,1,3,no
1888,2376376,Table 1,BaselineCharacteristic,xxx (xx)*,Control (n=xxx) ; ,"Patients with chemotherapy before study, N (%)"," Underlying cancer type, N (%)",29,2,3,no
1888,2376376,Table 1,BaselineCharacteristic,Chemotherapy, ; ,None,None,30,0,24,no
1888,2376376,Table 1,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,Chemotherapy,None,30,1,43,no
1888,2376376,Table 1,BaselineCharacteristic,,Control (n=xxx) ; ,Chemotherapy,None,30,2,43,no
1888,2376376,Table 1,BaselineCharacteristic,Alkylating agents, ; ,Alkylating agents, Chemotherapy,31,0,2,no
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,Alkylating agents, Chemotherapy,31,1,3,no
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,Alkylating agents, Chemotherapy,31,2,3,no
1888,2376376,Table 1,BaselineCharacteristic,Antimetabolites, ; ,Antimetabolites, Chemotherapy,32,0,2,no
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,Antimetabolites, Chemotherapy,32,1,3,no
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,Antimetabolites, Chemotherapy,32,2,3,no
1888,2376376,Table 1,BaselineCharacteristic,Plant alkaloids/other natural products, ; ,Plant alkaloids/other natural products, Chemotherapy,33,0,2,no
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,Plant alkaloids/other natural products, Chemotherapy,33,1,3,no
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,Plant alkaloids/other natural products, Chemotherapy,33,2,3,no
1888,2376376,Table 1,BaselineCharacteristic,Cytotoxic antibiotics/related substances, ; ,Cytotoxic antibiotics/related substances, Chemotherapy,34,0,2,no
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,Cytotoxic antibiotics/related substances, Chemotherapy,34,1,3,no
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,Cytotoxic antibiotics/related substances, Chemotherapy,34,2,3,no
1888,2376376,Table 1,BaselineCharacteristic,Other antineoplastic agents, ; ,Other antineoplastic agents, Chemotherapy,35,0,2,no
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,Other antineoplastic agents, Chemotherapy,35,1,3,no
1888,2376376,Table 1,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,Other antineoplastic agents, Chemotherapy,35,2,3,no
1888,2376376,Table 1,BaselineCharacteristic,Other, ; ,Other, Chemotherapy,36,0,2,no
1888,2376376,Table 1,BaselineCharacteristic,x (x),Epoetin ? (n=xxx) ; ,Other, Chemotherapy,36,1,3,no
1888,2376376,Table 1,BaselineCharacteristic,x (x),Control (n=xxx) ; ,Other, Chemotherapy,36,2,3,no
1888,2376376,Table 1,BaselineCharacteristic,"Median haemoglobin level, g dl?x (range)", ; ,"Median haemoglobin level, g dl?x (range)", Chemotherapy,37,0,2,no
1888,2376376,Table 1,BaselineCharacteristic,"Median serum erythropoietin level, mIU ml?x (range)", ; ,"Median serum erythropoietin level, mIU ml?x (range)", Chemotherapy,38,0,2,no
1888,2376376,Table 1,BaselineCharacteristic,"Median serum iron level, ?g dl?x (range)", ; ,"Median serum iron level, ?g dl?x (range)", Chemotherapy,39,0,2,no
1888,2376376,Table 1,BaselineCharacteristic,"Median transferrin saturation, % (range)", ; ,"Median transferrin saturation, % (range)", Chemotherapy,40,0,2,no
1888,2376376,Table 2,BaselineCharacteristic,,,None,None,0,0,12,no
1888,2376376,Table 2,BaselineCharacteristic,Epoetin ? (n=xxx),,,None,0,1,1,no
1888,2376376,Table 2,BaselineCharacteristic,Control (n=xxx),,,None,0,2,1,no
1888,2376376,Table 2,BaselineCharacteristic,Baseline quality-of-life score, ; ,None,None,1,0,2,no
1888,2376376,Table 2,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,None,None,1,1,3,no
1888,2376376,Table 2,BaselineCharacteristic,,Control (n=xxx) ; ,None,None,1,2,3,no
1888,2376376,Table 2,BaselineCharacteristic,SF-xx PCS, ; ,None,None,2,0,24,no
1888,2376376,Table 2,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,SF-xx PCS,None,2,1,43,no
1888,2376376,Table 2,BaselineCharacteristic,,Control (n=xxx) ; ,SF-xx PCS,None,2,2,43,no
1888,2376376,Table 2,BaselineCharacteristic,Mean (SD), ; ,Mean (SD), Baseline quality-of-life score SF-xx PCS,3,0,2,no
1888,2376376,Table 2,BaselineCharacteristic,xx (x.x),Epoetin ? (n=xxx) ; ,Mean (SD), Baseline quality-of-life score SF-xx PCS,3,1,3,no
1888,2376376,Table 2,BaselineCharacteristic,xx (x.x),Control (n=xxx) ; ,Mean (SD), Baseline quality-of-life score SF-xx PCS,3,2,3,no
1888,2376376,Table 2,BaselineCharacteristic,Median, ; ,Median, Baseline quality-of-life score SF-xx PCS,4,0,2,no
1888,2376376,Table 2,BaselineCharacteristic,xx,Epoetin ? (n=xxx) ; ,Median, Baseline quality-of-life score SF-xx PCS,4,1,3,no
1888,2376376,Table 2,BaselineCharacteristic,xx,Control (n=xxx) ; ,Median, Baseline quality-of-life score SF-xx PCS,4,2,3,no
1888,2376376,Table 2,BaselineCharacteristic,Range, ; ,Range, Baseline quality-of-life score SF-xx PCS,5,0,2,no
1888,2376376,Table 2,BaselineCharacteristic,, ; ,None,None,6,0,2,no
1888,2376376,Table 2,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,None,None,6,1,3,no
1888,2376376,Table 2,BaselineCharacteristic,,Control (n=xxx) ; ,None,None,6,2,3,no
1888,2376376,Table 2,BaselineCharacteristic,FACT-F, ; ,None,None,7,0,24,no
1888,2376376,Table 2,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,FACT-F,None,7,1,43,no
1888,2376376,Table 2,BaselineCharacteristic,,Control (n=xxx) ; ,FACT-F,None,7,2,43,no
1888,2376376,Table 2,BaselineCharacteristic,Mean (SD), ; ,Mean (SD), Baseline quality-of-life score FACT-F,8,0,2,no
1888,2376376,Table 2,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,Mean (SD), Baseline quality-of-life score FACT-F,8,1,3,no
1888,2376376,Table 2,BaselineCharacteristic,xx (xx)*,Control (n=xxx) ; ,Mean (SD), Baseline quality-of-life score FACT-F,8,2,3,no
1888,2376376,Table 2,BaselineCharacteristic,Median, ; ,Median, Baseline quality-of-life score FACT-F,9,0,2,no
1888,2376376,Table 2,BaselineCharacteristic,xx,Epoetin ? (n=xxx) ; ,Median, Baseline quality-of-life score FACT-F,9,1,3,no
1888,2376376,Table 2,BaselineCharacteristic,xx,Control (n=xxx) ; ,Median, Baseline quality-of-life score FACT-F,9,2,3,no
1888,2376376,Table 2,BaselineCharacteristic,Range, ; ,Range, Baseline quality-of-life score FACT-F,10,0,2,no
1888,2376376,Table 2,BaselineCharacteristic,, ; ,None,None,11,0,2,no
1888,2376376,Table 2,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,None,None,11,1,3,no
1888,2376376,Table 2,BaselineCharacteristic,,Control (n=xxx) ; ,None,None,11,2,3,no
1888,2376376,Table 2,BaselineCharacteristic,FACT-An, ; ,None,None,12,0,24,no
1888,2376376,Table 2,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,FACT-An,None,12,1,43,no
1888,2376376,Table 2,BaselineCharacteristic,,Control (n=xxx) ; ,FACT-An,None,12,2,43,no
1888,2376376,Table 2,BaselineCharacteristic,Mean (SD), ; ,Mean (SD), Baseline quality-of-life score FACT-An,13,0,2,no
1888,2376376,Table 2,BaselineCharacteristic,xx (x.x),Epoetin ? (n=xxx) ; ,Mean (SD), Baseline quality-of-life score FACT-An,13,1,3,no
1888,2376376,Table 2,BaselineCharacteristic,xx (x.x),Control (n=xxx) ; ,Mean (SD), Baseline quality-of-life score FACT-An,13,2,3,no
1888,2376376,Table 2,BaselineCharacteristic,Median, ; ,Median, Baseline quality-of-life score FACT-An,14,0,2,no
1888,2376376,Table 2,BaselineCharacteristic,xx,Epoetin ? (n=xxx) ; ,Median, Baseline quality-of-life score FACT-An,14,1,3,no
1888,2376376,Table 2,BaselineCharacteristic,xx,Control (n=xxx) ; ,Median, Baseline quality-of-life score FACT-An,14,2,3,no
1888,2376376,Table 2,BaselineCharacteristic,Range, ; ,Range, Baseline quality-of-life score FACT-An,15,0,2,no
1888,2376376,Table 2,BaselineCharacteristic,, ; ,None,None,16,0,2,no
1888,2376376,Table 2,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,None,None,16,1,3,no
1888,2376376,Table 2,BaselineCharacteristic,,Control (n=xxx) ; ,None,None,16,2,3,no
1888,2376376,Table 2,BaselineCharacteristic,VAS, ; ,None,None,17,0,24,no
1888,2376376,Table 2,BaselineCharacteristic,,Epoetin ? (n=xxx) ; ,VAS,None,17,1,43,no
1888,2376376,Table 2,BaselineCharacteristic,,Control (n=xxx) ; ,VAS,None,17,2,43,no
1888,2376376,Table 2,BaselineCharacteristic,Mean (SD), ; ,Mean (SD), Baseline quality-of-life score VAS,18,0,2,no
1888,2376376,Table 2,BaselineCharacteristic,xx (xx),Epoetin ? (n=xxx) ; ,Mean (SD), Baseline quality-of-life score VAS,18,1,3,no
1888,2376376,Table 2,BaselineCharacteristic,xx (xx),Control (n=xxx) ; ,Mean (SD), Baseline quality-of-life score VAS,18,2,3,no
1888,2376376,Table 2,BaselineCharacteristic,Median, ; ,Median, Baseline quality-of-life score VAS,19,0,2,no
1888,2376376,Table 2,BaselineCharacteristic,xx,Epoetin ? (n=xxx) ; ,Median, Baseline quality-of-life score VAS,19,1,3,no
1888,2376376,Table 2,BaselineCharacteristic,xx,Control (n=xxx) ; ,Median, Baseline quality-of-life score VAS,19,2,3,no
1888,2376376,Table 2,BaselineCharacteristic,Range, ; ,Range, Baseline quality-of-life score VAS,20,0,2,no
1906,2377091,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,0,12,no
1906,2377091,Table 1,BaselineCharacteristic,,,Characteristic,None,0,1,1,no
1906,2377091,Table 1,BaselineCharacteristic,Mean age (range),Characteristic ; ,Mean age (range),None,1,0,2,no
1906,2377091,Table 1,BaselineCharacteristic,Mean pretreatment PSA (range),Characteristic ; ,Mean pretreatment PSA (range),None,2,0,2,no
1906,2377091,Table 1,BaselineCharacteristic,Gleason score for histology (range),Characteristic ; ,Gleason score for histology (range),None,3,0,2,no
1906,2377091,Table 1,BaselineCharacteristic,Local stage (Tx/Tx),Characteristic ; ,Local stage (Tx/Tx),None,4,0,2,no
1906,2377091,Table 1,BaselineCharacteristic,xx/x, ; ,Local stage (Tx/Tx),None,4,1,3,no
1906,2377091,Table 1,BaselineCharacteristic,Bony metastases present,Characteristic ; ,Bony metastases present,None,5,0,2,no
1906,2377091,Table 1,BaselineCharacteristic,xx (xx%), ; ,Bony metastases present,None,5,1,3,no
1906,2377091,Table 1,BaselineCharacteristic,Concurrent LHRH analogue therapy,Characteristic ; ,Concurrent LHRH analogue therapy,None,6,0,2,no
1906,2377091,Table 1,BaselineCharacteristic,xx (xx%), ; ,Concurrent LHRH analogue therapy,None,6,1,3,no
1906,2377091,Table 1,BaselineCharacteristic,Previous bilateral subcapsular orchidectomy,Characteristic ; ,Previous bilateral subcapsular orchidectomy,None,7,0,2,no
1906,2377091,Table 1,BaselineCharacteristic,x (xx%), ; ,Previous bilateral subcapsular orchidectomy,None,7,1,3,no
1906,2377091,Table 2,BaselineCharacteristic,,,None,None,0,0,12,no
1906,2377091,Table 2,BaselineCharacteristic,,,None,None,1,0,3,no
1906,2377091,Table 2,BaselineCharacteristic,Time on study; mean (median), ; ,Time on study; mean (median),None,1,0,2,no
1906,2377091,Table 2,BaselineCharacteristic,xx (xx) days,,Time on study; mean (median),None,1,1,3,no
1906,2377091,Table 2,BaselineCharacteristic,Mean age (range), ; ,Mean age (range),None,2,0,2,no
1906,2377091,Table 2,BaselineCharacteristic,Mean pretreatment PSA (range), ; ,Mean pretreatment PSA (range),None,3,0,2,no
1906,2377091,Table 2,BaselineCharacteristic,Gleason score for histology (range), ; ,Gleason score for histology (range),None,4,0,2,no
1906,2377091,Table 2,BaselineCharacteristic,Local stage (Tx/Tx), ; ,Local stage (Tx/Tx),None,5,0,2,no
1906,2377091,Table 2,BaselineCharacteristic,x/x,,Local stage (Tx/Tx),None,5,1,3,no
1906,2377091,Table 2,BaselineCharacteristic,Bony metastases present, ; ,Bony metastases present,None,6,0,2,no
1906,2377091,Table 2,BaselineCharacteristic,x (xx%),,Bony metastases present,None,6,1,3,no
1906,2377091,Table 2,BaselineCharacteristic,Concurrent LHRH analogue therapy, ; ,Concurrent LHRH analogue therapy,None,7,0,2,no
1906,2377091,Table 2,BaselineCharacteristic,x (xx%),,Concurrent LHRH analogue therapy,None,7,1,3,no
1906,2377091,Table 2,BaselineCharacteristic,Previous bilateral subcapsular orchidectomy, ; ,Previous bilateral subcapsular orchidectomy,None,8,0,2,no
1906,2377091,Table 2,BaselineCharacteristic,x (xx%),,Previous bilateral subcapsular orchidectomy,None,8,1,3,no
1911,2377146,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no
1911,2377146,Table 1,BaselineCharacteristic,Patients,,,None,0,1,1,no
1911,2377146,Table 1,BaselineCharacteristic,Patients,,,None,0,2,1,no
1911,2377146,Table 1,BaselineCharacteristic,Characteristics, ; ,None,None,1,0,12,no
1911,2377146,Table 1,BaselineCharacteristic,n,Patients ; ,Characteristics,None,1,1,1,no
1911,2377146,Table 1,BaselineCharacteristic,(%),Patients ; ,Characteristics,None,1,2,1,no
1911,2377146,Table 1,BaselineCharacteristic,Number of patients, ; Characteristics ; ,Number of patients,,2,0,2,no
1911,2377146,Table 1,BaselineCharacteristic,xx,Patients ; n ; ,Number of patients,,2,1,3,no
1911,2377146,Table 1,BaselineCharacteristic,xx,Patients ; (%) ; ,Number of patients,,2,2,3,no
1911,2377146,Table 1,BaselineCharacteristic,Median age in years (range), ; Characteristics ; ,Median age in years (range),,3,0,2,no
1911,2377146,Table 1,BaselineCharacteristic,, ; Characteristics ; ,None,None,4,0,2,no
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; n ; ,None,None,4,1,3,no
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; (%) ; ,None,None,4,2,3,no
1911,2377146,Table 1,BaselineCharacteristic,WHO performance status, ; Characteristics ; ,None,None,5,0,24,no
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; n ; ,WHO performance status,None,5,1,43,no
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; (%) ; ,WHO performance status,None,5,2,43,no
1911,2377146,Table 1,BaselineCharacteristic,?x, ; Characteristics ; ,?x, WHO performance status,6,0,2,no
1911,2377146,Table 1,BaselineCharacteristic,xx,Patients ; n ; ,?x, WHO performance status,6,1,3,no
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,?x, WHO performance status,6,2,3,no
1911,2377146,Table 1,BaselineCharacteristic,?x, ; Characteristics ; ,?x, WHO performance status,7,0,2,no
1911,2377146,Table 1,BaselineCharacteristic,xx,Patients ; n ; ,?x, WHO performance status,7,1,3,no
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,?x, WHO performance status,7,2,3,no
1911,2377146,Table 1,BaselineCharacteristic,?x, ; Characteristics ; ,?x, WHO performance status,8,0,2,no
1911,2377146,Table 1,BaselineCharacteristic,x,Patients ; n ; ,?x, WHO performance status,8,1,3,no
1911,2377146,Table 1,BaselineCharacteristic,(x),Patients ; (%) ; ,?x, WHO performance status,8,2,3,no
1911,2377146,Table 1,BaselineCharacteristic,, ; Characteristics ; ,None,None,9,0,2,no
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; n ; ,None,None,9,1,3,no
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; (%) ; ,None,None,9,2,3,no
1911,2377146,Table 1,BaselineCharacteristic,Number of organs involved, ; Characteristics ; ,None,None,10,0,24,no
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; n ; ,Number of organs involved,None,10,1,43,no
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; (%) ; ,Number of organs involved,None,10,2,43,no
1911,2377146,Table 1,BaselineCharacteristic,?x, ; Characteristics ; ,?x, Number of organs involved,11,0,2,no
1911,2377146,Table 1,BaselineCharacteristic,xx,Patients ; n ; ,?x, Number of organs involved,11,1,3,no
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,?x, Number of organs involved,11,2,3,no
1911,2377146,Table 1,BaselineCharacteristic,?x, ; Characteristics ; ,?x, Number of organs involved,12,0,2,no
1911,2377146,Table 1,BaselineCharacteristic,xx,Patients ; n ; ,?x, Number of organs involved,12,1,3,no
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,?x, Number of organs involved,12,2,3,no
1911,2377146,Table 1,BaselineCharacteristic,??x, ; Characteristics ; ,??x, Number of organs involved,13,0,2,no
1911,2377146,Table 1,BaselineCharacteristic,x,Patients ; n ; ,??x, Number of organs involved,13,1,3,no
1911,2377146,Table 1,BaselineCharacteristic,(x),Patients ; (%) ; ,??x, Number of organs involved,13,2,3,no
1911,2377146,Table 1,BaselineCharacteristic,, ; Characteristics ; ,None,None,14,0,2,no
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; n ; ,None,None,14,1,3,no
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; (%) ; ,None,None,14,2,3,no
1911,2377146,Table 1,BaselineCharacteristic,Disease sites, ; Characteristics ; ,None,None,15,0,24,no
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; n ; ,Disease sites,None,15,1,43,no
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; (%) ; ,Disease sites,None,15,2,43,no
1911,2377146,Table 1,BaselineCharacteristic,?Bone, ; Characteristics ; ,?Bone, Disease sites,16,0,2,no
1911,2377146,Table 1,BaselineCharacteristic,xx,Patients ; n ; ,?Bone, Disease sites,16,1,3,no
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,?Bone, Disease sites,16,2,3,no
1911,2377146,Table 1,BaselineCharacteristic,?Liver, ; Characteristics ; ,?Liver, Disease sites,17,0,2,no
1911,2377146,Table 1,BaselineCharacteristic,xx,Patients ; n ; ,?Liver, Disease sites,17,1,3,no
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,?Liver, Disease sites,17,2,3,no
1911,2377146,Table 1,BaselineCharacteristic,?Skin, ; Characteristics ; ,?Skin, Disease sites,18,0,2,no
1911,2377146,Table 1,BaselineCharacteristic,x,Patients ; n ; ,?Skin, Disease sites,18,1,3,no
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,?Skin, Disease sites,18,2,3,no
1911,2377146,Table 1,BaselineCharacteristic,?Lung, ; Characteristics ; ,?Lung, Disease sites,19,0,2,no
1911,2377146,Table 1,BaselineCharacteristic,xx,Patients ; n ; ,?Lung, Disease sites,19,1,3,no
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,?Lung, Disease sites,19,2,3,no
1911,2377146,Table 1,BaselineCharacteristic,?Lymph node, ; Characteristics ; ,?Lymph node, Disease sites,20,0,2,no
1911,2377146,Table 1,BaselineCharacteristic,x,Patients ; n ; ,?Lymph node, Disease sites,20,1,3,no
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,?Lymph node, Disease sites,20,2,3,no
1911,2377146,Table 1,BaselineCharacteristic,?Other, ; Characteristics ; ,?Other, Disease sites,21,0,2,no
1911,2377146,Table 1,BaselineCharacteristic,x,Patients ; n ; ,?Other, Disease sites,21,1,3,no
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,?Other, Disease sites,21,2,3,no
1911,2377146,Table 1,BaselineCharacteristic,, ; Characteristics ; ,None,None,22,0,2,no
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; n ; ,None,None,22,1,3,no
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; (%) ; ,None,None,22,2,3,no
1911,2377146,Table 1,BaselineCharacteristic,Intent of previous chemotherapy, ; Characteristics ; ,None,None,23,0,24,no
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; n ; ,Intent of previous chemotherapy,None,23,1,43,no
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; (%) ; ,Intent of previous chemotherapy,None,23,2,43,no
1911,2377146,Table 1,BaselineCharacteristic,?Neoadjuvant and adjuvant, ; Characteristics ; ,?Neoadjuvant and adjuvant, Intent of previous chemotherapy,24,0,2,no
1911,2377146,Table 1,BaselineCharacteristic,x,Patients ; n ; ,?Neoadjuvant and adjuvant, Intent of previous chemotherapy,24,1,3,no
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,?Neoadjuvant and adjuvant, Intent of previous chemotherapy,24,2,3,no
1911,2377146,Table 1,BaselineCharacteristic,?Neoadjuvant only, ; Characteristics ; ,?Neoadjuvant only, Intent of previous chemotherapy,25,0,2,no
1911,2377146,Table 1,BaselineCharacteristic,x,Patients ; n ; ,?Neoadjuvant only, Intent of previous chemotherapy,25,1,3,no
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,?Neoadjuvant only, Intent of previous chemotherapy,25,2,3,no
1911,2377146,Table 1,BaselineCharacteristic,?Adjuvant only, ; Characteristics ; ,?Adjuvant only, Intent of previous chemotherapy,26,0,2,no
1911,2377146,Table 1,BaselineCharacteristic,xx,Patients ; n ; ,?Adjuvant only, Intent of previous chemotherapy,26,1,3,no
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,?Adjuvant only, Intent of previous chemotherapy,26,2,3,no
1911,2377146,Table 1,BaselineCharacteristic,?Neoadjuvant and adjuvant and metastatic, ; Characteristics ; ,?Neoadjuvant and adjuvant and metastatic, Intent of previous chemotherapy,27,0,2,no
1911,2377146,Table 1,BaselineCharacteristic,x,Patients ; n ; ,?Neoadjuvant and adjuvant and metastatic, Intent of previous chemotherapy,27,1,3,no
1911,2377146,Table 1,BaselineCharacteristic,(x),Patients ; (%) ; ,?Neoadjuvant and adjuvant and metastatic, Intent of previous chemotherapy,27,2,3,no
1911,2377146,Table 1,BaselineCharacteristic,?Adjuvant and metastatic, ; Characteristics ; ,?Adjuvant and metastatic, Intent of previous chemotherapy,28,0,2,no
1911,2377146,Table 1,BaselineCharacteristic,x,Patients ; n ; ,?Adjuvant and metastatic, Intent of previous chemotherapy,28,1,3,no
1911,2377146,Table 1,BaselineCharacteristic,(x),Patients ; (%) ; ,?Adjuvant and metastatic, Intent of previous chemotherapy,28,2,3,no
1911,2377146,Table 1,BaselineCharacteristic,?Metastatic, ; Characteristics ; ,?Metastatic, Intent of previous chemotherapy,29,0,2,no
1911,2377146,Table 1,BaselineCharacteristic,xx,Patients ; n ; ,?Metastatic, Intent of previous chemotherapy,29,1,3,no
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,?Metastatic, Intent of previous chemotherapy,29,2,3,no
1911,2377146,Table 1,BaselineCharacteristic,, ; Characteristics ; ,None,None,30,0,2,no
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; n ; ,None,None,30,1,3,no
1911,2377146,Table 1,BaselineCharacteristic,,Patients ; (%) ; ,None,None,30,2,3,no
1911,2377146,Table 1,BaselineCharacteristic,First-line metastatic, ; Characteristics ; ,First-line metastatic,,31,0,2,no
1911,2377146,Table 1,BaselineCharacteristic,xx,Patients ; n ; ,First-line metastatic,,31,1,3,no
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,First-line metastatic,,31,2,3,no
1911,2377146,Table 1,BaselineCharacteristic,Second-line metastatic, ; Characteristics ; ,Second-line metastatic,,32,0,2,no
1911,2377146,Table 1,BaselineCharacteristic,xx,Patients ; n ; ,Second-line metastatic,,32,1,3,no
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,Second-line metastatic,,32,2,3,no
1911,2377146,Table 1,BaselineCharacteristic,Anthracycline resistanta, ; Characteristics ; ,Anthracycline resistanta,,33,0,2,no
1911,2377146,Table 1,BaselineCharacteristic,xx,Patients ; n ; ,Anthracycline resistanta,,33,1,3,no
1911,2377146,Table 1,BaselineCharacteristic,(xx),Patients ; (%) ; ,Anthracycline resistanta,,33,2,3,no
1911,2377146,Table 1,BaselineCharacteristic,Anthracycline refractoryb, ; Characteristics ; ,Anthracycline refractoryb,,34,0,2,no
1911,2377146,Table 1,BaselineCharacteristic,x,Patients ; n ; ,Anthracycline refractoryb,,34,1,3,no
1911,2377146,Table 1,BaselineCharacteristic,(x),Patients ; (%) ; ,Anthracycline refractoryb,,34,2,3,no
1941,2394267,Table 1,BaselineCharacteristic,Characteristics,,None,None,0,0,12,no
1941,2394267,Table 1,BaselineCharacteristic,No. of patients (%),,Characteristics,None,0,1,1,no
1941,2394267,Table 1,BaselineCharacteristic,Gender,,None,None,1,0,12,no
1941,2394267,Table 1,BaselineCharacteristic,,,Gender,None,1,1,1,no
1941,2394267,Table 1,BaselineCharacteristic,?Male,,None,None,2,0,12,no
1941,2394267,Table 1,BaselineCharacteristic,xx (xx.x),,?Male,None,2,1,1,yes
1941,2394267,Table 1,BaselineCharacteristic,?Female,,None,None,3,0,12,no
1941,2394267,Table 1,BaselineCharacteristic,xx (xx.x),,?Female,None,3,1,1,yes
1941,2394267,Table 1,BaselineCharacteristic,,,None,None,4,0,2,no
1941,2394267,Table 1,BaselineCharacteristic,,,None,None,4,1,3,no
1941,2394267,Table 1,BaselineCharacteristic,Extent of disease,,None,None,5,0,24,no
1941,2394267,Table 1,BaselineCharacteristic,,,Extent of disease,None,5,1,43,no
1941,2394267,Table 1,BaselineCharacteristic,?Local,,?Local, Extent of disease,6,0,2,no
1941,2394267,Table 1,BaselineCharacteristic,xx (xx.x),,?Local, Extent of disease,6,1,3,no
1941,2394267,Table 1,BaselineCharacteristic,?Metastatic,,?Metastatic, Extent of disease,7,0,24,no
1941,2394267,Table 1,BaselineCharacteristic,xx (xx.x),,?Metastatic, Extent of disease,7,1,43,no
1941,2394267,Table 1,BaselineCharacteristic,??To lung/chest wall,,??To lung/chest wall, Extent of disease ?Metastatic,8,0,2,no
1941,2394267,Table 1,BaselineCharacteristic,x,,??To lung/chest wall, Extent of disease ?Metastatic,8,1,3,no
1941,2394267,Table 1,BaselineCharacteristic,"??To spleen, retroperitoneum, other abdomen",,"??To spleen, retroperitoneum, other abdomen", Extent of disease ?Metastatic,9,0,2,no
1941,2394267,Table 1,BaselineCharacteristic,x,,"??To spleen, retroperitoneum, other abdomen", Extent of disease ?Metastatic,9,1,3,no
1941,2394267,Table 1,BaselineCharacteristic,??To bone and abdomen,,??To bone and abdomen, Extent of disease ?Metastatic,10,0,2,no
1941,2394267,Table 1,BaselineCharacteristic,x,,??To bone and abdomen, Extent of disease ?Metastatic,10,1,3,no
1941,2394267,Table 1,BaselineCharacteristic,,,None,None,11,0,2,no
1941,2394267,Table 1,BaselineCharacteristic,,,None,None,11,1,3,no
1941,2394267,Table 1,BaselineCharacteristic,Previous treatmenta,,None,None,12,0,24,no
1941,2394267,Table 1,BaselineCharacteristic,,,Previous treatmenta,None,12,1,43,no
1941,2394267,Table 1,BaselineCharacteristic,?None,,?None, Previous treatmenta,13,0,2,no
1941,2394267,Table 1,BaselineCharacteristic,xx,,?None, Previous treatmenta,13,1,3,no
1941,2394267,Table 1,BaselineCharacteristic,?Surgery,,?Surgery, Previous treatmenta,14,0,2,no
1941,2394267,Table 1,BaselineCharacteristic,xx,,?Surgery, Previous treatmenta,14,1,3,no
1941,2394267,Table 1,BaselineCharacteristic,?Chemotherapy,,?Chemotherapy, Previous treatmenta,15,0,2,no
1941,2394267,Table 1,BaselineCharacteristic,x,,?Chemotherapy, Previous treatmenta,15,1,3,no
1941,2394267,Table 1,BaselineCharacteristic,?Hormone/immunotherapy,,?Hormone/immunotherapy, Previous treatmenta,16,0,2,no
1941,2394267,Table 1,BaselineCharacteristic,x,,?Hormone/immunotherapy, Previous treatmenta,16,1,3,no
1941,2394267,Table 1,BaselineCharacteristic,,,None,None,17,0,2,no
1941,2394267,Table 1,BaselineCharacteristic,,,None,None,17,1,3,no
1941,2394267,Table 1,BaselineCharacteristic,Performance status (WHO)b,,None,None,18,0,24,no
1941,2394267,Table 1,BaselineCharacteristic,,,Performance status (WHO)b,None,18,1,43,no
1941,2394267,Table 1,BaselineCharacteristic,?x,,?x, Performance status (WHO)b,19,0,2,no
1941,2394267,Table 1,BaselineCharacteristic,xx (xx.x),,?x, Performance status (WHO)b,19,1,3,no
1941,2394267,Table 1,BaselineCharacteristic,?x,,?x, Performance status (WHO)b,20,0,2,no
1941,2394267,Table 1,BaselineCharacteristic,xx (xx.x),,?x, Performance status (WHO)b,20,1,3,no
1941,2394267,Table 1,BaselineCharacteristic,?x,,?x, Performance status (WHO)b,21,0,2,no
1941,2394267,Table 1,BaselineCharacteristic,x (xx.x),,?x, Performance status (WHO)b,21,1,3,no
1941,2394267,Table 1,BaselineCharacteristic,,,None,None,22,0,2,no
1941,2394267,Table 1,BaselineCharacteristic,,,None,None,22,1,3,no
1941,2394267,Table 1,BaselineCharacteristic,"Age (years), median (range)",,"Age (years), median (range)",,23,0,2,no
1941,2394267,Table 1,BaselineCharacteristic,,,None,None,24,0,2,no
1941,2394267,Table 1,BaselineCharacteristic,,,None,None,24,1,3,no
1941,2394267,Table 1,BaselineCharacteristic,"AFP (ng?ml?x), median (range)",,"AFP (ng?ml?x), median (range)",,25,0,2,no
1976,2394470,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,0,12,no
1976,2394470,Table 1,BaselineCharacteristic,All patients (n=xx),,Characteristic,None,0,1,1,no
1976,2394470,Table 1,BaselineCharacteristic,Age (years): mean (range),Characteristic ; ,Age (years): mean (range),,1,0,2,no
1976,2394470,Table 1,BaselineCharacteristic,Male?:?female; n,Characteristic ; ,Male?:?female; n,,2,0,2,no
1976,2394470,Table 1,BaselineCharacteristic,xx?:?xx,All patients (n=xx) ; ,Male?:?female; n,,2,1,3,yes
1976,2394470,Table 1,BaselineCharacteristic,Caucasian: n,Characteristic ; ,Caucasian: n,,3,0,2,no
1976,2394470,Table 1,BaselineCharacteristic,xx,All patients (n=xx) ; ,Caucasian: n,,3,1,3,no
1976,2394470,Table 1,BaselineCharacteristic,Weight (kg): mean (range),Characteristic ; ,Weight (kg): mean (range),,4,0,2,no
1976,2394470,Table 1,BaselineCharacteristic,Site of current cancer: n,Characteristic ; ,None,None,5,0,24,no
1976,2394470,Table 1,BaselineCharacteristic,,All patients (n=xx) ; ,Site of current cancer: n,None,5,1,43,no
1976,2394470,Table 1,BaselineCharacteristic,?Colorectal,Characteristic ; ,?Colorectal, Site of current cancer: n,6,0,2,no
1976,2394470,Table 1,BaselineCharacteristic,x,All patients (n=xx) ; ,?Colorectal, Site of current cancer: n,6,1,3,no
1976,2394470,Table 1,BaselineCharacteristic,?Ovary,Characteristic ; ,?Ovary, Site of current cancer: n,7,0,2,no
1976,2394470,Table 1,BaselineCharacteristic,x,All patients (n=xx) ; ,?Ovary, Site of current cancer: n,7,1,3,no
1976,2394470,Table 1,BaselineCharacteristic,?Mesothelioma,Characteristic ; ,?Mesothelioma, Site of current cancer: n,8,0,2,no
1976,2394470,Table 1,BaselineCharacteristic,x,All patients (n=xx) ; ,?Mesothelioma, Site of current cancer: n,8,1,3,no
1976,2394470,Table 1,BaselineCharacteristic,?Lung,Characteristic ; ,?Lung, Site of current cancer: n,9,0,2,no
1976,2394470,Table 1,BaselineCharacteristic,x,All patients (n=xx) ; ,?Lung, Site of current cancer: n,9,1,3,no
1976,2394470,Table 1,BaselineCharacteristic,?Kidney,Characteristic ; ,?Kidney, Site of current cancer: n,10,0,2,no
1976,2394470,Table 1,BaselineCharacteristic,x,All patients (n=xx) ; ,?Kidney, Site of current cancer: n,10,1,3,no
1976,2394470,Table 1,BaselineCharacteristic,?Cervix,Characteristic ; ,?Cervix, Site of current cancer: n,11,0,2,no
1976,2394470,Table 1,BaselineCharacteristic,x,All patients (n=xx) ; ,?Cervix, Site of current cancer: n,11,1,3,no
1976,2394470,Table 1,BaselineCharacteristic,?Breast,Characteristic ; ,?Breast, Site of current cancer: n,12,0,2,no
1976,2394470,Table 1,BaselineCharacteristic,x,All patients (n=xx) ; ,?Breast, Site of current cancer: n,12,1,3,no
1976,2394470,Table 1,BaselineCharacteristic,?Skin,Characteristic ; ,?Skin, Site of current cancer: n,13,0,2,no
1976,2394470,Table 1,BaselineCharacteristic,x,All patients (n=xx) ; ,?Skin, Site of current cancer: n,13,1,3,no
1976,2394470,Table 1,BaselineCharacteristic,?Other,Characteristic ; ,?Other, Site of current cancer: n,14,0,2,no
1976,2394470,Table 1,BaselineCharacteristic,x,All patients (n=xx) ; ,?Other, Site of current cancer: n,14,1,3,no
1976,2394470,Table 1,BaselineCharacteristic,Prior anticancer treatment: na,Characteristic ; ,None,None,15,0,24,no
1976,2394470,Table 1,BaselineCharacteristic,,All patients (n=xx) ; ,Prior anticancer treatment: na,None,15,1,43,no
1976,2394470,Table 1,BaselineCharacteristic,?Chemotherapy,Characteristic ; ,?Chemotherapy, Prior anticancer treatment: na,16,0,2,no
1976,2394470,Table 1,BaselineCharacteristic,xx,All patients (n=xx) ; ,?Chemotherapy, Prior anticancer treatment: na,16,1,3,no
1976,2394470,Table 1,BaselineCharacteristic,?Radiation therapy,Characteristic ; ,?Radiation therapy, Prior anticancer treatment: na,17,0,2,no
1976,2394470,Table 1,BaselineCharacteristic,xx,All patients (n=xx) ; ,?Radiation therapy, Prior anticancer treatment: na,17,1,3,no
1976,2394470,Table 1,BaselineCharacteristic,?Surgery,Characteristic ; ,?Surgery, Prior anticancer treatment: na,18,0,2,no
1976,2394470,Table 1,BaselineCharacteristic,xx,All patients (n=xx) ; ,?Surgery, Prior anticancer treatment: na,18,1,3,no
1976,2394470,Table 1,BaselineCharacteristic,?Laser treatment,Characteristic ; ,?Laser treatment, Prior anticancer treatment: na,19,0,2,no
1976,2394470,Table 1,BaselineCharacteristic,x,All patients (n=xx) ; ,?Laser treatment, Prior anticancer treatment: na,19,1,3,no
1976,2394470,Table 1,BaselineCharacteristic,?Cryotherapy,Characteristic ; ,?Cryotherapy, Prior anticancer treatment: na,20,0,2,no
1976,2394470,Table 1,BaselineCharacteristic,x,All patients (n=xx) ; ,?Cryotherapy, Prior anticancer treatment: na,20,1,3,no
1988,2395326,Table 2,BaselineCharacteristic,,,None,None,0,0,12,no
1988,2395326,Table 2,BaselineCharacteristic,,,,None,0,1,1,no
1988,2395326,Table 2,BaselineCharacteristic,Docetaxel/cisplatin,,,None,0,2,1,no
1988,2395326,Table 2,BaselineCharacteristic,Docetaxel/irinotecan,,,None,0,3,1,no
1988,2395326,Table 2,BaselineCharacteristic,?x text,,,None,0,4,1,no
1988,2395326,Table 2,BaselineCharacteristic,No. of patients, ; ,No. of patients,None,1,0,2,no
1988,2395326,Table 2,BaselineCharacteristic,, ; ,No. of patients,None,1,1,3,no
1988,2395326,Table 2,BaselineCharacteristic,xx,Docetaxel/cisplatin ; ,No. of patients,None,1,2,3,no
1988,2395326,Table 2,BaselineCharacteristic,xx,Docetaxel/irinotecan ; ,No. of patients,None,1,3,3,no
1988,2395326,Table 2,BaselineCharacteristic,,?x text ; ,No. of patients,None,1,4,3,no
1988,2395326,Table 2,BaselineCharacteristic,Gender, ; ,Gender,None,2,0,2,no
1988,2395326,Table 2,BaselineCharacteristic,Male/female, ; ,Gender,None,2,1,3,no
1988,2395326,Table 2,BaselineCharacteristic,xx/xx,Docetaxel/cisplatin ; ,Gender,None,2,2,3,yes
1988,2395326,Table 2,BaselineCharacteristic,xx/xx,Docetaxel/irinotecan ; ,Gender,None,2,3,3,yes
1988,2395326,Table 2,BaselineCharacteristic,P=x.xxx,?x text ; ,Gender,None,2,4,3,no
1988,2395326,Table 2,BaselineCharacteristic,Age (years), ; ,Age (years),None,3,0,2,no
1988,2395326,Table 2,BaselineCharacteristic,Median, ; ,Age (years),None,3,1,3,no
1988,2395326,Table 2,BaselineCharacteristic,xx,Docetaxel/cisplatin ; ,Age (years),None,3,2,3,no
1988,2395326,Table 2,BaselineCharacteristic,xx,Docetaxel/irinotecan ; ,Age (years),None,3,3,3,no
1988,2395326,Table 2,BaselineCharacteristic,,?x text ; ,Age (years),None,3,4,3,no
1988,2395326,Table 2,BaselineCharacteristic,, ; ,None,None,4,0,2,no
1988,2395326,Table 2,BaselineCharacteristic,Range, ; ,None,None,4,1,3,no
1988,2395326,Table 2,BaselineCharacteristic,,?x text ; ,None,None,4,4,3,no
1988,2395326,Table 2,BaselineCharacteristic,PS, ; ,PS,None,5,0,2,no
1988,2395326,Table 2,BaselineCharacteristic,x/x, ; ,PS,None,5,1,3,no
1988,2395326,Table 2,BaselineCharacteristic,xx/xx,Docetaxel/cisplatin ; ,PS,None,5,2,3,no
1988,2395326,Table 2,BaselineCharacteristic,xx/xx,Docetaxel/irinotecan ; ,PS,None,5,3,3,no
1988,2395326,Table 2,BaselineCharacteristic,P=x.xxx,?x text ; ,PS,None,5,4,3,no
1988,2395326,Table 2,BaselineCharacteristic,Histology, ; ,Histology,None,6,0,2,no
1988,2395326,Table 2,BaselineCharacteristic,Adenocarcinoma, ; ,Histology,None,6,1,3,no
1988,2395326,Table 2,BaselineCharacteristic,xx,Docetaxel/cisplatin ; ,Histology,None,6,2,3,no
1988,2395326,Table 2,BaselineCharacteristic,xx,Docetaxel/irinotecan ; ,Histology,None,6,3,3,no
1988,2395326,Table 2,BaselineCharacteristic,P=x.xxx,?x text ; ,Histology,None,6,4,3,no
1988,2395326,Table 2,BaselineCharacteristic,, ; ,None,None,7,0,2,no
1988,2395326,Table 2,BaselineCharacteristic,Squamous cell carcinoma, ; ,None,None,7,1,3,no
1988,2395326,Table 2,BaselineCharacteristic,xx,Docetaxel/cisplatin ; ,None,None,7,2,3,no
1988,2395326,Table 2,BaselineCharacteristic,x,Docetaxel/irinotecan ; ,None,None,7,3,3,no
1988,2395326,Table 2,BaselineCharacteristic,,?x text ; ,None,None,7,4,3,no
1988,2395326,Table 2,BaselineCharacteristic,, ; ,None,None,8,0,2,no
1988,2395326,Table 2,BaselineCharacteristic,Others, ; ,None,None,8,1,3,no
1988,2395326,Table 2,BaselineCharacteristic,x,Docetaxel/cisplatin ; ,None,None,8,2,3,no
1988,2395326,Table 2,BaselineCharacteristic,x,Docetaxel/irinotecan ; ,None,None,8,3,3,no
1988,2395326,Table 2,BaselineCharacteristic,,?x text ; ,None,None,8,4,3,no
1988,2395326,Table 2,BaselineCharacteristic,Disease stage, ; ,Disease stage,None,9,0,2,no
1988,2395326,Table 2,BaselineCharacteristic,Illb/IV, ; ,Disease stage,None,9,1,3,no
1988,2395326,Table 2,BaselineCharacteristic,xx/xx,Docetaxel/cisplatin ; ,Disease stage,None,9,2,3,no
1988,2395326,Table 2,BaselineCharacteristic,xx/xx,Docetaxel/irinotecan ; ,Disease stage,None,9,3,3,no
1988,2395326,Table 2,BaselineCharacteristic,P=x.xxx,?x text ; ,Disease stage,None,9,4,3,no
1988,2395326,Table 2,BaselineCharacteristic,Brain metastasis, ; ,Brain metastasis,None,10,0,2,no
1988,2395326,Table 2,BaselineCharacteristic,(+)/(?), ; ,Brain metastasis,None,10,1,3,no
1988,2395326,Table 2,BaselineCharacteristic,x/xx,Docetaxel/cisplatin ; ,Brain metastasis,None,10,2,3,no
1988,2395326,Table 2,BaselineCharacteristic,xx/xx,Docetaxel/irinotecan ; ,Brain metastasis,None,10,3,3,no
1988,2395326,Table 2,BaselineCharacteristic,P=x.xxx,?x text ; ,Brain metastasis,None,10,4,3,no
2001,2409455,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no
2001,2409455,Table 1,BaselineCharacteristic,No. of patients,,,None,0,1,1,no
2001,2409455,Table 1,BaselineCharacteristic,%,,,None,0,2,1,no
2001,2409455,Table 1,BaselineCharacteristic,Age (years), ; ,None,None,1,0,24,no
2001,2409455,Table 1,BaselineCharacteristic,Age (years),No. of patients ; ,Age (years),None,1,1,43,no
2001,2409455,Table 1,BaselineCharacteristic,Age (years),% ; ,Age (years),None,1,2,43,no
2001,2409455,Table 1,BaselineCharacteristic,?Median, ; ,?Median, Age (years),2,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Median, Age (years),2,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx,% ; ,?Median, Age (years),2,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,?Range, ; ,?Range, Age (years),3,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,, ; ,None,None,4,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,4,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,,% ; ,None,None,4,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,Sex, ; ,None,None,5,0,24,no
2001,2409455,Table 1,BaselineCharacteristic,Sex,No. of patients ; ,Sex,None,5,1,43,no
2001,2409455,Table 1,BaselineCharacteristic,Sex,% ; ,Sex,None,5,2,43,no
2001,2409455,Table 1,BaselineCharacteristic,?Male, ; ,?Male, Sex,6,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Male, Sex,6,1,3,yes
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Male, Sex,6,2,3,yes
2001,2409455,Table 1,BaselineCharacteristic,?Female, ; ,?Female, Sex,7,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Female, Sex,7,1,3,yes
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Female, Sex,7,2,3,yes
2001,2409455,Table 1,BaselineCharacteristic,, ; ,None,None,8,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,8,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,,% ; ,None,None,8,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,Performance status, ; ,None,None,9,0,24,no
2001,2409455,Table 1,BaselineCharacteristic,Performance status,No. of patients ; ,Performance status,None,9,1,43,no
2001,2409455,Table 1,BaselineCharacteristic,Performance status,% ; ,Performance status,None,9,2,43,no
2001,2409455,Table 1,BaselineCharacteristic,?ECOG x, ; ,?ECOG x, Performance status,10,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?ECOG x, Performance status,10,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?ECOG x, Performance status,10,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,?ECOG x, ; ,?ECOG x, Performance status,11,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?ECOG x, Performance status,11,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?ECOG x, Performance status,11,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,?ECOG x, ; ,?ECOG x, Performance status,12,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,x,No. of patients ; ,?ECOG x, Performance status,12,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,x.x,% ; ,?ECOG x, Performance status,12,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,, ; ,None,None,13,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,13,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,,% ; ,None,None,13,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,Histology, ; ,None,None,14,0,24,no
2001,2409455,Table 1,BaselineCharacteristic,Histology,No. of patients ; ,Histology,None,14,1,43,no
2001,2409455,Table 1,BaselineCharacteristic,Histology,% ; ,Histology,None,14,2,43,no
2001,2409455,Table 1,BaselineCharacteristic,?WDA, ; ,?WDA, Histology,15,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?WDA, Histology,15,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?WDA, Histology,15,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,?PDC, ; ,?PDC, Histology,16,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?PDC, Histology,16,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?PDC, Histology,16,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,?SCC, ; ,?SCC, Histology,17,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,x,No. of patients ; ,?SCC, Histology,17,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,x.x,% ; ,?SCC, Histology,17,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,?UN, ; ,?UN, Histology,18,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?UN, Histology,18,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,x.x,% ; ,?UN, Histology,18,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,, ; ,None,None,19,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,19,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,,% ; ,None,None,19,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,Extension, ; ,None,None,20,0,24,no
2001,2409455,Table 1,BaselineCharacteristic,Extension,No. of patients ; ,Extension,None,20,1,43,no
2001,2409455,Table 1,BaselineCharacteristic,Extension,% ; ,Extension,None,20,2,43,no
2001,2409455,Table 1,BaselineCharacteristic,?Locoregional, ; ,?Locoregional, Extension,21,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Locoregional, Extension,21,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Locoregional, Extension,21,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,?Disseminated, ; ,?Disseminated, Extension,22,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Disseminated, Extension,22,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Disseminated, Extension,22,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,, ; ,None,None,23,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,23,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,,% ; ,None,None,23,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,Topography, ; ,None,None,24,0,24,no
2001,2409455,Table 1,BaselineCharacteristic,Topography,No. of patients ; ,Topography,None,24,1,43,no
2001,2409455,Table 1,BaselineCharacteristic,Topography,% ; ,Topography,None,24,2,43,no
2001,2409455,Table 1,BaselineCharacteristic,?Supradiaphragmatic, ; ,?Supradiaphragmatic, Topography,25,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Supradiaphragmatic, Topography,25,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Supradiaphragmatic, Topography,25,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,?Subdiaphragmatic, ; ,?Subdiaphragmatic, Topography,26,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Subdiaphragmatic, Topography,26,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Subdiaphragmatic, Topography,26,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,?Both sides, ; ,?Both sides, Topography,27,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Both sides, Topography,27,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Both sides, Topography,27,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,, ; ,None,None,28,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,28,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,,% ; ,None,None,28,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,Number of involved sites, ; ,None,None,29,0,24,no
2001,2409455,Table 1,BaselineCharacteristic,Number of involved sites,No. of patients ; ,Number of involved sites,None,29,1,43,no
2001,2409455,Table 1,BaselineCharacteristic,Number of involved sites,% ; ,Number of involved sites,None,29,2,43,no
2001,2409455,Table 1,BaselineCharacteristic,?x, ; ,?x, Number of involved sites,30,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?x, Number of involved sites,30,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?x, Number of involved sites,30,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,?x, ; ,?x, Number of involved sites,31,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?x, Number of involved sites,31,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?x, Number of involved sites,31,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,?x, ; ,?x, Number of involved sites,32,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?x, Number of involved sites,32,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?x, Number of involved sites,32,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,??x, ; ,??x, Number of involved sites,33,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,??x, Number of involved sites,33,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,??x, Number of involved sites,33,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,, ; ,None,None,34,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,34,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,,% ; ,None,None,34,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,Number of metastases, ; ,None,None,35,0,24,no
2001,2409455,Table 1,BaselineCharacteristic,Number of metastases,No. of patients ; ,Number of metastases,None,35,1,43,no
2001,2409455,Table 1,BaselineCharacteristic,Number of metastases,% ; ,Number of metastases,None,35,2,43,no
2001,2409455,Table 1,BaselineCharacteristic,?x, ; ,?x, Number of metastases,36,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?x, Number of metastases,36,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?x, Number of metastases,36,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,?x, ; ,?x, Number of metastases,37,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,x,No. of patients ; ,?x, Number of metastases,37,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,x.x,% ; ,?x, Number of metastases,37,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,?x, ; ,?x, Number of metastases,38,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?x, Number of metastases,38,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?x, Number of metastases,38,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,??x, ; ,??x, Number of metastases,39,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,??x, Number of metastases,39,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,??x, Number of metastases,39,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,, ; ,None,None,40,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,40,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,,% ; ,None,None,40,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,Main involved sites, ; ,None,None,41,0,24,no
2001,2409455,Table 1,BaselineCharacteristic,Main involved sites,No. of patients ; ,Main involved sites,None,41,1,43,no
2001,2409455,Table 1,BaselineCharacteristic,Main involved sites,% ; ,Main involved sites,None,41,2,43,no
2001,2409455,Table 1,BaselineCharacteristic,?Supraclavicular nodes, ; ,?Supraclavicular nodes, Main involved sites,42,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Supraclavicular nodes, Main involved sites,42,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Supraclavicular nodes, Main involved sites,42,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,?Hylomediastinal nodes, ; ,?Hylomediastinal nodes, Main involved sites,43,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Hylomediastinal nodes, Main involved sites,43,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Hylomediastinal nodes, Main involved sites,43,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,?Abdominal nodes, ; ,?Abdominal nodes, Main involved sites,44,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Abdominal nodes, Main involved sites,44,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Abdominal nodes, Main involved sites,44,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,?Bone, ; ,?Bone, Main involved sites,45,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Bone, Main involved sites,45,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Bone, Main involved sites,45,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,?Liver, ; ,?Liver, Main involved sites,46,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Liver, Main involved sites,46,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Liver, Main involved sites,46,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,?Lung, ; ,?Lung, Main involved sites,47,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Lung, Main involved sites,47,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Lung, Main involved sites,47,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,?Ascites, ; ,?Ascites, Main involved sites,48,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Ascites, Main involved sites,48,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Ascites, Main involved sites,48,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,?Pleural effusion, ; ,?Pleural effusion, Main involved sites,49,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Pleural effusion, Main involved sites,49,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,x.x,% ; ,?Pleural effusion, Main involved sites,49,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,?Nodes/soft tissues only, ; ,?Nodes/soft tissues only, Main involved sites,50,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Nodes/soft tissues only, Main involved sites,50,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Nodes/soft tissues only, Main involved sites,50,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,?Visceral/bone involvement, ; ,?Visceral/bone involvement, Main involved sites,51,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Visceral/bone involvement, Main involved sites,51,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Visceral/bone involvement, Main involved sites,51,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,, ; ,None,None,52,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,52,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,,% ; ,None,None,52,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,Main symptoms, ; ,None,None,53,0,24,no
2001,2409455,Table 1,BaselineCharacteristic,Main symptoms,No. of patients ; ,Main symptoms,None,53,1,43,no
2001,2409455,Table 1,BaselineCharacteristic,Main symptoms,% ; ,Main symptoms,None,53,2,43,no
2001,2409455,Table 1,BaselineCharacteristic,?Pain, ; ,?Pain, Main symptoms,54,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Pain, Main symptoms,54,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Pain, Main symptoms,54,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,?Gastrointestinal, ; ,?Gastrointestinal, Main symptoms,55,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Gastrointestinal, Main symptoms,55,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Gastrointestinal, Main symptoms,55,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,?Respiratory, ; ,?Respiratory, Main symptoms,56,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Respiratory, Main symptoms,56,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Respiratory, Main symptoms,56,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,?Fever, ; ,?Fever, Main symptoms,57,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Fever, Main symptoms,57,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Fever, Main symptoms,57,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,?Weight loss >xx%, ; ,?Weight loss >xx%, Main symptoms,58,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Weight loss >xx%, Main symptoms,58,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,x.x,% ; ,?Weight loss >xx%, Main symptoms,58,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,, ; ,None,None,59,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,59,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,,% ; ,None,None,59,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,Laboratory parameters, ; ,None,None,60,0,24,no
2001,2409455,Table 1,BaselineCharacteristic,Laboratory parameters,No. of patients ; ,Laboratory parameters,None,60,1,43,no
2001,2409455,Table 1,BaselineCharacteristic,Laboratory parameters,% ; ,Laboratory parameters,None,60,2,43,no
2001,2409455,Table 1,BaselineCharacteristic,?Hb <xx, ; ,?Hb <xx, Laboratory parameters,61,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Hb <xx, Laboratory parameters,61,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Hb <xx, Laboratory parameters,61,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,?CEA >x, ; ,?CEA >x, Laboratory parameters,65,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx/xx,No. of patients ; ,?CEA >x, Laboratory parameters,65,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?CEA >x, Laboratory parameters,65,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,?CA xx.x>xx, ; ,?CA xx.x>xx, Laboratory parameters,66,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx/xx,No. of patients ; ,?CA xx.x>xx, Laboratory parameters,66,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?CA xx.x>xx, Laboratory parameters,66,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,?CA xxx>xx, ; ,?CA xxx>xx, Laboratory parameters,67,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx/xx,No. of patients ; ,?CA xxx>xx, Laboratory parameters,67,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?CA xxx>xx, Laboratory parameters,67,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,?Any epithelial marker abnormal, ; ,?Any epithelial marker abnormal, Laboratory parameters,68,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Any epithelial marker abnormal, Laboratory parameters,68,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,xx.x,% ; ,?Any epithelial marker abnormal, Laboratory parameters,68,2,3,no
2001,2409455,Table 1,BaselineCharacteristic,?Any germ cell marker abnormal, ; ,?Any germ cell marker abnormal, Laboratory parameters,69,0,2,no
2001,2409455,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Any germ cell marker abnormal, Laboratory parameters,69,1,3,no
2001,2409455,Table 1,BaselineCharacteristic,x.x,% ; ,?Any germ cell marker abnormal, Laboratory parameters,69,2,3,no
2011,2409510,Table 2,BaselineCharacteristic,No. of patients,,No. of patients,,0,0,2,no
2011,2409510,Table 2,BaselineCharacteristic,,,No. of patients,,0,1,3,no
2011,2409510,Table 2,BaselineCharacteristic,xx,,No. of patients,,0,2,3,no
2011,2409510,Table 2,BaselineCharacteristic,"Age, years",,"Age, years",,1,0,24,no
2011,2409510,Table 2,BaselineCharacteristic,Median,,"Age, years",,1,1,43,no
2011,2409510,Table 2,BaselineCharacteristic,xx.x,,"Age, years",,1,2,43,no
2011,2409510,Table 2,BaselineCharacteristic,,,,,2,0,2,no
2011,2409510,Table 2,BaselineCharacteristic,Range,,,,2,1,3,no
2011,2409510,Table 2,BaselineCharacteristic,Sex,,Sex,,3,0,2,no
2011,2409510,Table 2,BaselineCharacteristic,Male/female,,Sex,,3,1,3,no
2011,2409510,Table 2,BaselineCharacteristic,xx/x,,Sex,,3,2,3,yes
2011,2409510,Table 2,BaselineCharacteristic,Performance status,,Performance status,,4,0,2,no
2011,2409510,Table 2,BaselineCharacteristic,x/x,,Performance status,,4,1,3,no
2011,2409510,Table 2,BaselineCharacteristic,x/xx,,Performance status,,4,2,3,no
2011,2409510,Table 2,BaselineCharacteristic,Histology,,Histology,,5,0,2,no
2011,2409510,Table 2,BaselineCharacteristic,Adeno/squamous,,Histology,,5,1,3,no
2011,2409510,Table 2,BaselineCharacteristic,xx/x,,Histology,,5,2,3,no
2011,2409510,Table 2,BaselineCharacteristic,Stage,,Stage,,6,0,2,no
2011,2409510,Table 2,BaselineCharacteristic,IIIB/IV,,Stage,,6,1,3,no
2011,2409510,Table 2,BaselineCharacteristic,x/xx,,Stage,,6,2,3,no
2011,2409510,Table 2,BaselineCharacteristic,Prior therapy,,Prior therapy,,7,0,24,no
2011,2409510,Table 2,BaselineCharacteristic,None,,Prior therapy,,7,1,43,no
2011,2409510,Table 2,BaselineCharacteristic,x,,Prior therapy,,7,2,43,no
2011,2409510,Table 2,BaselineCharacteristic,,,,,8,0,2,no
2011,2409510,Table 2,BaselineCharacteristic,Surgery,,,,8,1,3,no
2011,2409510,Table 2,BaselineCharacteristic,x,,,,8,2,3,no
2011,2409510,Table 2,BaselineCharacteristic,,,,,9,0,2,no
2011,2409510,Table 2,BaselineCharacteristic,Radiation,,,,9,1,3,no
2011,2409510,Table 2,BaselineCharacteristic,x,,,,9,2,3,no
2011,2409510,Table 2,BaselineCharacteristic,,,,,10,0,2,no
2011,2409510,Table 2,BaselineCharacteristic,Chemotherapy,,,,10,1,3,no
2011,2409510,Table 2,BaselineCharacteristic,xx,,,,10,2,3,no
2011,2409510,Table 2,BaselineCharacteristic,,,,,11,0,2,no
2011,2409510,Table 2,BaselineCharacteristic,?CDDP-based,,,,11,1,3,no
2011,2409510,Table 2,BaselineCharacteristic,x,,,,11,2,3,no
2011,2409510,Table 2,BaselineCharacteristic,,,,,12,0,2,no
2011,2409510,Table 2,BaselineCharacteristic,?CBDCA-based,,,,12,1,3,no
2011,2409510,Table 2,BaselineCharacteristic,x,,,,12,2,3,no
2011,2409510,Table 2,BaselineCharacteristic,,,,,13,0,2,no
2011,2409510,Table 2,BaselineCharacteristic,?Nonplatinum,,,,13,1,3,no
2011,2409510,Table 2,BaselineCharacteristic,x,,,,13,2,3,no
2011,2409510,Table 2,BaselineCharacteristic,,,,,14,0,2,no
2011,2409510,Table 2,BaselineCharacteristic,?UFT,,,,14,1,3,no
2011,2409510,Table 2,BaselineCharacteristic,x,,,,14,2,3,no
2011,2409510,Table 2,BaselineCharacteristic,,,,,15,0,2,no
2011,2409510,Table 2,BaselineCharacteristic,?Gefitinin,,,,15,1,3,no
2011,2409510,Table 2,BaselineCharacteristic,x,,,,15,2,3,no
2012,2409516,Table 1,BaselineCharacteristic,Patients entered,,None,None,0,0,12,no
2012,2409516,Table 1,BaselineCharacteristic,x,,Patients entered,None,0,1,1,no
2012,2409516,Table 1,BaselineCharacteristic,Male/female,,None,None,1,0,12,no
2012,2409516,Table 1,BaselineCharacteristic,x/x,,Male/female,None,1,1,1,yes
2012,2409516,Table 1,BaselineCharacteristic,"Median age, years (range)",,None,None,2,0,12,no
2012,2409516,Table 1,BaselineCharacteristic,,,None,None,3,0,2,no
2012,2409516,Table 1,BaselineCharacteristic,,,None,None,3,1,3,no
2012,2409516,Table 1,BaselineCharacteristic,Performance status,,None,None,4,0,24,no
2012,2409516,Table 1,BaselineCharacteristic,,,Performance status,None,4,1,43,no
2012,2409516,Table 1,BaselineCharacteristic,?x,,?x, Performance status,5,0,2,no
2012,2409516,Table 1,BaselineCharacteristic,x,,?x, Performance status,5,1,3,no
2012,2409516,Table 1,BaselineCharacteristic,?x,,?x, Performance status,6,0,2,no
2012,2409516,Table 1,BaselineCharacteristic,x,,?x, Performance status,6,1,3,no
2012,2409516,Table 1,BaselineCharacteristic,,,None,None,7,0,2,no
2012,2409516,Table 1,BaselineCharacteristic,,,None,None,7,1,3,no
2012,2409516,Table 1,BaselineCharacteristic,Malignancy,,None,None,8,0,24,no
2012,2409516,Table 1,BaselineCharacteristic,,,Malignancy,None,8,1,43,no
2012,2409516,Table 1,BaselineCharacteristic,?Melanoma,,?Melanoma, Malignancy,9,0,2,no
2012,2409516,Table 1,BaselineCharacteristic,x,,?Melanoma, Malignancy,9,1,3,no
2012,2409516,Table 1,BaselineCharacteristic,?Non-small-cell lung cancer,,?Non-small-cell lung cancer, Malignancy,10,0,2,no
2012,2409516,Table 1,BaselineCharacteristic,x,,?Non-small-cell lung cancer, Malignancy,10,1,3,no
2012,2409516,Table 1,BaselineCharacteristic,?Sarcoma,,?Sarcoma, Malignancy,11,0,2,no
2012,2409516,Table 1,BaselineCharacteristic,x,,?Sarcoma, Malignancy,11,1,3,no
2012,2409516,Table 1,BaselineCharacteristic,?Renal cell carcinoma,,?Renal cell carcinoma, Malignancy,12,0,2,no
2012,2409516,Table 1,BaselineCharacteristic,x,,?Renal cell carcinoma, Malignancy,12,1,3,no
2012,2409516,Table 1,BaselineCharacteristic,,,None,None,13,0,2,no
2012,2409516,Table 1,BaselineCharacteristic,,,None,None,13,1,3,no
2012,2409516,Table 1,BaselineCharacteristic,Prior therapy,,None,None,14,0,24,no
2012,2409516,Table 1,BaselineCharacteristic,,,Prior therapy,None,14,1,43,no
2012,2409516,Table 1,BaselineCharacteristic,?Chemotherapy,,?Chemotherapy, Prior therapy,15,0,2,no
2012,2409516,Table 1,BaselineCharacteristic,x,,?Chemotherapy, Prior therapy,15,1,3,no
2012,2409516,Table 1,BaselineCharacteristic,?Radiotherapy,,?Radiotherapy, Prior therapy,16,0,2,no
2012,2409516,Table 1,BaselineCharacteristic,x,,?Radiotherapy, Prior therapy,16,1,3,no
2012,2409516,Table 1,BaselineCharacteristic,?Immunotherapy,,?Immunotherapy, Prior therapy,17,0,2,no
2012,2409516,Table 1,BaselineCharacteristic,x,,?Immunotherapy, Prior therapy,17,1,3,no
2012,2409516,Table 1,BaselineCharacteristic,?Hormonal therapy,,?Hormonal therapy, Prior therapy,18,0,2,no
2012,2409516,Table 1,BaselineCharacteristic,x,,?Hormonal therapy, Prior therapy,18,1,3,no
2062,2409820,Table 2,BaselineCharacteristic,,,None,None,0,0,12,no
2062,2409820,Table 2,BaselineCharacteristic,n,,,None,0,1,1,no
2062,2409820,Table 2,BaselineCharacteristic,Entered/evaluable, ; ,Entered/evaluable,,1,0,2,no
2062,2409820,Table 2,BaselineCharacteristic,xx/xx,n ; ,Entered/evaluable,,1,1,3,no
2062,2409820,Table 2,BaselineCharacteristic,Male/female, ; ,Male/female,,2,0,2,no
2062,2409820,Table 2,BaselineCharacteristic,xx/xx,n ; ,Male/female,,2,1,3,yes
2062,2409820,Table 2,BaselineCharacteristic,Median age (range), ; ,Median age (range),,3,0,2,no
2062,2409820,Table 2,BaselineCharacteristic,, ; ,None,None,4,0,2,no
2062,2409820,Table 2,BaselineCharacteristic,,n ; ,None,None,4,1,3,no
2062,2409820,Table 2,BaselineCharacteristic,Performance status, ; ,None,None,5,0,24,no
2062,2409820,Table 2,BaselineCharacteristic,,n ; ,Performance status,None,5,1,43,no
2062,2409820,Table 2,BaselineCharacteristic,?x, ; ,?x, Performance status,6,0,2,no
2062,2409820,Table 2,BaselineCharacteristic,xx,n ; ,?x, Performance status,6,1,3,no
2062,2409820,Table 2,BaselineCharacteristic,?x, ; ,?x, Performance status,7,0,2,no
2062,2409820,Table 2,BaselineCharacteristic,xx,n ; ,?x, Performance status,7,1,3,no
2062,2409820,Table 2,BaselineCharacteristic,, ; ,None,None,8,0,2,no
2062,2409820,Table 2,BaselineCharacteristic,,n ; ,None,None,8,1,3,no
2062,2409820,Table 2,BaselineCharacteristic,Primary tumour site, ; ,None,None,9,0,24,no
2062,2409820,Table 2,BaselineCharacteristic,,n ; ,Primary tumour site,None,9,1,43,no
2062,2409820,Table 2,BaselineCharacteristic,?Lung (NSCLC), ; ,?Lung (NSCLC), Primary tumour site,10,0,2,no
2062,2409820,Table 2,BaselineCharacteristic,xx,n ; ,?Lung (NSCLC), Primary tumour site,10,1,3,no
2062,2409820,Table 2,BaselineCharacteristic,?Colon, ; ,?Colon, Primary tumour site,11,0,2,no
2062,2409820,Table 2,BaselineCharacteristic,x,n ; ,?Colon, Primary tumour site,11,1,3,no
2062,2409820,Table 2,BaselineCharacteristic,?Gastric, ; ,?Gastric, Primary tumour site,12,0,2,no
2062,2409820,Table 2,BaselineCharacteristic,x,n ; ,?Gastric, Primary tumour site,12,1,3,no
2062,2409820,Table 2,BaselineCharacteristic,?Adenoidcystic, ; ,?Adenoidcystic, Primary tumour site,13,0,2,no
2062,2409820,Table 2,BaselineCharacteristic,x,n ; ,?Adenoidcystic, Primary tumour site,13,1,3,no
2062,2409820,Table 2,BaselineCharacteristic,?Melanoma, ; ,?Melanoma, Primary tumour site,14,0,2,no
2062,2409820,Table 2,BaselineCharacteristic,x,n ; ,?Melanoma, Primary tumour site,14,1,3,no
2062,2409820,Table 2,BaselineCharacteristic,?Mesothelioma, ; ,?Mesothelioma, Primary tumour site,15,0,2,no
2062,2409820,Table 2,BaselineCharacteristic,x,n ; ,?Mesothelioma, Primary tumour site,15,1,3,no
2062,2409820,Table 2,BaselineCharacteristic,?Biliary tract, ; ,?Biliary tract, Primary tumour site,16,0,2,no
2062,2409820,Table 2,BaselineCharacteristic,x,n ; ,?Biliary tract, Primary tumour site,16,1,3,no
2062,2409820,Table 2,BaselineCharacteristic,?Ovary, ; ,?Ovary, Primary tumour site,17,0,2,no
2062,2409820,Table 2,BaselineCharacteristic,x,n ; ,?Ovary, Primary tumour site,17,1,3,no
2062,2409820,Table 2,BaselineCharacteristic,?Pancreas, ; ,?Pancreas, Primary tumour site,18,0,2,no
2062,2409820,Table 2,BaselineCharacteristic,x,n ; ,?Pancreas, Primary tumour site,18,1,3,no
2062,2409820,Table 2,BaselineCharacteristic,?Peritoneal, ; ,?Peritoneal, Primary tumour site,19,0,2,no
2062,2409820,Table 2,BaselineCharacteristic,x,n ; ,?Peritoneal, Primary tumour site,19,1,3,no
2062,2409820,Table 2,BaselineCharacteristic,?Sarcoma, ; ,?Sarcoma, Primary tumour site,20,0,2,no
2062,2409820,Table 2,BaselineCharacteristic,x,n ; ,?Sarcoma, Primary tumour site,20,1,3,no
2062,2409820,Table 2,BaselineCharacteristic,, ; ,None,None,21,0,2,no
2062,2409820,Table 2,BaselineCharacteristic,,n ; ,None,None,21,1,3,no
2062,2409820,Table 2,BaselineCharacteristic,Prior treatment, ; ,None,None,22,0,24,no
2062,2409820,Table 2,BaselineCharacteristic,,n ; ,Prior treatment,None,22,1,43,no
2062,2409820,Table 2,BaselineCharacteristic,?Previous chemotherapy, ; ,?Previous chemotherapy, Prior treatment,23,0,2,no
2062,2409820,Table 2,BaselineCharacteristic,xx,n ; ,?Previous chemotherapy, Prior treatment,23,1,3,no
2062,2409820,Table 2,BaselineCharacteristic,?Previous radiation, ; ,?Previous radiation, Prior treatment,24,0,2,no
2062,2409820,Table 2,BaselineCharacteristic,x,n ; ,?Previous radiation, Prior treatment,24,1,3,no
2062,2409820,Table 2,BaselineCharacteristic,?Previous chemotherapy and radiation, ; ,?Previous chemotherapy and radiation, Prior treatment,25,0,2,no
2062,2409820,Table 2,BaselineCharacteristic,x,n ; ,?Previous chemotherapy and radiation, Prior treatment,25,1,3,no
2062,2409820,Table 2,BaselineCharacteristic,?No Previous chemotherapy or radiation, ; ,?No Previous chemotherapy or radiation, Prior treatment,26,0,2,no
2062,2409820,Table 2,BaselineCharacteristic,xx,n ; ,?No Previous chemotherapy or radiation, Prior treatment,26,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,Characteristics,,None,None,0,0,12,no
2308,2570506,Table 1,BaselineCharacteristic,"CAP Ile/Ile, N=xx (xx%)",,Characteristics,None,0,1,1,no
2308,2570506,Table 1,BaselineCharacteristic,"Ile/Val, N=xx (xx%)",,Characteristics,None,0,2,1,no
2308,2570506,Table 1,BaselineCharacteristic,"Val/Val, N=xx (xx%)",,Characteristics,None,0,3,1,no
2308,2570506,Table 1,BaselineCharacteristic,"All patients, N=xxx",,Characteristics,None,0,4,1,no
2308,2570506,Table 1,BaselineCharacteristic,Age (years),Characteristics ; ,None,None,1,0,24,no
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",Age (years),None,1,1,43,no
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",Age (years),None,1,2,43,no
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",Age (years),None,1,3,43,no
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",Age (years),None,1,4,43,no
2308,2570506,Table 1,BaselineCharacteristic,?Median,Characteristics ; ,?Median, Age (years),2,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,xx,"CAP Ile/Ile, N=xx (xx%) ; ",?Median, Age (years),2,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx,"Ile/Val, N=xx (xx%) ; ",?Median, Age (years),2,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx,"Val/Val, N=xx (xx%) ; ",?Median, Age (years),2,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx.x,"All patients, N=xxx ; ",?Median, Age (years),2,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,?Range,Characteristics ; ,?Range, Age (years),3,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,?>xx,Characteristics ; ,?>xx, Age (years),4,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,x (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",?>xx, Age (years),4,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Ile/Val, N=xx (xx%) ; ",?>xx, Age (years),4,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,x (xx%),"Val/Val, N=xx (xx%) ; ",?>xx, Age (years),4,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,x (xx%),"All patients, N=xxx ; ",?>xx, Age (years),4,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,5,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",None,None,5,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",None,None,5,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",None,None,5,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",None,None,5,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,Gender,Characteristics ; ,None,None,6,0,24,no
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",Gender,None,6,1,43,no
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",Gender,None,6,2,43,no
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",Gender,None,6,3,43,no
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",Gender,None,6,4,43,no
2308,2570506,Table 1,BaselineCharacteristic,?Male (%),Characteristics ; ,?Male (%), Gender,7,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",?Male (%), Gender,7,1,3,yes
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Ile/Val, N=xx (xx%) ; ",?Male (%), Gender,7,2,3,yes
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Val/Val, N=xx (xx%) ; ",?Male (%), Gender,7,3,3,yes
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",?Male (%), Gender,7,4,3,yes
2308,2570506,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,8,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",None,None,8,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",None,None,8,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",None,None,8,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",None,None,8,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,WHO performance status (at start therapy),Characteristics ; ,None,None,9,0,24,no
2308,2570506,Table 1,BaselineCharacteristic,WHO performance status (at start therapy),"CAP Ile/Ile, N=xx (xx%) ; ",WHO performance status (at start therapy),None,9,1,43,no
2308,2570506,Table 1,BaselineCharacteristic,WHO performance status (at start therapy),"Ile/Val, N=xx (xx%) ; ",WHO performance status (at start therapy),None,9,2,43,no
2308,2570506,Table 1,BaselineCharacteristic,WHO performance status (at start therapy),"Val/Val, N=xx (xx%) ; ",WHO performance status (at start therapy),None,9,3,43,no
2308,2570506,Table 1,BaselineCharacteristic,WHO performance status (at start therapy),"All patients, N=xxx ; ",WHO performance status (at start therapy),None,9,4,43,no
2308,2570506,Table 1,BaselineCharacteristic,?x,Characteristics ; ,?x, WHO performance status (at start therapy),11,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,x (x%),"CAP Ile/Ile, N=xx (xx%) ; ",?x, WHO performance status (at start therapy),11,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,x (x%),"Ile/Val, N=xx (xx%) ; ",?x, WHO performance status (at start therapy),11,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,x,"Val/Val, N=xx (xx%) ; ",?x, WHO performance status (at start therapy),11,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,x (x%),"All patients, N=xxx ; ",?x, WHO performance status (at start therapy),11,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,12,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",None,None,12,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",None,None,12,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",None,None,12,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",None,None,12,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,Prior adjuvant therapy,Characteristics ; ,Prior adjuvant therapy,,13,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,x (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",Prior adjuvant therapy,,13,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,x (x%),"Ile/Val, N=xx (xx%) ; ",Prior adjuvant therapy,,13,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,x (xx%),"Val/Val, N=xx (xx%) ; ",Prior adjuvant therapy,,13,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",Prior adjuvant therapy,,13,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,14,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",None,None,14,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",None,None,14,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",None,None,14,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",None,None,14,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,Predominant localisation of metastases (at inclusion),Characteristics ; ,None,None,15,0,24,no
2308,2570506,Table 1,BaselineCharacteristic,Predominant localisation of metastases (at inclusion),"CAP Ile/Ile, N=xx (xx%) ; ",Predominant localisation of metastases (at inclusion),None,15,1,43,no
2308,2570506,Table 1,BaselineCharacteristic,Predominant localisation of metastases (at inclusion),"Ile/Val, N=xx (xx%) ; ",Predominant localisation of metastases (at inclusion),None,15,2,43,no
2308,2570506,Table 1,BaselineCharacteristic,Predominant localisation of metastases (at inclusion),"Val/Val, N=xx (xx%) ; ",Predominant localisation of metastases (at inclusion),None,15,3,43,no
2308,2570506,Table 1,BaselineCharacteristic,Predominant localisation of metastases (at inclusion),"All patients, N=xxx ; ",Predominant localisation of metastases (at inclusion),None,15,4,43,no
2308,2570506,Table 1,BaselineCharacteristic,?Liver,Characteristics ; ,?Liver, Predominant localisation of metastases (at inclusion),16,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",?Liver, Predominant localisation of metastases (at inclusion),16,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Ile/Val, N=xx (xx%) ; ",?Liver, Predominant localisation of metastases (at inclusion),16,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Val/Val, N=xx (xx%) ; ",?Liver, Predominant localisation of metastases (at inclusion),16,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",?Liver, Predominant localisation of metastases (at inclusion),16,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,?Extrahepatic,Characteristics ; ,?Extrahepatic, Predominant localisation of metastases (at inclusion),17,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",?Extrahepatic, Predominant localisation of metastases (at inclusion),17,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Ile/Val, N=xx (xx%) ; ",?Extrahepatic, Predominant localisation of metastases (at inclusion),17,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,x (xx%),"Val/Val, N=xx (xx%) ; ",?Extrahepatic, Predominant localisation of metastases (at inclusion),17,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",?Extrahepatic, Predominant localisation of metastases (at inclusion),17,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,?Unknown,Characteristics ; ,?Unknown, Predominant localisation of metastases (at inclusion),18,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,x (x%),"CAP Ile/Ile, N=xx (xx%) ; ",?Unknown, Predominant localisation of metastases (at inclusion),18,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,x (x%),"Ile/Val, N=xx (xx%) ; ",?Unknown, Predominant localisation of metastases (at inclusion),18,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,x (x%),"All patients, N=xxx ; ",?Unknown, Predominant localisation of metastases (at inclusion),18,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,19,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",None,None,19,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",None,None,19,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",None,None,19,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",None,None,19,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,Site of primary,Characteristics ; ,None,None,20,0,24,no
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",Site of primary,None,20,1,43,no
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",Site of primary,None,20,2,43,no
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",Site of primary,None,20,3,43,no
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",Site of primary,None,20,4,43,no
2308,2570506,Table 1,BaselineCharacteristic,?Colon and sigmoid,Characteristics ; ,?Colon and sigmoid, Site of primary,21,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",?Colon and sigmoid, Site of primary,21,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Ile/Val, N=xx (xx%) ; ",?Colon and sigmoid, Site of primary,21,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Val/Val, N=xx (xx%) ; ",?Colon and sigmoid, Site of primary,21,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",?Colon and sigmoid, Site of primary,21,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,?Rectum,Characteristics ; ,?Rectum, Site of primary,22,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",?Rectum, Site of primary,22,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Ile/Val, N=xx (xx%) ; ",?Rectum, Site of primary,22,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,x (xx%),"Val/Val, N=xx (xx%) ; ",?Rectum, Site of primary,22,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",?Rectum, Site of primary,22,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,?Multiple tumours,Characteristics ; ,?Multiple tumours, Site of primary,23,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,x (x%),"CAP Ile/Ile, N=xx (xx%) ; ",?Multiple tumours, Site of primary,23,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,x (<x%),"All patients, N=xxx ; ",?Multiple tumours, Site of primary,23,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,24,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",None,None,24,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",None,None,24,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",None,None,24,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",None,None,24,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,Serum LDH,Characteristics ; ,None,None,25,0,24,no
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",Serum LDH,None,25,1,43,no
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",Serum LDH,None,25,2,43,no
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",Serum LDH,None,25,3,43,no
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",Serum LDH,None,25,4,43,no
2308,2570506,Table 1,BaselineCharacteristic,?Normal,Characteristics ; ,?Normal, Serum LDH,26,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",?Normal, Serum LDH,26,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Ile/Val, N=xx (xx%) ; ",?Normal, Serum LDH,26,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Val/Val, N=xx (xx%) ; ",?Normal, Serum LDH,26,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",?Normal, Serum LDH,26,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,??ULN,Characteristics ; ,??ULN, Serum LDH,27,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",??ULN, Serum LDH,27,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Ile/Val, N=xx (xx%) ; ",??ULN, Serum LDH,27,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,x (xx%),"Val/Val, N=xx (xx%) ; ",??ULN, Serum LDH,27,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",??ULN, Serum LDH,27,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,28,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",None,None,28,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",None,None,28,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",None,None,28,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",None,None,28,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,Characteristics,Characteristics ; ,Characteristics,,29,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,"CAPIRI Ile/Ile, N=xx (xx%)","CAP Ile/Ile, N=xx (xx%) ; ",Characteristics,,29,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,"Ile/Val, N=xx (xx%)","Ile/Val, N=xx (xx%) ; ",Characteristics,,29,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,"Val/Val, N=xx (xx%)","Val/Val, N=xx (xx%) ; ",Characteristics,,29,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,"All patients, N=xxx","All patients, N=xxx ; ",Characteristics,,29,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,Age (years),Characteristics ; ,None,None,30,0,24,no
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",Age (years),None,30,1,43,no
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",Age (years),None,30,2,43,no
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",Age (years),None,30,3,43,no
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",Age (years),None,30,4,43,no
2308,2570506,Table 1,BaselineCharacteristic,?Median,Characteristics ; ,?Median, Age (years),31,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,xx.x,"CAP Ile/Ile, N=xx (xx%) ; ",?Median, Age (years),31,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx,"Ile/Val, N=xx (xx%) ; ",?Median, Age (years),31,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx,"Val/Val, N=xx (xx%) ; ",?Median, Age (years),31,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx,"All patients, N=xxx ; ",?Median, Age (years),31,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,?Range,Characteristics ; ,?Range, Age (years),32,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,?>xx,Characteristics ; ,?>xx, Age (years),33,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",?>xx, Age (years),33,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Ile/Val, N=xx (xx%) ; ",?>xx, Age (years),33,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,x (x%),"Val/Val, N=xx (xx%) ; ",?>xx, Age (years),33,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",?>xx, Age (years),33,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,34,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",None,None,34,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",None,None,34,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",None,None,34,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",None,None,34,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,Gender,Characteristics ; ,None,None,35,0,24,no
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",Gender,None,35,1,43,no
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",Gender,None,35,2,43,no
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",Gender,None,35,3,43,no
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",Gender,None,35,4,43,no
2308,2570506,Table 1,BaselineCharacteristic,?Male (%),Characteristics ; ,?Male (%), Gender,36,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",?Male (%), Gender,36,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Ile/Val, N=xx (xx%) ; ",?Male (%), Gender,36,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,x (xx%),"Val/Val, N=xx (xx%) ; ",?Male (%), Gender,36,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",?Male (%), Gender,36,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,37,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",None,None,37,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",None,None,37,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",None,None,37,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",None,None,37,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,WHO performance status (at start therapy),Characteristics ; ,None,None,38,0,24,no
2308,2570506,Table 1,BaselineCharacteristic,WHO performance status (at start therapy),"CAP Ile/Ile, N=xx (xx%) ; ",WHO performance status (at start therapy),None,38,1,43,no
2308,2570506,Table 1,BaselineCharacteristic,WHO performance status (at start therapy),"Ile/Val, N=xx (xx%) ; ",WHO performance status (at start therapy),None,38,2,43,no
2308,2570506,Table 1,BaselineCharacteristic,WHO performance status (at start therapy),"Val/Val, N=xx (xx%) ; ",WHO performance status (at start therapy),None,38,3,43,no
2308,2570506,Table 1,BaselineCharacteristic,WHO performance status (at start therapy),"All patients, N=xxx ; ",WHO performance status (at start therapy),None,38,4,43,no
2308,2570506,Table 1,BaselineCharacteristic,?x,Characteristics ; ,?x, WHO performance status (at start therapy),40,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,x (x%),"CAP Ile/Ile, N=xx (xx%) ; ",?x, WHO performance status (at start therapy),40,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,x (x%),"Ile/Val, N=xx (xx%) ; ",?x, WHO performance status (at start therapy),40,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,x (x%),"All patients, N=xxx ; ",?x, WHO performance status (at start therapy),40,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,41,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",None,None,41,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",None,None,41,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",None,None,41,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",None,None,41,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,Prior adjuvant therapy,Characteristics ; ,Prior adjuvant therapy,,42,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",Prior adjuvant therapy,,42,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,x (xx%),"Ile/Val, N=xx (xx%) ; ",Prior adjuvant therapy,,42,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,x (x%),"Val/Val, N=xx (xx%) ; ",Prior adjuvant therapy,,42,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",Prior adjuvant therapy,,42,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,43,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",None,None,43,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",None,None,43,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",None,None,43,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",None,None,43,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,Predominant localisation of metastases (at inclusion),Characteristics ; ,None,None,44,0,24,no
2308,2570506,Table 1,BaselineCharacteristic,Predominant localisation of metastases (at inclusion),"CAP Ile/Ile, N=xx (xx%) ; ",Predominant localisation of metastases (at inclusion),None,44,1,43,no
2308,2570506,Table 1,BaselineCharacteristic,Predominant localisation of metastases (at inclusion),"Ile/Val, N=xx (xx%) ; ",Predominant localisation of metastases (at inclusion),None,44,2,43,no
2308,2570506,Table 1,BaselineCharacteristic,Predominant localisation of metastases (at inclusion),"Val/Val, N=xx (xx%) ; ",Predominant localisation of metastases (at inclusion),None,44,3,43,no
2308,2570506,Table 1,BaselineCharacteristic,Predominant localisation of metastases (at inclusion),"All patients, N=xxx ; ",Predominant localisation of metastases (at inclusion),None,44,4,43,no
2308,2570506,Table 1,BaselineCharacteristic,?Liver,Characteristics ; ,?Liver, Predominant localisation of metastases (at inclusion),45,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",?Liver, Predominant localisation of metastases (at inclusion),45,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Ile/Val, N=xx (xx%) ; ",?Liver, Predominant localisation of metastases (at inclusion),45,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Val/Val, N=xx (xx%) ; ",?Liver, Predominant localisation of metastases (at inclusion),45,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",?Liver, Predominant localisation of metastases (at inclusion),45,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,?Extrahepatic,Characteristics ; ,?Extrahepatic, Predominant localisation of metastases (at inclusion),46,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",?Extrahepatic, Predominant localisation of metastases (at inclusion),46,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Ile/Val, N=xx (xx%) ; ",?Extrahepatic, Predominant localisation of metastases (at inclusion),46,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,x (xx%),"Val/Val, N=xx (xx%) ; ",?Extrahepatic, Predominant localisation of metastases (at inclusion),46,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",?Extrahepatic, Predominant localisation of metastases (at inclusion),46,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,47,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",None,None,47,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",None,None,47,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",None,None,47,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",None,None,47,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,Site of primary,Characteristics ; ,None,None,48,0,24,no
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",Site of primary,None,48,1,43,no
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",Site of primary,None,48,2,43,no
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",Site of primary,None,48,3,43,no
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",Site of primary,None,48,4,43,no
2308,2570506,Table 1,BaselineCharacteristic,?Colon and sigmoid,Characteristics ; ,?Colon and sigmoid, Site of primary,49,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",?Colon and sigmoid, Site of primary,49,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Ile/Val, N=xx (xx%) ; ",?Colon and sigmoid, Site of primary,49,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,x (xx%),"Val/Val, N=xx (xx%) ; ",?Colon and sigmoid, Site of primary,49,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",?Colon and sigmoid, Site of primary,49,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,?Rectum,Characteristics ; ,?Rectum, Site of primary,50,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",?Rectum, Site of primary,50,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Ile/Val, N=xx (xx%) ; ",?Rectum, Site of primary,50,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,x (xx%),"Val/Val, N=xx (xx%) ; ",?Rectum, Site of primary,50,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",?Rectum, Site of primary,50,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,51,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",None,None,51,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",None,None,51,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",None,None,51,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",None,None,51,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,Serum LDH,Characteristics ; ,None,None,52,0,24,no
2308,2570506,Table 1,BaselineCharacteristic,,"CAP Ile/Ile, N=xx (xx%) ; ",Serum LDH,None,52,1,43,no
2308,2570506,Table 1,BaselineCharacteristic,,"Ile/Val, N=xx (xx%) ; ",Serum LDH,None,52,2,43,no
2308,2570506,Table 1,BaselineCharacteristic,,"Val/Val, N=xx (xx%) ; ",Serum LDH,None,52,3,43,no
2308,2570506,Table 1,BaselineCharacteristic,,"All patients, N=xxx ; ",Serum LDH,None,52,4,43,no
2308,2570506,Table 1,BaselineCharacteristic,?Normal,Characteristics ; ,?Normal, Serum LDH,53,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",?Normal, Serum LDH,53,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Ile/Val, N=xx (xx%) ; ",?Normal, Serum LDH,53,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Val/Val, N=xx (xx%) ; ",?Normal, Serum LDH,53,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",?Normal, Serum LDH,53,4,3,no
2308,2570506,Table 1,BaselineCharacteristic,??ULN,Characteristics ; ,??ULN, Serum LDH,54,0,2,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"CAP Ile/Ile, N=xx (xx%) ; ",??ULN, Serum LDH,54,1,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"Ile/Val, N=xx (xx%) ; ",??ULN, Serum LDH,54,2,3,no
2308,2570506,Table 1,BaselineCharacteristic,x (xx%),"Val/Val, N=xx (xx%) ; ",??ULN, Serum LDH,54,3,3,no
2308,2570506,Table 1,BaselineCharacteristic,xx (xx%),"All patients, N=xxx ; ",??ULN, Serum LDH,54,4,3,no
2472,2653739,Table 1,BaselineCharacteristic,Characteristics,,None,None,0,0,12,no
2472,2653739,Table 1,BaselineCharacteristic,%,,Characteristics,None,0,1,1,no
2472,2653739,Table 1,BaselineCharacteristic,n,,Characteristics,None,0,2,1,no
2472,2653739,Table 1,BaselineCharacteristic,Age (years),Characteristics ; ,None,None,1,0,24,no
2472,2653739,Table 1,BaselineCharacteristic,Age (years),% ; ,Age (years),None,1,1,43,no
2472,2653739,Table 1,BaselineCharacteristic,Age (years),n ; ,Age (years),None,1,2,43,no
2472,2653739,Table 1,BaselineCharacteristic,?Median,Characteristics ; ,?Median, Age (years),2,0,2,no
2472,2653739,Table 1,BaselineCharacteristic,,% ; ,?Median, Age (years),2,1,3,no
2472,2653739,Table 1,BaselineCharacteristic,xx,n ; ,?Median, Age (years),2,2,3,no
2472,2653739,Table 1,BaselineCharacteristic,?Range,Characteristics ; ,?Range, Age (years),3,0,2,no
2472,2653739,Table 1,BaselineCharacteristic,,% ; ,?Range, Age (years),3,1,3,no
2472,2653739,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,4,0,2,no
2472,2653739,Table 1,BaselineCharacteristic,,% ; ,None,None,4,1,3,no
2472,2653739,Table 1,BaselineCharacteristic,,n ; ,None,None,4,2,3,no
2472,2653739,Table 1,BaselineCharacteristic,Histological type,Characteristics ; ,None,None,5,0,24,no
2472,2653739,Table 1,BaselineCharacteristic,Histological type,% ; ,Histological type,None,5,1,43,no
2472,2653739,Table 1,BaselineCharacteristic,Histological type,n ; ,Histological type,None,5,2,43,no
2472,2653739,Table 1,BaselineCharacteristic,?Serous,Characteristics ; ,?Serous, Histological type,6,0,2,no
2472,2653739,Table 1,BaselineCharacteristic,xx,% ; ,?Serous, Histological type,6,1,3,no
2472,2653739,Table 1,BaselineCharacteristic,xx,n ; ,?Serous, Histological type,6,2,3,no
2472,2653739,Table 1,BaselineCharacteristic,?Endometrioid,Characteristics ; ,?Endometrioid, Histological type,7,0,2,no
2472,2653739,Table 1,BaselineCharacteristic,x,% ; ,?Endometrioid, Histological type,7,1,3,no
2472,2653739,Table 1,BaselineCharacteristic,x,n ; ,?Endometrioid, Histological type,7,2,3,no
2472,2653739,Table 1,BaselineCharacteristic,?Others,Characteristics ; ,?Others, Histological type,8,0,2,no
2472,2653739,Table 1,BaselineCharacteristic,xx,% ; ,?Others, Histological type,8,1,3,no
2472,2653739,Table 1,BaselineCharacteristic,x,n ; ,?Others, Histological type,8,2,3,no
2472,2653739,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,9,0,2,no
2472,2653739,Table 1,BaselineCharacteristic,,% ; ,None,None,9,1,3,no
2472,2653739,Table 1,BaselineCharacteristic,,n ; ,None,None,9,2,3,no
2472,2653739,Table 1,BaselineCharacteristic,Histological grade,Characteristics ; ,None,None,10,0,24,no
2472,2653739,Table 1,BaselineCharacteristic,Histological grade,% ; ,Histological grade,None,10,1,43,no
2472,2653739,Table 1,BaselineCharacteristic,Histological grade,n ; ,Histological grade,None,10,2,43,no
2472,2653739,Table 1,BaselineCharacteristic,?x,Characteristics ; ,?x, Histological grade,11,0,2,no
2472,2653739,Table 1,BaselineCharacteristic,xx,% ; ,?x, Histological grade,11,1,3,no
2472,2653739,Table 1,BaselineCharacteristic,x,n ; ,?x, Histological grade,11,2,3,no
2472,2653739,Table 1,BaselineCharacteristic,?x,Characteristics ; ,?x, Histological grade,12,0,2,no
2472,2653739,Table 1,BaselineCharacteristic,xx,% ; ,?x, Histological grade,12,1,3,no
2472,2653739,Table 1,BaselineCharacteristic,xx,n ; ,?x, Histological grade,12,2,3,no
2472,2653739,Table 1,BaselineCharacteristic,?x,Characteristics ; ,?x, Histological grade,13,0,2,no
2472,2653739,Table 1,BaselineCharacteristic,xx,% ; ,?x, Histological grade,13,1,3,no
2472,2653739,Table 1,BaselineCharacteristic,xx,n ; ,?x, Histological grade,13,2,3,no
2472,2653739,Table 1,BaselineCharacteristic,?Unknown,Characteristics ; ,?Unknown, Histological grade,14,0,2,no
2472,2653739,Table 1,BaselineCharacteristic,xx,% ; ,?Unknown, Histological grade,14,1,3,no
2472,2653739,Table 1,BaselineCharacteristic,xx,n ; ,?Unknown, Histological grade,14,2,3,no
2472,2653739,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,15,0,2,no
2472,2653739,Table 1,BaselineCharacteristic,,% ; ,None,None,15,1,3,no
2472,2653739,Table 1,BaselineCharacteristic,,n ; ,None,None,15,2,3,no
2472,2653739,Table 1,BaselineCharacteristic,Number of earlier chemotherapy regimens,Characteristics ; ,None,None,16,0,24,no
2472,2653739,Table 1,BaselineCharacteristic,Number of earlier chemotherapy regimens,% ; ,Number of earlier chemotherapy regimens,None,16,1,43,no
2472,2653739,Table 1,BaselineCharacteristic,Number of earlier chemotherapy regimens,n ; ,Number of earlier chemotherapy regimens,None,16,2,43,no
2472,2653739,Table 1,BaselineCharacteristic,?One,Characteristics ; ,?One, Number of earlier chemotherapy regimens,17,0,2,no
2472,2653739,Table 1,BaselineCharacteristic,xx,% ; ,?One, Number of earlier chemotherapy regimens,17,1,3,no
2472,2653739,Table 1,BaselineCharacteristic,xx,n ; ,?One, Number of earlier chemotherapy regimens,17,2,3,no
2472,2653739,Table 1,BaselineCharacteristic,?Two,Characteristics ; ,?Two, Number of earlier chemotherapy regimens,18,0,2,no
2472,2653739,Table 1,BaselineCharacteristic,xx,% ; ,?Two, Number of earlier chemotherapy regimens,18,1,3,no
2472,2653739,Table 1,BaselineCharacteristic,x,n ; ,?Two, Number of earlier chemotherapy regimens,18,2,3,no
2472,2653739,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,19,0,2,no
2472,2653739,Table 1,BaselineCharacteristic,,% ; ,None,None,19,1,3,no
2472,2653739,Table 1,BaselineCharacteristic,,n ; ,None,None,19,2,3,no
2472,2653739,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,26,0,2,no
2472,2653739,Table 1,BaselineCharacteristic,,% ; ,None,None,26,1,3,no
2472,2653739,Table 1,BaselineCharacteristic,,n ; ,None,None,26,2,3,no
2472,2653739,Table 1,BaselineCharacteristic,Performance status,Characteristics ; ,None,None,27,0,24,no
2472,2653739,Table 1,BaselineCharacteristic,Performance status,% ; ,Performance status,None,27,1,43,no
2472,2653739,Table 1,BaselineCharacteristic,Performance status,n ; ,Performance status,None,27,2,43,no
2472,2653739,Table 1,BaselineCharacteristic,?x,Characteristics ; ,?x, Performance status,28,0,2,no
2472,2653739,Table 1,BaselineCharacteristic,xx,% ; ,?x, Performance status,28,1,3,no
2472,2653739,Table 1,BaselineCharacteristic,xx,n ; ,?x, Performance status,28,2,3,no
2472,2653739,Table 1,BaselineCharacteristic,?x,Characteristics ; ,?x, Performance status,29,0,2,no
2472,2653739,Table 1,BaselineCharacteristic,xx,% ; ,?x, Performance status,29,1,3,no
2472,2653739,Table 1,BaselineCharacteristic,xx,n ; ,?x, Performance status,29,2,3,no
2472,2653739,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,30,0,2,no
2472,2653739,Table 1,BaselineCharacteristic,,% ; ,None,None,30,1,3,no
2472,2653739,Table 1,BaselineCharacteristic,,n ; ,None,None,30,2,3,no
2472,2653739,Table 1,BaselineCharacteristic,Ascites,Characteristics ; ,Ascites,,31,0,2,no
2472,2653739,Table 1,BaselineCharacteristic,xx,% ; ,Ascites,,31,1,3,no
2472,2653739,Table 1,BaselineCharacteristic,xx,n ; ,Ascites,,31,2,3,no
2472,2653739,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,32,0,2,no
2472,2653739,Table 1,BaselineCharacteristic,,% ; ,None,None,32,1,3,no
2472,2653739,Table 1,BaselineCharacteristic,,n ; ,None,None,32,2,3,no
2472,2653739,Table 1,BaselineCharacteristic,Measurable lesion,Characteristics ; ,None,None,33,0,24,no
2472,2653739,Table 1,BaselineCharacteristic,Measurable lesion,% ; ,Measurable lesion,None,33,1,43,no
2472,2653739,Table 1,BaselineCharacteristic,Measurable lesion,n ; ,Measurable lesion,None,33,2,43,no
2472,2653739,Table 1,BaselineCharacteristic,?<x?cm,Characteristics ; ,?<x?cm, Measurable lesion,34,0,2,no
2472,2653739,Table 1,BaselineCharacteristic,xx,% ; ,?<x?cm, Measurable lesion,34,1,3,no
2472,2653739,Table 1,BaselineCharacteristic,xx,n ; ,?<x?cm, Measurable lesion,34,2,3,no
2472,2653739,Table 1,BaselineCharacteristic,??x?cm,Characteristics ; ,??x?cm, Measurable lesion,35,0,2,no
2472,2653739,Table 1,BaselineCharacteristic,xx,% ; ,??x?cm, Measurable lesion,35,1,3,no
2472,2653739,Table 1,BaselineCharacteristic,x,n ; ,??x?cm, Measurable lesion,35,2,3,no
2472,2653739,Table 1,BaselineCharacteristic,?Not evaluable,Characteristics ; ,?Not evaluable, Measurable lesion,37,0,2,no
2472,2653739,Table 1,BaselineCharacteristic,x,% ; ,?Not evaluable, Measurable lesion,37,1,3,no
2472,2653739,Table 1,BaselineCharacteristic,x,n ; ,?Not evaluable, Measurable lesion,37,2,3,no
2472,2653739,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,38,0,2,no
2472,2653739,Table 1,BaselineCharacteristic,,% ; ,None,None,38,1,3,no
2472,2653739,Table 1,BaselineCharacteristic,,n ; ,None,None,38,2,3,no
2472,2653739,Table 1,BaselineCharacteristic,Number of disease sitesa,Characteristics ; ,None,None,39,0,24,no
2472,2653739,Table 1,BaselineCharacteristic,Number of disease sitesa,% ; ,Number of disease sitesa,None,39,1,43,no
2472,2653739,Table 1,BaselineCharacteristic,Number of disease sitesa,n ; ,Number of disease sitesa,None,39,2,43,no
2472,2653739,Table 1,BaselineCharacteristic,?x,Characteristics ; ,?x, Number of disease sitesa,40,0,2,no
2472,2653739,Table 1,BaselineCharacteristic,xx,% ; ,?x, Number of disease sitesa,40,1,3,no
2472,2653739,Table 1,BaselineCharacteristic,xx,n ; ,?x, Number of disease sitesa,40,2,3,no
2472,2653739,Table 1,BaselineCharacteristic,?>x,Characteristics ; ,?>x, Number of disease sitesa,41,0,2,no
2472,2653739,Table 1,BaselineCharacteristic,xx,% ; ,?>x, Number of disease sitesa,41,1,3,no
2472,2653739,Table 1,BaselineCharacteristic,xx,n ; ,?>x, Number of disease sitesa,41,2,3,no
2528,2674549,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,0,12,no
2528,2674549,Table 1,BaselineCharacteristic,Group x,,Characteristic,None,0,1,1,no
2528,2674549,Table 1,BaselineCharacteristic,Group x,,Characteristic,None,0,2,1,no
2528,2674549,Table 1,BaselineCharacteristic,Golimumab + methotrexate,,Characteristic,None,0,3,1,no
2528,2674549,Table 1,BaselineCharacteristic,Golimumab + methotrexate,,Characteristic,None,0,4,1,no
2528,2674549,Table 1,BaselineCharacteristic,Golimumab + methotrexate,,Characteristic,None,0,5,1,no
2528,2674549,Table 1,BaselineCharacteristic,Characteristic,Characteristic ; ,None,None,1,0,12,no
2528,2674549,Table 1,BaselineCharacteristic,Group x,Group x ; ,Characteristic,None,1,1,1,no
2528,2674549,Table 1,BaselineCharacteristic,Group x,Group x ; ,Characteristic,None,1,2,1,no
2528,2674549,Table 1,BaselineCharacteristic,Group x,Golimumab + methotrexate ; ,Characteristic,None,1,3,1,no
2528,2674549,Table 1,BaselineCharacteristic,Group x,Golimumab + methotrexate ; ,Characteristic,None,1,4,1,no
2528,2674549,Table 1,BaselineCharacteristic,Groups x and x combined,Golimumab + methotrexate ; ,Characteristic,None,1,5,1,no
2528,2674549,Table 1,BaselineCharacteristic,Characteristic,Characteristic ; Characteristic ; ,None,None,2,0,12,no
2528,2674549,Table 1,BaselineCharacteristic,Placebo + methotrexate,Group x ; Group x ; ,Characteristic,None,2,1,1,no
2528,2674549,Table 1,BaselineCharacteristic,Golimumab xxx mg + placebo,Group x ; Group x ; ,Characteristic,None,2,2,1,no
2528,2674549,Table 1,BaselineCharacteristic,xx mg,Golimumab + methotrexate ; Group x ; ,Characteristic,None,2,3,1,no
2528,2674549,Table 1,BaselineCharacteristic,xxx mg,Golimumab + methotrexate ; Group x ; ,Characteristic,None,2,4,1,no
2528,2674549,Table 1,BaselineCharacteristic,,Golimumab + methotrexate ; Groups x and x combined ; ,Characteristic,None,2,5,1,no
2528,2674549,Table 1,BaselineCharacteristic,Patients randomly assigned,Characteristic ; Characteristic ; Characteristic ; ,Patients randomly assigned,,3,0,2,no
2528,2674549,Table 1,BaselineCharacteristic,xxx,Group x ; Group x ; Placebo + methotrexate ; ,Patients randomly assigned,,3,1,3,no
2528,2674549,Table 1,BaselineCharacteristic,xxx,Group x ; Group x ; Golimumab xxx mg + placebo ; ,Patients randomly assigned,,3,2,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx,Golimumab + methotrexate ; Group x ; xx mg ; ,Patients randomly assigned,,3,3,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx,Golimumab + methotrexate ; Group x ; xxx mg ; ,Patients randomly assigned,,3,4,3,no
2528,2674549,Table 1,BaselineCharacteristic,xxx,Golimumab + methotrexate ; Groups x and x combined ;  ; ,Patients randomly assigned,,3,5,3,no
2528,2674549,Table 1,BaselineCharacteristic,"Sex, n (%) women",Characteristic ; Characteristic ; Characteristic ; ,"Sex, n (%) women",,4,0,2,no
2528,2674549,Table 1,BaselineCharacteristic,xxx (xx.x%),Group x ; Group x ; Placebo + methotrexate ; ,"Sex, n (%) women",,4,1,3,yes
2528,2674549,Table 1,BaselineCharacteristic,xxx (xx.x%),Group x ; Group x ; Golimumab xxx mg + placebo ; ,"Sex, n (%) women",,4,2,3,yes
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xx mg ; ,"Sex, n (%) women",,4,3,3,yes
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xxx mg ; ,"Sex, n (%) women",,4,4,3,yes
2528,2674549,Table 1,BaselineCharacteristic,xxx (xx.x%),Golimumab + methotrexate ; Groups x and x combined ;  ; ,"Sex, n (%) women",,4,5,3,yes
2528,2674549,Table 1,BaselineCharacteristic,"Age, years",Characteristic ; Characteristic ; Characteristic ; ,"Age, years",,5,0,2,no
2528,2674549,Table 1,BaselineCharacteristic,xx.x (xx.x to xx.x),Group x ; Group x ; Placebo + methotrexate ; ,"Age, years",,5,1,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx.x (xx.x to xx.x),Group x ; Group x ; Golimumab xxx mg + placebo ; ,"Age, years",,5,2,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx.x (xx.x to xx.x),Golimumab + methotrexate ; Group x ; xx mg ; ,"Age, years",,5,3,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx.x (xx.x to xx.x),Golimumab + methotrexate ; Group x ; xxx mg ; ,"Age, years",,5,4,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx.x (xx.x to xx.x),Golimumab + methotrexate ; Groups x and x combined ;  ; ,"Age, years",,5,5,3,no
2528,2674549,Table 1,BaselineCharacteristic,"Disease duration, years",Characteristic ; Characteristic ; Characteristic ; ,"Disease duration, years",,6,0,2,no
2528,2674549,Table 1,BaselineCharacteristic,x.x (x.x to xx.x),Group x ; Group x ; Placebo + methotrexate ; ,"Disease duration, years",,6,1,3,no
2528,2674549,Table 1,BaselineCharacteristic,x.x (x.x to xx.x),Group x ; Group x ; Golimumab xxx mg + placebo ; ,"Disease duration, years",,6,2,3,no
2528,2674549,Table 1,BaselineCharacteristic,x.xx (x.x to x.x),Golimumab + methotrexate ; Group x ; xx mg ; ,"Disease duration, years",,6,3,3,no
2528,2674549,Table 1,BaselineCharacteristic,x.xx (x.x to xx.x),Golimumab + methotrexate ; Group x ; xxx mg ; ,"Disease duration, years",,6,4,3,no
2528,2674549,Table 1,BaselineCharacteristic,x.x (x.x to xx.x),Golimumab + methotrexate ; Groups x and x combined ;  ; ,"Disease duration, years",,6,5,3,no
2528,2674549,Table 1,BaselineCharacteristic,Anti-CCP antibodies,Characteristic ; Characteristic ; Characteristic ; ,Anti-CCP antibodies,,9,0,2,no
2528,2674549,Table 1,BaselineCharacteristic,xxx (xx.x%),Group x ; Group x ; Placebo + methotrexate ; ,Anti-CCP antibodies,,9,1,3,no
2528,2674549,Table 1,BaselineCharacteristic,xxx (xx.x%),Group x ; Group x ; Golimumab xxx mg + placebo ; ,Anti-CCP antibodies,,9,2,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xx mg ; ,Anti-CCP antibodies,,9,3,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xxx mg ; ,Anti-CCP antibodies,,9,4,3,no
2528,2674549,Table 1,BaselineCharacteristic,xxx (xx.x%),Golimumab + methotrexate ; Groups x and x combined ;  ; ,Anti-CCP antibodies,,9,5,3,no
2528,2674549,Table 1,BaselineCharacteristic,Rheumatoid factor,Characteristic ; Characteristic ; Characteristic ; ,Rheumatoid factor,,10,0,2,no
2528,2674549,Table 1,BaselineCharacteristic,xxx (xx.x%),Group x ; Group x ; Placebo + methotrexate ; ,Rheumatoid factor,,10,1,3,no
2528,2674549,Table 1,BaselineCharacteristic,xxx (xx.x%),Group x ; Group x ; Golimumab xxx mg + placebo ; ,Rheumatoid factor,,10,2,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xx mg ; ,Rheumatoid factor,,10,3,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xxx mg ; ,Rheumatoid factor,,10,4,3,no
2528,2674549,Table 1,BaselineCharacteristic,xxx (xx.x%),Golimumab + methotrexate ; Groups x and x combined ;  ; ,Rheumatoid factor,,10,5,3,no
2528,2674549,Table 1,BaselineCharacteristic,"CRP, mg/dl",Characteristic ; Characteristic ; Characteristic ; ,"CRP, mg/dl",,15,0,2,no
2528,2674549,Table 1,BaselineCharacteristic,x.xx (x.xx to x.xx),Group x ; Group x ; Placebo + methotrexate ; ,"CRP, mg/dl",,15,1,3,no
2528,2674549,Table 1,BaselineCharacteristic,x.xx (x.xx to x.xx),Group x ; Group x ; Golimumab xxx mg + placebo ; ,"CRP, mg/dl",,15,2,3,no
2528,2674549,Table 1,BaselineCharacteristic,x.xx (x.xx to x.xx),Golimumab + methotrexate ; Group x ; xx mg ; ,"CRP, mg/dl",,15,3,3,no
2528,2674549,Table 1,BaselineCharacteristic,x.xx (x.xx to x.xx),Golimumab + methotrexate ; Group x ; xxx mg ; ,"CRP, mg/dl",,15,4,3,no
2528,2674549,Table 1,BaselineCharacteristic,x.xx (x.xx to x.xx),Golimumab + methotrexate ; Groups x and x combined ;  ; ,"CRP, mg/dl",,15,5,3,no
2528,2674549,Table 1,BaselineCharacteristic,DASxx using CRP,Characteristic ; Characteristic ; Characteristic ; ,DASxx using CRP,,16,0,2,no
2528,2674549,Table 1,BaselineCharacteristic,x.xxx (x.xxx to x.xxx),Group x ; Group x ; Placebo + methotrexate ; ,DASxx using CRP,,16,1,3,no
2528,2674549,Table 1,BaselineCharacteristic,x.xxx (x.xxx to x.xxx),Group x ; Group x ; Golimumab xxx mg + placebo ; ,DASxx using CRP,,16,2,3,no
2528,2674549,Table 1,BaselineCharacteristic,x.xxx (x.xxx to x.xxx),Golimumab + methotrexate ; Group x ; xx mg ; ,DASxx using CRP,,16,3,3,no
2528,2674549,Table 1,BaselineCharacteristic,x.xxx (x.xxx to x.xxx),Golimumab + methotrexate ; Group x ; xxx mg ; ,DASxx using CRP,,16,4,3,no
2528,2674549,Table 1,BaselineCharacteristic,x.xxx (x.xxx to x.xxx),Golimumab + methotrexate ; Groups x and x combined ;  ; ,DASxx using CRP,,16,5,3,no
2528,2674549,Table 1,BaselineCharacteristic,DASxx using ESR,Characteristic ; Characteristic ; Characteristic ; ,DASxx using ESR,,17,0,2,no
2528,2674549,Table 1,BaselineCharacteristic,x.xxx (x.xxx to x.xxx),Group x ; Group x ; Placebo + methotrexate ; ,DASxx using ESR,,17,1,3,no
2528,2674549,Table 1,BaselineCharacteristic,x.xxx (x.xxx to x.xxx),Group x ; Group x ; Golimumab xxx mg + placebo ; ,DASxx using ESR,,17,2,3,no
2528,2674549,Table 1,BaselineCharacteristic,x.xxx (x.xxx to x.xxx),Golimumab + methotrexate ; Group x ; xx mg ; ,DASxx using ESR,,17,3,3,no
2528,2674549,Table 1,BaselineCharacteristic,x.xxx (x.xxx to x.xxx),Golimumab + methotrexate ; Group x ; xxx mg ; ,DASxx using ESR,,17,4,3,no
2528,2674549,Table 1,BaselineCharacteristic,x.xxx (x.xxx to x.xxx),Golimumab + methotrexate ; Groups x and x combined ;  ; ,DASxx using ESR,,17,5,3,no
2528,2674549,Table 1,BaselineCharacteristic,"Methotrexate dose, mg/week",Characteristic ; Characteristic ; Characteristic ; ,"Methotrexate dose, mg/week",,18,0,2,no
2528,2674549,Table 1,BaselineCharacteristic,xx.x (xx.x to xx.x),Group x ; Group x ; Placebo + methotrexate ; ,"Methotrexate dose, mg/week",,18,1,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx.x (xx.x to xx.x),Group x ; Group x ; Golimumab xxx mg + placebo ; ,"Methotrexate dose, mg/week",,18,2,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx.x (xx.x to xx.x),Golimumab + methotrexate ; Group x ; xx mg ; ,"Methotrexate dose, mg/week",,18,3,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx.x (xx.x to xx.x),Golimumab + methotrexate ; Group x ; xxx mg ; ,"Methotrexate dose, mg/week",,18,4,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx.x (xx.x to xx.x),Golimumab + methotrexate ; Groups x and x combined ;  ; ,"Methotrexate dose, mg/week",,18,5,3,no
2528,2674549,Table 1,BaselineCharacteristic,"Duration of previous methotrexate use, years",Characteristic ; Characteristic ; Characteristic ; ,None,None,19,0,24,no
2528,2674549,Table 1,BaselineCharacteristic,,Group x ; Group x ; Placebo + methotrexate ; ,"Duration of previous methotrexate use, years",None,19,1,43,no
2528,2674549,Table 1,BaselineCharacteristic,,Group x ; Group x ; Golimumab xxx mg + placebo ; ,"Duration of previous methotrexate use, years",None,19,2,43,no
2528,2674549,Table 1,BaselineCharacteristic,,Golimumab + methotrexate ; Group x ; xx mg ; ,"Duration of previous methotrexate use, years",None,19,3,43,no
2528,2674549,Table 1,BaselineCharacteristic,,Golimumab + methotrexate ; Group x ; xxx mg ; ,"Duration of previous methotrexate use, years",None,19,4,43,no
2528,2674549,Table 1,BaselineCharacteristic,,Golimumab + methotrexate ; Groups x and x combined ;  ; ,"Duration of previous methotrexate use, years",None,19,5,43,no
2528,2674549,Table 1,BaselineCharacteristic,,Characteristic ; Characteristic ; Characteristic ; ,," Duration of previous methotrexate use, years",20,0,2,no
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Group x ; Group x ; Placebo + methotrexate ; ,," Duration of previous methotrexate use, years",20,1,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Group x ; Group x ; Golimumab xxx mg + placebo ; ,," Duration of previous methotrexate use, years",20,2,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xx mg ; ,," Duration of previous methotrexate use, years",20,3,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xxx mg ; ,," Duration of previous methotrexate use, years",20,4,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Groups x and x combined ;  ; ,," Duration of previous methotrexate use, years",20,5,3,no
2528,2674549,Table 1,BaselineCharacteristic,,Characteristic ; Characteristic ; Characteristic ; ,," Duration of previous methotrexate use, years",21,0,2,no
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Group x ; Group x ; Placebo + methotrexate ; ,," Duration of previous methotrexate use, years",21,1,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Group x ; Group x ; Golimumab xxx mg + placebo ; ,," Duration of previous methotrexate use, years",21,2,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xx mg ; ,," Duration of previous methotrexate use, years",21,3,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xxx mg ; ,," Duration of previous methotrexate use, years",21,4,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Groups x and x combined ;  ; ,," Duration of previous methotrexate use, years",21,5,3,no
2528,2674549,Table 1,BaselineCharacteristic,,Characteristic ; Characteristic ; Characteristic ; ,," Duration of previous methotrexate use, years",22,0,2,no
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Group x ; Group x ; Placebo + methotrexate ; ,," Duration of previous methotrexate use, years",22,1,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Group x ; Group x ; Golimumab xxx mg + placebo ; ,," Duration of previous methotrexate use, years",22,2,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xx mg ; ,," Duration of previous methotrexate use, years",22,3,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xxx mg ; ,," Duration of previous methotrexate use, years",22,4,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Groups x and x combined ;  ; ,," Duration of previous methotrexate use, years",22,5,3,no
2528,2674549,Table 1,BaselineCharacteristic,Patients taking corticosteroids,Characteristic ; Characteristic ; Characteristic ; ,Patients taking corticosteroids," Duration of previous methotrexate use, years",23,0,2,no
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Group x ; Group x ; Placebo + methotrexate ; ,Patients taking corticosteroids," Duration of previous methotrexate use, years",23,1,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Group x ; Group x ; Golimumab xxx mg + placebo ; ,Patients taking corticosteroids," Duration of previous methotrexate use, years",23,2,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xx mg ; ,Patients taking corticosteroids," Duration of previous methotrexate use, years",23,3,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xxx mg ; ,Patients taking corticosteroids," Duration of previous methotrexate use, years",23,4,3,no
2528,2674549,Table 1,BaselineCharacteristic,xxx (xx.x%),Golimumab + methotrexate ; Groups x and x combined ;  ; ,Patients taking corticosteroids," Duration of previous methotrexate use, years",23,5,3,no
2528,2674549,Table 1,BaselineCharacteristic,"Prednisone or equivalent dose, mg/day",Characteristic ; Characteristic ; Characteristic ; ,"Prednisone or equivalent dose, mg/day"," Duration of previous methotrexate use, years",24,0,2,no
2528,2674549,Table 1,BaselineCharacteristic,x.x (x.x to xx.x),Group x ; Group x ; Placebo + methotrexate ; ,"Prednisone or equivalent dose, mg/day"," Duration of previous methotrexate use, years",24,1,3,no
2528,2674549,Table 1,BaselineCharacteristic,x.x (x.x to xx.x),Group x ; Group x ; Golimumab xxx mg + placebo ; ,"Prednisone or equivalent dose, mg/day"," Duration of previous methotrexate use, years",24,2,3,no
2528,2674549,Table 1,BaselineCharacteristic,x.x (x.x to xx.x),Golimumab + methotrexate ; Group x ; xx mg ; ,"Prednisone or equivalent dose, mg/day"," Duration of previous methotrexate use, years",24,3,3,no
2528,2674549,Table 1,BaselineCharacteristic,x.x (x.x to xx.x),Golimumab + methotrexate ; Group x ; xxx mg ; ,"Prednisone or equivalent dose, mg/day"," Duration of previous methotrexate use, years",24,4,3,no
2528,2674549,Table 1,BaselineCharacteristic,x.x (x.x to xx.x),Golimumab + methotrexate ; Groups x and x combined ;  ; ,"Prednisone or equivalent dose, mg/day"," Duration of previous methotrexate use, years",24,5,3,no
2528,2674549,Table 1,BaselineCharacteristic,Patients with previous use of DMARD other than methotrexate,Characteristic ; Characteristic ; Characteristic ; ,Patients with previous use of DMARD other than methotrexate," Duration of previous methotrexate use, years",25,0,2,no
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Group x ; Group x ; Placebo + methotrexate ; ,Patients with previous use of DMARD other than methotrexate," Duration of previous methotrexate use, years",25,1,3,no
2528,2674549,Table 1,BaselineCharacteristic,xxx (xx.x%),Group x ; Group x ; Golimumab xxx mg + placebo ; ,Patients with previous use of DMARD other than methotrexate," Duration of previous methotrexate use, years",25,2,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xx mg ; ,Patients with previous use of DMARD other than methotrexate," Duration of previous methotrexate use, years",25,3,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xxx mg ; ,Patients with previous use of DMARD other than methotrexate," Duration of previous methotrexate use, years",25,4,3,no
2528,2674549,Table 1,BaselineCharacteristic,xxx (xx.x%),Golimumab + methotrexate ; Groups x and x combined ;  ; ,Patients with previous use of DMARD other than methotrexate," Duration of previous methotrexate use, years",25,5,3,no
2528,2674549,Table 1,BaselineCharacteristic,Patients who required treatment for latent tuberculosis at baseline*,Characteristic ; Characteristic ; Characteristic ; ,Patients who required treatment for latent tuberculosis at baseline*," Duration of previous methotrexate use, years",26,0,2,no
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Group x ; Group x ; Placebo + methotrexate ; ,Patients who required treatment for latent tuberculosis at baseline*," Duration of previous methotrexate use, years",26,1,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Group x ; Group x ; Golimumab xxx mg + placebo ; ,Patients who required treatment for latent tuberculosis at baseline*," Duration of previous methotrexate use, years",26,2,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xx mg ; ,Patients who required treatment for latent tuberculosis at baseline*," Duration of previous methotrexate use, years",26,3,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Group x ; xxx mg ; ,Patients who required treatment for latent tuberculosis at baseline*," Duration of previous methotrexate use, years",26,4,3,no
2528,2674549,Table 1,BaselineCharacteristic,xx (xx.x%),Golimumab + methotrexate ; Groups x and x combined ;  ; ,Patients who required treatment for latent tuberculosis at baseline*," Duration of previous methotrexate use, years",26,5,3,no
2529,2674556,Table 1,BaselineCharacteristic,Characteristics,,None,None,0,0,12,no
2529,2674556,Table 1,BaselineCharacteristic,Placebo + MTX (n?=?xxx),,Characteristics,None,0,1,1,no
2529,2674556,Table 1,BaselineCharacteristic,Certolizumab pegol xxx mg + MTX (n?=?xxx),,Characteristics,None,0,2,1,no
2529,2674556,Table 1,BaselineCharacteristic,Certolizumab pegol xxx mg + MTX (n?=?xxx),,Characteristics,None,0,3,1,no
2529,2674556,Table 1,BaselineCharacteristic,Demographics,Characteristics ; ,None,None,1,0,24,no
2529,2674556,Table 1,BaselineCharacteristic,,Placebo + MTX (n?=?xxx) ; ,Demographics,None,1,1,43,no
2529,2674556,Table 1,BaselineCharacteristic,,Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,Demographics,None,1,2,43,no
2529,2674556,Table 1,BaselineCharacteristic,,Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,Demographics,None,1,3,43,no
2529,2674556,Table 1,BaselineCharacteristic,"Age (years), mean (SD)",Characteristics ; ,"Age (years), mean (SD)", Demographics,2,0,2,no
2529,2674556,Table 1,BaselineCharacteristic,xx.x (xx.x),Placebo + MTX (n?=?xxx) ; ,"Age (years), mean (SD)", Demographics,2,1,3,no
2529,2674556,Table 1,BaselineCharacteristic,xx.x (xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"Age (years), mean (SD)", Demographics,2,2,3,no
2529,2674556,Table 1,BaselineCharacteristic,xx.x (xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"Age (years), mean (SD)", Demographics,2,3,3,no
2529,2674556,Table 1,BaselineCharacteristic,"Female, n (%)",Characteristics ; ,"Female, n (%)", Demographics,3,0,2,no
2529,2674556,Table 1,BaselineCharacteristic,xxx (xx.x),Placebo + MTX (n?=?xxx) ; ,"Female, n (%)", Demographics,3,1,3,yes
2529,2674556,Table 1,BaselineCharacteristic,xxx (xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"Female, n (%)", Demographics,3,2,3,yes
2529,2674556,Table 1,BaselineCharacteristic,xxx (xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"Female, n (%)", Demographics,3,3,3,yes
2529,2674556,Table 1,BaselineCharacteristic,"Disease duration (years), mean (SD)",Characteristics ; ,"Disease duration (years), mean (SD)", Demographics,4,0,2,no
2529,2674556,Table 1,BaselineCharacteristic,x.x (x.x),Placebo + MTX (n?=?xxx) ; ,"Disease duration (years), mean (SD)", Demographics,4,1,3,no
2529,2674556,Table 1,BaselineCharacteristic,x.x (x.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"Disease duration (years), mean (SD)", Demographics,4,2,3,no
2529,2674556,Table 1,BaselineCharacteristic,x.x (x.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"Disease duration (years), mean (SD)", Demographics,4,3,3,no
2529,2674556,Table 1,BaselineCharacteristic,"No of prior DMARDs (excluding MTX), mean (SD)",Characteristics ; ,"No of prior DMARDs (excluding MTX), mean (SD)", Demographics,5,0,2,no
2529,2674556,Table 1,BaselineCharacteristic,x.x (x.x),Placebo + MTX (n?=?xxx) ; ,"No of prior DMARDs (excluding MTX), mean (SD)", Demographics,5,1,3,no
2529,2674556,Table 1,BaselineCharacteristic,x.x (x.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"No of prior DMARDs (excluding MTX), mean (SD)", Demographics,5,2,3,no
2529,2674556,Table 1,BaselineCharacteristic,x.x (x.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"No of prior DMARDs (excluding MTX), mean (SD)", Demographics,5,3,3,no
2529,2674556,Table 1,BaselineCharacteristic,"MTX (mg/week), mean (SD)",Characteristics ; ,"MTX (mg/week), mean (SD)", Demographics,6,0,2,no
2529,2674556,Table 1,BaselineCharacteristic,xx.x (x.x),Placebo + MTX (n?=?xxx) ; ,"MTX (mg/week), mean (SD)", Demographics,6,1,3,no
2529,2674556,Table 1,BaselineCharacteristic,xx.x (x.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"MTX (mg/week), mean (SD)", Demographics,6,2,3,no
2529,2674556,Table 1,BaselineCharacteristic,xx.x (x.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"MTX (mg/week), mean (SD)", Demographics,6,3,3,no
2529,2674556,Table 1,BaselineCharacteristic,"Steroid use, n (%)",Characteristics ; ,"Steroid use, n (%)", Demographics,7,0,2,no
2529,2674556,Table 1,BaselineCharacteristic,xx (xx.x),Placebo + MTX (n?=?xxx) ; ,"Steroid use, n (%)", Demographics,7,1,3,no
2529,2674556,Table 1,BaselineCharacteristic,xxx (xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"Steroid use, n (%)", Demographics,7,2,3,no
2529,2674556,Table 1,BaselineCharacteristic,xxx (xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"Steroid use, n (%)", Demographics,7,3,3,no
2529,2674556,Table 1,BaselineCharacteristic,"Previous anti-TNF use, n (%)*",Characteristics ; ,"Previous anti-TNF use, n (%)*", Demographics,8,0,2,no
2529,2674556,Table 1,BaselineCharacteristic,x (x.x),Placebo + MTX (n?=?xxx) ; ,"Previous anti-TNF use, n (%)*", Demographics,8,1,3,no
2529,2674556,Table 1,BaselineCharacteristic,x (x.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"Previous anti-TNF use, n (%)*", Demographics,8,2,3,no
2529,2674556,Table 1,BaselineCharacteristic,x (x.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"Previous anti-TNF use, n (%)*", Demographics,8,3,3,no
2529,2674556,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,9,0,2,no
2529,2674556,Table 1,BaselineCharacteristic,,Placebo + MTX (n?=?xxx) ; ,None,None,9,1,3,no
2529,2674556,Table 1,BaselineCharacteristic,,Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,None,None,9,2,3,no
2529,2674556,Table 1,BaselineCharacteristic,,Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,None,None,9,3,3,no
2529,2674556,Table 1,BaselineCharacteristic,ACR core components,Characteristics ; ,None,None,10,0,24,no
2529,2674556,Table 1,BaselineCharacteristic,,Placebo + MTX (n?=?xxx) ; ,ACR core components,None,10,1,43,no
2529,2674556,Table 1,BaselineCharacteristic,,Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,ACR core components,None,10,2,43,no
2529,2674556,Table 1,BaselineCharacteristic,,Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,ACR core components,None,10,3,43,no
2529,2674556,Table 1,BaselineCharacteristic,"ESR (mm/h), geometric mean (CV)",Characteristics ; ,"ESR (mm/h), geometric mean (CV)", ACR core components,17,0,2,no
2529,2674556,Table 1,BaselineCharacteristic,xx.x (xx.x),Placebo + MTX (n?=?xxx) ; ,"ESR (mm/h), geometric mean (CV)", ACR core components,17,1,3,no
2529,2674556,Table 1,BaselineCharacteristic,xx.x (xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"ESR (mm/h), geometric mean (CV)", ACR core components,17,2,3,no
2529,2674556,Table 1,BaselineCharacteristic,xx.x (xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"ESR (mm/h), geometric mean (CV)", ACR core components,17,3,3,no
2529,2674556,Table 1,BaselineCharacteristic,"HAQ-DI, mean (SD)",Characteristics ; ,"HAQ-DI, mean (SD)", ACR core components,18,0,2,no
2529,2674556,Table 1,BaselineCharacteristic,x.x (x.x),Placebo + MTX (n?=?xxx) ; ,"HAQ-DI, mean (SD)", ACR core components,18,1,3,no
2529,2674556,Table 1,BaselineCharacteristic,x.x (x.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"HAQ-DI, mean (SD)", ACR core components,18,2,3,no
2529,2674556,Table 1,BaselineCharacteristic,x.x (x.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"HAQ-DI, mean (SD)", ACR core components,18,3,3,no
2529,2674556,Table 1,BaselineCharacteristic,"Duration of morning stiffness (h), median (range)",Characteristics ; ,"Duration of morning stiffness (h), median (range)", ACR core components,19,0,2,no
2529,2674556,Table 1,BaselineCharacteristic,x.x (x to xx.x),Placebo + MTX (n?=?xxx) ; ,"Duration of morning stiffness (h), median (range)", ACR core components,19,1,3,no
2529,2674556,Table 1,BaselineCharacteristic,x.x (x to xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"Duration of morning stiffness (h), median (range)", ACR core components,19,2,3,no
2529,2674556,Table 1,BaselineCharacteristic,x.x (x to xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"Duration of morning stiffness (h), median (range)", ACR core components,19,3,3,no
2529,2674556,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,20,0,2,no
2529,2674556,Table 1,BaselineCharacteristic,,Placebo + MTX (n?=?xxx) ; ,None,None,20,1,3,no
2529,2674556,Table 1,BaselineCharacteristic,,Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,None,None,20,2,3,no
2529,2674556,Table 1,BaselineCharacteristic,,Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,None,None,20,3,3,no
2529,2674556,Table 1,BaselineCharacteristic,Rheumatoid factor,Characteristics ; ,None,None,21,0,24,no
2529,2674556,Table 1,BaselineCharacteristic,,Placebo + MTX (n?=?xxx) ; ,Rheumatoid factor,None,21,1,43,no
2529,2674556,Table 1,BaselineCharacteristic,,Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,Rheumatoid factor,None,21,2,43,no
2529,2674556,Table 1,BaselineCharacteristic,,Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,Rheumatoid factor,None,21,3,43,no
2529,2674556,Table 1,BaselineCharacteristic,"RF positive (?xx IU/ml), n (%)",Characteristics ; ,"RF positive (?xx IU/ml), n (%)", Rheumatoid factor,22,0,2,no
2529,2674556,Table 1,BaselineCharacteristic,xx (xx.x),Placebo + MTX (n?=?xxx) ; ,"RF positive (?xx IU/ml), n (%)", Rheumatoid factor,22,1,3,no
2529,2674556,Table 1,BaselineCharacteristic,xxx (xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"RF positive (?xx IU/ml), n (%)", Rheumatoid factor,22,2,3,no
2529,2674556,Table 1,BaselineCharacteristic,xxx (xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"RF positive (?xx IU/ml), n (%)", Rheumatoid factor,22,3,3,no
2529,2674556,Table 1,BaselineCharacteristic,"RF plasma concentration (IU/ml), mean (SD)",Characteristics ; ,"RF plasma concentration (IU/ml), mean (SD)", Rheumatoid factor,23,0,2,no
2529,2674556,Table 1,BaselineCharacteristic,xxx.x (xxx.x),Placebo + MTX (n?=?xxx) ; ,"RF plasma concentration (IU/ml), mean (SD)", Rheumatoid factor,23,1,3,no
2529,2674556,Table 1,BaselineCharacteristic,xxx.x (xxx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"RF plasma concentration (IU/ml), mean (SD)", Rheumatoid factor,23,2,3,no
2529,2674556,Table 1,BaselineCharacteristic,xxx.x (xxx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"RF plasma concentration (IU/ml), mean (SD)", Rheumatoid factor,23,3,3,no
2529,2674556,Table 1,BaselineCharacteristic,,Characteristics ; ,None,None,24,0,2,no
2529,2674556,Table 1,BaselineCharacteristic,,Placebo + MTX (n?=?xxx) ; ,None,None,24,1,3,no
2529,2674556,Table 1,BaselineCharacteristic,,Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,None,None,24,2,3,no
2529,2674556,Table 1,BaselineCharacteristic,,Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,None,None,24,3,3,no
2529,2674556,Table 1,BaselineCharacteristic,x-Ray progression,Characteristics ; ,None,None,25,0,24,no
2529,2674556,Table 1,BaselineCharacteristic,,Placebo + MTX (n?=?xxx) ; ,x-Ray progression,None,25,1,43,no
2529,2674556,Table 1,BaselineCharacteristic,,Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,x-Ray progression,None,25,2,43,no
2529,2674556,Table 1,BaselineCharacteristic,,Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,x-Ray progression,None,25,3,43,no
2529,2674556,Table 1,BaselineCharacteristic,"mTSS, mean (SD)",Characteristics ; ,"mTSS, mean (SD)", x-Ray progression,27,0,2,no
2529,2674556,Table 1,BaselineCharacteristic,xx.x (xx.x),Placebo + MTX (n?=?xxx) ; ,"mTSS, mean (SD)", x-Ray progression,27,1,3,no
2529,2674556,Table 1,BaselineCharacteristic,xx.x (xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"mTSS, mean (SD)", x-Ray progression,27,2,3,no
2529,2674556,Table 1,BaselineCharacteristic,xx.x (xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"mTSS, mean (SD)", x-Ray progression,27,3,3,no
2529,2674556,Table 1,BaselineCharacteristic,,Characteristics ; ,, x-Ray progression,28,0,2,no
2529,2674556,Table 1,BaselineCharacteristic,xx.x (xx.x),Placebo + MTX (n?=?xxx) ; ,, x-Ray progression,28,1,3,no
2529,2674556,Table 1,BaselineCharacteristic,xx.x (xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,, x-Ray progression,28,2,3,no
2529,2674556,Table 1,BaselineCharacteristic,xx.x (xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,, x-Ray progression,28,3,3,no
2529,2674556,Table 1,BaselineCharacteristic,,Characteristics ; ,, x-Ray progression,29,0,2,no
2529,2674556,Table 1,BaselineCharacteristic,xx.x (xx.x),Placebo + MTX (n?=?xxx) ; ,, x-Ray progression,29,1,3,no
2529,2674556,Table 1,BaselineCharacteristic,xx.x (xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,, x-Ray progression,29,2,3,no
2529,2674556,Table 1,BaselineCharacteristic,xx.x (xx.x),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,, x-Ray progression,29,3,3,no
2529,2674556,Table 1,BaselineCharacteristic,"Disease activity (DASxx (ESR)), mean (SD)",Characteristics ; ,"Disease activity (DASxx (ESR)), mean (SD)", x-Ray progression,30,0,2,no
2529,2674556,Table 1,BaselineCharacteristic,x.xx (x.xx),Placebo + MTX (n?=?xxx) ; ,"Disease activity (DASxx (ESR)), mean (SD)", x-Ray progression,30,1,3,no
2529,2674556,Table 1,BaselineCharacteristic,x.xx (x.xx),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"Disease activity (DASxx (ESR)), mean (SD)", x-Ray progression,30,2,3,no
2529,2674556,Table 1,BaselineCharacteristic,x.xx (x.xx),Certolizumab pegol xxx mg + MTX (n?=?xxx) ; ,"Disease activity (DASxx (ESR)), mean (SD)", x-Ray progression,30,3,3,no
2536,2678276,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no
2536,2678276,Table 1,BaselineCharacteristic,XELIRI,,,None,0,1,1,no
2536,2678276,Table 1,BaselineCharacteristic,FOLFIRI,,,None,0,2,1,no
2536,2678276,Table 1,BaselineCharacteristic,,,,None,0,3,1,no
2536,2678276,Table 1,BaselineCharacteristic,, ; ,None,None,1,0,12,no
2536,2678276,Table 1,BaselineCharacteristic,n = xx,XELIRI ; ,,None,1,1,1,no
2536,2678276,Table 1,BaselineCharacteristic,n = xx,FOLFIRI ; ,,None,1,2,1,no
2536,2678276,Table 1,BaselineCharacteristic,p, ; ,,None,1,3,1,no
2536,2678276,Table 1,BaselineCharacteristic,Median age-years, ;  ; ,Median age-years,,2,0,2,no
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,Median age-years,,2,3,3,no
2536,2678276,Table 1,BaselineCharacteristic,Gender, ;  ; ,None,None,3,0,24,no
2536,2678276,Table 1,BaselineCharacteristic,,XELIRI ; n = xx ; ,Gender,None,3,1,43,no
2536,2678276,Table 1,BaselineCharacteristic,,FOLFIRI ; n = xx ; ,Gender,None,3,2,43,no
2536,2678276,Table 1,BaselineCharacteristic,, ; p ; ,Gender,None,3,3,43,no
2536,2678276,Table 1,BaselineCharacteristic,?Male, ;  ; ,?Male, Gender,4,0,2,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,?Male, Gender,4,1,3,yes
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?Male, Gender,4,2,3,yes
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?Male, Gender,4,3,3,no
2536,2678276,Table 1,BaselineCharacteristic,?Female, ;  ; ,?Female, Gender,5,0,2,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,?Female, Gender,5,1,3,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?Female, Gender,5,2,3,no
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?Female, Gender,5,3,3,no
2536,2678276,Table 1,BaselineCharacteristic,WHO performance status, ;  ; ,None,None,6,0,24,no
2536,2678276,Table 1,BaselineCharacteristic,,XELIRI ; n = xx ; ,WHO performance status,None,6,1,43,no
2536,2678276,Table 1,BaselineCharacteristic,,FOLFIRI ; n = xx ; ,WHO performance status,None,6,2,43,no
2536,2678276,Table 1,BaselineCharacteristic,, ; p ; ,WHO performance status,None,6,3,43,no
2536,2678276,Table 1,BaselineCharacteristic,?Performance status x, ;  ; ,?Performance status x, WHO performance status,7,0,2,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,?Performance status x, WHO performance status,7,1,3,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?Performance status x, WHO performance status,7,2,3,no
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?Performance status x, WHO performance status,7,3,3,no
2536,2678276,Table 1,BaselineCharacteristic,?Performance status x, ;  ; ,?Performance status x, WHO performance status,8,0,2,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,?Performance status x, WHO performance status,8,1,3,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?Performance status x, WHO performance status,8,2,3,no
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?Performance status x, WHO performance status,8,3,3,no
2536,2678276,Table 1,BaselineCharacteristic,Primary tumour, ;  ; ,None,None,9,0,24,no
2536,2678276,Table 1,BaselineCharacteristic,,XELIRI ; n = xx ; ,Primary tumour,None,9,1,43,no
2536,2678276,Table 1,BaselineCharacteristic,,FOLFIRI ; n = xx ; ,Primary tumour,None,9,2,43,no
2536,2678276,Table 1,BaselineCharacteristic,, ; p ; ,Primary tumour,None,9,3,43,no
2536,2678276,Table 1,BaselineCharacteristic,?Colon, ;  ; ,?Colon, Primary tumour,10,0,2,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,?Colon, Primary tumour,10,1,3,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?Colon, Primary tumour,10,2,3,no
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?Colon, Primary tumour,10,3,3,no
2536,2678276,Table 1,BaselineCharacteristic,?Rectum, ;  ; ,?Rectum, Primary tumour,11,0,2,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,?Rectum, Primary tumour,11,1,3,no
2536,2678276,Table 1,BaselineCharacteristic,x (xx%),FOLFIRI ; n = xx ; ,?Rectum, Primary tumour,11,2,3,no
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?Rectum, Primary tumour,11,3,3,no
2536,2678276,Table 1,BaselineCharacteristic,Initial stage of disease at diagnosis, ;  ; ,None,None,12,0,24,no
2536,2678276,Table 1,BaselineCharacteristic,,XELIRI ; n = xx ; ,Initial stage of disease at diagnosis,None,12,1,43,no
2536,2678276,Table 1,BaselineCharacteristic,,FOLFIRI ; n = xx ; ,Initial stage of disease at diagnosis,None,12,2,43,no
2536,2678276,Table 1,BaselineCharacteristic,, ; p ; ,Initial stage of disease at diagnosis,None,12,3,43,no
2536,2678276,Table 1,BaselineCharacteristic,?Stage x, ;  ; ,?Stage x, Initial stage of disease at diagnosis,13,0,2,no
2536,2678276,Table 1,BaselineCharacteristic,x,XELIRI ; n = xx ; ,?Stage x, Initial stage of disease at diagnosis,13,1,3,no
2536,2678276,Table 1,BaselineCharacteristic,x (x%),FOLFIRI ; n = xx ; ,?Stage x, Initial stage of disease at diagnosis,13,2,3,no
2536,2678276,Table 1,BaselineCharacteristic,-, ; p ; ,?Stage x, Initial stage of disease at diagnosis,13,3,3,no
2536,2678276,Table 1,BaselineCharacteristic,?Stage x, ;  ; ,?Stage x, Initial stage of disease at diagnosis,14,0,2,no
2536,2678276,Table 1,BaselineCharacteristic,x (xx%),XELIRI ; n = xx ; ,?Stage x, Initial stage of disease at diagnosis,14,1,3,no
2536,2678276,Table 1,BaselineCharacteristic,x (x%),FOLFIRI ; n = xx ; ,?Stage x, Initial stage of disease at diagnosis,14,2,3,no
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?Stage x, Initial stage of disease at diagnosis,14,3,3,no
2536,2678276,Table 1,BaselineCharacteristic,?Stage x, ;  ; ,?Stage x, Initial stage of disease at diagnosis,15,0,2,no
2536,2678276,Table 1,BaselineCharacteristic,x (xx%),XELIRI ; n = xx ; ,?Stage x, Initial stage of disease at diagnosis,15,1,3,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?Stage x, Initial stage of disease at diagnosis,15,2,3,no
2536,2678276,Table 1,BaselineCharacteristic,"x,xx", ; p ; ,?Stage x, Initial stage of disease at diagnosis,15,3,3,no
2536,2678276,Table 1,BaselineCharacteristic,?Stage x, ;  ; ,?Stage x, Initial stage of disease at diagnosis,16,0,2,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,?Stage x, Initial stage of disease at diagnosis,16,1,3,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?Stage x, Initial stage of disease at diagnosis,16,2,3,no
2536,2678276,Table 1,BaselineCharacteristic,x.x, ; p ; ,?Stage x, Initial stage of disease at diagnosis,16,3,3,no
2536,2678276,Table 1,BaselineCharacteristic,Previous adjuvant treatment*, ;  ; ,None,None,17,0,24,no
2536,2678276,Table 1,BaselineCharacteristic,,XELIRI ; n = xx ; ,Previous adjuvant treatment*,None,17,1,43,no
2536,2678276,Table 1,BaselineCharacteristic,,FOLFIRI ; n = xx ; ,Previous adjuvant treatment*,None,17,2,43,no
2536,2678276,Table 1,BaselineCharacteristic,, ; p ; ,Previous adjuvant treatment*,None,17,3,43,no
2536,2678276,Table 1,BaselineCharacteristic,?Yes, ;  ; ,?Yes, Previous adjuvant treatment*,18,0,2,no
2536,2678276,Table 1,BaselineCharacteristic,x (xx%),XELIRI ; n = xx ; ,?Yes, Previous adjuvant treatment*,18,1,3,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?Yes, Previous adjuvant treatment*,18,2,3,no
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?Yes, Previous adjuvant treatment*,18,3,3,no
2536,2678276,Table 1,BaselineCharacteristic,?No, ;  ; ,?No, Previous adjuvant treatment*,19,0,2,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,?No, Previous adjuvant treatment*,19,1,3,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?No, Previous adjuvant treatment*,19,2,3,no
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?No, Previous adjuvant treatment*,19,3,3,no
2536,2678276,Table 1,BaselineCharacteristic,Median time from diagnosis to randomisation (months), ;  ; ,Median time from diagnosis to randomisation (months),,20,0,2,no
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,Median time from diagnosis to randomisation (months),,20,3,3,no
2536,2678276,Table 1,BaselineCharacteristic,Number of liver metastases, ;  ; ,None,None,21,0,24,no
2536,2678276,Table 1,BaselineCharacteristic,,XELIRI ; n = xx ; ,Number of liver metastases,None,21,1,43,no
2536,2678276,Table 1,BaselineCharacteristic,,FOLFIRI ; n = xx ; ,Number of liver metastases,None,21,2,43,no
2536,2678276,Table 1,BaselineCharacteristic,, ; p ; ,Number of liver metastases,None,21,3,43,no
2536,2678276,Table 1,BaselineCharacteristic,?> xx, ;  ; ,?> xx, Number of liver metastases,24,0,2,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,?> xx, Number of liver metastases,24,1,3,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?> xx, Number of liver metastases,24,2,3,no
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?> xx, Number of liver metastases,24,3,3,no
2536,2678276,Table 1,BaselineCharacteristic,Liver involvement (%), ;  ; ,None,None,25,0,24,no
2536,2678276,Table 1,BaselineCharacteristic,,XELIRI ; n = xx ; ,Liver involvement (%),None,25,1,43,no
2536,2678276,Table 1,BaselineCharacteristic,,FOLFIRI ; n = xx ; ,Liver involvement (%),None,25,2,43,no
2536,2678276,Table 1,BaselineCharacteristic,, ; p ; ,Liver involvement (%),None,25,3,43,no
2536,2678276,Table 1,BaselineCharacteristic,?< xx, ;  ; ,?< xx, Liver involvement (%),26,0,2,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,?< xx, Liver involvement (%),26,1,3,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?< xx, Liver involvement (%),26,2,3,no
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?< xx, Liver involvement (%),26,3,3,no
2536,2678276,Table 1,BaselineCharacteristic,?> xx, ;  ; ,?> xx, Liver involvement (%),28,0,2,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,?> xx, Liver involvement (%),28,1,3,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?> xx, Liver involvement (%),28,2,3,no
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?> xx, Liver involvement (%),28,3,3,no
2536,2678276,Table 1,BaselineCharacteristic,Median size of liver metastases (cm), ;  ; ,Median size of liver metastases (cm),,29,0,2,no
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,Median size of liver metastases (cm),,29,3,3,no
2536,2678276,Table 1,BaselineCharacteristic,"Bilateral liver metastases, n (%)", ;  ; ,"Bilateral liver metastases, n (%)",,30,0,2,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,"Bilateral liver metastases, n (%)",,30,1,3,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,"Bilateral liver metastases, n (%)",,30,2,3,no
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,"Bilateral liver metastases, n (%)",,30,3,3,no
2536,2678276,Table 1,BaselineCharacteristic,Baseline CEA, ;  ; ,None,None,31,0,24,no
2536,2678276,Table 1,BaselineCharacteristic,,XELIRI ; n = xx ; ,Baseline CEA,None,31,1,43,no
2536,2678276,Table 1,BaselineCharacteristic,,FOLFIRI ; n = xx ; ,Baseline CEA,None,31,2,43,no
2536,2678276,Table 1,BaselineCharacteristic,, ; p ; ,Baseline CEA,None,31,3,43,no
2536,2678276,Table 1,BaselineCharacteristic,?Normal, ;  ; ,?Normal, Baseline CEA,32,0,2,no
2536,2678276,Table 1,BaselineCharacteristic,x (xx%),XELIRI ; n = xx ; ,?Normal, Baseline CEA,32,1,3,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?Normal, Baseline CEA,32,2,3,no
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?Normal, Baseline CEA,32,3,3,no
2536,2678276,Table 1,BaselineCharacteristic,?> x.x ?g/l, ;  ; ,?> x.x ?g/l, Baseline CEA,33,0,2,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,?> x.x ?g/l, Baseline CEA,33,1,3,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?> x.x ?g/l, Baseline CEA,33,2,3,no
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?> x.x ?g/l, Baseline CEA,33,3,3,no
2536,2678276,Table 1,BaselineCharacteristic,Baseline LDH, ;  ; ,None,None,34,0,24,no
2536,2678276,Table 1,BaselineCharacteristic,,XELIRI ; n = xx ; ,Baseline LDH,None,34,1,43,no
2536,2678276,Table 1,BaselineCharacteristic,,FOLFIRI ; n = xx ; ,Baseline LDH,None,34,2,43,no
2536,2678276,Table 1,BaselineCharacteristic,, ; p ; ,Baseline LDH,None,34,3,43,no
2536,2678276,Table 1,BaselineCharacteristic,?Normal, ;  ; ,?Normal, Baseline LDH,35,0,2,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,?Normal, Baseline LDH,35,1,3,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?Normal, Baseline LDH,35,2,3,no
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?Normal, Baseline LDH,35,3,3,no
2536,2678276,Table 1,BaselineCharacteristic,?> x.xx ?kat/l, ;  ; ,?> x.xx ?kat/l, Baseline LDH,36,0,2,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,?> x.xx ?kat/l, Baseline LDH,36,1,3,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?> x.xx ?kat/l, Baseline LDH,36,2,3,no
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?> x.xx ?kat/l, Baseline LDH,36,3,3,no
2536,2678276,Table 1,BaselineCharacteristic,Reasons for initial unresectability, ;  ; ,None,None,37,0,24,no
2536,2678276,Table 1,BaselineCharacteristic,,XELIRI ; n = xx ; ,Reasons for initial unresectability,None,37,1,43,no
2536,2678276,Table 1,BaselineCharacteristic,,FOLFIRI ; n = xx ; ,Reasons for initial unresectability,None,37,2,43,no
2536,2678276,Table 1,BaselineCharacteristic,, ; p ; ,Reasons for initial unresectability,None,37,3,43,no
2536,2678276,Table 1,BaselineCharacteristic,?Location of metastases, ;  ; ,?Location of metastases, Reasons for initial unresectability,38,0,2,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,?Location of metastases, Reasons for initial unresectability,38,1,3,no
2536,2678276,Table 1,BaselineCharacteristic,x (xx%),FOLFIRI ; n = xx ; ,?Location of metastases, Reasons for initial unresectability,38,2,3,no
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?Location of metastases, Reasons for initial unresectability,38,3,3,no
2536,2678276,Table 1,BaselineCharacteristic,?Number of metastases, ;  ; ,?Number of metastases, Reasons for initial unresectability,39,0,2,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),XELIRI ; n = xx ; ,?Number of metastases, Reasons for initial unresectability,39,1,3,no
2536,2678276,Table 1,BaselineCharacteristic,xx (xx%),FOLFIRI ; n = xx ; ,?Number of metastases, Reasons for initial unresectability,39,2,3,no
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?Number of metastases, Reasons for initial unresectability,39,3,3,no
2536,2678276,Table 1,BaselineCharacteristic,?Size of metastases, ;  ; ,?Size of metastases, Reasons for initial unresectability,40,0,2,no
2536,2678276,Table 1,BaselineCharacteristic,x (xx%),XELIRI ; n = xx ; ,?Size of metastases, Reasons for initial unresectability,40,1,3,no
2536,2678276,Table 1,BaselineCharacteristic,x (xx%),FOLFIRI ; n = xx ; ,?Size of metastases, Reasons for initial unresectability,40,2,3,no
2536,2678276,Table 1,BaselineCharacteristic,x.xx, ; p ; ,?Size of metastases, Reasons for initial unresectability,40,3,3,no
2602,2694271,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no
2602,2694271,Table 1,BaselineCharacteristic,Gender, ; ,Gender,,1,0,24,no
2602,2694271,Table 1,BaselineCharacteristic,, ; ,,,2,0,2,no
2602,2694271,Table 1,BaselineCharacteristic,Country of birth, ; ,None,None,5,0,24,no
2602,2694271,Table 1,BaselineCharacteristic,UK, ; ,UK, Country of birth,6,0,2,no
2602,2694271,Table 1,BaselineCharacteristic,Africa, ; ,Africa, Country of birth,7,0,2,no
2602,2694271,Table 1,BaselineCharacteristic,Other, ; ,Other, Country of birth,8,0,2,no
2602,2694271,Table 1,BaselineCharacteristic,Healthcare worker, ; ,Healthcare worker, Country of birth,9,0,2,no
2602,2694271,Table 1,BaselineCharacteristic,Significant travel history, ; ,Significant travel history, Country of birth,10,0,2,no
2650,2705818,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no
2650,2705818,Table 1,BaselineCharacteristic,Men,,,None,0,1,1,no
2650,2705818,Table 1,BaselineCharacteristic,Women,,,None,0,2,1,no
2650,2705818,Table 1,BaselineCharacteristic,Total,,,None,0,3,1,no
2650,2705818,Table 1,BaselineCharacteristic,"Gender, n (%)", ; ,"Gender, n (%)",,1,0,2,no
2650,2705818,Table 1,BaselineCharacteristic,xxx (xx),Men ; ,"Gender, n (%)",,1,1,3,yes
2650,2705818,Table 1,BaselineCharacteristic,xxx (xx),Women ; ,"Gender, n (%)",,1,2,3,yes
2650,2705818,Table 1,BaselineCharacteristic,xxx,Total ; ,"Gender, n (%)",,1,3,3,no
2650,2705818,Table 1,BaselineCharacteristic,Range, ; ,Range,,3,0,2,no
2650,2705818,Table 1,BaselineCharacteristic,"Race, n (%)", ; ,None,None,4,0,24,no
2650,2705818,Table 1,BaselineCharacteristic,"Race, n (%)",Men ; ,"Race, n (%)",None,4,1,43,no
2650,2705818,Table 1,BaselineCharacteristic,"Race, n (%)",Women ; ,"Race, n (%)",None,4,2,43,no
2650,2705818,Table 1,BaselineCharacteristic,"Race, n (%)",Total ; ,"Race, n (%)",None,4,3,43,no
2650,2705818,Table 1,BaselineCharacteristic,White, ; ,White," Race, n (%)",5,0,2,no
2650,2705818,Table 1,BaselineCharacteristic,xx (xx),Men ; ,White," Race, n (%)",5,1,3,no
2650,2705818,Table 1,BaselineCharacteristic,xxx (xx),Women ; ,White," Race, n (%)",5,2,3,no
2650,2705818,Table 1,BaselineCharacteristic,xxx (xx),Total ; ,White," Race, n (%)",5,3,3,no
2650,2705818,Table 1,BaselineCharacteristic,Black, ; ,Black," Race, n (%)",6,0,2,no
2650,2705818,Table 1,BaselineCharacteristic,x (x),Men ; ,Black," Race, n (%)",6,1,3,no
2650,2705818,Table 1,BaselineCharacteristic,x (x),Women ; ,Black," Race, n (%)",6,2,3,no
2650,2705818,Table 1,BaselineCharacteristic,xx (x),Total ; ,Black," Race, n (%)",6,3,3,no
2650,2705818,Table 1,BaselineCharacteristic,Asian, ; ,Asian," Race, n (%)",7,0,2,no
2650,2705818,Table 1,BaselineCharacteristic,xx (xx),Men ; ,Asian," Race, n (%)",7,1,3,no
2650,2705818,Table 1,BaselineCharacteristic,xx (xx),Women ; ,Asian," Race, n (%)",7,2,3,no
2650,2705818,Table 1,BaselineCharacteristic,xx (xx),Total ; ,Asian," Race, n (%)",7,3,3,no
2650,2705818,Table 1,BaselineCharacteristic,Other, ; ,Other," Race, n (%)",8,0,2,no
2650,2705818,Table 1,BaselineCharacteristic,x,Men ; ,Other," Race, n (%)",8,1,3,no
2650,2705818,Table 1,BaselineCharacteristic,xx (x),Women ; ,Other," Race, n (%)",8,2,3,no
2650,2705818,Table 1,BaselineCharacteristic,xx (x),Total ; ,Other," Race, n (%)",8,3,3,no
2650,2705818,Table 1,BaselineCharacteristic,"Postmenopausal,n (%)", ; ,"Postmenopausal,n (%)"," Race, n (%)",9,0,2,no
2650,2705818,Table 1,BaselineCharacteristic,NA,Men ; ,"Postmenopausal,n (%)"," Race, n (%)",9,1,3,no
2650,2705818,Table 1,BaselineCharacteristic,xxx (xx),Women ; ,"Postmenopausal,n (%)"," Race, n (%)",9,2,3,no
2650,2705818,Table 1,BaselineCharacteristic,NA,Total ; ,"Postmenopausal,n (%)"," Race, n (%)",9,3,3,no
2650,2705818,Table 1,BaselineCharacteristic,"Past or presentBPH, n (%)", ; ,"Past or presentBPH, n (%)"," Race, n (%)",10,0,2,no
2650,2705818,Table 1,BaselineCharacteristic,xx (xx),Men ; ,"Past or presentBPH, n (%)"," Race, n (%)",10,1,3,no
2650,2705818,Table 1,BaselineCharacteristic,NA,Women ; ,"Past or presentBPH, n (%)"," Race, n (%)",10,2,3,no
2650,2705818,Table 1,BaselineCharacteristic,NA,Total ; ,"Past or presentBPH, n (%)"," Race, n (%)",10,3,3,no
2748,2736828,Table 1,BaselineCharacteristic,Parameter,,None,None,0,0,12,no
2748,2736828,Table 1,BaselineCharacteristic,TMZ+IFN,,Parameter,None,0,1,1,no
2748,2736828,Table 1,BaselineCharacteristic,TMZ+PEG,,Parameter,None,0,2,1,no
2748,2736828,Table 1,BaselineCharacteristic,Number of patients,Parameter ; ,Number of patients,,1,0,2,no
2748,2736828,Table 1,BaselineCharacteristic,xx,TMZ+IFN ; ,Number of patients,,1,1,3,no
2748,2736828,Table 1,BaselineCharacteristic,xx,TMZ+PEG ; ,Number of patients,,1,2,3,no
2748,2736828,Table 1,BaselineCharacteristic,Age: median (range),Parameter ; ,Age: median (range),,2,0,2,no
2748,2736828,Table 1,BaselineCharacteristic,Gender: M/F (%),Parameter ; ,Gender: M/F (%),,3,0,2,no
2748,2736828,Table 1,BaselineCharacteristic,xx?:?x (xx:xx),TMZ+IFN ; ,Gender: M/F (%),,3,1,3,yes
2748,2736828,Table 1,BaselineCharacteristic,xx?:?xx (xx?:?xx),TMZ+PEG ; ,Gender: M/F (%),,3,2,3,yes
2748,2736828,Table 1,BaselineCharacteristic,,Parameter ; ,None,None,4,0,2,no
2748,2736828,Table 1,BaselineCharacteristic,,TMZ+IFN ; ,None,None,4,1,3,no
2748,2736828,Table 1,BaselineCharacteristic,,TMZ+PEG ; ,None,None,4,2,3,no
2748,2736828,Table 1,BaselineCharacteristic,KPS,Parameter ; ,None,None,5,0,24,no
2748,2736828,Table 1,BaselineCharacteristic,,TMZ+IFN ; ,KPS,None,5,1,43,no
2748,2736828,Table 1,BaselineCharacteristic,,TMZ+PEG ; ,KPS,None,5,2,43,no
2748,2736828,Table 1,BaselineCharacteristic,?Median,Parameter ; ,?Median, KPS,6,0,2,no
2748,2736828,Table 1,BaselineCharacteristic,xx,TMZ+IFN ; ,?Median, KPS,6,1,3,no
2748,2736828,Table 1,BaselineCharacteristic,xx,TMZ+PEG ; ,?Median, KPS,6,2,3,no
2748,2736828,Table 1,BaselineCharacteristic,?xxx%,Parameter ; ,?xxx%, KPS,7,0,2,no
2748,2736828,Table 1,BaselineCharacteristic,x (x%),TMZ+IFN ; ,?xxx%, KPS,7,1,3,no
2748,2736828,Table 1,BaselineCharacteristic,x (xx%),TMZ+PEG ; ,?xxx%, KPS,7,2,3,no
2748,2736828,Table 1,BaselineCharacteristic,?xx%,Parameter ; ,?xx%, KPS,8,0,2,no
2748,2736828,Table 1,BaselineCharacteristic,x (xx%),TMZ+IFN ; ,?xx%, KPS,8,1,3,no
2748,2736828,Table 1,BaselineCharacteristic,xx (xx%),TMZ+PEG ; ,?xx%, KPS,8,2,3,no
2748,2736828,Table 1,BaselineCharacteristic,?xx%,Parameter ; ,?xx%, KPS,9,0,2,no
2748,2736828,Table 1,BaselineCharacteristic,xx (xx%),TMZ+IFN ; ,?xx%, KPS,9,1,3,no
2748,2736828,Table 1,BaselineCharacteristic,x (xx%),TMZ+PEG ; ,?xx%, KPS,9,2,3,no
2748,2736828,Table 1,BaselineCharacteristic,?xx%,Parameter ; ,?xx%, KPS,10,0,2,no
2748,2736828,Table 1,BaselineCharacteristic,x (xx%),TMZ+IFN ; ,?xx%, KPS,10,1,3,no
2748,2736828,Table 1,BaselineCharacteristic,x (xx%),TMZ+PEG ; ,?xx%, KPS,10,2,3,no
2748,2736828,Table 1,BaselineCharacteristic,,Parameter ; ,None,None,11,0,2,no
2748,2736828,Table 1,BaselineCharacteristic,,TMZ+IFN ; ,None,None,11,1,3,no
2748,2736828,Table 1,BaselineCharacteristic,,TMZ+PEG ; ,None,None,11,2,3,no
2748,2736828,Table 1,BaselineCharacteristic,Maximum prior resection,Parameter ; ,None,None,12,0,24,no
2748,2736828,Table 1,BaselineCharacteristic,Maximum prior resection,TMZ+IFN ; ,Maximum prior resection,None,12,1,43,no
2748,2736828,Table 1,BaselineCharacteristic,Maximum prior resection,TMZ+PEG ; ,Maximum prior resection,None,12,2,43,no
2748,2736828,Table 1,BaselineCharacteristic,?Biopsy,Parameter ; ,?Biopsy, Maximum prior resection,13,0,2,no
2748,2736828,Table 1,BaselineCharacteristic,x (x%),TMZ+IFN ; ,?Biopsy, Maximum prior resection,13,1,3,no
2748,2736828,Table 1,BaselineCharacteristic,x (xx%),TMZ+PEG ; ,?Biopsy, Maximum prior resection,13,2,3,no
2748,2736828,Table 1,BaselineCharacteristic,?Subtotal resection,Parameter ; ,?Subtotal resection, Maximum prior resection,14,0,2,no
2748,2736828,Table 1,BaselineCharacteristic,xx (xx%),TMZ+IFN ; ,?Subtotal resection, Maximum prior resection,14,1,3,no
2748,2736828,Table 1,BaselineCharacteristic,x (xx%),TMZ+PEG ; ,?Subtotal resection, Maximum prior resection,14,2,3,no
2748,2736828,Table 1,BaselineCharacteristic,?Gross total resection,Parameter ; ,?Gross total resection, Maximum prior resection,15,0,2,no
2748,2736828,Table 1,BaselineCharacteristic,xx (xx%),TMZ+IFN ; ,?Gross total resection, Maximum prior resection,15,1,3,no
2748,2736828,Table 1,BaselineCharacteristic,xx (xx%),TMZ+PEG ; ,?Gross total resection, Maximum prior resection,15,2,3,no
2748,2736828,Table 1,BaselineCharacteristic,,Parameter ; ,None,None,16,0,2,no
2748,2736828,Table 1,BaselineCharacteristic,,TMZ+IFN ; ,None,None,16,1,3,no
2748,2736828,Table 1,BaselineCharacteristic,,TMZ+PEG ; ,None,None,16,2,3,no
2748,2736828,Table 1,BaselineCharacteristic,Number of prior chemotherapies,Parameter ; ,None,None,17,0,24,no
2748,2736828,Table 1,BaselineCharacteristic,Number of prior chemotherapies,TMZ+IFN ; ,Number of prior chemotherapies,None,17,1,43,no
2748,2736828,Table 1,BaselineCharacteristic,Number of prior chemotherapies,TMZ+PEG ; ,Number of prior chemotherapies,None,17,2,43,no
2748,2736828,Table 1,BaselineCharacteristic,?x,Parameter ; ,?x, Number of prior chemotherapies,18,0,2,no
2748,2736828,Table 1,BaselineCharacteristic,x (xx%),TMZ+IFN ; ,?x, Number of prior chemotherapies,18,1,3,no
2748,2736828,Table 1,BaselineCharacteristic,xx (xx%),TMZ+PEG ; ,?x, Number of prior chemotherapies,18,2,3,no
2748,2736828,Table 1,BaselineCharacteristic,?x,Parameter ; ,?x, Number of prior chemotherapies,19,0,2,no
2748,2736828,Table 1,BaselineCharacteristic,xx (xx%)a,TMZ+IFN ; ,?x, Number of prior chemotherapies,19,1,3,no
2748,2736828,Table 1,BaselineCharacteristic,xx (xx%)b,TMZ+PEG ; ,?x, Number of prior chemotherapies,19,2,3,no
2748,2736828,Table 1,BaselineCharacteristic,?x,Parameter ; ,?x, Number of prior chemotherapies,20,0,2,no
2748,2736828,Table 1,BaselineCharacteristic,x (x%),TMZ+IFN ; ,?x, Number of prior chemotherapies,20,1,3,no
2748,2736828,Table 1,BaselineCharacteristic,x (x%),TMZ+PEG ; ,?x, Number of prior chemotherapies,20,2,3,no
2787,2747698,Table 2,BaselineCharacteristic,Characteristic,,None,None,0,0,12,no
2787,2747698,Table 2,BaselineCharacteristic,n,,Characteristic,None,0,1,1,no
2787,2747698,Table 2,BaselineCharacteristic,Age (years),Characteristic ; ,None,None,1,0,24,no
2787,2747698,Table 2,BaselineCharacteristic,Age (years),n ; ,Age (years),None,1,1,43,no
2787,2747698,Table 2,BaselineCharacteristic,?Median,Characteristic ; ,?Median, Age (years),2,0,2,no
2787,2747698,Table 2,BaselineCharacteristic,xx,n ; ,?Median, Age (years),2,1,3,no
2787,2747698,Table 2,BaselineCharacteristic,?Range,Characteristic ; ,?Range, Age (years),3,0,2,no
2787,2747698,Table 2,BaselineCharacteristic,WHO PS,Characteristic ; ,None,None,4,0,24,no
2787,2747698,Table 2,BaselineCharacteristic,WHO PS,n ; ,WHO PS,None,4,1,43,no
2787,2747698,Table 2,BaselineCharacteristic,?x,Characteristic ; ,?x, WHO PS,5,0,2,no
2787,2747698,Table 2,BaselineCharacteristic,xx,n ; ,?x, WHO PS,5,1,3,no
2787,2747698,Table 2,BaselineCharacteristic,?x,Characteristic ; ,?x, WHO PS,6,0,2,no
2787,2747698,Table 2,BaselineCharacteristic,x,n ; ,?x, WHO PS,6,1,3,no
2787,2747698,Table 2,BaselineCharacteristic,?x,Characteristic ; ,?x, WHO PS,7,0,2,no
2787,2747698,Table 2,BaselineCharacteristic,x,n ; ,?x, WHO PS,7,1,3,no
2787,2747698,Table 2,BaselineCharacteristic,FIGO stage,Characteristic ; ,None,None,8,0,24,no
2787,2747698,Table 2,BaselineCharacteristic,FIGO stage,n ; ,FIGO stage,None,8,1,43,no
2787,2747698,Table 2,BaselineCharacteristic,?IVA,Characteristic ; ,?IVA, FIGO stage,9,0,2,no
2787,2747698,Table 2,BaselineCharacteristic,x,n ; ,?IVA, FIGO stage,9,1,3,no
2787,2747698,Table 2,BaselineCharacteristic,?IVB,Characteristic ; ,?IVB, FIGO stage,10,0,2,no
2787,2747698,Table 2,BaselineCharacteristic,x,n ; ,?IVB, FIGO stage,10,1,3,no
2787,2747698,Table 2,BaselineCharacteristic,?Recurrent,Characteristic ; ,?Recurrent, FIGO stage,11,0,2,no
2787,2747698,Table 2,BaselineCharacteristic,xx,n ; ,?Recurrent, FIGO stage,11,1,3,no
2787,2747698,Table 2,BaselineCharacteristic,Site of recurrent,Characteristic ; ,None,None,12,0,24,no
2787,2747698,Table 2,BaselineCharacteristic,Site of recurrent,n ; ,Site of recurrent,None,12,1,43,no
2787,2747698,Table 2,BaselineCharacteristic,?Inside radiation field,Characteristic ; ,?Inside radiation field, Site of recurrent,13,0,2,no
2787,2747698,Table 2,BaselineCharacteristic,x,n ; ,?Inside radiation field, Site of recurrent,13,1,3,no
2787,2747698,Table 2,BaselineCharacteristic,?Outside radiation field,Characteristic ; ,?Outside radiation field, Site of recurrent,14,0,2,no
2787,2747698,Table 2,BaselineCharacteristic,xx,n ; ,?Outside radiation field, Site of recurrent,14,1,3,no
2787,2747698,Table 2,BaselineCharacteristic,Histology,Characteristic ; ,None,None,15,0,24,no
2787,2747698,Table 2,BaselineCharacteristic,Histology,n ; ,Histology,None,15,1,43,no
2787,2747698,Table 2,BaselineCharacteristic,?Squamous cell carcinoma,Characteristic ; ,?Squamous cell carcinoma, Histology,16,0,2,no
2787,2747698,Table 2,BaselineCharacteristic,xx,n ; ,?Squamous cell carcinoma, Histology,16,1,3,no
2787,2747698,Table 2,BaselineCharacteristic,?Adenosquamous cell carcinoma,Characteristic ; ,?Adenosquamous cell carcinoma, Histology,17,0,2,no
2787,2747698,Table 2,BaselineCharacteristic,x,n ; ,?Adenosquamous cell carcinoma, Histology,17,1,3,no
2787,2747698,Table 2,BaselineCharacteristic,?Adenocarcinoma,Characteristic ; ,?Adenocarcinoma, Histology,18,0,2,no
2787,2747698,Table 2,BaselineCharacteristic,x,n ; ,?Adenocarcinoma, Histology,18,1,3,no
2787,2747698,Table 2,BaselineCharacteristic,Prior therapy,Characteristic ; ,None,None,19,0,24,no
2787,2747698,Table 2,BaselineCharacteristic,Prior therapy,n ; ,Prior therapy,None,19,1,43,no
2787,2747698,Table 2,BaselineCharacteristic,?None,Characteristic ; ,?None, Prior therapy,20,0,2,no
2787,2747698,Table 2,BaselineCharacteristic,x,n ; ,?None, Prior therapy,20,1,3,no
2787,2747698,Table 2,BaselineCharacteristic,?Chemoradiation,Characteristic ; ,?Chemoradiation, Prior therapy,21,0,2,no
2787,2747698,Table 2,BaselineCharacteristic,x,n ; ,?Chemoradiation, Prior therapy,21,1,3,no
2787,2747698,Table 2,BaselineCharacteristic,?Surgery,Characteristic ; ,?Surgery, Prior therapy,22,0,2,no
2787,2747698,Table 2,BaselineCharacteristic,x,n ; ,?Surgery, Prior therapy,22,1,3,no
2787,2747698,Table 2,BaselineCharacteristic,?Surgery plus chemoradiation,Characteristic ; ,?Surgery plus chemoradiation, Prior therapy,23,0,2,no
2787,2747698,Table 2,BaselineCharacteristic,xx,n ; ,?Surgery plus chemoradiation, Prior therapy,23,1,3,no
2787,2747698,Table 6,BaselineCharacteristic,,,None,None,0,0,12,no
2787,2747698,Table 6,BaselineCharacteristic,,,,None,0,1,1,no
2787,2747698,Table 6,BaselineCharacteristic,Response,,,None,0,2,1,no
2787,2747698,Table 6,BaselineCharacteristic,Response,,,None,0,3,1,no
2787,2747698,Table 6,BaselineCharacteristic,Response,,,None,0,4,1,no
2787,2747698,Table 6,BaselineCharacteristic,Response,,,None,0,5,1,no
2787,2747698,Table 6,BaselineCharacteristic,,,,None,0,6,1,no
2787,2747698,Table 6,BaselineCharacteristic,Characteristic, ; ,None,None,1,0,12,no
2787,2747698,Table 6,BaselineCharacteristic,No. of Patients, ; ,Characteristic,None,1,1,1,no
2787,2747698,Table 6,BaselineCharacteristic,CR,Response ; ,Characteristic,None,1,2,1,no
2787,2747698,Table 6,BaselineCharacteristic,PR,Response ; ,Characteristic,None,1,3,1,no
2787,2747698,Table 6,BaselineCharacteristic,NC,Response ; ,Characteristic,None,1,4,1,no
2787,2747698,Table 6,BaselineCharacteristic,PD,Response ; ,Characteristic,None,1,5,1,no
2787,2747698,Table 6,BaselineCharacteristic,Response rate (%) (xx% CI), ; ,Characteristic,None,1,6,1,no
2787,2747698,Table 6,BaselineCharacteristic,Total, ; Characteristic ; ,Total,,2,0,2,no
2787,2747698,Table 6,BaselineCharacteristic,xx, ; No. of Patients ; ,Total,,2,1,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; CR ; ,Total,,2,2,3,no
2787,2747698,Table 6,BaselineCharacteristic,xx,Response ; PR ; ,Total,,2,3,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; NC ; ,Total,,2,4,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PD ; ,Total,,2,5,3,no
2787,2747698,Table 6,BaselineCharacteristic,, ; Characteristic ; ,None,None,3,0,2,no
2787,2747698,Table 6,BaselineCharacteristic,, ; No. of Patients ; ,None,None,3,1,3,no
2787,2747698,Table 6,BaselineCharacteristic,,Response ; CR ; ,None,None,3,2,3,no
2787,2747698,Table 6,BaselineCharacteristic,,Response ; PR ; ,None,None,3,3,3,no
2787,2747698,Table 6,BaselineCharacteristic,,Response ; NC ; ,None,None,3,4,3,no
2787,2747698,Table 6,BaselineCharacteristic,,Response ; PD ; ,None,None,3,5,3,no
2787,2747698,Table 6,BaselineCharacteristic,, ; Response rate (%) (xx% CI) ; ,None,None,3,6,3,no
2787,2747698,Table 6,BaselineCharacteristic,Stage, ; Characteristic ; ,None,None,4,0,24,no
2787,2747698,Table 6,BaselineCharacteristic,Stage, ; No. of Patients ; ,Stage,None,4,1,43,no
2787,2747698,Table 6,BaselineCharacteristic,Stage,Response ; CR ; ,Stage,None,4,2,43,no
2787,2747698,Table 6,BaselineCharacteristic,Stage,Response ; PR ; ,Stage,None,4,3,43,no
2787,2747698,Table 6,BaselineCharacteristic,Stage,Response ; NC ; ,Stage,None,4,4,43,no
2787,2747698,Table 6,BaselineCharacteristic,Stage,Response ; PD ; ,Stage,None,4,5,43,no
2787,2747698,Table 6,BaselineCharacteristic,Stage, ; Response rate (%) (xx% CI) ; ,Stage,None,4,6,43,no
2787,2747698,Table 6,BaselineCharacteristic,?IV, ; Characteristic ; ,?IV, Stage,5,0,2,no
2787,2747698,Table 6,BaselineCharacteristic,x, ; No. of Patients ; ,?IV, Stage,5,1,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; CR ; ,?IV, Stage,5,2,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PR ; ,?IV, Stage,5,3,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; NC ; ,?IV, Stage,5,4,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PD ; ,?IV, Stage,5,5,3,no
2787,2747698,Table 6,BaselineCharacteristic,?Recurrent, ; Characteristic ; ,?Recurrent, Stage,6,0,2,no
2787,2747698,Table 6,BaselineCharacteristic,xx, ; No. of Patients ; ,?Recurrent, Stage,6,1,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; CR ; ,?Recurrent, Stage,6,2,3,no
2787,2747698,Table 6,BaselineCharacteristic,xx,Response ; PR ; ,?Recurrent, Stage,6,3,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; NC ; ,?Recurrent, Stage,6,4,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PD ; ,?Recurrent, Stage,6,5,3,no
2787,2747698,Table 6,BaselineCharacteristic,Histology, ; Characteristic ; ,None,None,7,0,24,no
2787,2747698,Table 6,BaselineCharacteristic,Histology, ; No. of Patients ; ,Histology,None,7,1,43,no
2787,2747698,Table 6,BaselineCharacteristic,Histology,Response ; CR ; ,Histology,None,7,2,43,no
2787,2747698,Table 6,BaselineCharacteristic,Histology,Response ; PR ; ,Histology,None,7,3,43,no
2787,2747698,Table 6,BaselineCharacteristic,Histology,Response ; NC ; ,Histology,None,7,4,43,no
2787,2747698,Table 6,BaselineCharacteristic,Histology,Response ; PD ; ,Histology,None,7,5,43,no
2787,2747698,Table 6,BaselineCharacteristic,Histology, ; Response rate (%) (xx% CI) ; ,Histology,None,7,6,43,no
2787,2747698,Table 6,BaselineCharacteristic,?Squamous cell carcinoma, ; Characteristic ; ,?Squamous cell carcinoma, Histology,8,0,2,no
2787,2747698,Table 6,BaselineCharacteristic,xx, ; No. of Patients ; ,?Squamous cell carcinoma, Histology,8,1,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; CR ; ,?Squamous cell carcinoma, Histology,8,2,3,no
2787,2747698,Table 6,BaselineCharacteristic,xx,Response ; PR ; ,?Squamous cell carcinoma, Histology,8,3,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; NC ; ,?Squamous cell carcinoma, Histology,8,4,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PD ; ,?Squamous cell carcinoma, Histology,8,5,3,no
2787,2747698,Table 6,BaselineCharacteristic,?Nonsquamous cell carcinoma, ; Characteristic ; ,?Nonsquamous cell carcinoma, Histology,9,0,2,no
2787,2747698,Table 6,BaselineCharacteristic,x, ; No. of Patients ; ,?Nonsquamous cell carcinoma, Histology,9,1,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; CR ; ,?Nonsquamous cell carcinoma, Histology,9,2,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PR ; ,?Nonsquamous cell carcinoma, Histology,9,3,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; NC ; ,?Nonsquamous cell carcinoma, Histology,9,4,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PD ; ,?Nonsquamous cell carcinoma, Histology,9,5,3,no
2787,2747698,Table 6,BaselineCharacteristic,Prior therapy, ; Characteristic ; ,None,None,10,0,24,no
2787,2747698,Table 6,BaselineCharacteristic,Prior therapy, ; No. of Patients ; ,Prior therapy,None,10,1,43,no
2787,2747698,Table 6,BaselineCharacteristic,Prior therapy,Response ; CR ; ,Prior therapy,None,10,2,43,no
2787,2747698,Table 6,BaselineCharacteristic,Prior therapy,Response ; PR ; ,Prior therapy,None,10,3,43,no
2787,2747698,Table 6,BaselineCharacteristic,Prior therapy,Response ; NC ; ,Prior therapy,None,10,4,43,no
2787,2747698,Table 6,BaselineCharacteristic,Prior therapy,Response ; PD ; ,Prior therapy,None,10,5,43,no
2787,2747698,Table 6,BaselineCharacteristic,Prior therapy, ; Response rate (%) (xx% CI) ; ,Prior therapy,None,10,6,43,no
2787,2747698,Table 6,BaselineCharacteristic,?No, ; Characteristic ; ,?No, Prior therapy,11,0,2,no
2787,2747698,Table 6,BaselineCharacteristic,xx, ; No. of Patients ; ,?No, Prior therapy,11,1,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; CR ; ,?No, Prior therapy,11,2,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PR ; ,?No, Prior therapy,11,3,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; NC ; ,?No, Prior therapy,11,4,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PD ; ,?No, Prior therapy,11,5,3,no
2787,2747698,Table 6,BaselineCharacteristic,?Yes, ; Characteristic ; ,?Yes, Prior therapy,12,0,2,no
2787,2747698,Table 6,BaselineCharacteristic,xx, ; No. of Patients ; ,?Yes, Prior therapy,12,1,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; CR ; ,?Yes, Prior therapy,12,2,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PR ; ,?Yes, Prior therapy,12,3,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; NC ; ,?Yes, Prior therapy,12,4,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PD ; ,?Yes, Prior therapy,12,5,3,no
2787,2747698,Table 6,BaselineCharacteristic,Site, ; Characteristic ; ,None,None,13,0,24,no
2787,2747698,Table 6,BaselineCharacteristic,Site, ; No. of Patients ; ,Site,None,13,1,43,no
2787,2747698,Table 6,BaselineCharacteristic,Site,Response ; CR ; ,Site,None,13,2,43,no
2787,2747698,Table 6,BaselineCharacteristic,Site,Response ; PR ; ,Site,None,13,3,43,no
2787,2747698,Table 6,BaselineCharacteristic,Site,Response ; NC ; ,Site,None,13,4,43,no
2787,2747698,Table 6,BaselineCharacteristic,Site,Response ; PD ; ,Site,None,13,5,43,no
2787,2747698,Table 6,BaselineCharacteristic,Site, ; Response rate (%) (xx% CI) ; ,Site,None,13,6,43,no
2787,2747698,Table 6,BaselineCharacteristic,?Inside radiation field, ; Characteristic ; ,?Inside radiation field, Site,14,0,2,no
2787,2747698,Table 6,BaselineCharacteristic,x, ; No. of Patients ; ,?Inside radiation field, Site,14,1,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; CR ; ,?Inside radiation field, Site,14,2,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PR ; ,?Inside radiation field, Site,14,3,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; NC ; ,?Inside radiation field, Site,14,4,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PD ; ,?Inside radiation field, Site,14,5,3,no
2787,2747698,Table 6,BaselineCharacteristic,?Outside radiation field, ; Characteristic ; ,?Outside radiation field, Site,15,0,2,no
2787,2747698,Table 6,BaselineCharacteristic,xx, ; No. of Patients ; ,?Outside radiation field, Site,15,1,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; CR ; ,?Outside radiation field, Site,15,2,3,no
2787,2747698,Table 6,BaselineCharacteristic,xx,Response ; PR ; ,?Outside radiation field, Site,15,3,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; NC ; ,?Outside radiation field, Site,15,4,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PD ; ,?Outside radiation field, Site,15,5,3,no
2787,2747698,Table 6,BaselineCharacteristic,Age (years), ; Characteristic ; ,None,None,16,0,24,no
2787,2747698,Table 6,BaselineCharacteristic,Age (years), ; No. of Patients ; ,Age (years),None,16,1,43,no
2787,2747698,Table 6,BaselineCharacteristic,Age (years),Response ; CR ; ,Age (years),None,16,2,43,no
2787,2747698,Table 6,BaselineCharacteristic,Age (years),Response ; PR ; ,Age (years),None,16,3,43,no
2787,2747698,Table 6,BaselineCharacteristic,Age (years),Response ; NC ; ,Age (years),None,16,4,43,no
2787,2747698,Table 6,BaselineCharacteristic,Age (years),Response ; PD ; ,Age (years),None,16,5,43,no
2787,2747698,Table 6,BaselineCharacteristic,Age (years), ; Response rate (%) (xx% CI) ; ,Age (years),None,16,6,43,no
2787,2747698,Table 6,BaselineCharacteristic,??xx, ; Characteristic ; ,??xx, Age (years),17,0,2,no
2787,2747698,Table 6,BaselineCharacteristic,xx, ; No. of Patients ; ,??xx, Age (years),17,1,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; CR ; ,??xx, Age (years),17,2,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PR ; ,??xx, Age (years),17,3,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; NC ; ,??xx, Age (years),17,4,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PD ; ,??xx, Age (years),17,5,3,no
2787,2747698,Table 6,BaselineCharacteristic,?>xx, ; Characteristic ; ,?>xx, Age (years),18,0,2,no
2787,2747698,Table 6,BaselineCharacteristic,xx, ; No. of Patients ; ,?>xx, Age (years),18,1,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; CR ; ,?>xx, Age (years),18,2,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PR ; ,?>xx, Age (years),18,3,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; NC ; ,?>xx, Age (years),18,4,3,no
2787,2747698,Table 6,BaselineCharacteristic,x,Response ; PD ; ,?>xx, Age (years),18,5,3,no
2848,2768436,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no
2848,2768436,Table 1,BaselineCharacteristic,No. xx,,,None,0,1,1,no
2848,2768436,Table 1,BaselineCharacteristic,No. xx,,,None,0,2,1,no
2848,2768436,Table 1,BaselineCharacteristic,Characteristics, ; ,None,None,1,0,12,no
2848,2768436,Table 1,BaselineCharacteristic,No.,No. xx ; ,Characteristics,None,1,1,1,no
2848,2768436,Table 1,BaselineCharacteristic,%,No. xx ; ,Characteristics,None,1,2,1,no
2848,2768436,Table 1,BaselineCharacteristic,Sex, ; Characteristics ; ,None,None,2,0,24,no
2848,2768436,Table 1,BaselineCharacteristic,Sex,No. xx ; No. ; ,Sex,None,2,1,43,no
2848,2768436,Table 1,BaselineCharacteristic,Sex,No. xx ; % ; ,Sex,None,2,2,43,no
2848,2768436,Table 1,BaselineCharacteristic,?Male, ; Characteristics ; ,?Male, Sex,3,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?Male, Sex,3,1,3,yes
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?Male, Sex,3,2,3,yes
2848,2768436,Table 1,BaselineCharacteristic,?Female, ; Characteristics ; ,?Female, Sex,4,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?Female, Sex,4,1,3,yes
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?Female, Sex,4,2,3,yes
2848,2768436,Table 1,BaselineCharacteristic,, ; Characteristics ; ,None,None,5,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; No. ; ,None,None,5,1,3,no
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; % ; ,None,None,5,2,3,no
2848,2768436,Table 1,BaselineCharacteristic,"Age, years", ; Characteristics ; ,None,None,6,0,24,no
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; No. ; ,"Age, years",None,6,1,43,no
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; % ; ,"Age, years",None,6,2,43,no
2848,2768436,Table 1,BaselineCharacteristic,?Median, ; Characteristics ; ,?Median," Age, years",7,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?Median," Age, years",7,1,3,no
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; % ; ,?Median," Age, years",7,2,3,no
2848,2768436,Table 1,BaselineCharacteristic,?Range, ; Characteristics ; ,?Range," Age, years",8,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,, ; Characteristics ; ,None,None,9,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; No. ; ,None,None,9,1,3,no
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; % ; ,None,None,9,2,3,no
2848,2768436,Table 1,BaselineCharacteristic,Karnofsky performance status, ; Characteristics ; ,None,None,10,0,24,no
2848,2768436,Table 1,BaselineCharacteristic,Karnofsky performance status,No. xx ; No. ; ,Karnofsky performance status,None,10,1,43,no
2848,2768436,Table 1,BaselineCharacteristic,Karnofsky performance status,No. xx ; % ; ,Karnofsky performance status,None,10,2,43,no
2848,2768436,Table 1,BaselineCharacteristic,?xxx, ; Characteristics ; ,?xxx, Karnofsky performance status,11,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?xxx, Karnofsky performance status,11,1,3,no
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?xxx, Karnofsky performance status,11,2,3,no
2848,2768436,Table 1,BaselineCharacteristic,?xx, ; Characteristics ; ,?xx, Karnofsky performance status,12,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?xx, Karnofsky performance status,12,1,3,no
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; % ; ,?xx, Karnofsky performance status,12,2,3,no
2848,2768436,Table 1,BaselineCharacteristic,?xx, ; Characteristics ; ,?xx, Karnofsky performance status,13,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?xx, Karnofsky performance status,13,1,3,no
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; % ; ,?xx, Karnofsky performance status,13,2,3,no
2848,2768436,Table 1,BaselineCharacteristic,?xx, ; Characteristics ; ,?xx, Karnofsky performance status,14,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,x,No. xx ; No. ; ,?xx, Karnofsky performance status,14,1,3,no
2848,2768436,Table 1,BaselineCharacteristic,x.x,No. xx ; % ; ,?xx, Karnofsky performance status,14,2,3,no
2848,2768436,Table 1,BaselineCharacteristic,, ; Characteristics ; ,None,None,15,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; No. ; ,None,None,15,1,3,no
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; % ; ,None,None,15,2,3,no
2848,2768436,Table 1,BaselineCharacteristic,Primary tumour site, ; Characteristics ; ,None,None,16,0,24,no
2848,2768436,Table 1,BaselineCharacteristic,Primary tumour site,No. xx ; No. ; ,Primary tumour site,None,16,1,43,no
2848,2768436,Table 1,BaselineCharacteristic,Primary tumour site,No. xx ; % ; ,Primary tumour site,None,16,2,43,no
2848,2768436,Table 1,BaselineCharacteristic,?Stomach, ; Characteristics ; ,?Stomach, Primary tumour site,17,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?Stomach, Primary tumour site,17,1,3,no
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?Stomach, Primary tumour site,17,2,3,no
2848,2768436,Table 1,BaselineCharacteristic,?Gastro-oesophageal junction, ; Characteristics ; ,?Gastro-oesophageal junction, Primary tumour site,18,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?Gastro-oesophageal junction, Primary tumour site,18,1,3,no
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?Gastro-oesophageal junction, Primary tumour site,18,2,3,no
2848,2768436,Table 1,BaselineCharacteristic,, ; Characteristics ; ,None,None,19,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; No. ; ,None,None,19,1,3,no
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; % ; ,None,None,19,2,3,no
2848,2768436,Table 1,BaselineCharacteristic,Histotype, ; Characteristics ; ,None,None,20,0,24,no
2848,2768436,Table 1,BaselineCharacteristic,Histotype,No. xx ; No. ; ,Histotype,None,20,1,43,no
2848,2768436,Table 1,BaselineCharacteristic,Histotype,No. xx ; % ; ,Histotype,None,20,2,43,no
2848,2768436,Table 1,BaselineCharacteristic,?Intestinal adenocarcinoma, ; Characteristics ; ,?Intestinal adenocarcinoma, Histotype,21,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?Intestinal adenocarcinoma, Histotype,21,1,3,no
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?Intestinal adenocarcinoma, Histotype,21,2,3,no
2848,2768436,Table 1,BaselineCharacteristic,?Non-intestinal adenocarcinomaa, ; Characteristics ; ,?Non-intestinal adenocarcinomaa, Histotype,22,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?Non-intestinal adenocarcinomaa, Histotype,22,1,3,no
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?Non-intestinal adenocarcinomaa, Histotype,22,2,3,no
2848,2768436,Table 1,BaselineCharacteristic,, ; Characteristics ; ,None,None,23,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; No. ; ,None,None,23,1,3,no
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; % ; ,None,None,23,2,3,no
2848,2768436,Table 1,BaselineCharacteristic,State of disease, ; Characteristics ; ,None,None,24,0,24,no
2848,2768436,Table 1,BaselineCharacteristic,State of disease,No. xx ; No. ; ,State of disease,None,24,1,43,no
2848,2768436,Table 1,BaselineCharacteristic,State of disease,No. xx ; % ; ,State of disease,None,24,2,43,no
2848,2768436,Table 1,BaselineCharacteristic,?Locally advanced, ; Characteristics ; ,?Locally advanced, State of disease,25,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,x,No. xx ; No. ; ,?Locally advanced, State of disease,25,1,3,no
2848,2768436,Table 1,BaselineCharacteristic,x.x,No. xx ; % ; ,?Locally advanced, State of disease,25,2,3,no
2848,2768436,Table 1,BaselineCharacteristic,?Metastatic, ; Characteristics ; ,?Metastatic, State of disease,26,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?Metastatic, State of disease,26,1,3,no
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?Metastatic, State of disease,26,2,3,no
2848,2768436,Table 1,BaselineCharacteristic,, ; Characteristics ; ,None,None,27,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; No. ; ,None,None,27,1,3,no
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; % ; ,None,None,27,2,3,no
2848,2768436,Table 1,BaselineCharacteristic,Prior surgery, ; Characteristics ; ,None,None,28,0,24,no
2848,2768436,Table 1,BaselineCharacteristic,Prior surgery,No. xx ; No. ; ,Prior surgery,None,28,1,43,no
2848,2768436,Table 1,BaselineCharacteristic,Prior surgery,No. xx ; % ; ,Prior surgery,None,28,2,43,no
2848,2768436,Table 1,BaselineCharacteristic,?Total/partial gastrectomy, ; Characteristics ; ,?Total/partial gastrectomy, Prior surgery,29,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?Total/partial gastrectomy, Prior surgery,29,1,3,no
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?Total/partial gastrectomy, Prior surgery,29,2,3,no
2848,2768436,Table 1,BaselineCharacteristic,?Protesis/anastomosis, ; Characteristics ; ,?Protesis/anastomosis, Prior surgery,30,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,x,No. xx ; No. ; ,?Protesis/anastomosis, Prior surgery,30,1,3,no
2848,2768436,Table 1,BaselineCharacteristic,x.x,No. xx ; % ; ,?Protesis/anastomosis, Prior surgery,30,2,3,no
2848,2768436,Table 1,BaselineCharacteristic,, ; Characteristics ; ,None,None,31,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; No. ; ,None,None,31,1,3,no
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; % ; ,None,None,31,2,3,no
2848,2768436,Table 1,BaselineCharacteristic,Adjuvant chemotherapy, ; Characteristics ; ,Adjuvant chemotherapy,,32,0,24,no
2848,2768436,Table 1,BaselineCharacteristic,x,No. xx ; No. ; ,Adjuvant chemotherapy,,32,1,43,no
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,Adjuvant chemotherapy,,32,2,43,no
2848,2768436,Table 1,BaselineCharacteristic,?x-FU/AF regimens, ; Characteristics ; ,?x-FU/AF regimens, Adjuvant chemotherapy,33,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,x,No. xx ; No. ; ,?x-FU/AF regimens, Adjuvant chemotherapy,33,1,3,no
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?x-FU/AF regimens, Adjuvant chemotherapy,33,2,3,no
2848,2768436,Table 1,BaselineCharacteristic,?x-FU/CDDP regimens, ; Characteristics ; ,?x-FU/CDDP regimens, Adjuvant chemotherapy,34,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,x,No. xx ; No. ; ,?x-FU/CDDP regimens, Adjuvant chemotherapy,34,1,3,no
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?x-FU/CDDP regimens, Adjuvant chemotherapy,34,2,3,no
2848,2768436,Table 1,BaselineCharacteristic,?x-FU/CDDP/EPI regimens, ; Characteristics ; ,?x-FU/CDDP/EPI regimens, Adjuvant chemotherapy,35,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,x,No. xx ; No. ; ,?x-FU/CDDP/EPI regimens, Adjuvant chemotherapy,35,1,3,no
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?x-FU/CDDP/EPI regimens, Adjuvant chemotherapy,35,2,3,no
2848,2768436,Table 1,BaselineCharacteristic,, ; Characteristics ; ,None,None,36,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; No. ; ,None,None,36,1,3,no
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; % ; ,None,None,36,2,3,no
2848,2768436,Table 1,BaselineCharacteristic,Site of disease, ; Characteristics ; ,None,None,37,0,24,no
2848,2768436,Table 1,BaselineCharacteristic,Site of disease,No. xx ; No. ; ,Site of disease,None,37,1,43,no
2848,2768436,Table 1,BaselineCharacteristic,Site of disease,No. xx ; % ; ,Site of disease,None,37,2,43,no
2848,2768436,Table 1,BaselineCharacteristic,?Primary, ; Characteristics ; ,?Primary, Site of disease,38,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?Primary, Site of disease,38,1,3,no
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?Primary, Site of disease,38,2,3,no
2848,2768436,Table 1,BaselineCharacteristic,?Lymph nodes, ; Characteristics ; ,?Lymph nodes, Site of disease,39,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?Lymph nodes, Site of disease,39,1,3,no
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?Lymph nodes, Site of disease,39,2,3,no
2848,2768436,Table 1,BaselineCharacteristic,?Liver, ; Characteristics ; ,?Liver, Site of disease,40,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?Liver, Site of disease,40,1,3,no
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?Liver, Site of disease,40,2,3,no
2848,2768436,Table 1,BaselineCharacteristic,?Peritoneum/local recurrence, ; Characteristics ; ,?Peritoneum/local recurrence, Site of disease,41,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?Peritoneum/local recurrence, Site of disease,41,1,3,no
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?Peritoneum/local recurrence, Site of disease,41,2,3,no
2848,2768436,Table 1,BaselineCharacteristic,?Other, ; Characteristics ; ,?Other, Site of disease,42,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?Other, Site of disease,42,1,3,no
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?Other, Site of disease,42,2,3,no
2848,2768436,Table 1,BaselineCharacteristic,, ; Characteristics ; ,None,None,43,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; No. ; ,None,None,43,1,3,no
2848,2768436,Table 1,BaselineCharacteristic,,No. xx ; % ; ,None,None,43,2,3,no
2848,2768436,Table 1,BaselineCharacteristic,No. of organs involved, ; Characteristics ; ,None,None,44,0,24,no
2848,2768436,Table 1,BaselineCharacteristic,No. of organs involved,No. xx ; No. ; ,No. of organs involved,None,44,1,43,no
2848,2768436,Table 1,BaselineCharacteristic,No. of organs involved,No. xx ; % ; ,No. of organs involved,None,44,2,43,no
2848,2768436,Table 1,BaselineCharacteristic,?x, ; Characteristics ; ,?x, No. of organs involved,45,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?x, No. of organs involved,45,1,3,no
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?x, No. of organs involved,45,2,3,no
2848,2768436,Table 1,BaselineCharacteristic,?x, ; Characteristics ; ,?x, No. of organs involved,46,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?x, No. of organs involved,46,1,3,no
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?x, No. of organs involved,46,2,3,no
2848,2768436,Table 1,BaselineCharacteristic,?>x, ; Characteristics ; ,?>x, No. of organs involved,47,0,2,no
2848,2768436,Table 1,BaselineCharacteristic,xx,No. xx ; No. ; ,?>x, No. of organs involved,47,1,3,no
2848,2768436,Table 1,BaselineCharacteristic,xx.x,No. xx ; % ; ,?>x, No. of organs involved,47,2,3,no
2866,2775018,Table 1,BaselineCharacteristic,Characteristics,,None,None,0,0,,no
2866,2775018,Table 1,BaselineCharacteristic,,,None,None,0,1,,no
2866,2775018,Table 1,BaselineCharacteristic,Acupuncture,,None,None,0,2,,no
2866,2775018,Table 1,BaselineCharacteristic,Control,,None,None,0,3,,no
2866,2775018,Table 1,BaselineCharacteristic,Total,,None,None,0,4,,no
2866,2775018,Table 1,BaselineCharacteristic,Mean Age,Characteristics ; ,None,None,1,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ; ,None,None,1,1,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.x (x.x),Acupuncture ; ,None,None,1,2,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.x (x.x),Control ; ,None,None,1,3,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.x (x.x),Total ; ,None,None,1,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ; ,None,None,2,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ;  ; ,None,None,2,1,,no
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ; ,None,None,2,2,,no
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ; ,None,None,2,3,,no
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ; ,None,None,2,4,,no
2866,2775018,Table 1,BaselineCharacteristic,Female Sex (%),Characteristics ; Mean Age ;  ; ,None,None,3,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ; ,None,None,3,1,,no
2866,2775018,Table 1,BaselineCharacteristic,x (xx),Acupuncture ; xx.x (x.x) ;  ; ,None,None,3,2,,yes
2866,2775018,Table 1,BaselineCharacteristic,x (xx),Control ; xx.x (x.x) ;  ; ,None,None,3,3,,yes
2866,2775018,Table 1,BaselineCharacteristic,xx (xx),Total ; xx.x (x.x) ;  ; ,None,None,3,4,,yes
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ; ,None,None,4,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ; ,None,None,4,1,,no
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ; ,None,None,4,2,,no
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ; ,None,None,4,3,,no
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ; ,None,None,4,4,,no
2866,2775018,Table 1,BaselineCharacteristic,Ethnicity (%),Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; ,None,None,5,0,,no
2866,2775018,Table 1,BaselineCharacteristic,White, ;  ;  ;  ;  ; ,None,None,5,1,,no
2866,2775018,Table 1,BaselineCharacteristic,xx (xxx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; ,None,None,5,2,,no
2866,2775018,Table 1,BaselineCharacteristic,xx(xxx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; ,None,None,5,3,,no
2866,2775018,Table 1,BaselineCharacteristic,xx(xxx),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; ,None,None,5,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ; ,None,None,6,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ; ,None,None,6,1,,no
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ; ,None,None,6,2,,no
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ; ,None,None,6,3,,no
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ; ,None,None,6,4,,no
2866,2775018,Table 1,BaselineCharacteristic,Employment History (%),Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,7,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,7,1,,no
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,7,2,,no
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,7,3,,no
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,7,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,8,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,8,1,,no
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,8,2,,no
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,8,3,,no
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,8,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,,,9,0,,no
2866,2775018,Table 1,BaselineCharacteristic,Employed part-time, ;  ;  ;  ;  ; White ;  ; ,,,9,1,,no
2866,2775018,Table 1,BaselineCharacteristic,x (x),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,,,9,2,,no
2866,2775018,Table 1,BaselineCharacteristic,x (x),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,,,9,3,,no
2866,2775018,Table 1,BaselineCharacteristic,x (x.x),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,,,9,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,10,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,10,1,,no
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,10,2,,no
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,10,3,,no
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,10,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,,,11,0,,no
2866,2775018,Table 1,BaselineCharacteristic,Employed full-time, ;  ;  ;  ;  ; White ;  ; ,,,11,1,,no
2866,2775018,Table 1,BaselineCharacteristic,x (xx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,,,11,2,,no
2866,2775018,Table 1,BaselineCharacteristic,x (xx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,,,11,3,,no
2866,2775018,Table 1,BaselineCharacteristic,x (xx),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,,,11,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,12,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,12,1,,no
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,12,2,,no
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,12,3,,no
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,12,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,,,13,0,,no
2866,2775018,Table 1,BaselineCharacteristic,Self employed, ;  ;  ;  ;  ; White ;  ; ,,,13,1,,no
2866,2775018,Table 1,BaselineCharacteristic,x (x.x),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,,,13,2,,no
2866,2775018,Table 1,BaselineCharacteristic,x (x),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,,,13,3,,no
2866,2775018,Table 1,BaselineCharacteristic,x (x.x),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,,,13,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,14,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,14,1,,no
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,14,2,,no
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,14,3,,no
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,14,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,,,15,0,,no
2866,2775018,Table 1,BaselineCharacteristic,Retired, ;  ;  ;  ;  ; White ;  ; ,,,15,1,,no
2866,2775018,Table 1,BaselineCharacteristic,x (xx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,,,15,2,,no
2866,2775018,Table 1,BaselineCharacteristic,xx (xx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,,,15,3,,no
2866,2775018,Table 1,BaselineCharacteristic,xx (xx),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,,,15,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,16,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,16,1,,no
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,16,2,,no
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,16,3,,no
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,16,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,,,17,0,,no
2866,2775018,Table 1,BaselineCharacteristic,Not employed but seeking work, ;  ;  ;  ;  ; White ;  ; ,,,17,1,,no
2866,2775018,Table 1,BaselineCharacteristic,x (x.x),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,,,17,2,,no
2866,2775018,Table 1,BaselineCharacteristic,x (x),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,,,17,3,,no
2866,2775018,Table 1,BaselineCharacteristic,x (x.x),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,,,17,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,18,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,18,1,,no
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,18,2,,no
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,18,3,,no
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,18,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,,,19,0,,no
2866,2775018,Table 1,BaselineCharacteristic,Not employed/not seeking work due to ill health, ;  ;  ;  ;  ; White ;  ; ,,,19,1,,no
2866,2775018,Table 1,BaselineCharacteristic,x (x),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,,,19,2,,no
2866,2775018,Table 1,BaselineCharacteristic,x (x),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,,,19,3,,no
2866,2775018,Table 1,BaselineCharacteristic,x (x.x),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,,,19,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,20,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,20,1,,no
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,20,2,,no
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,20,3,,no
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,20,4,,no
2866,2775018,Table 1,BaselineCharacteristic,Education,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,21,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,21,1,,no
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,21,2,,no
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,21,3,,no
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,21,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,22,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,22,1,,no
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,22,2,,no
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,22,3,,no
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,22,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,,,23,0,,no
2866,2775018,Table 1,BaselineCharacteristic,Not in full time education (%), ;  ;  ;  ;  ; White ;  ; ,,,23,1,,no
2866,2775018,Table 1,BaselineCharacteristic,xx (xxx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,,,23,2,,no
2866,2775018,Table 1,BaselineCharacteristic,xx (xxx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,,,23,3,,no
2866,2775018,Table 1,BaselineCharacteristic,xx (xxx),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,,,23,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,24,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,24,1,,no
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,24,2,,no
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,24,3,,no
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,24,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,,,25,0,,no
2866,2775018,Table 1,BaselineCharacteristic,Age when leaving full time education (SD), ;  ;  ;  ;  ; White ;  ; ,,,25,1,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.x (x.x),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,,,25,2,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.x (x.x),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,,,25,3,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.x (x.x),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,,,25,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,26,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,26,1,,no
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,26,2,,no
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,26,3,,no
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,26,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,,,27,0,,no
2866,2775018,Table 1,BaselineCharacteristic,Since leaving school/college/uni have had more part-time further/higher education (%), ;  ;  ;  ;  ; White ;  ; ,,,27,1,,no
2866,2775018,Table 1,BaselineCharacteristic,x (xx%),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,,,27,2,,no
2866,2775018,Table 1,BaselineCharacteristic,x (xx%),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,,,27,3,,no
2866,2775018,Table 1,BaselineCharacteristic,xx (xx%),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,,,27,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,28,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,28,1,,no
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,28,2,,no
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,28,3,,no
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,28,4,,no
2866,2775018,Table 1,BaselineCharacteristic,Mean OKS (SD),Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,29,0,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (x.xx), ;  ;  ;  ;  ; White ;  ; ,None,None,29,1,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.x (x.xx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,29,2,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (x.xx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,29,3,,no
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,29,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,30,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,30,1,,no
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,30,2,,no
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,30,3,,no
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,30,4,,no
2866,2775018,Table 1,BaselineCharacteristic,Mean WOMAC Scores (SD),Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,31,0,,no
2866,2775018,Table 1,BaselineCharacteristic,Mean WOMAC Scores (SD), ;  ;  ;  ;  ; White ;  ; ,None,None,31,1,,no
2866,2775018,Table 1,BaselineCharacteristic,Mean WOMAC Scores (SD),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,31,2,,no
2866,2775018,Table 1,BaselineCharacteristic,Mean WOMAC Scores (SD),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,31,3,,no
2866,2775018,Table 1,BaselineCharacteristic,Mean WOMAC Scores (SD),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,31,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,32,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,32,1,,no
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,32,2,,no
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,32,3,,no
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,32,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,, Mean WOMAC Scores (SD),33,0,,no
2866,2775018,Table 1,BaselineCharacteristic,Pain x-xx, ;  ;  ;  ;  ; White ;  ; ,, Mean WOMAC Scores (SD),33,1,,no
2866,2775018,Table 1,BaselineCharacteristic,x.xx (x.xx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,, Mean WOMAC Scores (SD),33,2,,no
2866,2775018,Table 1,BaselineCharacteristic,x.xx (x.xx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,, Mean WOMAC Scores (SD),33,3,,no
2866,2775018,Table 1,BaselineCharacteristic,x.xx (x.xx),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,, Mean WOMAC Scores (SD),33,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,34,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,34,1,,no
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,34,2,,no
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,34,3,,no
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,34,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,, Mean WOMAC Scores (SD),35,0,,no
2866,2775018,Table 1,BaselineCharacteristic,Stiffness x-x, ;  ;  ;  ;  ; White ;  ; ,, Mean WOMAC Scores (SD),35,1,,no
2866,2775018,Table 1,BaselineCharacteristic,x.xx (x.xx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,, Mean WOMAC Scores (SD),35,2,,no
2866,2775018,Table 1,BaselineCharacteristic,x.x (x.xx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,, Mean WOMAC Scores (SD),35,3,,no
2866,2775018,Table 1,BaselineCharacteristic,x.xx (x.xx),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,, Mean WOMAC Scores (SD),35,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,36,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,36,1,,no
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,36,2,,no
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,36,3,,no
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,36,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,, Mean WOMAC Scores (SD),37,0,,no
2866,2775018,Table 1,BaselineCharacteristic,Function x-xx, ;  ;  ;  ;  ; White ;  ; ,, Mean WOMAC Scores (SD),37,1,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,, Mean WOMAC Scores (SD),37,2,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,, Mean WOMAC Scores (SD),37,3,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.x (xx.xx),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,, Mean WOMAC Scores (SD),37,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,38,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,38,1,,no
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,38,2,,no
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,38,3,,no
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,38,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,, Mean WOMAC Scores (SD),39,0,,no
2866,2775018,Table 1,BaselineCharacteristic,Global x-xxx = best health, ;  ;  ;  ;  ; White ;  ; ,, Mean WOMAC Scores (SD),39,1,,no
2866,2775018,Table 1,BaselineCharacteristic,xx (xx.xx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,, Mean WOMAC Scores (SD),39,2,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,, Mean WOMAC Scores (SD),39,3,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,, Mean WOMAC Scores (SD),39,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,40,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,40,1,,no
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,40,2,,no
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,40,3,,no
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,40,4,,no
2866,2775018,Table 1,BaselineCharacteristic,Mean SFxx Scores (SD),Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,41,0,,no
2866,2775018,Table 1,BaselineCharacteristic,Mean SFxx Scores (SD), ;  ;  ;  ;  ; White ;  ; ,None,None,41,1,,no
2866,2775018,Table 1,BaselineCharacteristic,Mean SFxx Scores (SD),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,41,2,,no
2866,2775018,Table 1,BaselineCharacteristic,Mean SFxx Scores (SD),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,41,3,,no
2866,2775018,Table 1,BaselineCharacteristic,Mean SFxx Scores (SD),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,41,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,42,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,42,1,,no
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,42,2,,no
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,42,3,,no
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,42,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,, Mean SFxx Scores (SD),43,0,,no
2866,2775018,Table 1,BaselineCharacteristic,Physical Functioning, ;  ;  ;  ;  ; White ;  ; ,, Mean SFxx Scores (SD),43,1,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,, Mean SFxx Scores (SD),43,2,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,, Mean SFxx Scores (SD),43,3,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,, Mean SFxx Scores (SD),43,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,44,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,44,1,,no
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,44,2,,no
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,44,3,,no
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,44,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,, Mean SFxx Scores (SD),45,0,,no
2866,2775018,Table 1,BaselineCharacteristic,Social Functioning, ;  ;  ;  ;  ; White ;  ; ,, Mean SFxx Scores (SD),45,1,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,, Mean SFxx Scores (SD),45,2,,no
2866,2775018,Table 1,BaselineCharacteristic,xx (xx.xx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,, Mean SFxx Scores (SD),45,3,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,, Mean SFxx Scores (SD),45,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,46,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,46,1,,no
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,46,2,,no
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,46,3,,no
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,46,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,, Mean SFxx Scores (SD),47,0,,no
2866,2775018,Table 1,BaselineCharacteristic,Role Physical Functioning, ;  ;  ;  ;  ; White ;  ; ,, Mean SFxx Scores (SD),47,1,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.x (xx.xx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,, Mean SFxx Scores (SD),47,2,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,, Mean SFxx Scores (SD),47,3,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.x),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,, Mean SFxx Scores (SD),47,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,48,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,48,1,,no
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,48,2,,no
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,48,3,,no
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,48,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,, Mean SFxx Scores (SD),49,0,,no
2866,2775018,Table 1,BaselineCharacteristic,Role Mental Functioning, ;  ;  ;  ;  ; White ;  ; ,, Mean SFxx Scores (SD),49,1,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,, Mean SFxx Scores (SD),49,2,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,, Mean SFxx Scores (SD),49,3,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,, Mean SFxx Scores (SD),49,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,50,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,50,1,,no
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,50,2,,no
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,50,3,,no
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,50,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,, Mean SFxx Scores (SD),51,0,,no
2866,2775018,Table 1,BaselineCharacteristic,Mental Health, ;  ;  ;  ;  ; White ;  ; ,, Mean SFxx Scores (SD),51,1,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,, Mean SFxx Scores (SD),51,2,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.x),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,, Mean SFxx Scores (SD),51,3,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,, Mean SFxx Scores (SD),51,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,52,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,52,1,,no
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,52,2,,no
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,52,3,,no
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,52,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,, Mean SFxx Scores (SD),53,0,,no
2866,2775018,Table 1,BaselineCharacteristic,Vitality, ;  ;  ;  ;  ; White ;  ; ,, Mean SFxx Scores (SD),53,1,,no
2866,2775018,Table 1,BaselineCharacteristic,xx (xx.xx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,, Mean SFxx Scores (SD),53,2,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,, Mean SFxx Scores (SD),53,3,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,, Mean SFxx Scores (SD),53,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,54,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,54,1,,no
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,54,2,,no
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,54,3,,no
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,54,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,, Mean SFxx Scores (SD),55,0,,no
2866,2775018,Table 1,BaselineCharacteristic,Pain, ;  ;  ;  ;  ; White ;  ; ,, Mean SFxx Scores (SD),55,1,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,, Mean SFxx Scores (SD),55,2,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,, Mean SFxx Scores (SD),55,3,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,, Mean SFxx Scores (SD),55,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,56,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,56,1,,no
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,56,2,,no
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,56,3,,no
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,56,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,, Mean SFxx Scores (SD),57,0,,no
2866,2775018,Table 1,BaselineCharacteristic,General Health, ;  ;  ;  ;  ; White ;  ; ,, Mean SFxx Scores (SD),57,1,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,, Mean SFxx Scores (SD),57,2,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,, Mean SFxx Scores (SD),57,3,,no
2866,2775018,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,, Mean SFxx Scores (SD),57,4,,no
2866,2775018,Table 1,BaselineCharacteristic,,Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,None,None,58,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,None,None,58,1,,no
2866,2775018,Table 1,BaselineCharacteristic,,Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,None,None,58,2,,no
2866,2775018,Table 1,BaselineCharacteristic,,Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,None,None,58,3,,no
2866,2775018,Table 1,BaselineCharacteristic,,Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,None,None,58,4,,no
2866,2775018,Table 1,BaselineCharacteristic,EQxD (SD),Characteristics ; Mean Age ;  ; Female Sex (%) ;  ; Ethnicity (%) ;  ; ,EQxD (SD),,59,0,,no
2866,2775018,Table 1,BaselineCharacteristic,, ;  ;  ;  ;  ; White ;  ; ,EQxD (SD),,59,1,,no
2866,2775018,Table 1,BaselineCharacteristic,x.xx (x.xx),Acupuncture ; xx.x (x.x) ;  ; x (xx) ;  ; xx (xxx) ;  ; ,EQxD (SD),,59,2,,no
2866,2775018,Table 1,BaselineCharacteristic,x.xx (x.xx),Control ; xx.x (x.x) ;  ; x (xx) ;  ; xx(xxx) ;  ; ,EQxD (SD),,59,3,,no
2866,2775018,Table 1,BaselineCharacteristic,x.xx (x.x),Total ; xx.x (x.x) ;  ; xx (xx) ;  ; xx(xxx) ;  ; ,EQxD (SD),,59,4,,no
2880,2778527,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no
2880,2778527,Table 1,BaselineCharacteristic,Sunitinib (N=xx),,,None,0,1,1,no
2880,2778527,Table 1,BaselineCharacteristic,"Age in years, median (range)", ; ,"Age in years, median (range)",,1,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,"Male/female, n (%)", ; ,"Male/female, n (%)",,2,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x)/xx (xx.x),Sunitinib (N=xx) ; ,"Male/female, n (%)",,2,1,3,yes
2880,2778527,Table 1,BaselineCharacteristic,"ECOG PS x/x, n (%)", ; ,"ECOG PS x/x, n (%)",,3,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x)/xx (xx.x)a,Sunitinib (N=xx) ; ,"ECOG PS x/x, n (%)",,3,1,3,no
2880,2778527,Table 1,BaselineCharacteristic,, ; ,None,None,4,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,,Sunitinib (N=xx) ; ,None,None,4,1,3,no
2880,2778527,Table 1,BaselineCharacteristic,"Smoking status, n (%)", ; ,None,None,5,0,24,no
2880,2778527,Table 1,BaselineCharacteristic,"Smoking status, n (%)",Sunitinib (N=xx) ; ,"Smoking status, n (%)",None,5,1,43,no
2880,2778527,Table 1,BaselineCharacteristic,?Ever smoked, ; ,?Ever smoked," Smoking status, n (%)",6,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x),Sunitinib (N=xx) ; ,?Ever smoked," Smoking status, n (%)",6,1,3,no
2880,2778527,Table 1,BaselineCharacteristic,?Never smoked, ; ,?Never smoked," Smoking status, n (%)",7,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,x (xx.x),Sunitinib (N=xx) ; ,?Never smoked," Smoking status, n (%)",7,1,3,no
2880,2778527,Table 1,BaselineCharacteristic,?Not known, ; ,?Not known," Smoking status, n (%)",8,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,x (x.x),Sunitinib (N=xx) ; ,?Not known," Smoking status, n (%)",8,1,3,no
2880,2778527,Table 1,BaselineCharacteristic,, ; ,None,None,9,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,,Sunitinib (N=xx) ; ,None,None,9,1,3,no
2880,2778527,Table 1,BaselineCharacteristic,"NSCLC histology, n (%)", ; ,None,None,10,0,24,no
2880,2778527,Table 1,BaselineCharacteristic,"NSCLC histology, n (%)",Sunitinib (N=xx) ; ,"NSCLC histology, n (%)",None,10,1,43,no
2880,2778527,Table 1,BaselineCharacteristic,?Adenocarcinoma, ; ,?Adenocarcinoma," NSCLC histology, n (%)",11,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x),Sunitinib (N=xx) ; ,?Adenocarcinoma," NSCLC histology, n (%)",11,1,3,no
2880,2778527,Table 1,BaselineCharacteristic,?Squamous cell carcinoma, ; ,?Squamous cell carcinoma," NSCLC histology, n (%)",12,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,x (xx.x),Sunitinib (N=xx) ; ,?Squamous cell carcinoma," NSCLC histology, n (%)",12,1,3,no
2880,2778527,Table 1,BaselineCharacteristic,?Large cell carcinoma, ; ,?Large cell carcinoma," NSCLC histology, n (%)",13,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,x (x.x),Sunitinib (N=xx) ; ,?Large cell carcinoma," NSCLC histology, n (%)",13,1,3,no
2880,2778527,Table 1,BaselineCharacteristic,?Bronchioloalveolar, ; ,?Bronchioloalveolar," NSCLC histology, n (%)",14,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,x (x.x),Sunitinib (N=xx) ; ,?Bronchioloalveolar," NSCLC histology, n (%)",14,1,3,no
2880,2778527,Table 1,BaselineCharacteristic,?Other, ; ,?Other," NSCLC histology, n (%)",15,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x),Sunitinib (N=xx) ; ,?Other," NSCLC histology, n (%)",15,1,3,no
2880,2778527,Table 1,BaselineCharacteristic,, ; ,None,None,16,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,,Sunitinib (N=xx) ; ,None,None,16,1,3,no
2880,2778527,Table 1,BaselineCharacteristic,"Disease stage, n (%)", ; ,None,None,17,0,24,no
2880,2778527,Table 1,BaselineCharacteristic,"Disease stage, n (%)",Sunitinib (N=xx) ; ,"Disease stage, n (%)",None,17,1,43,no
2880,2778527,Table 1,BaselineCharacteristic,?IIIB, ; ,?IIIB," Disease stage, n (%)",18,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,x (xx.x),Sunitinib (N=xx) ; ,?IIIB," Disease stage, n (%)",18,1,3,no
2880,2778527,Table 1,BaselineCharacteristic,?IV, ; ,?IV," Disease stage, n (%)",19,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x),Sunitinib (N=xx) ; ,?IV," Disease stage, n (%)",19,1,3,no
2880,2778527,Table 1,BaselineCharacteristic,, ; ,None,None,20,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,,Sunitinib (N=xx) ; ,None,None,20,1,3,no
2880,2778527,Table 1,BaselineCharacteristic,"Metastatic sites, n (%)", ; ,None,None,21,0,24,no
2880,2778527,Table 1,BaselineCharacteristic,"Metastatic sites, n (%)",Sunitinib (N=xx) ; ,"Metastatic sites, n (%)",None,21,1,43,no
2880,2778527,Table 1,BaselineCharacteristic,?Lung, ; ,?Lung," Metastatic sites, n (%)",22,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x),Sunitinib (N=xx) ; ,?Lung," Metastatic sites, n (%)",22,1,3,no
2880,2778527,Table 1,BaselineCharacteristic,?Lymph nodes, ; ,?Lymph nodes," Metastatic sites, n (%)",23,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x),Sunitinib (N=xx) ; ,?Lymph nodes," Metastatic sites, n (%)",23,1,3,no
2880,2778527,Table 1,BaselineCharacteristic,?Bone, ; ,?Bone," Metastatic sites, n (%)",24,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x),Sunitinib (N=xx) ; ,?Bone," Metastatic sites, n (%)",24,1,3,no
2880,2778527,Table 1,BaselineCharacteristic,?Liver, ; ,?Liver," Metastatic sites, n (%)",25,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x),Sunitinib (N=xx) ; ,?Liver," Metastatic sites, n (%)",25,1,3,no
2880,2778527,Table 1,BaselineCharacteristic,?Otherb, ; ,?Otherb," Metastatic sites, n (%)",26,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x),Sunitinib (N=xx) ; ,?Otherb," Metastatic sites, n (%)",26,1,3,no
2880,2778527,Table 1,BaselineCharacteristic,, ; ,None,None,27,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,,Sunitinib (N=xx) ; ,None,None,27,1,3,no
2880,2778527,Table 1,BaselineCharacteristic,"Previous chemotherapy, n (%)", ; ,"Previous chemotherapy, n (%)",,28,0,24,no
2880,2778527,Table 1,BaselineCharacteristic,xx (xxx),Sunitinib (N=xx) ; ,"Previous chemotherapy, n (%)",,28,1,43,no
2880,2778527,Table 1,BaselineCharacteristic,?Carboplatin, ; ,?Carboplatin," Previous chemotherapy, n (%)",29,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x),Sunitinib (N=xx) ; ,?Carboplatin," Previous chemotherapy, n (%)",29,1,3,no
2880,2778527,Table 1,BaselineCharacteristic,?Cisplatin, ; ,?Cisplatin," Previous chemotherapy, n (%)",30,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x),Sunitinib (N=xx) ; ,?Cisplatin," Previous chemotherapy, n (%)",30,1,3,no
2880,2778527,Table 1,BaselineCharacteristic,?Gemcitabine, ; ,?Gemcitabine," Previous chemotherapy, n (%)",31,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x),Sunitinib (N=xx) ; ,?Gemcitabine," Previous chemotherapy, n (%)",31,1,3,no
2880,2778527,Table 1,BaselineCharacteristic,?Docetaxel, ; ,?Docetaxel," Previous chemotherapy, n (%)",32,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x),Sunitinib (N=xx) ; ,?Docetaxel," Previous chemotherapy, n (%)",32,1,3,no
2880,2778527,Table 1,BaselineCharacteristic,?Paclitaxel, ; ,?Paclitaxel," Previous chemotherapy, n (%)",33,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x),Sunitinib (N=xx) ; ,?Paclitaxel," Previous chemotherapy, n (%)",33,1,3,no
2880,2778527,Table 1,BaselineCharacteristic,?Pemetrexed, ; ,?Pemetrexed," Previous chemotherapy, n (%)",34,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x),Sunitinib (N=xx) ; ,?Pemetrexed," Previous chemotherapy, n (%)",34,1,3,no
2880,2778527,Table 1,BaselineCharacteristic,?Other, ; ,?Other," Previous chemotherapy, n (%)",35,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,x (xx.x),Sunitinib (N=xx) ; ,?Other," Previous chemotherapy, n (%)",35,1,3,no
2880,2778527,Table 1,BaselineCharacteristic,, ; ,None,None,36,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,,Sunitinib (N=xx) ; ,None,None,36,1,3,no
2880,2778527,Table 1,BaselineCharacteristic,"Maximum number of previous regimens, n (%)", ; ,None,None,37,0,24,no
2880,2778527,Table 1,BaselineCharacteristic,"Maximum number of previous regimens, n (%)",Sunitinib (N=xx) ; ,"Maximum number of previous regimens, n (%)",None,37,1,43,no
2880,2778527,Table 1,BaselineCharacteristic,?Chemotherapy x/x/>x (%), ; ,?Chemotherapy x/x/>x (%)," Maximum number of previous regimens, n (%)",38,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x)/xx (xx.x)/x (x.x),Sunitinib (N=xx) ; ,?Chemotherapy x/x/>x (%)," Maximum number of previous regimens, n (%)",38,1,3,no
2880,2778527,Table 1,BaselineCharacteristic,?EGFR inhibitorc x/x (%), ; ,?EGFR inhibitorc x/x (%)," Maximum number of previous regimens, n (%)",39,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x)/x (x.x),Sunitinib (N=xx) ; ,?EGFR inhibitorc x/x (%)," Maximum number of previous regimens, n (%)",39,1,3,no
2880,2778527,Table 1,BaselineCharacteristic,?Total x/x/>x (%), ; ,?Total x/x/>x (%)," Maximum number of previous regimens, n (%)",40,0,2,no
2880,2778527,Table 1,BaselineCharacteristic,xx (xx.x)/xx (xx.x)/xx (xx.x),Sunitinib (N=xx) ; ,?Total x/x/>x (%)," Maximum number of previous regimens, n (%)",40,1,3,no
2995,2813746,Table 1,BaselineCharacteristic,Number of patients,,None,None,0,0,12,no
2995,2813746,Table 1,BaselineCharacteristic,(n=xx),,Number of patients,None,0,1,1,no
2995,2813746,Table 1,BaselineCharacteristic,"Median age, years",,None,None,1,0,12,no
2995,2813746,Table 1,BaselineCharacteristic,,,None,None,2,0,2,no
2995,2813746,Table 1,BaselineCharacteristic,,,None,None,2,1,3,no
2995,2813746,Table 1,BaselineCharacteristic,Gender,,Gender,,3,0,24,no
2995,2813746,Table 1,BaselineCharacteristic,n (%),,Gender,,3,1,43,no
2995,2813746,Table 1,BaselineCharacteristic,?Male,,?Male, Gender,4,0,2,no
2995,2813746,Table 1,BaselineCharacteristic,xx (xx),,?Male, Gender,4,1,3,yes
2995,2813746,Table 1,BaselineCharacteristic,?Female,,?Female, Gender,5,0,2,no
2995,2813746,Table 1,BaselineCharacteristic,xx (xx),,?Female, Gender,5,1,3,yes
2995,2813746,Table 1,BaselineCharacteristic,,,None,None,6,0,2,no
2995,2813746,Table 1,BaselineCharacteristic,,,None,None,6,1,3,no
2995,2813746,Table 1,BaselineCharacteristic,ECOG performance status,,None,None,7,0,24,no
2995,2813746,Table 1,BaselineCharacteristic,ECOG performance status,,ECOG performance status,None,7,1,43,no
2995,2813746,Table 1,BaselineCharacteristic,?ECOG x,,?ECOG x, ECOG performance status,8,0,2,no
2995,2813746,Table 1,BaselineCharacteristic,xx (xx),,?ECOG x, ECOG performance status,8,1,3,no
2995,2813746,Table 1,BaselineCharacteristic,?ECOG x,,?ECOG x, ECOG performance status,9,0,2,no
2995,2813746,Table 1,BaselineCharacteristic,xx (xx),,?ECOG x, ECOG performance status,9,1,3,no
2995,2813746,Table 1,BaselineCharacteristic,,,None,None,10,0,2,no
2995,2813746,Table 1,BaselineCharacteristic,,,None,None,10,1,3,no
2995,2813746,Table 1,BaselineCharacteristic,Site,,None,None,11,0,24,no
2995,2813746,Table 1,BaselineCharacteristic,Site,,Site,None,11,1,43,no
2995,2813746,Table 1,BaselineCharacteristic,?Gallbladder,,?Gallbladder, Site,12,0,2,no
2995,2813746,Table 1,BaselineCharacteristic,xx (xx),,?Gallbladder, Site,12,1,3,no
2995,2813746,Table 1,BaselineCharacteristic,?Extrahepatic,,?Extrahepatic, Site,13,0,2,no
2995,2813746,Table 1,BaselineCharacteristic,x (xx),,?Extrahepatic, Site,13,1,3,no
2995,2813746,Table 1,BaselineCharacteristic,?Intrahepatic,,?Intrahepatic, Site,14,0,2,no
2995,2813746,Table 1,BaselineCharacteristic,xx (xx),,?Intrahepatic, Site,14,1,3,no
2995,2813746,Table 1,BaselineCharacteristic,,,None,None,15,0,2,no
2995,2813746,Table 1,BaselineCharacteristic,,,None,None,15,1,3,no
2995,2813746,Table 1,BaselineCharacteristic,TNM stage,,None,None,16,0,24,no
2995,2813746,Table 1,BaselineCharacteristic,TNM stage,,TNM stage,None,16,1,43,no
2995,2813746,Table 1,BaselineCharacteristic,?II,,?II, TNM stage,17,0,2,no
2995,2813746,Table 1,BaselineCharacteristic,x (x),,?II, TNM stage,17,1,3,no
2995,2813746,Table 1,BaselineCharacteristic,?III,,?III, TNM stage,18,0,2,no
2995,2813746,Table 1,BaselineCharacteristic,x (xx),,?III, TNM stage,18,1,3,no
2995,2813746,Table 1,BaselineCharacteristic,?IV,,?IV, TNM stage,19,0,2,no
2995,2813746,Table 1,BaselineCharacteristic,xx (xx),,?IV, TNM stage,19,1,3,no
2995,2813746,Table 1,BaselineCharacteristic,,,None,None,20,0,2,no
2995,2813746,Table 1,BaselineCharacteristic,,,None,None,20,1,3,no
2995,2813746,Table 1,BaselineCharacteristic,Previous treatments,,None,None,21,0,24,no
2995,2813746,Table 1,BaselineCharacteristic,Previous treatments,,Previous treatments,None,21,1,43,no
2995,2813746,Table 1,BaselineCharacteristic,?Surgery,,?Surgery, Previous treatments,22,0,24,no
2995,2813746,Table 1,BaselineCharacteristic,xx (xx),,?Surgery, Previous treatments,22,1,43,no
2995,2813746,Table 1,BaselineCharacteristic,??Radical,,??Radical, Previous treatments ?Surgery,23,0,2,no
2995,2813746,Table 1,BaselineCharacteristic,xx (xx),,??Radical, Previous treatments ?Surgery,23,1,3,no
2995,2813746,Table 1,BaselineCharacteristic,??Palliative/biopsy,,??Palliative/biopsy, Previous treatments ?Surgery,24,0,2,no
2995,2813746,Table 1,BaselineCharacteristic,x (xx),,??Palliative/biopsy, Previous treatments ?Surgery,24,1,3,no
2995,2813746,Table 1,BaselineCharacteristic,?Chemotherapy lines,,?Chemotherapy lines, Previous treatments,25,0,24,no
2995,2813746,Table 1,BaselineCharacteristic,xx (xx),,?Chemotherapy lines, Previous treatments,25,1,43,no
2995,2813746,Table 1,BaselineCharacteristic,??x,,??x, Previous treatments ?Chemotherapy lines,26,0,2,no
2995,2813746,Table 1,BaselineCharacteristic,x (xx),,??x, Previous treatments ?Chemotherapy lines,26,1,3,no
2995,2813746,Table 1,BaselineCharacteristic,??x,,??x, Previous treatments ?Chemotherapy lines,27,0,2,no
2995,2813746,Table 1,BaselineCharacteristic,xx (xx),,??x, Previous treatments ?Chemotherapy lines,27,1,3,no
2995,2813746,Table 1,BaselineCharacteristic,??x,,??x, Previous treatments ?Chemotherapy lines,28,0,2,no
2995,2813746,Table 1,BaselineCharacteristic,x (xx),,??x, Previous treatments ?Chemotherapy lines,28,1,3,no
2995,2813746,Table 1,BaselineCharacteristic,??>x,,??>x, Previous treatments ?Chemotherapy lines,29,0,2,no
2995,2813746,Table 1,BaselineCharacteristic,x (x),,??>x, Previous treatments ?Chemotherapy lines,29,1,3,no
2995,2813746,Table 1,BaselineCharacteristic,?Radiotherapy,,?Radiotherapy, Previous treatments,30,0,24,no
2995,2813746,Table 1,BaselineCharacteristic,x (xx),,?Radiotherapy, Previous treatments,30,1,43,no
2995,2813746,Table 1,BaselineCharacteristic,??Stereotactic,,??Stereotactic, Previous treatments ?Radiotherapy,31,0,2,no
2995,2813746,Table 1,BaselineCharacteristic,x (x),,??Stereotactic, Previous treatments ?Radiotherapy,31,1,3,no
2995,2813746,Table 1,BaselineCharacteristic,??Palliative,,??Palliative, Previous treatments ?Radiotherapy,32,0,2,no
2995,2813746,Table 1,BaselineCharacteristic,x (x),,??Palliative, Previous treatments ?Radiotherapy,32,1,3,no
2995,2813746,Table 1,BaselineCharacteristic,?Local treatments,,?Local treatments, Previous treatments,33,0,24,no
2995,2813746,Table 1,BaselineCharacteristic,x (x),,?Local treatments, Previous treatments,33,1,43,no
2995,2813746,Table 1,BaselineCharacteristic,??Hyperthermy,,??Hyperthermy, Previous treatments ?Local treatments,34,0,2,no
2995,2813746,Table 1,BaselineCharacteristic,x (x),,??Hyperthermy, Previous treatments ?Local treatments,34,1,3,no
2995,2813746,Table 1,BaselineCharacteristic,??RF,,??RF, Previous treatments ?Local treatments,35,0,2,no
2995,2813746,Table 1,BaselineCharacteristic,x (x),,??RF, Previous treatments ?Local treatments,35,1,3,no
2995,2813746,Table 1,BaselineCharacteristic,??TACE/RF,,??TACE/RF, Previous treatments ?Local treatments,36,0,2,no
2995,2813746,Table 1,BaselineCharacteristic,x (x),,??TACE/RF, Previous treatments ?Local treatments,36,1,3,no
3036,2820465,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no
3036,2820465,Table 1,BaselineCharacteristic,Anti-IL-xx,,,None,0,1,1,no
3036,2820465,Table 1,BaselineCharacteristic,Anti-IL-xx,,,None,0,2,1,no
3036,2820465,Table 1,BaselineCharacteristic,Anti-IL-xx,,,None,0,3,1,no
3036,2820465,Table 1,BaselineCharacteristic,,,,None,0,4,1,no
3036,2820465,Table 1,BaselineCharacteristic,, ; ,None,None,1,0,12,no
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ; ,,None,1,1,1,no
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ; ,,None,1,2,1,no
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ; ,,None,1,3,1,no
3036,2820465,Table 1,BaselineCharacteristic,, ; ,,None,1,4,1,no
3036,2820465,Table 1,BaselineCharacteristic,, ;  ; ,None,None,2,0,12,no
3036,2820465,Table 1,BaselineCharacteristic,x mg/kg (n = x),Anti-IL-xx ;  ; ,,None,2,1,1,no
3036,2820465,Table 1,BaselineCharacteristic,x mg/kg (n = x),Anti-IL-xx ;  ; ,,None,2,2,1,no
3036,2820465,Table 1,BaselineCharacteristic,xx mg/kg (n = x),Anti-IL-xx ;  ; ,,None,2,3,1,no
3036,2820465,Table 1,BaselineCharacteristic,Placebo (n = x), ;  ; ,,None,2,4,1,no
3036,2820465,Table 1,BaselineCharacteristic,"Randomised, n", ;  ;  ; ,"Randomised, n",,3,0,2,no
3036,2820465,Table 1,BaselineCharacteristic,x,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,"Randomised, n",,3,1,3,no
3036,2820465,Table 1,BaselineCharacteristic,x,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,"Randomised, n",,3,2,3,no
3036,2820465,Table 1,BaselineCharacteristic,x,Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,"Randomised, n",,3,3,3,no
3036,2820465,Table 1,BaselineCharacteristic,x, ;  ; Placebo (n = x) ; ,"Randomised, n",,3,4,3,no
3036,2820465,Table 1,BaselineCharacteristic,"Completed study, n (%)", ;  ;  ; ,"Completed study, n (%)",,4,0,2,no
3036,2820465,Table 1,BaselineCharacteristic,x (xx.x),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,"Completed study, n (%)",,4,1,3,no
3036,2820465,Table 1,BaselineCharacteristic,x (xx.x),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,"Completed study, n (%)",,4,2,3,no
3036,2820465,Table 1,BaselineCharacteristic,x (xx.x),Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,"Completed study, n (%)",,4,3,3,no
3036,2820465,Table 1,BaselineCharacteristic,x (xx.x), ;  ; Placebo (n = x) ; ,"Completed study, n (%)",,4,4,3,no
3036,2820465,Table 1,BaselineCharacteristic,"Sex, n (%)", ;  ;  ; ,None,None,5,0,24,no
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,"Sex, n (%)",None,5,1,43,no
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,"Sex, n (%)",None,5,2,43,no
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,"Sex, n (%)",None,5,3,43,no
3036,2820465,Table 1,BaselineCharacteristic,, ;  ; Placebo (n = x) ; ,"Sex, n (%)",None,5,4,43,no
3036,2820465,Table 1,BaselineCharacteristic,?Male, ;  ;  ; ,?Male," Sex, n (%)",6,0,2,no
3036,2820465,Table 1,BaselineCharacteristic,x (xxx),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Male," Sex, n (%)",6,1,3,yes
3036,2820465,Table 1,BaselineCharacteristic,x (xxx),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Male," Sex, n (%)",6,2,3,yes
3036,2820465,Table 1,BaselineCharacteristic,x (xx.x),Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,?Male," Sex, n (%)",6,3,3,yes
3036,2820465,Table 1,BaselineCharacteristic,x (xxx), ;  ; Placebo (n = x) ; ,?Male," Sex, n (%)",6,4,3,yes
3036,2820465,Table 1,BaselineCharacteristic,?Female, ;  ;  ; ,?Female," Sex, n (%)",7,0,2,no
3036,2820465,Table 1,BaselineCharacteristic,x,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Female," Sex, n (%)",7,1,3,yes
3036,2820465,Table 1,BaselineCharacteristic,x,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Female," Sex, n (%)",7,2,3,yes
3036,2820465,Table 1,BaselineCharacteristic,x (xx.x),Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,?Female," Sex, n (%)",7,3,3,yes
3036,2820465,Table 1,BaselineCharacteristic,x, ;  ; Placebo (n = x) ; ,?Female," Sex, n (%)",7,4,3,yes
3036,2820465,Table 1,BaselineCharacteristic,"Age, years", ;  ;  ; ,None,None,8,0,24,no
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,"Age, years",None,8,1,43,no
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,"Age, years",None,8,2,43,no
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,"Age, years",None,8,3,43,no
3036,2820465,Table 1,BaselineCharacteristic,, ;  ; Placebo (n = x) ; ,"Age, years",None,8,4,43,no
3036,2820465,Table 1,BaselineCharacteristic,?Mean (SD), ;  ;  ; ,?Mean (SD)," Age, years",9,0,2,no
3036,2820465,Table 1,BaselineCharacteristic,xx.x (x.x),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Mean (SD)," Age, years",9,1,3,no
3036,2820465,Table 1,BaselineCharacteristic,xx.x (x.x),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Mean (SD)," Age, years",9,2,3,no
3036,2820465,Table 1,BaselineCharacteristic,xx.x (xx.x),Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,?Mean (SD)," Age, years",9,3,3,no
3036,2820465,Table 1,BaselineCharacteristic,xx.x (xx.x), ;  ; Placebo (n = x) ; ,?Mean (SD)," Age, years",9,4,3,no
3036,2820465,Table 1,BaselineCharacteristic,?Range, ;  ;  ; ,?Range," Age, years",10,0,2,no
3036,2820465,Table 1,BaselineCharacteristic,xx-xx,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Range," Age, years",10,1,3,no
3036,2820465,Table 1,BaselineCharacteristic,xx-xx,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Range," Age, years",10,2,3,no
3036,2820465,Table 1,BaselineCharacteristic,xx-xx,Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,?Range," Age, years",10,3,3,no
3036,2820465,Table 1,BaselineCharacteristic,xx-xx, ;  ; Placebo (n = x) ; ,?Range," Age, years",10,4,3,no
3036,2820465,Table 1,BaselineCharacteristic,"Race, n (%)", ;  ;  ; ,None,None,11,0,24,no
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,"Race, n (%)",None,11,1,43,no
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,"Race, n (%)",None,11,2,43,no
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,"Race, n (%)",None,11,3,43,no
3036,2820465,Table 1,BaselineCharacteristic,, ;  ; Placebo (n = x) ; ,"Race, n (%)",None,11,4,43,no
3036,2820465,Table 1,BaselineCharacteristic,?White, ;  ;  ; ,?White," Race, n (%)",12,0,2,no
3036,2820465,Table 1,BaselineCharacteristic,x (xxx),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?White," Race, n (%)",12,1,3,no
3036,2820465,Table 1,BaselineCharacteristic,x (xx.x),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?White," Race, n (%)",12,2,3,no
3036,2820465,Table 1,BaselineCharacteristic,x (xxx),Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,?White," Race, n (%)",12,3,3,no
3036,2820465,Table 1,BaselineCharacteristic,x (xxx), ;  ; Placebo (n = x) ; ,?White," Race, n (%)",12,4,3,no
3036,2820465,Table 1,BaselineCharacteristic,?Black, ;  ;  ; ,?Black," Race, n (%)",13,0,2,no
3036,2820465,Table 1,BaselineCharacteristic,x,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Black," Race, n (%)",13,1,3,no
3036,2820465,Table 1,BaselineCharacteristic,x (xx.x),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Black," Race, n (%)",13,2,3,no
3036,2820465,Table 1,BaselineCharacteristic,x,Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,?Black," Race, n (%)",13,3,3,no
3036,2820465,Table 1,BaselineCharacteristic,x, ;  ; Placebo (n = x) ; ,?Black," Race, n (%)",13,4,3,no
3036,2820465,Table 1,BaselineCharacteristic,"Weight, kg", ;  ;  ; ,None,None,14,0,24,no
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,"Weight, kg",None,14,1,43,no
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,"Weight, kg",None,14,2,43,no
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,"Weight, kg",None,14,3,43,no
3036,2820465,Table 1,BaselineCharacteristic,, ;  ; Placebo (n = x) ; ,"Weight, kg",None,14,4,43,no
3036,2820465,Table 1,BaselineCharacteristic,?Mean (SD), ;  ;  ; ,?Mean (SD)," Weight, kg",15,0,2,no
3036,2820465,Table 1,BaselineCharacteristic,xx.x (xx.x),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Mean (SD)," Weight, kg",15,1,3,no
3036,2820465,Table 1,BaselineCharacteristic,xx.x (xx.x),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Mean (SD)," Weight, kg",15,2,3,no
3036,2820465,Table 1,BaselineCharacteristic,xx.x (xx.x),Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,?Mean (SD)," Weight, kg",15,3,3,no
3036,2820465,Table 1,BaselineCharacteristic,xx.x (x.x), ;  ; Placebo (n = x) ; ,?Mean (SD)," Weight, kg",15,4,3,no
3036,2820465,Table 1,BaselineCharacteristic,"BMI, kg/mx", ;  ;  ; ,None,None,16,0,24,no
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,"BMI, kg/mx",None,16,1,43,no
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,"BMI, kg/mx",None,16,2,43,no
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,"BMI, kg/mx",None,16,3,43,no
3036,2820465,Table 1,BaselineCharacteristic,, ;  ; Placebo (n = x) ; ,"BMI, kg/mx",None,16,4,43,no
3036,2820465,Table 1,BaselineCharacteristic,?Mean (SD), ;  ;  ; ,?Mean (SD)," BMI, kg/mx",17,0,2,no
3036,2820465,Table 1,BaselineCharacteristic,xx.x (x.x),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Mean (SD)," BMI, kg/mx",17,1,3,no
3036,2820465,Table 1,BaselineCharacteristic,xx.x (x.x),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Mean (SD)," BMI, kg/mx",17,2,3,no
3036,2820465,Table 1,BaselineCharacteristic,xx.x (x.x),Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,?Mean (SD)," BMI, kg/mx",17,3,3,no
3036,2820465,Table 1,BaselineCharacteristic,xx (x.x), ;  ; Placebo (n = x) ; ,?Mean (SD)," BMI, kg/mx",17,4,3,no
3036,2820465,Table 1,BaselineCharacteristic,% predicted FEVx, ;  ;  ; ,None,None,18,0,24,no
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,% predicted FEVx,None,18,1,43,no
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,% predicted FEVx,None,18,2,43,no
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,% predicted FEVx,None,18,3,43,no
3036,2820465,Table 1,BaselineCharacteristic,, ;  ; Placebo (n = x) ; ,% predicted FEVx,None,18,4,43,no
3036,2820465,Table 1,BaselineCharacteristic,?Mean (SD), ;  ;  ; ,?Mean (SD), % predicted FEVx,19,0,2,no
3036,2820465,Table 1,BaselineCharacteristic,xx.x (x.x),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Mean (SD), % predicted FEVx,19,1,3,no
3036,2820465,Table 1,BaselineCharacteristic,xx.x (x.x),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Mean (SD), % predicted FEVx,19,2,3,no
3036,2820465,Table 1,BaselineCharacteristic,xx.x (x.x),Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,?Mean (SD), % predicted FEVx,19,3,3,no
3036,2820465,Table 1,BaselineCharacteristic,xx.x (x.x), ;  ; Placebo (n = x) ; ,?Mean (SD), % predicted FEVx,19,4,3,no
3036,2820465,Table 1,BaselineCharacteristic,FEVx, ;  ;  ; ,None,None,20,0,24,no
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,FEVx,None,20,1,43,no
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,FEVx,None,20,2,43,no
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,FEVx,None,20,3,43,no
3036,2820465,Table 1,BaselineCharacteristic,, ;  ; Placebo (n = x) ; ,FEVx,None,20,4,43,no
3036,2820465,Table 1,BaselineCharacteristic,?Mean (SD), ;  ;  ; ,?Mean (SD), FEVx,21,0,2,no
3036,2820465,Table 1,BaselineCharacteristic,x.xx (x.xx),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Mean (SD), FEVx,21,1,3,no
3036,2820465,Table 1,BaselineCharacteristic,x.xx (x.xx),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Mean (SD), FEVx,21,2,3,no
3036,2820465,Table 1,BaselineCharacteristic,x.xx (x.xx),Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,?Mean (SD), FEVx,21,3,3,no
3036,2820465,Table 1,BaselineCharacteristic,x.xx (x.xx), ;  ; Placebo (n = x) ; ,?Mean (SD), FEVx,21,4,3,no
3036,2820465,Table 1,BaselineCharacteristic,"ICS dose, ?g/d", ;  ;  ; ,None,None,22,0,24,no
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,"ICS dose, ?g/d",None,22,1,43,no
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; x mg/kg (n = x) ; ,"ICS dose, ?g/d",None,22,2,43,no
3036,2820465,Table 1,BaselineCharacteristic,,Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,"ICS dose, ?g/d",None,22,3,43,no
3036,2820465,Table 1,BaselineCharacteristic,, ;  ; Placebo (n = x) ; ,"ICS dose, ?g/d",None,22,4,43,no
3036,2820465,Table 1,BaselineCharacteristic,?Median (range), ;  ;  ; ,?Median (range)," ICS dose, ?g/d",23,0,2,no
3036,2820465,Table 1,BaselineCharacteristic,xxx (xxx-xxx),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Median (range)," ICS dose, ?g/d",23,1,3,no
3036,2820465,Table 1,BaselineCharacteristic,xxx (xxx-xxxx),Anti-IL-xx ;  ; x mg/kg (n = x) ; ,?Median (range)," ICS dose, ?g/d",23,2,3,no
3036,2820465,Table 1,BaselineCharacteristic,xxx (xxx-xxx),Anti-IL-xx ;  ; xx mg/kg (n = x) ; ,?Median (range)," ICS dose, ?g/d",23,3,3,no
3036,2820465,Table 1,BaselineCharacteristic,, ;  ; Placebo (n = x) ; ,?Median (range)," ICS dose, ?g/d",23,4,3,no
3304,2905291,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,0,12,no
3304,2905291,Table 1,BaselineCharacteristic,No. of patients,,Characteristic,None,0,1,1,no
3304,2905291,Table 1,BaselineCharacteristic,Total,Characteristic ; ,Total,,1,0,2,no
3304,2905291,Table 1,BaselineCharacteristic,xx,No. of patients ; ,Total,,1,1,3,no
3304,2905291,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,2,0,2,no
3304,2905291,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,2,1,3,no
3304,2905291,Table 1,BaselineCharacteristic,Age (years),Characteristic ; ,None,None,3,0,24,no
3304,2905291,Table 1,BaselineCharacteristic,,No. of patients ; ,Age (years),None,3,1,43,no
3304,2905291,Table 1,BaselineCharacteristic,?Median,Characteristic ; ,?Median, Age (years),4,0,2,no
3304,2905291,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Median, Age (years),4,1,3,no
3304,2905291,Table 1,BaselineCharacteristic,?Range,Characteristic ; ,?Range, Age (years),5,0,2,no
3304,2905291,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,6,0,2,no
3304,2905291,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,6,1,3,no
3304,2905291,Table 1,BaselineCharacteristic,Sex,Characteristic ; ,None,None,7,0,24,no
3304,2905291,Table 1,BaselineCharacteristic,,No. of patients ; ,Sex,None,7,1,43,no
3304,2905291,Table 1,BaselineCharacteristic,?Male,Characteristic ; ,?Male, Sex,8,0,2,no
3304,2905291,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Male, Sex,8,1,3,yes
3304,2905291,Table 1,BaselineCharacteristic,?Female,Characteristic ; ,?Female, Sex,9,0,2,no
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Female, Sex,9,1,3,yes
3304,2905291,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,10,0,2,no
3304,2905291,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,10,1,3,no
3304,2905291,Table 1,BaselineCharacteristic,ECOG performance status,Characteristic ; ,None,None,11,0,24,no
3304,2905291,Table 1,BaselineCharacteristic,,No. of patients ; ,ECOG performance status,None,11,1,43,no
3304,2905291,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, ECOG performance status,12,0,2,no
3304,2905291,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?x, ECOG performance status,12,1,3,no
3304,2905291,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, ECOG performance status,13,0,2,no
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?x, ECOG performance status,13,1,3,no
3304,2905291,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, ECOG performance status,14,0,2,no
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?x, ECOG performance status,14,1,3,no
3304,2905291,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,15,0,2,no
3304,2905291,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,15,1,3,no
3304,2905291,Table 1,BaselineCharacteristic,Previous anti-tumour regimens,Characteristic ; ,None,None,16,0,24,no
3304,2905291,Table 1,BaselineCharacteristic,,No. of patients ; ,Previous anti-tumour regimens,None,16,1,43,no
3304,2905291,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, Previous anti-tumour regimens,17,0,2,no
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?x, Previous anti-tumour regimens,17,1,3,no
3304,2905291,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, Previous anti-tumour regimens,18,0,2,no
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?x, Previous anti-tumour regimens,18,1,3,no
3304,2905291,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, Previous anti-tumour regimens,19,0,2,no
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?x, Previous anti-tumour regimens,19,1,3,no
3304,2905291,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, Previous anti-tumour regimens,20,0,2,no
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?x, Previous anti-tumour regimens,20,1,3,no
3304,2905291,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, Previous anti-tumour regimens,21,0,2,no
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?x, Previous anti-tumour regimens,21,1,3,no
3304,2905291,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,22,0,2,no
3304,2905291,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,22,1,3,no
3304,2905291,Table 1,BaselineCharacteristic,Primary tumour type,Characteristic ; ,None,None,23,0,24,no
3304,2905291,Table 1,BaselineCharacteristic,,No. of patients ; ,Primary tumour type,None,23,1,43,no
3304,2905291,Table 1,BaselineCharacteristic,?Pancreatic carcinoma,Characteristic ; ,?Pancreatic carcinoma, Primary tumour type,24,0,2,no
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Pancreatic carcinoma, Primary tumour type,24,1,3,no
3304,2905291,Table 1,BaselineCharacteristic,?Osteo/chondrosarcoma,Characteristic ; ,?Osteo/chondrosarcoma, Primary tumour type,25,0,2,no
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Osteo/chondrosarcoma, Primary tumour type,25,1,3,no
3304,2905291,Table 1,BaselineCharacteristic,?Soft tissue sarcoma,Characteristic ; ,?Soft tissue sarcoma, Primary tumour type,26,0,2,no
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Soft tissue sarcoma, Primary tumour type,26,1,3,no
3304,2905291,Table 1,BaselineCharacteristic,?Rectal carcinoma,Characteristic ; ,?Rectal carcinoma, Primary tumour type,27,0,2,no
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Rectal carcinoma, Primary tumour type,27,1,3,no
3304,2905291,Table 1,BaselineCharacteristic,?Gastric carcinoma,Characteristic ; ,?Gastric carcinoma, Primary tumour type,28,0,2,no
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Gastric carcinoma, Primary tumour type,28,1,3,no
3304,2905291,Table 1,BaselineCharacteristic,?Carcinoma of unknown primary,Characteristic ; ,?Carcinoma of unknown primary, Primary tumour type,29,0,2,no
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Carcinoma of unknown primary, Primary tumour type,29,1,3,no
3304,2905291,Table 1,BaselineCharacteristic,?Ovarian carcinoma,Characteristic ; ,?Ovarian carcinoma, Primary tumour type,30,0,2,no
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Ovarian carcinoma, Primary tumour type,30,1,3,no
3304,2905291,Table 1,BaselineCharacteristic,?Malignant melanoma,Characteristic ; ,?Malignant melanoma, Primary tumour type,31,0,2,no
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Malignant melanoma, Primary tumour type,31,1,3,no
3304,2905291,Table 1,BaselineCharacteristic,?Mesothelioma,Characteristic ; ,?Mesothelioma, Primary tumour type,32,0,2,no
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Mesothelioma, Primary tumour type,32,1,3,no
3304,2905291,Table 1,BaselineCharacteristic,?Bladder carcinoma,Characteristic ; ,?Bladder carcinoma, Primary tumour type,33,0,2,no
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Bladder carcinoma, Primary tumour type,33,1,3,no
3304,2905291,Table 1,BaselineCharacteristic,?Hepatocellular carcinoma,Characteristic ; ,?Hepatocellular carcinoma, Primary tumour type,34,0,2,no
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Hepatocellular carcinoma, Primary tumour type,34,1,3,no
3304,2905291,Table 1,BaselineCharacteristic,?Cholangiocarcinoma,Characteristic ; ,?Cholangiocarcinoma, Primary tumour type,35,0,2,no
3304,2905291,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Cholangiocarcinoma, Primary tumour type,35,1,3,no
3424,2941791,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no
3424,2941791,Table 1,BaselineCharacteristic,Data available,,,None,0,1,1,no
3424,2941791,Table 1,BaselineCharacteristic,n,,,None,0,2,1,no
3424,2941791,Table 1,BaselineCharacteristic,Value,,,None,0,3,1,no
3424,2941791,Table 1,BaselineCharacteristic,Female (%), ; ,Female (%),,3,0,2,no
3424,2941791,Table 1,BaselineCharacteristic,xxxx,Data available ; ,Female (%),,3,1,3,yes
3424,2941791,Table 1,BaselineCharacteristic,xxxx,n ; ,Female (%),,3,2,3,yes
3424,2941791,Table 1,BaselineCharacteristic,xx.x,Value ; ,Female (%),,3,3,3,yes
3424,2941791,Table 1,BaselineCharacteristic,Waist circumference, ; ,None,None,6,0,24,no
3424,2941791,Table 1,BaselineCharacteristic,,Data available ; ,Waist circumference,None,6,1,43,no
3424,2941791,Table 1,BaselineCharacteristic,,n ; ,Waist circumference,None,6,2,43,no
3424,2941791,Table 1,BaselineCharacteristic,,Value ; ,Waist circumference,None,6,3,43,no
3424,2941791,Table 1,BaselineCharacteristic,??Men (% ? xxx cm), ; ,??Men (% ? xxx cm), Waist circumference ,7,0,2,no
3424,2941791,Table 1,BaselineCharacteristic,xxxx,Data available ; ,??Men (% ? xxx cm), Waist circumference ,7,1,3,no
3424,2941791,Table 1,BaselineCharacteristic,xxxx,n ; ,??Men (% ? xxx cm), Waist circumference ,7,2,3,no
3424,2941791,Table 1,BaselineCharacteristic,xx.x,Value ; ,??Men (% ? xxx cm), Waist circumference ,7,3,3,no
3424,2941791,Table 1,BaselineCharacteristic,??Women (% ? xx cm), ; ,??Women (% ? xx cm), Waist circumference ,8,0,2,no
3424,2941791,Table 1,BaselineCharacteristic,xxxx,Data available ; ,??Women (% ? xx cm), Waist circumference ,8,1,3,no
3424,2941791,Table 1,BaselineCharacteristic,xxxx,n ; ,??Women (% ? xx cm), Waist circumference ,8,2,3,no
3424,2941791,Table 1,BaselineCharacteristic,xx.x,Value ; ,??Women (% ? xx cm), Waist circumference ,8,3,3,no
3424,2941791,Table 1,BaselineCharacteristic,Hypertension (%), ; ,Hypertension (%),,9,0,24,no
3424,2941791,Table 1,BaselineCharacteristic,xxxx,Data available ; ,Hypertension (%),,9,1,43,no
3424,2941791,Table 1,BaselineCharacteristic,xxxx,n ; ,Hypertension (%),,9,2,43,no
3424,2941791,Table 1,BaselineCharacteristic,xx.x,Value ; ,Hypertension (%),,9,3,43,no
3424,2941791,Table 1,BaselineCharacteristic,??>x years (%), ; ,??>x years (%), Hypertension (%) ,10,0,2,no
3424,2941791,Table 1,BaselineCharacteristic,xxxx,Data available ; ,??>x years (%), Hypertension (%) ,10,1,3,no
3424,2941791,Table 1,BaselineCharacteristic,xxxx,n ; ,??>x years (%), Hypertension (%) ,10,2,3,no
3424,2941791,Table 1,BaselineCharacteristic,xx.x,Value ; ,??>x years (%), Hypertension (%) ,10,3,3,no
3490,2964613,Table 1,BaselineCharacteristic,Characteristics,,None,None,0,0,12,no
3490,2964613,Table 1,BaselineCharacteristic,Patients (N = xxx),,Characteristics,None,0,1,1,no
3490,2964613,Table 1,BaselineCharacteristic,"Age (years), mean (SD)",Characteristics ; ,"Age (years), mean (SD)",None,1,0,2,no
3490,2964613,Table 1,BaselineCharacteristic,xx.x (x.xx),Patients (N = xxx) ; ,"Age (years), mean (SD)",None,1,1,3,no
3490,2964613,Table 1,BaselineCharacteristic,"Sex, n (%)",Characteristics ; ,"Sex, n (%)",None,2,0,2,no
3490,2964613,Table 1,BaselineCharacteristic,,Patients (N = xxx) ; ,"Sex, n (%)",None,2,1,3,no
3490,2964613,Table 1,BaselineCharacteristic,Male,Characteristics ; ,Male,None,3,0,2,no
3490,2964613,Table 1,BaselineCharacteristic,xxx (xx.x),Patients (N = xxx) ; ,Male,None,3,1,3,yes
3490,2964613,Table 1,BaselineCharacteristic,Female,Characteristics ; ,Female,None,4,0,2,no
3490,2964613,Table 1,BaselineCharacteristic,xx (xx.x),Patients (N = xxx) ; ,Female,None,4,1,3,yes
3490,2964613,Table 1,BaselineCharacteristic,"Race, n (%)",Characteristics ; ,"Race, n (%)",None,5,0,2,no
3490,2964613,Table 1,BaselineCharacteristic,,Patients (N = xxx) ; ,"Race, n (%)",None,5,1,3,no
3490,2964613,Table 1,BaselineCharacteristic,Caucasian,Characteristics ; ,Caucasian,None,6,0,2,no
3490,2964613,Table 1,BaselineCharacteristic,xxx (xx.x),Patients (N = xxx) ; ,Caucasian,None,6,1,3,no
3490,2964613,Table 1,BaselineCharacteristic,Others,Characteristics ; ,Others,None,7,0,2,no
3490,2964613,Table 1,BaselineCharacteristic,x (x.x),Patients (N = xxx) ; ,Others,None,7,1,3,no
3490,2964613,Table 1,BaselineCharacteristic,"BMI (kg/mx), mean (SD)",Characteristics ; ,"BMI (kg/mx), mean (SD)",None,8,0,2,no
3490,2964613,Table 1,BaselineCharacteristic,xx.x (x.xx),Patients (N = xxx) ; ,"BMI (kg/mx), mean (SD)",None,8,1,3,no
3490,2964613,Table 1,BaselineCharacteristic,"Duration of COPD (years), mean (SD)",Characteristics ; ,"Duration of COPD (years), mean (SD)",None,9,0,2,no
3490,2964613,Table 1,BaselineCharacteristic,x.x (x.xx),Patients (N = xxx) ; ,"Duration of COPD (years), mean (SD)",None,9,1,3,no
3490,2964613,Table 1,BaselineCharacteristic,"Smoking history, n (%)",Characteristics ; ,"Smoking history, n (%)",None,10,0,2,no
3490,2964613,Table 1,BaselineCharacteristic,,Patients (N = xxx) ; ,"Smoking history, n (%)",None,10,1,3,no
3490,2964613,Table 1,BaselineCharacteristic,Ex-smoker,Characteristics ; ,Ex-smoker,None,11,0,2,no
3490,2964613,Table 1,BaselineCharacteristic,xx (xx.x),Patients (N = xxx) ; ,Ex-smoker,None,11,1,3,no
3490,2964613,Table 1,BaselineCharacteristic,Current smoker,Characteristics ; ,Current smoker,None,12,0,2,no
3490,2964613,Table 1,BaselineCharacteristic,xx (xx.x),Patients (N = xxx) ; ,Current smoker,None,12,1,3,no
3490,2964613,Table 1,BaselineCharacteristic,"Number of pack-years, mean (SD)",Characteristics ; ,"Number of pack-years, mean (SD)",None,13,0,2,no
3490,2964613,Table 1,BaselineCharacteristic,xx.x (xx.xx),Patients (N = xxx) ; ,"Number of pack-years, mean (SD)",None,13,1,3,no
3490,2964613,Table 1,BaselineCharacteristic,"Post-bronchodilator FEVx (% predicted), mean (SD)",Characteristics ; ,"Post-bronchodilator FEVx (% predicted), mean (SD)",None,14,0,2,no
3490,2964613,Table 1,BaselineCharacteristic,xx.x (xx.xx),Patients (N = xxx) ; ,"Post-bronchodilator FEVx (% predicted), mean (SD)",None,14,1,3,no
3490,2964613,Table 1,BaselineCharacteristic,"Post-bronchodilator FEVx/FVC (%), mean (SD)",Characteristics ; ,"Post-bronchodilator FEVx/FVC (%), mean (SD)",None,15,0,2,no
3490,2964613,Table 1,BaselineCharacteristic,xx.x (xx.xx),Patients (N = xxx) ; ,"Post-bronchodilator FEVx/FVC (%), mean (SD)",None,15,1,3,no
3490,2964613,Table 1,BaselineCharacteristic,"FEVx reversibility (% increase), mean (SD)",Characteristics ; ,"FEVx reversibility (% increase), mean (SD)",None,16,0,2,no
3490,2964613,Table 1,BaselineCharacteristic,xx.x (xx.xx),Patients (N = xxx) ; ,"FEVx reversibility (% increase), mean (SD)",None,16,1,3,no
3496,2965867,Table 1,BaselineCharacteristic,Parameter/dose level,,None,None,0,0,12,no
3496,2965867,Table 1,BaselineCharacteristic,xxx?IU?m?x,,Parameter/dose level,None,0,1,1,no
3496,2965867,Table 1,BaselineCharacteristic,xxx?IU?m?x,,Parameter/dose level,None,0,2,1,no
3496,2965867,Table 1,BaselineCharacteristic,Overall,,Parameter/dose level,None,0,3,1,no
3496,2965867,Table 1,BaselineCharacteristic,"Case, number",Parameter/dose level ; ,"Case, number",,1,0,2,no
3496,2965867,Table 1,BaselineCharacteristic,xx,xxx?IU?m?x ; ,"Case, number",,1,1,3,no
3496,2965867,Table 1,BaselineCharacteristic,xx,xxx?IU?m?x ; ,"Case, number",,1,2,3,no
3496,2965867,Table 1,BaselineCharacteristic,xx,Overall ; ,"Case, number",,1,3,3,no
3496,2965867,Table 1,BaselineCharacteristic,,Parameter/dose level ; ,None,None,2,0,2,no
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,2,1,3,no
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,2,2,3,no
3496,2965867,Table 1,BaselineCharacteristic,,Overall ; ,None,None,2,3,3,no
3496,2965867,Table 1,BaselineCharacteristic,Gender,Parameter/dose level ; ,None,None,3,0,24,no
3496,2965867,Table 1,BaselineCharacteristic,Gender,xxx?IU?m?x ; ,Gender,None,3,1,43,no
3496,2965867,Table 1,BaselineCharacteristic,Gender,xxx?IU?m?x ; ,Gender,None,3,2,43,no
3496,2965867,Table 1,BaselineCharacteristic,Gender,Overall ; ,Gender,None,3,3,43,no
3496,2965867,Table 1,BaselineCharacteristic,?Male,Parameter/dose level ; ,?Male, Gender,4,0,2,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Male, Gender,4,1,3,yes
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Male, Gender,4,2,3,yes
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?Male, Gender,4,3,3,yes
3496,2965867,Table 1,BaselineCharacteristic,?Female,Parameter/dose level ; ,?Female, Gender,5,0,2,no
3496,2965867,Table 1,BaselineCharacteristic,x (xx.x%),xxx?IU?m?x ; ,?Female, Gender,5,1,3,yes
3496,2965867,Table 1,BaselineCharacteristic,x (xx.x%),xxx?IU?m?x ; ,?Female, Gender,5,2,3,yes
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?Female, Gender,5,3,3,yes
3496,2965867,Table 1,BaselineCharacteristic,,Parameter/dose level ; ,None,None,6,0,2,no
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,6,1,3,no
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,6,2,3,no
3496,2965867,Table 1,BaselineCharacteristic,,Overall ; ,None,None,6,3,3,no
3496,2965867,Table 1,BaselineCharacteristic,Age,Parameter/dose level ; ,None,None,7,0,24,no
3496,2965867,Table 1,BaselineCharacteristic,Age,xxx?IU?m?x ; ,Age,None,7,1,43,no
3496,2965867,Table 1,BaselineCharacteristic,Age,xxx?IU?m?x ; ,Age,None,7,2,43,no
3496,2965867,Table 1,BaselineCharacteristic,Age,Overall ; ,Age,None,7,3,43,no
3496,2965867,Table 1,BaselineCharacteristic,?Median,Parameter/dose level ; ,?Median, Age,8,0,2,no
3496,2965867,Table 1,BaselineCharacteristic,xx,xxx?IU?m?x ; ,?Median, Age,8,1,3,no
3496,2965867,Table 1,BaselineCharacteristic,xx,xxx?IU?m?x ; ,?Median, Age,8,2,3,no
3496,2965867,Table 1,BaselineCharacteristic,xx,Overall ; ,?Median, Age,8,3,3,no
3496,2965867,Table 1,BaselineCharacteristic,?Range,Parameter/dose level ; ,?Range, Age,9,0,2,no
3496,2965867,Table 1,BaselineCharacteristic,,Parameter/dose level ; ,None,None,10,0,2,no
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,10,1,3,no
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,10,2,3,no
3496,2965867,Table 1,BaselineCharacteristic,,Overall ; ,None,None,10,3,3,no
3496,2965867,Table 1,BaselineCharacteristic,Karnofsky performance status,Parameter/dose level ; ,None,None,11,0,24,no
3496,2965867,Table 1,BaselineCharacteristic,Karnofsky performance status,xxx?IU?m?x ; ,Karnofsky performance status,None,11,1,43,no
3496,2965867,Table 1,BaselineCharacteristic,Karnofsky performance status,xxx?IU?m?x ; ,Karnofsky performance status,None,11,2,43,no
3496,2965867,Table 1,BaselineCharacteristic,Karnofsky performance status,Overall ; ,Karnofsky performance status,None,11,3,43,no
3496,2965867,Table 1,BaselineCharacteristic,?xxx,Parameter/dose level ; ,?xxx, Karnofsky performance status,12,0,2,no
3496,2965867,Table 1,BaselineCharacteristic,x (xx.x%),xxx?IU?m?x ; ,?xxx, Karnofsky performance status,12,1,3,no
3496,2965867,Table 1,BaselineCharacteristic,x (xx.x%),xxx?IU?m?x ; ,?xxx, Karnofsky performance status,12,2,3,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?xxx, Karnofsky performance status,12,3,3,no
3496,2965867,Table 1,BaselineCharacteristic,?xx,Parameter/dose level ; ,?xx, Karnofsky performance status,13,0,2,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?xx, Karnofsky performance status,13,1,3,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?xx, Karnofsky performance status,13,2,3,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?xx, Karnofsky performance status,13,3,3,no
3496,2965867,Table 1,BaselineCharacteristic,?xx,Parameter/dose level ; ,?xx, Karnofsky performance status,14,0,2,no
3496,2965867,Table 1,BaselineCharacteristic,x (xx.x%),xxx?IU?m?x ; ,?xx, Karnofsky performance status,14,1,3,no
3496,2965867,Table 1,BaselineCharacteristic,x (xx.x%),xxx?IU?m?x ; ,?xx, Karnofsky performance status,14,2,3,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?xx, Karnofsky performance status,14,3,3,no
3496,2965867,Table 1,BaselineCharacteristic,,Parameter/dose level ; ,None,None,15,0,2,no
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,15,1,3,no
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,15,2,3,no
3496,2965867,Table 1,BaselineCharacteristic,,Overall ; ,None,None,15,3,3,no
3496,2965867,Table 1,BaselineCharacteristic,,Parameter/dose level ; ,None,None,19,0,2,no
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,19,1,3,no
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,19,2,3,no
3496,2965867,Table 1,BaselineCharacteristic,,Overall ; ,None,None,19,3,3,no
3496,2965867,Table 1,BaselineCharacteristic,HbsAg,Parameter/dose level ; ,None,None,20,0,24,no
3496,2965867,Table 1,BaselineCharacteristic,HbsAg,xxx?IU?m?x ; ,HbsAg,None,20,1,43,no
3496,2965867,Table 1,BaselineCharacteristic,HbsAg,xxx?IU?m?x ; ,HbsAg,None,20,2,43,no
3496,2965867,Table 1,BaselineCharacteristic,HbsAg,Overall ; ,HbsAg,None,20,3,43,no
3496,2965867,Table 1,BaselineCharacteristic,?Positive,Parameter/dose level ; ,?Positive, HbsAg,21,0,2,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Positive, HbsAg,21,1,3,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Positive, HbsAg,21,2,3,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?Positive, HbsAg,21,3,3,no
3496,2965867,Table 1,BaselineCharacteristic,?Negative,Parameter/dose level ; ,?Negative, HbsAg,22,0,2,no
3496,2965867,Table 1,BaselineCharacteristic,x (xx.x%),xxx?IU?m?x ; ,?Negative, HbsAg,22,1,3,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Negative, HbsAg,22,2,3,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?Negative, HbsAg,22,3,3,no
3496,2965867,Table 1,BaselineCharacteristic,,Parameter/dose level ; ,None,None,23,0,2,no
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,23,1,3,no
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,23,2,3,no
3496,2965867,Table 1,BaselineCharacteristic,,Overall ; ,None,None,23,3,3,no
3496,2965867,Table 1,BaselineCharacteristic,Anti-HCV antibody,Parameter/dose level ; ,None,None,24,0,24,no
3496,2965867,Table 1,BaselineCharacteristic,Anti-HCV antibody,xxx?IU?m?x ; ,Anti-HCV antibody,None,24,1,43,no
3496,2965867,Table 1,BaselineCharacteristic,Anti-HCV antibody,xxx?IU?m?x ; ,Anti-HCV antibody,None,24,2,43,no
3496,2965867,Table 1,BaselineCharacteristic,Anti-HCV antibody,Overall ; ,Anti-HCV antibody,None,24,3,43,no
3496,2965867,Table 1,BaselineCharacteristic,?Positive,Parameter/dose level ; ,?Positive, Anti-HCV antibody,25,0,2,no
3496,2965867,Table 1,BaselineCharacteristic,x (xx.x%),xxx?IU?m?x ; ,?Positive, Anti-HCV antibody,25,1,3,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Positive, Anti-HCV antibody,25,2,3,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?Positive, Anti-HCV antibody,25,3,3,no
3496,2965867,Table 1,BaselineCharacteristic,?Negative,Parameter/dose level ; ,?Negative, Anti-HCV antibody,26,0,2,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Negative, Anti-HCV antibody,26,1,3,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Negative, Anti-HCV antibody,26,2,3,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?Negative, Anti-HCV antibody,26,3,3,no
3496,2965867,Table 1,BaselineCharacteristic,?Unknown,Parameter/dose level ; ,?Unknown, Anti-HCV antibody,27,0,2,no
3496,2965867,Table 1,BaselineCharacteristic,x (x.x%),xxx?IU?m?x ; ,?Unknown, Anti-HCV antibody,27,1,3,no
3496,2965867,Table 1,BaselineCharacteristic,x (x.x%),xxx?IU?m?x ; ,?Unknown, Anti-HCV antibody,27,2,3,no
3496,2965867,Table 1,BaselineCharacteristic,x (x.x%),Overall ; ,?Unknown, Anti-HCV antibody,27,3,3,no
3496,2965867,Table 1,BaselineCharacteristic,,Parameter/dose level ; ,None,None,28,0,2,no
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,28,1,3,no
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,28,2,3,no
3496,2965867,Table 1,BaselineCharacteristic,,Overall ; ,None,None,28,3,3,no
3496,2965867,Table 1,BaselineCharacteristic,Vascular invasion,Parameter/dose level ; ,None,None,29,0,24,no
3496,2965867,Table 1,BaselineCharacteristic,Vascular invasion,xxx?IU?m?x ; ,Vascular invasion,None,29,1,43,no
3496,2965867,Table 1,BaselineCharacteristic,Vascular invasion,xxx?IU?m?x ; ,Vascular invasion,None,29,2,43,no
3496,2965867,Table 1,BaselineCharacteristic,Vascular invasion,Overall ; ,Vascular invasion,None,29,3,43,no
3496,2965867,Table 1,BaselineCharacteristic,?Absent,Parameter/dose level ; ,?Absent, Vascular invasion,30,0,2,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Absent, Vascular invasion,30,1,3,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Absent, Vascular invasion,30,2,3,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?Absent, Vascular invasion,30,3,3,no
3496,2965867,Table 1,BaselineCharacteristic,?Present,Parameter/dose level ; ,?Present, Vascular invasion,31,0,2,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Present, Vascular invasion,31,1,3,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Present, Vascular invasion,31,2,3,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?Present, Vascular invasion,31,3,3,no
3496,2965867,Table 1,BaselineCharacteristic,,Parameter/dose level ; ,None,None,32,0,2,no
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,32,1,3,no
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,32,2,3,no
3496,2965867,Table 1,BaselineCharacteristic,,Overall ; ,None,None,32,3,3,no
3496,2965867,Table 1,BaselineCharacteristic,Extrahepatic metastases,Parameter/dose level ; ,None,None,33,0,24,no
3496,2965867,Table 1,BaselineCharacteristic,Extrahepatic metastases,xxx?IU?m?x ; ,Extrahepatic metastases,None,33,1,43,no
3496,2965867,Table 1,BaselineCharacteristic,Extrahepatic metastases,xxx?IU?m?x ; ,Extrahepatic metastases,None,33,2,43,no
3496,2965867,Table 1,BaselineCharacteristic,Extrahepatic metastases,Overall ; ,Extrahepatic metastases,None,33,3,43,no
3496,2965867,Table 1,BaselineCharacteristic,?Absent,Parameter/dose level ; ,?Absent, Extrahepatic metastases,34,0,2,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Absent, Extrahepatic metastases,34,1,3,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Absent, Extrahepatic metastases,34,2,3,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?Absent, Extrahepatic metastases,34,3,3,no
3496,2965867,Table 1,BaselineCharacteristic,?Present,Parameter/dose level ; ,?Present, Extrahepatic metastases,35,0,2,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Present, Extrahepatic metastases,35,1,3,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Present, Extrahepatic metastases,35,2,3,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?Present, Extrahepatic metastases,35,3,3,no
3496,2965867,Table 1,BaselineCharacteristic,,Parameter/dose level ; ,None,None,36,0,2,no
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,36,1,3,no
3496,2965867,Table 1,BaselineCharacteristic,,xxx?IU?m?x ; ,None,None,36,2,3,no
3496,2965867,Table 1,BaselineCharacteristic,,Overall ; ,None,None,36,3,3,no
3496,2965867,Table 1,BaselineCharacteristic,Prior therapy,Parameter/dose level ; ,None,None,37,0,24,no
3496,2965867,Table 1,BaselineCharacteristic,Prior therapy,xxx?IU?m?x ; ,Prior therapy,None,37,1,43,no
3496,2965867,Table 1,BaselineCharacteristic,Prior therapy,xxx?IU?m?x ; ,Prior therapy,None,37,2,43,no
3496,2965867,Table 1,BaselineCharacteristic,Prior therapy,Overall ; ,Prior therapy,None,37,3,43,no
3496,2965867,Table 1,BaselineCharacteristic,?Hepatic resection,Parameter/dose level ; ,?Hepatic resection, Prior therapy,38,0,2,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Hepatic resection, Prior therapy,38,1,3,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Hepatic resection, Prior therapy,38,2,3,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?Hepatic resection, Prior therapy,38,3,3,no
3496,2965867,Table 1,BaselineCharacteristic,?Transcatheter arterial chemoembolization,Parameter/dose level ; ,?Transcatheter arterial chemoembolization, Prior therapy,39,0,2,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Transcatheter arterial chemoembolization, Prior therapy,39,1,3,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Transcatheter arterial chemoembolization, Prior therapy,39,2,3,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?Transcatheter arterial chemoembolization, Prior therapy,39,3,3,no
3496,2965867,Table 1,BaselineCharacteristic,?Radiotherapy,Parameter/dose level ; ,?Radiotherapy, Prior therapy,40,0,2,no
3496,2965867,Table 1,BaselineCharacteristic,x (xx.x%),xxx?IU?m?x ; ,?Radiotherapy, Prior therapy,40,1,3,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Radiotherapy, Prior therapy,40,2,3,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?Radiotherapy, Prior therapy,40,3,3,no
3496,2965867,Table 1,BaselineCharacteristic,?Systemic therapy,Parameter/dose level ; ,?Systemic therapy, Prior therapy,41,0,24,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Systemic therapy, Prior therapy,41,1,43,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),xxx?IU?m?x ; ,?Systemic therapy, Prior therapy,41,2,43,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,?Systemic therapy, Prior therapy,41,3,43,no
3496,2965867,Table 1,BaselineCharacteristic,??Thalidomide alone,Parameter/dose level ; ,??Thalidomide alone, Prior therapy ?Systemic therapy,42,0,2,no
3496,2965867,Table 1,BaselineCharacteristic,x (xx.x%),xxx?IU?m?x ; ,??Thalidomide alone, Prior therapy ?Systemic therapy,42,1,3,no
3496,2965867,Table 1,BaselineCharacteristic,x (x.x%),xxx?IU?m?x ; ,??Thalidomide alone, Prior therapy ?Systemic therapy,42,2,3,no
3496,2965867,Table 1,BaselineCharacteristic,x (x.x%),Overall ; ,??Thalidomide alone, Prior therapy ?Systemic therapy,42,3,3,no
3496,2965867,Table 1,BaselineCharacteristic,??Chemotherapy with/without thalidomide,Parameter/dose level ; ,??Chemotherapy with/without thalidomide, Prior therapy ?Systemic therapy,43,0,2,no
3496,2965867,Table 1,BaselineCharacteristic,x (xx.x%),xxx?IU?m?x ; ,??Chemotherapy with/without thalidomide, Prior therapy ?Systemic therapy,43,1,3,no
3496,2965867,Table 1,BaselineCharacteristic,x (xx.x%),xxx?IU?m?x ; ,??Chemotherapy with/without thalidomide, Prior therapy ?Systemic therapy,43,2,3,no
3496,2965867,Table 1,BaselineCharacteristic,xx (xx.x%),Overall ; ,??Chemotherapy with/without thalidomide, Prior therapy ?Systemic therapy,43,3,3,no
3496,2965867,Table 1,BaselineCharacteristic,??Anti-angiogenic therapya,Parameter/dose level ; ,??Anti-angiogenic therapya, Prior therapy ?Systemic therapy,44,0,2,no
3496,2965867,Table 1,BaselineCharacteristic,x (xx.x%),xxx?IU?m?x ; ,??Anti-angiogenic therapya, Prior therapy ?Systemic therapy,44,1,3,no
3496,2965867,Table 1,BaselineCharacteristic,x (xx.x%),xxx?IU?m?x ; ,??Anti-angiogenic therapya, Prior therapy ?Systemic therapy,44,2,3,no
3496,2965867,Table 1,BaselineCharacteristic,x (xx.x%),Overall ; ,??Anti-angiogenic therapya, Prior therapy ?Systemic therapy,44,3,3,no
3503,2967062,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,0,12,no
3503,2967062,Table 1,BaselineCharacteristic,Number (%),,Characteristic,None,0,1,1,no
3503,2967062,Table 1,BaselineCharacteristic,,Number (%) ; ,None,None,1,1,3,no
3503,2967062,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,2,0,2,no
3503,2967062,Table 1,BaselineCharacteristic,,Number (%) ; ,None,None,2,1,3,no
3503,2967062,Table 1,BaselineCharacteristic,Performance status,Characteristic ; ,None,None,3,0,24,no
3503,2967062,Table 1,BaselineCharacteristic,Performance status,Number (%) ; ,Performance status,None,3,1,43,no
3503,2967062,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, Performance status,4,0,2,no
3503,2967062,Table 1,BaselineCharacteristic,x (xx),Number (%) ; ,?x, Performance status,4,1,3,no
3503,2967062,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, Performance status,5,0,2,no
3503,2967062,Table 1,BaselineCharacteristic,x (xx),Number (%) ; ,?x, Performance status,5,1,3,no
3503,2967062,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,6,0,2,no
3503,2967062,Table 1,BaselineCharacteristic,,Number (%) ; ,None,None,6,1,3,no
3503,2967062,Table 1,BaselineCharacteristic,Gender,Characteristic ; ,None,None,7,0,24,no
3503,2967062,Table 1,BaselineCharacteristic,Gender,Number (%) ; ,Gender,None,7,1,43,no
3503,2967062,Table 1,BaselineCharacteristic,?Male,Characteristic ; ,?Male, Gender,8,0,2,no
3503,2967062,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,?Male, Gender,8,1,3,yes
3503,2967062,Table 1,BaselineCharacteristic,?Female,Characteristic ; ,?Female, Gender,9,0,2,no
3503,2967062,Table 1,BaselineCharacteristic,x (xx),Number (%) ; ,?Female, Gender,9,1,3,yes
3503,2967062,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,10,0,2,no
3503,2967062,Table 1,BaselineCharacteristic,,Number (%) ; ,None,None,10,1,3,no
3503,2967062,Table 1,BaselineCharacteristic,Histology,Characteristic ; ,None,None,11,0,24,no
3503,2967062,Table 1,BaselineCharacteristic,Histology,Number (%) ; ,Histology,None,11,1,43,no
3503,2967062,Table 1,BaselineCharacteristic,?Clear cell,Characteristic ; ,?Clear cell, Histology,12,0,2,no
3503,2967062,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,?Clear cell, Histology,12,1,3,no
3503,2967062,Table 1,BaselineCharacteristic,?Clear cell/sarcomatoid,Characteristic ; ,?Clear cell/sarcomatoid, Histology,13,0,2,no
3503,2967062,Table 1,BaselineCharacteristic,x (x),Number (%) ; ,?Clear cell/sarcomatoid, Histology,13,1,3,no
3503,2967062,Table 1,BaselineCharacteristic,?Clear cell/papillary,Characteristic ; ,?Clear cell/papillary, Histology,14,0,2,no
3503,2967062,Table 1,BaselineCharacteristic,x (x),Number (%) ; ,?Clear cell/papillary, Histology,14,1,3,no
3503,2967062,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,15,0,2,no
3503,2967062,Table 1,BaselineCharacteristic,,Number (%) ; ,None,None,15,1,3,no
3503,2967062,Table 1,BaselineCharacteristic,Grade,Characteristic ; ,None,None,16,0,24,no
3503,2967062,Table 1,BaselineCharacteristic,Grade,Number (%) ; ,Grade,None,16,1,43,no
3503,2967062,Table 1,BaselineCharacteristic,?Gx,Characteristic ; ,?Gx, Grade,17,0,2,no
3503,2967062,Table 1,BaselineCharacteristic,x (xx),Number (%) ; ,?Gx, Grade,17,1,3,no
3503,2967062,Table 1,BaselineCharacteristic,?Gx,Characteristic ; ,?Gx, Grade,18,0,2,no
3503,2967062,Table 1,BaselineCharacteristic,x (xx),Number (%) ; ,?Gx, Grade,18,1,3,no
3503,2967062,Table 1,BaselineCharacteristic,?Gx,Characteristic ; ,?Gx, Grade,19,0,2,no
3503,2967062,Table 1,BaselineCharacteristic,x (xx),Number (%) ; ,?Gx, Grade,19,1,3,no
3503,2967062,Table 1,BaselineCharacteristic,?GX,Characteristic ; ,?GX, Grade,20,0,2,no
3503,2967062,Table 1,BaselineCharacteristic,x (x),Number (%) ; ,?GX, Grade,20,1,3,no
3503,2967062,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,21,0,2,no
3503,2967062,Table 1,BaselineCharacteristic,,Number (%) ; ,None,None,21,1,3,no
3503,2967062,Table 1,BaselineCharacteristic,Disease status at study entry,Characteristic ; ,None,None,22,0,24,no
3503,2967062,Table 1,BaselineCharacteristic,Disease status at study entry,Number (%) ; ,Disease status at study entry,None,22,1,43,no
3503,2967062,Table 1,BaselineCharacteristic,?Progressive disease,Characteristic ; ,?Progressive disease, Disease status at study entry,23,0,2,no
3503,2967062,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,?Progressive disease, Disease status at study entry,23,1,3,no
3503,2967062,Table 1,BaselineCharacteristic,?Stable disease,Characteristic ; ,?Stable disease, Disease status at study entry,24,0,2,no
3503,2967062,Table 1,BaselineCharacteristic,x (x),Number (%) ; ,?Stable disease, Disease status at study entry,24,1,3,no
3503,2967062,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,25,0,2,no
3503,2967062,Table 1,BaselineCharacteristic,,Number (%) ; ,None,None,25,1,3,no
3503,2967062,Table 1,BaselineCharacteristic,MSKCC risk group,Characteristic ; ,None,None,26,0,24,no
3503,2967062,Table 1,BaselineCharacteristic,,Number (%) ; ,MSKCC risk group,None,26,1,43,no
3503,2967062,Table 1,BaselineCharacteristic,?High,Characteristic ; ,?High, MSKCC risk group,27,0,2,no
3503,2967062,Table 1,BaselineCharacteristic,x (x),Number (%) ; ,?High, MSKCC risk group,27,1,3,no
3503,2967062,Table 1,BaselineCharacteristic,?Intermediate,Characteristic ; ,?Intermediate, MSKCC risk group,28,0,2,no
3503,2967062,Table 1,BaselineCharacteristic,x (xx),Number (%) ; ,?Intermediate, MSKCC risk group,28,1,3,no
3503,2967062,Table 1,BaselineCharacteristic,?Low,Characteristic ; ,?Low, MSKCC risk group,29,0,2,no
3503,2967062,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,?Low, MSKCC risk group,29,1,3,no
3503,2967062,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,30,0,2,no
3503,2967062,Table 1,BaselineCharacteristic,,Number (%) ; ,None,None,30,1,3,no
3503,2967062,Table 1,BaselineCharacteristic,Previous nephrectomy,Characteristic ; ,None,None,31,0,24,no
3503,2967062,Table 1,BaselineCharacteristic,Previous nephrectomy,Number (%) ; ,Previous nephrectomy,None,31,1,43,no
3503,2967062,Table 1,BaselineCharacteristic,?Yes,Characteristic ; ,?Yes, Previous nephrectomy,32,0,2,no
3503,2967062,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,?Yes, Previous nephrectomy,32,1,3,no
3503,2967062,Table 1,BaselineCharacteristic,?No,Characteristic ; ,?No, Previous nephrectomy,33,0,2,no
3503,2967062,Table 1,BaselineCharacteristic,x (xx),Number (%) ; ,?No, Previous nephrectomy,33,1,3,no
3503,2967062,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,34,0,2,no
3503,2967062,Table 1,BaselineCharacteristic,,Number (%) ; ,None,None,34,1,3,no
3503,2967062,Table 1,BaselineCharacteristic,Previous systemic treatment,Characteristic ; ,None,None,35,0,24,no
3503,2967062,Table 1,BaselineCharacteristic,Previous systemic treatment,Number (%) ; ,Previous systemic treatment,None,35,1,43,no
3503,2967062,Table 1,BaselineCharacteristic,?Cytokine,Characteristic ; ,?Cytokine, Previous systemic treatment,36,0,2,no
3503,2967062,Table 1,BaselineCharacteristic,x (xx),Number (%) ; ,?Cytokine, Previous systemic treatment,36,1,3,no
3503,2967062,Table 1,BaselineCharacteristic,?Nil,Characteristic ; ,?Nil, Previous systemic treatment,37,0,2,no
3503,2967062,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,?Nil, Previous systemic treatment,37,1,3,no
3559,2990596,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no
3559,2990596,Table 1,BaselineCharacteristic,No. of patients,,,None,0,1,1,no
3559,2990596,Table 1,BaselineCharacteristic,Total, ; ,Total,,1,0,2,no
3559,2990596,Table 1,BaselineCharacteristic,xx,No. of patients ; ,Total,,1,1,3,no
3559,2990596,Table 1,BaselineCharacteristic,, ; ,None,None,2,0,2,no
3559,2990596,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,2,1,3,no
3559,2990596,Table 1,BaselineCharacteristic,Age (years), ; ,None,None,3,0,24,no
3559,2990596,Table 1,BaselineCharacteristic,Age (years),No. of patients ; ,Age (years),None,3,1,43,no
3559,2990596,Table 1,BaselineCharacteristic,?Median, ; ,?Median, Age (years),4,0,2,no
3559,2990596,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Median, Age (years),4,1,3,no
3559,2990596,Table 1,BaselineCharacteristic,?Range, ; ,?Range, Age (years),5,0,2,no
3559,2990596,Table 1,BaselineCharacteristic,, ; ,None,None,6,0,2,no
3559,2990596,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,6,1,3,no
3559,2990596,Table 1,BaselineCharacteristic,Gender, ; ,None,None,7,0,24,no
3559,2990596,Table 1,BaselineCharacteristic,Gender,No. of patients ; ,Gender,None,7,1,43,no
3559,2990596,Table 1,BaselineCharacteristic,?Male, ; ,?Male, Gender,8,0,2,no
3559,2990596,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Male, Gender,8,1,3,yes
3559,2990596,Table 1,BaselineCharacteristic,?Female, ; ,?Female, Gender,9,0,2,no
3559,2990596,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Female, Gender,9,1,3,yes
3559,2990596,Table 1,BaselineCharacteristic,, ; ,None,None,10,0,2,no
3559,2990596,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,10,1,3,no
3559,2990596,Table 1,BaselineCharacteristic,PS (ECOG), ; ,None,None,11,0,24,no
3559,2990596,Table 1,BaselineCharacteristic,PS (ECOG),No. of patients ; ,PS (ECOG),None,11,1,43,no
3559,2990596,Table 1,BaselineCharacteristic,?x, ; ,?x, PS (ECOG),12,0,2,no
3559,2990596,Table 1,BaselineCharacteristic,x,No. of patients ; ,?x, PS (ECOG),12,1,3,no
3559,2990596,Table 1,BaselineCharacteristic,?x, ; ,?x, PS (ECOG),13,0,2,no
3559,2990596,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?x, PS (ECOG),13,1,3,no
3559,2990596,Table 1,BaselineCharacteristic,, ; ,None,None,14,0,2,no
3559,2990596,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,14,1,3,no
3559,2990596,Table 1,BaselineCharacteristic,Pathology, ; ,None,None,15,0,24,no
3559,2990596,Table 1,BaselineCharacteristic,Pathology,No. of patients ; ,Pathology,None,15,1,43,no
3559,2990596,Table 1,BaselineCharacteristic,?Adenocarcinoma, ; ,?Adenocarcinoma, Pathology,16,0,2,no
3559,2990596,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Adenocarcinoma, Pathology,16,1,3,no
3559,2990596,Table 1,BaselineCharacteristic,?Squamous cell carcinoma, ; ,?Squamous cell carcinoma, Pathology,17,0,2,no
3559,2990596,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?Squamous cell carcinoma, Pathology,17,1,3,no
3559,2990596,Table 1,BaselineCharacteristic,?Others, ; ,?Others, Pathology,18,0,2,no
3559,2990596,Table 1,BaselineCharacteristic,x,No. of patients ; ,?Others, Pathology,18,1,3,no
3559,2990596,Table 1,BaselineCharacteristic,, ; ,None,None,19,0,2,no
3559,2990596,Table 1,BaselineCharacteristic,,No. of patients ; ,None,None,19,1,3,no
3559,2990596,Table 1,BaselineCharacteristic,Clinical stage, ; ,None,None,20,0,24,no
3559,2990596,Table 1,BaselineCharacteristic,Clinical stage,No. of patients ; ,Clinical stage,None,20,1,43,no
3559,2990596,Table 1,BaselineCharacteristic,?IIIA, ; ,?IIIA, Clinical stage,21,0,2,no
3559,2990596,Table 1,BaselineCharacteristic,xx,No. of patients ; ,?IIIA, Clinical stage,21,1,3,no
3559,2990596,Table 1,BaselineCharacteristic,?IIIB, ; ,?IIIB, Clinical stage,22,0,2,no
3559,2990596,Table 1,BaselineCharacteristic,x,No. of patients ; ,?IIIB, Clinical stage,22,1,3,no
3566,2991028,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no
3566,2991028,Table 1,BaselineCharacteristic,,,,None,0,1,1,no
3566,2991028,Table 1,BaselineCharacteristic,AMG xxx,,,None,0,2,1,no
3566,2991028,Table 1,BaselineCharacteristic,AMG xxx,,,None,0,3,1,no
3566,2991028,Table 1,BaselineCharacteristic,AMG xxx,,,None,0,4,1,no
3566,2991028,Table 1,BaselineCharacteristic,AMG xxx,,,None,0,5,1,no
3566,2991028,Table 1,BaselineCharacteristic,, ; ,None,None,1,0,12,no
3566,2991028,Table 1,BaselineCharacteristic,, ; ,,None,1,1,1,no
3566,2991028,Table 1,BaselineCharacteristic,,AMG xxx ; ,,None,1,2,1,no
3566,2991028,Table 1,BaselineCharacteristic,,AMG xxx ; ,,None,1,3,1,no
3566,2991028,Table 1,BaselineCharacteristic,,AMG xxx ; ,,None,1,4,1,no
3566,2991028,Table 1,BaselineCharacteristic,,AMG xxx ; ,,None,1,5,1,no
3566,2991028,Table 1,BaselineCharacteristic,, ;  ; ,None,None,2,0,12,no
3566,2991028,Table 1,BaselineCharacteristic,Placebo(n = xxx), ;  ; ,,None,2,1,1,no
3566,2991028,Table 1,BaselineCharacteristic,xx mg(n = xxx),AMG xxx ;  ; ,,None,2,2,1,no
3566,2991028,Table 1,BaselineCharacteristic,xxx mg(n = xxx),AMG xxx ;  ; ,,None,2,3,1,no
3566,2991028,Table 1,BaselineCharacteristic,xxx mg(n = xxx),AMG xxx ;  ; ,,None,2,4,1,no
3566,2991028,Table 1,BaselineCharacteristic,Total(n = xxx),AMG xxx ;  ; ,,None,2,5,1,no
3566,2991028,Table 1,BaselineCharacteristic,Mean age (years), ;  ;  ; ,Mean age (years),,3,0,2,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x, ;  ; Placebo(n = xxx) ; ,Mean age (years),,3,1,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xx mg(n = xxx) ; ,Mean age (years),,3,2,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean age (years),,3,3,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean age (years),,3,4,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; Total(n = xxx) ; ,Mean age (years),,3,5,3,no
3566,2991028,Table 1,BaselineCharacteristic,"Age group, n (%)", ;  ;  ; ,None,None,4,0,24,no
3566,2991028,Table 1,BaselineCharacteristic,, ;  ; Placebo(n = xxx) ; ,"Age group, n (%)",None,4,1,43,no
3566,2991028,Table 1,BaselineCharacteristic,,AMG xxx ;  ; xx mg(n = xxx) ; ,"Age group, n (%)",None,4,2,43,no
3566,2991028,Table 1,BaselineCharacteristic,,AMG xxx ;  ; xxx mg(n = xxx) ; ,"Age group, n (%)",None,4,3,43,no
3566,2991028,Table 1,BaselineCharacteristic,,AMG xxx ;  ; xxx mg(n = xxx) ; ,"Age group, n (%)",None,4,4,43,no
3566,2991028,Table 1,BaselineCharacteristic,,AMG xxx ;  ; Total(n = xxx) ; ,"Age group, n (%)",None,4,5,43,no
3566,2991028,Table 1,BaselineCharacteristic,?< xx years, ;  ;  ; ,?< xx years," Age group, n (%)",5,0,2,no
3566,2991028,Table 1,BaselineCharacteristic,xxx (xx.x), ;  ; Placebo(n = xxx) ; ,?< xx years," Age group, n (%)",5,1,3,no
3566,2991028,Table 1,BaselineCharacteristic,xxx (xx.x),AMG xxx ;  ; xx mg(n = xxx) ; ,?< xx years," Age group, n (%)",5,2,3,no
3566,2991028,Table 1,BaselineCharacteristic,xxx (xx.x),AMG xxx ;  ; xxx mg(n = xxx) ; ,?< xx years," Age group, n (%)",5,3,3,no
3566,2991028,Table 1,BaselineCharacteristic,xxx (xx.x),AMG xxx ;  ; xxx mg(n = xxx) ; ,?< xx years," Age group, n (%)",5,4,3,no
3566,2991028,Table 1,BaselineCharacteristic,xxx (xx.x),AMG xxx ;  ; Total(n = xxx) ; ,?< xx years," Age group, n (%)",5,5,3,no
3566,2991028,Table 1,BaselineCharacteristic,??xx years, ;  ;  ; ,??xx years," Age group, n (%)",6,0,2,no
3566,2991028,Table 1,BaselineCharacteristic,xx (x.x), ;  ; Placebo(n = xxx) ; ,??xx years," Age group, n (%)",6,1,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx (xx.x),AMG xxx ;  ; xx mg(n = xxx) ; ,??xx years," Age group, n (%)",6,2,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx (xx.x),AMG xxx ;  ; xxx mg(n = xxx) ; ,??xx years," Age group, n (%)",6,3,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx (x.x),AMG xxx ;  ; xxx mg(n = xxx) ; ,??xx years," Age group, n (%)",6,4,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx (xx.x),AMG xxx ;  ; Total(n = xxx) ; ,??xx years," Age group, n (%)",6,5,3,no
3566,2991028,Table 1,BaselineCharacteristic,"Female, n (%)", ;  ;  ; ,"Female, n (%)",,7,0,2,no
3566,2991028,Table 1,BaselineCharacteristic,xxx (xx.x), ;  ; Placebo(n = xxx) ; ,"Female, n (%)",,7,1,3,yes
3566,2991028,Table 1,BaselineCharacteristic,xxx (xx.x),AMG xxx ;  ; xx mg(n = xxx) ; ,"Female, n (%)",,7,2,3,yes
3566,2991028,Table 1,BaselineCharacteristic,xxx (xx.x),AMG xxx ;  ; xxx mg(n = xxx) ; ,"Female, n (%)",,7,3,3,yes
3566,2991028,Table 1,BaselineCharacteristic,xxx (xx.x),AMG xxx ;  ; xxx mg(n = xxx) ; ,"Female, n (%)",,7,4,3,yes
3566,2991028,Table 1,BaselineCharacteristic,xxx (xx.x),AMG xxx ;  ; Total(n = xxx) ; ,"Female, n (%)",,7,5,3,yes
3566,2991028,Table 1,BaselineCharacteristic,"Ethnicity, n (%)", ;  ;  ; ,None,None,8,0,24,no
3566,2991028,Table 1,BaselineCharacteristic,, ;  ; Placebo(n = xxx) ; ,"Ethnicity, n (%)",None,8,1,43,no
3566,2991028,Table 1,BaselineCharacteristic,,AMG xxx ;  ; xx mg(n = xxx) ; ,"Ethnicity, n (%)",None,8,2,43,no
3566,2991028,Table 1,BaselineCharacteristic,,AMG xxx ;  ; xxx mg(n = xxx) ; ,"Ethnicity, n (%)",None,8,3,43,no
3566,2991028,Table 1,BaselineCharacteristic,,AMG xxx ;  ; xxx mg(n = xxx) ; ,"Ethnicity, n (%)",None,8,4,43,no
3566,2991028,Table 1,BaselineCharacteristic,,AMG xxx ;  ; Total(n = xxx) ; ,"Ethnicity, n (%)",None,8,5,43,no
3566,2991028,Table 1,BaselineCharacteristic,?White, ;  ;  ; ,?White," Ethnicity, n (%)",9,0,2,no
3566,2991028,Table 1,BaselineCharacteristic,xxx (xx.x), ;  ; Placebo(n = xxx) ; ,?White," Ethnicity, n (%)",9,1,3,no
3566,2991028,Table 1,BaselineCharacteristic,xxx (xx.x),AMG xxx ;  ; xx mg(n = xxx) ; ,?White," Ethnicity, n (%)",9,2,3,no
3566,2991028,Table 1,BaselineCharacteristic,xxx (xx.x),AMG xxx ;  ; xxx mg(n = xxx) ; ,?White," Ethnicity, n (%)",9,3,3,no
3566,2991028,Table 1,BaselineCharacteristic,xxx (xx.x),AMG xxx ;  ; xxx mg(n = xxx) ; ,?White," Ethnicity, n (%)",9,4,3,no
3566,2991028,Table 1,BaselineCharacteristic,xxx (xx.x),AMG xxx ;  ; Total(n = xxx) ; ,?White," Ethnicity, n (%)",9,5,3,no
3566,2991028,Table 1,BaselineCharacteristic,?Hispanic, ;  ;  ; ,?Hispanic," Ethnicity, n (%)",10,0,2,no
3566,2991028,Table 1,BaselineCharacteristic,xx (xx.x), ;  ; Placebo(n = xxx) ; ,?Hispanic," Ethnicity, n (%)",10,1,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx (xx.x),AMG xxx ;  ; xx mg(n = xxx) ; ,?Hispanic," Ethnicity, n (%)",10,2,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx (x.x),AMG xxx ;  ; xxx mg(n = xxx) ; ,?Hispanic," Ethnicity, n (%)",10,3,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx (x.x),AMG xxx ;  ; xxx mg(n = xxx) ; ,?Hispanic," Ethnicity, n (%)",10,4,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx (x.x),AMG xxx ;  ; Total(n = xxx) ; ,?Hispanic," Ethnicity, n (%)",10,5,3,no
3566,2991028,Table 1,BaselineCharacteristic,?Othera, ;  ;  ; ,?Othera," Ethnicity, n (%)",11,0,2,no
3566,2991028,Table 1,BaselineCharacteristic,x (x.x), ;  ; Placebo(n = xxx) ; ,?Othera," Ethnicity, n (%)",11,1,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx (x.x),AMG xxx ;  ; xx mg(n = xxx) ; ,?Othera," Ethnicity, n (%)",11,2,3,no
3566,2991028,Table 1,BaselineCharacteristic,x (x.x),AMG xxx ;  ; xxx mg(n = xxx) ; ,?Othera," Ethnicity, n (%)",11,3,3,no
3566,2991028,Table 1,BaselineCharacteristic,x (x.x),AMG xxx ;  ; xxx mg(n = xxx) ; ,?Othera," Ethnicity, n (%)",11,4,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx (x.x),AMG xxx ;  ; Total(n = xxx) ; ,?Othera," Ethnicity, n (%)",11,5,3,no
3566,2991028,Table 1,BaselineCharacteristic,Mean weight (kg), ;  ;  ; ,Mean weight (kg),,12,0,2,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x, ;  ; Placebo(n = xxx) ; ,Mean weight (kg),,12,1,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xx mg(n = xxx) ; ,Mean weight (kg),,12,2,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean weight (kg),,12,3,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean weight (kg),,12,4,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; Total(n = xxx) ; ,Mean weight (kg),,12,5,3,no
3566,2991028,Table 1,BaselineCharacteristic,Mean height (cm), ;  ;  ; ,Mean height (cm),,13,0,2,no
3566,2991028,Table 1,BaselineCharacteristic,xxx.x, ;  ; Placebo(n = xxx) ; ,Mean height (cm),,13,1,3,no
3566,2991028,Table 1,BaselineCharacteristic,xxx.x,AMG xxx ;  ; xx mg(n = xxx) ; ,Mean height (cm),,13,2,3,no
3566,2991028,Table 1,BaselineCharacteristic,xxx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean height (cm),,13,3,3,no
3566,2991028,Table 1,BaselineCharacteristic,xxx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean height (cm),,13,4,3,no
3566,2991028,Table 1,BaselineCharacteristic,xxx.x,AMG xxx ;  ; Total(n = xxx) ; ,Mean height (cm),,13,5,3,no
3566,2991028,Table 1,BaselineCharacteristic,Mean body mass index (kg/mx), ;  ;  ; ,Mean body mass index (kg/mx),,14,0,2,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x, ;  ; Placebo(n = xxx) ; ,Mean body mass index (kg/mx),,14,1,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xx mg(n = xxx) ; ,Mean body mass index (kg/mx),,14,2,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean body mass index (kg/mx),,14,3,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean body mass index (kg/mx),,14,4,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; Total(n = xxx) ; ,Mean body mass index (kg/mx),,14,5,3,no
3566,2991028,Table 1,BaselineCharacteristic,Mean duration of RA (years), ;  ;  ; ,Mean duration of RA (years),,15,0,2,no
3566,2991028,Table 1,BaselineCharacteristic,x.x, ;  ; Placebo(n = xxx) ; ,Mean duration of RA (years),,15,1,3,no
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xx mg(n = xxx) ; ,Mean duration of RA (years),,15,2,3,no
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean duration of RA (years),,15,3,3,no
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean duration of RA (years),,15,4,3,no
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; Total(n = xxx) ; ,Mean duration of RA (years),,15,5,3,no
3566,2991028,Table 1,BaselineCharacteristic,Subcomponent of ACR (mean), ;  ;  ; ,None,None,16,0,24,no
3566,2991028,Table 1,BaselineCharacteristic,, ;  ; Placebo(n = xxx) ; ,Subcomponent of ACR (mean),None,16,1,43,no
3566,2991028,Table 1,BaselineCharacteristic,,AMG xxx ;  ; xx mg(n = xxx) ; ,Subcomponent of ACR (mean),None,16,2,43,no
3566,2991028,Table 1,BaselineCharacteristic,,AMG xxx ;  ; xxx mg(n = xxx) ; ,Subcomponent of ACR (mean),None,16,3,43,no
3566,2991028,Table 1,BaselineCharacteristic,,AMG xxx ;  ; xxx mg(n = xxx) ; ,Subcomponent of ACR (mean),None,16,4,43,no
3566,2991028,Table 1,BaselineCharacteristic,,AMG xxx ;  ; Total(n = xxx) ; ,Subcomponent of ACR (mean),None,16,5,43,no
3566,2991028,Table 1,BaselineCharacteristic,?Tender joint count, ;  ;  ; ,?Tender joint count, Subcomponent of ACR (mean),17,0,2,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x, ;  ; Placebo(n = xxx) ; ,?Tender joint count, Subcomponent of ACR (mean),17,1,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xx mg(n = xxx) ; ,?Tender joint count, Subcomponent of ACR (mean),17,2,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,?Tender joint count, Subcomponent of ACR (mean),17,3,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,?Tender joint count, Subcomponent of ACR (mean),17,4,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; Total(n = xxx) ; ,?Tender joint count, Subcomponent of ACR (mean),17,5,3,no
3566,2991028,Table 1,BaselineCharacteristic,?Swollen joint count, ;  ;  ; ,?Swollen joint count, Subcomponent of ACR (mean),18,0,2,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x, ;  ; Placebo(n = xxx) ; ,?Swollen joint count, Subcomponent of ACR (mean),18,1,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xx mg(n = xxx) ; ,?Swollen joint count, Subcomponent of ACR (mean),18,2,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,?Swollen joint count, Subcomponent of ACR (mean),18,3,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,?Swollen joint count, Subcomponent of ACR (mean),18,4,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; Total(n = xxx) ; ,?Swollen joint count, Subcomponent of ACR (mean),18,5,3,no
3566,2991028,Table 1,BaselineCharacteristic,?Patient global assessment, ;  ;  ; ,?Patient global assessment, Subcomponent of ACR (mean),19,0,2,no
3566,2991028,Table 1,BaselineCharacteristic,x.x, ;  ; Placebo(n = xxx) ; ,?Patient global assessment, Subcomponent of ACR (mean),19,1,3,no
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xx mg(n = xxx) ; ,?Patient global assessment, Subcomponent of ACR (mean),19,2,3,no
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,?Patient global assessment, Subcomponent of ACR (mean),19,3,3,no
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,?Patient global assessment, Subcomponent of ACR (mean),19,4,3,no
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; Total(n = xxx) ; ,?Patient global assessment, Subcomponent of ACR (mean),19,5,3,no
3566,2991028,Table 1,BaselineCharacteristic,?Physician global assessment, ;  ;  ; ,?Physician global assessment, Subcomponent of ACR (mean),20,0,2,no
3566,2991028,Table 1,BaselineCharacteristic,x.x, ;  ; Placebo(n = xxx) ; ,?Physician global assessment, Subcomponent of ACR (mean),20,1,3,no
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xx mg(n = xxx) ; ,?Physician global assessment, Subcomponent of ACR (mean),20,2,3,no
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,?Physician global assessment, Subcomponent of ACR (mean),20,3,3,no
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,?Physician global assessment, Subcomponent of ACR (mean),20,4,3,no
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; Total(n = xxx) ; ,?Physician global assessment, Subcomponent of ACR (mean),20,5,3,no
3566,2991028,Table 1,BaselineCharacteristic,?Patient pain assessment, ;  ;  ; ,?Patient pain assessment, Subcomponent of ACR (mean),21,0,2,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x, ;  ; Placebo(n = xxx) ; ,?Patient pain assessment, Subcomponent of ACR (mean),21,1,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xx mg(n = xxx) ; ,?Patient pain assessment, Subcomponent of ACR (mean),21,2,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,?Patient pain assessment, Subcomponent of ACR (mean),21,3,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,?Patient pain assessment, Subcomponent of ACR (mean),21,4,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; Total(n = xxx) ; ,?Patient pain assessment, Subcomponent of ACR (mean),21,5,3,no
3566,2991028,Table 1,BaselineCharacteristic,HAQ Disability Index, ;  ;  ; ,HAQ Disability Index,,22,0,2,no
3566,2991028,Table 1,BaselineCharacteristic,x.x, ;  ; Placebo(n = xxx) ; ,HAQ Disability Index,,22,1,3,no
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xx mg(n = xxx) ; ,HAQ Disability Index,,22,2,3,no
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,HAQ Disability Index,,22,3,3,no
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,HAQ Disability Index,,22,4,3,no
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; Total(n = xxx) ; ,HAQ Disability Index,,22,5,3,no
3566,2991028,Table 1,BaselineCharacteristic,C-reactive protein (mg/dl), ;  ;  ; ,C-reactive protein (mg/dl),,23,0,2,no
3566,2991028,Table 1,BaselineCharacteristic,x.x, ;  ; Placebo(n = xxx) ; ,C-reactive protein (mg/dl),,23,1,3,no
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xx mg(n = xxx) ; ,C-reactive protein (mg/dl),,23,2,3,no
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,C-reactive protein (mg/dl),,23,3,3,no
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,C-reactive protein (mg/dl),,23,4,3,no
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; Total(n = xxx) ; ,C-reactive protein (mg/dl),,23,5,3,no
3566,2991028,Table 1,BaselineCharacteristic,ESR (mm/hour), ;  ;  ; ,ESR (mm/hour),,24,0,2,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x, ;  ; Placebo(n = xxx) ; ,ESR (mm/hour),,24,1,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xx mg(n = xxx) ; ,ESR (mm/hour),,24,2,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,ESR (mm/hour),,24,3,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,ESR (mm/hour),,24,4,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; Total(n = xxx) ; ,ESR (mm/hour),,24,5,3,no
3566,2991028,Table 1,BaselineCharacteristic,Mean DASxx CRP, ;  ;  ; ,Mean DASxx CRP,,25,0,2,no
3566,2991028,Table 1,BaselineCharacteristic,x.x, ;  ; Placebo(n = xxx) ; ,Mean DASxx CRP,,25,1,3,no
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xx mg(n = xxx) ; ,Mean DASxx CRP,,25,2,3,no
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean DASxx CRP,,25,3,3,no
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean DASxx CRP,,25,4,3,no
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; Total(n = xxx) ; ,Mean DASxx CRP,,25,5,3,no
3566,2991028,Table 1,BaselineCharacteristic,Mean DASxx ESR, ;  ;  ; ,Mean DASxx ESR,,26,0,2,no
3566,2991028,Table 1,BaselineCharacteristic,x.x, ;  ; Placebo(n = xxx) ; ,Mean DASxx ESR,,26,1,3,no
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xx mg(n = xxx) ; ,Mean DASxx ESR,,26,2,3,no
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean DASxx ESR,,26,3,3,no
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean DASxx ESR,,26,4,3,no
3566,2991028,Table 1,BaselineCharacteristic,x.x,AMG xxx ;  ; Total(n = xxx) ; ,Mean DASxx ESR,,26,5,3,no
3566,2991028,Table 1,BaselineCharacteristic,Mean tender joint count (xx joints), ;  ;  ; ,Mean tender joint count (xx joints),,27,0,2,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x, ;  ; Placebo(n = xxx) ; ,Mean tender joint count (xx joints),,27,1,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xx mg(n = xxx) ; ,Mean tender joint count (xx joints),,27,2,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean tender joint count (xx joints),,27,3,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean tender joint count (xx joints),,27,4,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; Total(n = xxx) ; ,Mean tender joint count (xx joints),,27,5,3,no
3566,2991028,Table 1,BaselineCharacteristic,Mean swollen joint count (xx joints), ;  ;  ; ,Mean swollen joint count (xx joints),,28,0,2,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x, ;  ; Placebo(n = xxx) ; ,Mean swollen joint count (xx joints),,28,1,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xx mg(n = xxx) ; ,Mean swollen joint count (xx joints),,28,2,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean swollen joint count (xx joints),,28,3,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; xxx mg(n = xxx) ; ,Mean swollen joint count (xx joints),,28,4,3,no
3566,2991028,Table 1,BaselineCharacteristic,xx.x,AMG xxx ;  ; Total(n = xxx) ; ,Mean swollen joint count (xx joints),,28,5,3,no
3596,3001966,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,0,12,no
3596,3001966,Table 1,BaselineCharacteristic,Celecoxib group (n = xxx),,Characteristic,None,0,1,1,no
3596,3001966,Table 1,BaselineCharacteristic,Placebo group (n = xxx),,Characteristic,None,0,2,1,no
3596,3001966,Table 1,BaselineCharacteristic,P*,,Characteristic,None,0,3,1,no
3596,3001966,Table 1,BaselineCharacteristic,"Age, y",Characteristic ; ,None,None,1,0,24,no
3596,3001966,Table 1,BaselineCharacteristic,,Celecoxib group (n = xxx) ; ,"Age, y",None,1,1,43,no
3596,3001966,Table 1,BaselineCharacteristic,,Placebo group (n = xxx) ; ,"Age, y",None,1,2,43,no
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,"Age, y",None,1,3,43,no
3596,3001966,Table 1,BaselineCharacteristic,????Mean (SD),Characteristic ; ,????Mean (SD)," Age, y   ",2,0,2,no
3596,3001966,Table 1,BaselineCharacteristic,xx.x (x.x),Celecoxib group (n = xxx) ; ,????Mean (SD)," Age, y   ",2,1,3,no
3596,3001966,Table 1,BaselineCharacteristic,xx.x (xx.x),Placebo group (n = xxx) ; ,????Mean (SD)," Age, y   ",2,2,3,no
3596,3001966,Table 1,BaselineCharacteristic,.xx,P* ; ,????Mean (SD)," Age, y   ",2,3,3,no
3596,3001966,Table 1,BaselineCharacteristic,????Median (range),Characteristic ; ,????Median (range)," Age, y   ",3,0,2,no
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,????Median (range)," Age, y   ",3,3,3,no
3596,3001966,Table 1,BaselineCharacteristic,"Sex, No. (%)",Characteristic ; ,None,None,4,0,24,no
3596,3001966,Table 1,BaselineCharacteristic,,Celecoxib group (n = xxx) ; ,"Sex, No. (%)",None,4,1,43,no
3596,3001966,Table 1,BaselineCharacteristic,,Placebo group (n = xxx) ; ,"Sex, No. (%)",None,4,2,43,no
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,"Sex, No. (%)",None,4,3,43,no
3596,3001966,Table 1,BaselineCharacteristic,????Male,Characteristic ; ,????Male," Sex, No. (%)   ",5,0,2,no
3596,3001966,Table 1,BaselineCharacteristic,xxx (xx),Celecoxib group (n = xxx) ; ,????Male," Sex, No. (%)   ",5,1,3,yes
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Placebo group (n = xxx) ; ,????Male," Sex, No. (%)   ",5,2,3,yes
3596,3001966,Table 1,BaselineCharacteristic,.xx,P* ; ,????Male," Sex, No. (%)   ",5,3,3,no
3596,3001966,Table 1,BaselineCharacteristic,????Female,Characteristic ; ,????Female," Sex, No. (%)   ",6,0,2,no
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Celecoxib group (n = xxx) ; ,????Female," Sex, No. (%)   ",6,1,3,yes
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Placebo group (n = xxx) ; ,????Female," Sex, No. (%)   ",6,2,3,yes
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,????Female," Sex, No. (%)   ",6,3,3,no
3596,3001966,Table 1,BaselineCharacteristic,"Race, No. (%)",Characteristic ; ,None,None,7,0,24,no
3596,3001966,Table 1,BaselineCharacteristic,,Celecoxib group (n = xxx) ; ,"Race, No. (%)",None,7,1,43,no
3596,3001966,Table 1,BaselineCharacteristic,,Placebo group (n = xxx) ; ,"Race, No. (%)",None,7,2,43,no
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,"Race, No. (%)",None,7,3,43,no
3596,3001966,Table 1,BaselineCharacteristic,????White,Characteristic ; ,????White," Race, No. (%)   ",8,0,2,no
3596,3001966,Table 1,BaselineCharacteristic,xxx (xx),Celecoxib group (n = xxx) ; ,????White," Race, No. (%)   ",8,1,3,no
3596,3001966,Table 1,BaselineCharacteristic,xxx (xxx),Placebo group (n = xxx) ; ,????White," Race, No. (%)   ",8,2,3,no
3596,3001966,Table 1,BaselineCharacteristic,x.xx,P* ; ,????White," Race, No. (%)   ",8,3,3,no
3596,3001966,Table 1,BaselineCharacteristic,????Other,Characteristic ; ,????Other," Race, No. (%)   ",9,0,2,no
3596,3001966,Table 1,BaselineCharacteristic,x ( x),Celecoxib group (n = xxx) ; ,????Other," Race, No. (%)   ",9,1,3,no
3596,3001966,Table 1,BaselineCharacteristic,x (x),Placebo group (n = xxx) ; ,????Other," Race, No. (%)   ",9,2,3,no
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,????Other," Race, No. (%)   ",9,3,3,no
3596,3001966,Table 1,BaselineCharacteristic,"Fitzpatrick skin type, No. (%)",Characteristic ; ,None,None,10,0,24,no
3596,3001966,Table 1,BaselineCharacteristic,,Celecoxib group (n = xxx) ; ,"Fitzpatrick skin type, No. (%)",None,10,1,43,no
3596,3001966,Table 1,BaselineCharacteristic,,Placebo group (n = xxx) ; ,"Fitzpatrick skin type, No. (%)",None,10,2,43,no
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,"Fitzpatrick skin type, No. (%)",None,10,3,43,no
3596,3001966,Table 1,BaselineCharacteristic,????I,Characteristic ; ,????I," Fitzpatrick skin type, No. (%)   ",11,0,2,no
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Celecoxib group (n = xxx) ; ,????I," Fitzpatrick skin type, No. (%)   ",11,1,3,no
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Placebo group (n = xxx) ; ,????I," Fitzpatrick skin type, No. (%)   ",11,2,3,no
3596,3001966,Table 1,BaselineCharacteristic,.xx,P* ; ,????I," Fitzpatrick skin type, No. (%)   ",11,3,3,no
3596,3001966,Table 1,BaselineCharacteristic,????II,Characteristic ; ,????II," Fitzpatrick skin type, No. (%)   ",12,0,2,no
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Celecoxib group (n = xxx) ; ,????II," Fitzpatrick skin type, No. (%)   ",12,1,3,no
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Placebo group (n = xxx) ; ,????II," Fitzpatrick skin type, No. (%)   ",12,2,3,no
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,????II," Fitzpatrick skin type, No. (%)   ",12,3,3,no
3596,3001966,Table 1,BaselineCharacteristic,????III,Characteristic ; ,????III," Fitzpatrick skin type, No. (%)   ",13,0,2,no
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Celecoxib group (n = xxx) ; ,????III," Fitzpatrick skin type, No. (%)   ",13,1,3,no
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Placebo group (n = xxx) ; ,????III," Fitzpatrick skin type, No. (%)   ",13,2,3,no
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,????III," Fitzpatrick skin type, No. (%)   ",13,3,3,no
3596,3001966,Table 1,BaselineCharacteristic,Number of actinic keratoses at screening,Characteristic ; ,None,None,14,0,24,no
3596,3001966,Table 1,BaselineCharacteristic,,Celecoxib group (n = xxx) ; ,Number of actinic keratoses at screening,None,14,1,43,no
3596,3001966,Table 1,BaselineCharacteristic,,Placebo group (n = xxx) ; ,Number of actinic keratoses at screening,None,14,2,43,no
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,Number of actinic keratoses at screening,None,14,3,43,no
3596,3001966,Table 1,BaselineCharacteristic,????Mean (SD),Characteristic ; ,????Mean (SD), Number of actinic keratoses at screening   ,15,0,2,no
3596,3001966,Table 1,BaselineCharacteristic,xx.x (x.x),Celecoxib group (n = xxx) ; ,????Mean (SD), Number of actinic keratoses at screening   ,15,1,3,no
3596,3001966,Table 1,BaselineCharacteristic,xx.x (x.x),Placebo group (n = xxx) ; ,????Mean (SD), Number of actinic keratoses at screening   ,15,2,3,no
3596,3001966,Table 1,BaselineCharacteristic,.xx,P* ; ,????Mean (SD), Number of actinic keratoses at screening   ,15,3,3,no
3596,3001966,Table 1,BaselineCharacteristic,????Median (range),Characteristic ; ,????Median (range), Number of actinic keratoses at screening   ,16,0,2,no
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,????Median (range), Number of actinic keratoses at screening   ,16,3,3,no
3596,3001966,Table 1,BaselineCharacteristic,"History of skin cancer, No. (%)",Characteristic ; ,None,None,17,0,24,no
3596,3001966,Table 1,BaselineCharacteristic,,Celecoxib group (n = xxx) ; ,"History of skin cancer, No. (%)",None,17,1,43,no
3596,3001966,Table 1,BaselineCharacteristic,,Placebo group (n = xxx) ; ,"History of skin cancer, No. (%)",None,17,2,43,no
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,"History of skin cancer, No. (%)",None,17,3,43,no
3596,3001966,Table 1,BaselineCharacteristic,????Yes,Characteristic ; ,????Yes," History of skin cancer, No. (%)   ",18,0,2,no
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Celecoxib group (n = xxx) ; ,????Yes," History of skin cancer, No. (%)   ",18,1,3,no
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Placebo group (n = xxx) ; ,????Yes," History of skin cancer, No. (%)   ",18,2,3,no
3596,3001966,Table 1,BaselineCharacteristic,.xx,P* ; ,????Yes," History of skin cancer, No. (%)   ",18,3,3,no
3596,3001966,Table 1,BaselineCharacteristic,????No,Characteristic ; ,????No," History of skin cancer, No. (%)   ",19,0,2,no
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Celecoxib group (n = xxx) ; ,????No," History of skin cancer, No. (%)   ",19,1,3,no
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Placebo group (n = xxx) ; ,????No," History of skin cancer, No. (%)   ",19,2,3,no
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,????No," History of skin cancer, No. (%)   ",19,3,3,no
3596,3001966,Table 1,BaselineCharacteristic,"Total number of skin cancer diagnoses per patient before screening, No. (%)",Characteristic ; ,None,None,20,0,24,no
3596,3001966,Table 1,BaselineCharacteristic,,Celecoxib group (n = xxx) ; ,"Total number of skin cancer diagnoses per patient before screening, No. (%)",None,1,20,43,no
3596,3001966,Table 1,BaselineCharacteristic,,Placebo group (n = xxx) ; ,"Total number of skin cancer diagnoses per patient before screening, No. (%)",None,2,20,43,no
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,"Total number of skin cancer diagnoses per patient before screening, No. (%)",None,3,20,43,no
3596,3001966,Table 1,BaselineCharacteristic,????x,Characteristic ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",21,0,2,no
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Celecoxib group (n = xxx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",21,1,3,no
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Placebo group (n = xxx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",21,2,3,no
3596,3001966,Table 1,BaselineCharacteristic,.xx,P* ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",21,3,3,no
3596,3001966,Table 1,BaselineCharacteristic,????x,Characteristic ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",22,0,2,no
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Celecoxib group (n = xxx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",22,1,3,no
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Placebo group (n = xxx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",22,2,3,no
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",22,3,3,no
3596,3001966,Table 1,BaselineCharacteristic,????x,Characteristic ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",23,0,2,no
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Celecoxib group (n = xxx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",23,1,3,no
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Placebo group (n = xxx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",23,2,3,no
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",23,3,3,no
3596,3001966,Table 1,BaselineCharacteristic,????>x,Characteristic ; ,????>x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",24,0,2,no
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Celecoxib group (n = xxx) ; ,????>x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",24,1,3,no
3596,3001966,Table 1,BaselineCharacteristic,xx (xx),Placebo group (n = xxx) ; ,????>x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",24,2,3,no
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,????>x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",24,3,3,no
3596,3001966,Table 1,BaselineCharacteristic,????Mean (SD),Characteristic ; ,????Mean (SD)," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",25,0,2,no
3596,3001966,Table 1,BaselineCharacteristic,x.x (x.x),Celecoxib group (n = xxx) ; ,????Mean (SD)," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",25,1,3,no
3596,3001966,Table 1,BaselineCharacteristic,x.x (x.x),Placebo group (n = xxx) ; ,????Mean (SD)," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",25,2,3,no
3596,3001966,Table 1,BaselineCharacteristic,.xx,P* ; ,????Mean (SD)," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",25,3,3,no
3596,3001966,Table 1,BaselineCharacteristic,????Median (range),Characteristic ; ,????Median (range)," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",26,0,2,no
3596,3001966,Table 1,BaselineCharacteristic,,P* ; ,????Median (range)," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",26,3,3,no
3596,3001966,Table 4,BaselineCharacteristic,,,None,None,0,0,12,no
3596,3001966,Table 4,BaselineCharacteristic,Celecoxib group,,,None,0,1,1,no
3596,3001966,Table 4,BaselineCharacteristic,Celecoxib group,,,None,0,2,1,no
3596,3001966,Table 4,BaselineCharacteristic,Celecoxib group,,,None,0,3,1,no
3596,3001966,Table 4,BaselineCharacteristic,Placebo group,,,None,0,4,1,no
3596,3001966,Table 4,BaselineCharacteristic,Placebo group,,,None,0,5,1,no
3596,3001966,Table 4,BaselineCharacteristic,Placebo group,,,None,0,6,1,no
3596,3001966,Table 4,BaselineCharacteristic,Characteristic, ; ,None,None,1,0,12,no
3596,3001966,Table 4,BaselineCharacteristic,Withdrew (n = xx),Celecoxib group ; ,Characteristic,None,1,1,1,no
3596,3001966,Table 4,BaselineCharacteristic,Completed (n = xx),Celecoxib group ; ,Characteristic,None,1,2,1,no
3596,3001966,Table 4,BaselineCharacteristic,P,Celecoxib group ; ,Characteristic,None,1,3,1,no
3596,3001966,Table 4,BaselineCharacteristic,Withdrew (n = xx),Placebo group ; ,Characteristic,None,1,4,1,no
3596,3001966,Table 4,BaselineCharacteristic,Completed (n = xx),Placebo group ; ,Characteristic,None,1,5,1,no
3596,3001966,Table 4,BaselineCharacteristic,P,Placebo group ; ,Characteristic,None,1,6,1,no
3596,3001966,Table 4,BaselineCharacteristic,"Age, y", ; Characteristic ; ,None,None,2,0,24,no
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; Withdrew (n = xx) ; ,"Age, y",None,2,1,43,no
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; Completed (n = xx) ; ,"Age, y",None,2,2,43,no
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,"Age, y",None,2,3,43,no
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; Withdrew (n = xx) ; ,"Age, y",None,2,4,43,no
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; Completed (n = xx) ; ,"Age, y",None,2,5,43,no
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,"Age, y",None,2,6,43,no
3596,3001966,Table 4,BaselineCharacteristic,????Mean (SD), ; Characteristic ; ,????Mean (SD)," Age, y   ",3,0,2,no
3596,3001966,Table 4,BaselineCharacteristic,xx.x (xx.x),Celecoxib group ; Withdrew (n = xx) ; ,????Mean (SD)," Age, y   ",3,1,3,no
3596,3001966,Table 4,BaselineCharacteristic,xx.x (x.x),Celecoxib group ; Completed (n = xx) ; ,????Mean (SD)," Age, y   ",3,2,3,no
3596,3001966,Table 4,BaselineCharacteristic,.xx,Celecoxib group ; P ; ,????Mean (SD)," Age, y   ",3,3,3,no
3596,3001966,Table 4,BaselineCharacteristic,xx.x (x.x),Placebo group ; Withdrew (n = xx) ; ,????Mean (SD)," Age, y   ",3,4,3,no
3596,3001966,Table 4,BaselineCharacteristic,xx.x (xx.x),Placebo group ; Completed (n = xx) ; ,????Mean (SD)," Age, y   ",3,5,3,no
3596,3001966,Table 4,BaselineCharacteristic,.xx,Placebo group ; P ; ,????Mean (SD)," Age, y   ",3,6,3,no
3596,3001966,Table 4,BaselineCharacteristic,????Median (range), ; Characteristic ; ,????Median (range)," Age, y   ",4,0,2,no
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,????Median (range)," Age, y   ",4,3,3,no
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,????Median (range)," Age, y   ",4,6,3,no
3596,3001966,Table 4,BaselineCharacteristic,"Sex, No. (%)", ; Characteristic ; ,None,None,5,0,24,no
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; Withdrew (n = xx) ; ,"Sex, No. (%)",None,5,1,43,no
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; Completed (n = xx) ; ,"Sex, No. (%)",None,5,2,43,no
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,"Sex, No. (%)",None,5,3,43,no
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; Withdrew (n = xx) ; ,"Sex, No. (%)",None,5,4,43,no
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; Completed (n = xx) ; ,"Sex, No. (%)",None,5,5,43,no
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,"Sex, No. (%)",None,5,6,43,no
3596,3001966,Table 4,BaselineCharacteristic,????Male, ; Characteristic ; ,????Male," Sex, No. (%)   ",6,0,2,no
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Withdrew (n = xx) ; ,????Male," Sex, No. (%)   ",6,1,3,yes
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Completed (n = xx) ; ,????Male," Sex, No. (%)   ",6,2,3,yes
3596,3001966,Table 4,BaselineCharacteristic,.xx,Celecoxib group ; P ; ,????Male," Sex, No. (%)   ",6,3,3,no
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Placebo group ; Withdrew (n = xx) ; ,????Male," Sex, No. (%)   ",6,4,3,yes
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Placebo group ; Completed (n = xx) ; ,????Male," Sex, No. (%)   ",6,5,3,yes
3596,3001966,Table 4,BaselineCharacteristic,.xx,Placebo group ; P ; ,????Male," Sex, No. (%)   ",6,6,3,no
3596,3001966,Table 4,BaselineCharacteristic,????Female, ; Characteristic ; ,????Female," Sex, No. (%)   ",7,0,2,yes
3596,3001966,Table 4,BaselineCharacteristic,x (xx),Celecoxib group ; Withdrew (n = xx) ; ,????Female," Sex, No. (%)   ",7,1,3,yes
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Completed (n = xx) ; ,????Female," Sex, No. (%)   ",7,2,3,no
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,????Female," Sex, No. (%)   ",7,3,3,yes
3596,3001966,Table 4,BaselineCharacteristic,x (xx),Placebo group ; Withdrew (n = xx) ; ,????Female," Sex, No. (%)   ",7,4,3,yes
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Placebo group ; Completed (n = xx) ; ,????Female," Sex, No. (%)   ",7,5,3,no
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,????Female," Sex, No. (%)   ",7,6,3,no
3596,3001966,Table 4,BaselineCharacteristic,"Race, No. (%)", ; Characteristic ; ,None,None,8,0,24,no
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; Withdrew (n = xx) ; ,"Race, No. (%)",None,8,1,43,no
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; Completed (n = xx) ; ,"Race, No. (%)",None,8,2,43,no
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,"Race, No. (%)",None,8,3,43,no
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; Withdrew (n = xx) ; ,"Race, No. (%)",None,8,4,43,no
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; Completed (n = xx) ; ,"Race, No. (%)",None,8,5,43,no
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,"Race, No. (%)",None,8,6,43,no
3596,3001966,Table 4,BaselineCharacteristic,????White, ; Characteristic ; ,????White," Race, No. (%)   ",9,0,2,no
3596,3001966,Table 4,BaselineCharacteristic,xx (xxx),Celecoxib group ; Withdrew (n = xx) ; ,????White," Race, No. (%)   ",9,1,3,no
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Completed (n = xx) ; ,????White," Race, No. (%)   ",9,2,3,no
3596,3001966,Table 4,BaselineCharacteristic,x.xx,Celecoxib group ; P ; ,????White," Race, No. (%)   ",9,3,3,no
3596,3001966,Table 4,BaselineCharacteristic,xx (xxx),Placebo group ; Withdrew (n = xx) ; ,????White," Race, No. (%)   ",9,4,3,no
3596,3001966,Table 4,BaselineCharacteristic,xx (xxx),Placebo group ; Completed (n = xx) ; ,????White," Race, No. (%)   ",9,5,3,no
3596,3001966,Table 4,BaselineCharacteristic,????Other, ; Characteristic ; ,????Other," Race, No. (%)   ",10,0,2,no
3596,3001966,Table 4,BaselineCharacteristic,x,Celecoxib group ; Withdrew (n = xx) ; ,????Other," Race, No. (%)   ",10,1,3,no
3596,3001966,Table 4,BaselineCharacteristic,x (x),Celecoxib group ; Completed (n = xx) ; ,????Other," Race, No. (%)   ",10,2,3,no
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,????Other," Race, No. (%)   ",10,3,3,no
3596,3001966,Table 4,BaselineCharacteristic,x,Placebo group ; Withdrew (n = xx) ; ,????Other," Race, No. (%)   ",10,4,3,no
3596,3001966,Table 4,BaselineCharacteristic,x,Placebo group ; Completed (n = xx) ; ,????Other," Race, No. (%)   ",10,5,3,no
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,????Other," Race, No. (%)   ",10,6,3,no
3596,3001966,Table 4,BaselineCharacteristic,"Fitzpatrick skin type, No. (%)", ; Characteristic ; ,"Fitzpatrick skin type, No. (%)",,11,0,24,no
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; Withdrew (n = xx) ; ,"Fitzpatrick skin type, No. (%)",,11,1,43,no
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; Completed (n = xx) ; ,"Fitzpatrick skin type, No. (%)",,11,2,43,no
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,"Fitzpatrick skin type, No. (%)",,11,3,43,no
3596,3001966,Table 4,BaselineCharacteristic,x (xx),Placebo group ; Withdrew (n = xx) ; ,"Fitzpatrick skin type, No. (%)",,11,4,43,no
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Placebo group ; Completed (n = xx) ; ,"Fitzpatrick skin type, No. (%)",,11,5,43,no
3596,3001966,Table 4,BaselineCharacteristic,.xx,Placebo group ; P ; ,"Fitzpatrick skin type, No. (%)",,11,6,43,no
3596,3001966,Table 4,BaselineCharacteristic,????I, ; Characteristic ; ,????I," Fitzpatrick skin type, No. (%)   ",12,0,2,no
3596,3001966,Table 4,BaselineCharacteristic,x (xx),Celecoxib group ; Withdrew (n = xx) ; ,????I," Fitzpatrick skin type, No. (%)   ",12,1,3,no
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Completed (n = xx) ; ,????I," Fitzpatrick skin type, No. (%)   ",12,2,3,no
3596,3001966,Table 4,BaselineCharacteristic,.xx,Celecoxib group ; P ; ,????I," Fitzpatrick skin type, No. (%)   ",12,3,3,no
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Placebo group ; Withdrew (n = xx) ; ,????I," Fitzpatrick skin type, No. (%)   ",12,4,3,no
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Placebo group ; Completed (n = xx) ; ,????I," Fitzpatrick skin type, No. (%)   ",12,5,3,no
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,????I," Fitzpatrick skin type, No. (%)   ",12,6,3,no
3596,3001966,Table 4,BaselineCharacteristic,????II, ; Characteristic ; ,????II," Fitzpatrick skin type, No. (%)   ",13,0,2,no
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Withdrew (n = xx) ; ,????II," Fitzpatrick skin type, No. (%)   ",13,1,3,no
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Completed (n = xx) ; ,????II," Fitzpatrick skin type, No. (%)   ",13,2,3,no
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,????II," Fitzpatrick skin type, No. (%)   ",13,3,3,no
3596,3001966,Table 4,BaselineCharacteristic,x (xx),Placebo group ; Withdrew (n = xx) ; ,????II," Fitzpatrick skin type, No. (%)   ",13,4,3,no
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Placebo group ; Completed (n = xx) ; ,????II," Fitzpatrick skin type, No. (%)   ",13,5,3,no
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,????II," Fitzpatrick skin type, No. (%)   ",13,6,3,no
3596,3001966,Table 4,BaselineCharacteristic,????III, ; Characteristic ; ,????III," Fitzpatrick skin type, No. (%)   ",14,0,2,no
3596,3001966,Table 4,BaselineCharacteristic,x (xx),Celecoxib group ; Withdrew (n = xx) ; ,????III," Fitzpatrick skin type, No. (%)   ",14,1,3,no
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Completed (n = xx) ; ,????III," Fitzpatrick skin type, No. (%)   ",14,2,3,no
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,????III," Fitzpatrick skin type, No. (%)   ",14,3,3,no
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; Withdrew (n = xx) ; ,????III," Fitzpatrick skin type, No. (%)   ",14,4,3,no
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; Completed (n = xx) ; ,????III," Fitzpatrick skin type, No. (%)   ",14,5,3,no
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,????III," Fitzpatrick skin type, No. (%)   ",14,6,3,no
3596,3001966,Table 4,BaselineCharacteristic,No. of actinic keratoses at screening, ; Characteristic ; ,None,None,15,0,24,no
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; Withdrew (n = xx) ; ,No. of actinic keratoses at screening,None,1,15,43,no
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; Completed (n = xx) ; ,No. of actinic keratoses at screening,None,2,15,43,no
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,No. of actinic keratoses at screening,None,3,15,43,no
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; Withdrew (n = xx) ; ,No. of actinic keratoses at screening,None,4,15,43,no
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; Completed (n = xx) ; ,No. of actinic keratoses at screening,None,5,15,43,no
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,No. of actinic keratoses at screening,None,6,15,43,no
3596,3001966,Table 4,BaselineCharacteristic,????Mean (SD), ; Characteristic ; ,????Mean (SD), No. of actinic keratoses at screening   ,16,0,2,no
3596,3001966,Table 4,BaselineCharacteristic,xx.x (x.x),Celecoxib group ; Withdrew (n = xx) ; ,????Mean (SD), No. of actinic keratoses at screening   ,16,1,3,no
3596,3001966,Table 4,BaselineCharacteristic,xx.x (x.x),Celecoxib group ; Completed (n = xx) ; ,????Mean (SD), No. of actinic keratoses at screening   ,16,2,3,no
3596,3001966,Table 4,BaselineCharacteristic,.xx,Celecoxib group ; P ; ,????Mean (SD), No. of actinic keratoses at screening   ,16,3,3,no
3596,3001966,Table 4,BaselineCharacteristic,xx.x (x.x),Placebo group ; Withdrew (n = xx) ; ,????Mean (SD), No. of actinic keratoses at screening   ,16,4,3,no
3596,3001966,Table 4,BaselineCharacteristic,xx.x (x.x),Placebo group ; Completed (n = xx) ; ,????Mean (SD), No. of actinic keratoses at screening   ,16,5,3,no
3596,3001966,Table 4,BaselineCharacteristic,x.xx,Placebo group ; P ; ,????Mean (SD), No. of actinic keratoses at screening   ,16,6,3,no
3596,3001966,Table 4,BaselineCharacteristic,????Median (range), ; Characteristic ; ,????Median (range), No. of actinic keratoses at screening   ,17,0,2,no
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,????Median (range), No. of actinic keratoses at screening   ,17,3,3,no
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,????Median (range), No. of actinic keratoses at screening   ,17,6,3,no
3596,3001966,Table 4,BaselineCharacteristic,"History of skin cancer, No. (%)", ; Characteristic ; ,None,None,18,0,24,no
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; Withdrew (n = xx) ; ,"History of skin cancer, No. (%)",None,18,1,43,no
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; Completed (n = xx) ; ,"History of skin cancer, No. (%)",None,18,2,43,no
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,"History of skin cancer, No. (%)",None,18,3,43,no
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; Withdrew (n = xx) ; ,"History of skin cancer, No. (%)",None,18,4,43,no
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; Completed (n = xx) ; ,"History of skin cancer, No. (%)",None,18,5,43,no
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,"History of skin cancer, No. (%)",None,18,6,43,no
3596,3001966,Table 4,BaselineCharacteristic,????Yes, ; Characteristic ; ,????Yes," History of skin cancer, No. (%)   ",19,0,2,no
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Withdrew (n = xx) ; ,????Yes," History of skin cancer, No. (%)   ",19,1,3,no
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Completed (n = xx) ; ,????Yes," History of skin cancer, No. (%)   ",19,2,3,no
3596,3001966,Table 4,BaselineCharacteristic,.xx,Celecoxib group ; P ; ,????Yes," History of skin cancer, No. (%)   ",19,3,3,no
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Placebo group ; Withdrew (n = xx) ; ,????Yes," History of skin cancer, No. (%)   ",19,4,3,no
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Placebo group ; Completed (n = xx) ; ,????Yes," History of skin cancer, No. (%)   ",19,5,3,no
3596,3001966,Table 4,BaselineCharacteristic,.xx,Placebo group ; P ; ,????Yes," History of skin cancer, No. (%)   ",19,6,3,no
3596,3001966,Table 4,BaselineCharacteristic,????No, ; Characteristic ; ,????No," History of skin cancer, No. (%)   ",20,0,2,no
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Withdrew (n = xx) ; ,????No," History of skin cancer, No. (%)   ",20,1,3,no
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Completed (n = xx) ; ,????No," History of skin cancer, No. (%)   ",20,2,3,no
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,????No," History of skin cancer, No. (%)   ",20,3,3,no
3596,3001966,Table 4,BaselineCharacteristic,x (xx),Placebo group ; Withdrew (n = xx) ; ,????No," History of skin cancer, No. (%)   ",20,4,3,no
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Placebo group ; Completed (n = xx) ; ,????No," History of skin cancer, No. (%)   ",20,5,3,no
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,????No," History of skin cancer, No. (%)   ",20,6,3,no
3596,3001966,Table 4,BaselineCharacteristic,"Total number of skin cancer diagnoses per patient before screening, No. (%)", ; Characteristic ; ,None,None,21,0,24,no
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; Withdrew (n = xx) ; ,"Total number of skin cancer diagnoses per patient before screening, No. (%)",None,1,21,43,no
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; Completed (n = xx) ; ,"Total number of skin cancer diagnoses per patient before screening, No. (%)",None,2,21,43,no
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,"Total number of skin cancer diagnoses per patient before screening, No. (%)",None,3,21,43,no
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; Withdrew (n = xx) ; ,"Total number of skin cancer diagnoses per patient before screening, No. (%)",None,4,21,43,no
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; Completed (n = xx) ; ,"Total number of skin cancer diagnoses per patient before screening, No. (%)",None,5,21,43,no
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,"Total number of skin cancer diagnoses per patient before screening, No. (%)",None,6,21,43,no
3596,3001966,Table 4,BaselineCharacteristic,????x, ; Characteristic ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",22,0,2,no
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Withdrew (n = xx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",22,1,3,no
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Completed (n = xx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",22,2,3,no
3596,3001966,Table 4,BaselineCharacteristic,.xx,Celecoxib group ; P ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",22,3,3,no
3596,3001966,Table 4,BaselineCharacteristic,x (xx),Placebo group ; Withdrew (n = xx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",22,4,3,no
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Placebo group ; Completed (n = xx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",22,5,3,no
3596,3001966,Table 4,BaselineCharacteristic,.xx,Placebo group ; P ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",22,6,3,no
3596,3001966,Table 4,BaselineCharacteristic,????x, ; Characteristic ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",23,0,2,no
3596,3001966,Table 4,BaselineCharacteristic,x (xx),Celecoxib group ; Withdrew (n = xx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",23,1,3,no
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Completed (n = xx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",23,2,3,no
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",23,3,3,no
3596,3001966,Table 4,BaselineCharacteristic,x (xx),Placebo group ; Withdrew (n = xx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",23,4,3,no
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Placebo group ; Completed (n = xx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",23,5,3,no
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",23,6,3,no
3596,3001966,Table 4,BaselineCharacteristic,????x, ; Characteristic ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",24,0,2,no
3596,3001966,Table 4,BaselineCharacteristic,x (xx),Celecoxib group ; Withdrew (n = xx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",24,1,3,no
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Completed (n = xx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",24,2,3,no
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",24,3,3,no
3596,3001966,Table 4,BaselineCharacteristic,x (xx),Placebo group ; Withdrew (n = xx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",24,4,3,no
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Placebo group ; Completed (n = xx) ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",24,5,3,no
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,????x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",24,6,3,no
3596,3001966,Table 4,BaselineCharacteristic,????>x, ; Characteristic ; ,????>x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",25,0,2,no
3596,3001966,Table 4,BaselineCharacteristic,x (xx),Celecoxib group ; Withdrew (n = xx) ; ,????>x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",25,1,3,no
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Celecoxib group ; Completed (n = xx) ; ,????>x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",25,2,3,no
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,????>x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",25,3,3,no
3596,3001966,Table 4,BaselineCharacteristic,x (xx),Placebo group ; Withdrew (n = xx) ; ,????>x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",25,4,3,no
3596,3001966,Table 4,BaselineCharacteristic,xx (xx),Placebo group ; Completed (n = xx) ; ,????>x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",25,5,3,no
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,????>x," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",25,6,3,no
3596,3001966,Table 4,BaselineCharacteristic,????Mean (SD), ; Characteristic ; ,????Mean (SD)," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",26,0,2,no
3596,3001966,Table 4,BaselineCharacteristic,x.x (x.x),Celecoxib group ; Withdrew (n = xx) ; ,????Mean (SD)," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",26,1,3,no
3596,3001966,Table 4,BaselineCharacteristic,x.x (x.x),Celecoxib group ; Completed (n = xx) ; ,????Mean (SD)," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",26,2,3,no
3596,3001966,Table 4,BaselineCharacteristic,.xx,Celecoxib group ; P ; ,????Mean (SD)," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",26,3,3,no
3596,3001966,Table 4,BaselineCharacteristic,x.x (x.x),Placebo group ; Withdrew (n = xx) ; ,????Mean (SD)," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",26,4,3,no
3596,3001966,Table 4,BaselineCharacteristic,x.x (x.x),Placebo group ; Completed (n = xx) ; ,????Mean (SD)," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",26,5,3,no
3596,3001966,Table 4,BaselineCharacteristic,.xx,Placebo group ; P ; ,????Mean (SD)," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",26,6,3,no
3596,3001966,Table 4,BaselineCharacteristic,????Median (range), ; Characteristic ; ,????Median (range)," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",27,0,2,no
3596,3001966,Table 4,BaselineCharacteristic,,Celecoxib group ; P ; ,????Median (range)," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",27,3,3,no
3596,3001966,Table 4,BaselineCharacteristic,,Placebo group ; P ; ,????Median (range)," Total number of skin cancer diagnoses per patient before screening, No. (%)   ",27,6,3,no
3654,3015435,Table 1.,BaselineCharacteristic,,,None,None,0,0,12,no
3654,3015435,Table 1.,BaselineCharacteristic,Ondansetron,,,None,0,1,1,no
3654,3015435,Table 1.,BaselineCharacteristic,Droperidol,,,None,0,2,1,no
3654,3015435,Table 1.,BaselineCharacteristic,Metoclopramide,,,None,0,3,1,no
3654,3015435,Table 1.,BaselineCharacteristic,N, ; ,N,,1,0,2,no
3654,3015435,Table 1.,BaselineCharacteristic,xx,Ondansetron ; ,N,,1,1,3,no
3654,3015435,Table 1.,BaselineCharacteristic,xx,Droperidol ; ,N,,1,2,3,no
3654,3015435,Table 1.,BaselineCharacteristic,xx,Metoclopramide ; ,N,,1,3,3,no
3654,3015435,Table 1.,BaselineCharacteristic,Sex: Female, ; ,Sex: Female,,2,0,24,no
3654,3015435,Table 1.,BaselineCharacteristic,xx,Ondansetron ; ,Sex: Female,,2,1,43,yes
3654,3015435,Table 1.,BaselineCharacteristic,xx,Droperidol ; ,Sex: Female,,2,2,43,yes
3654,3015435,Table 1.,BaselineCharacteristic,xx,Metoclopramide ; ,Sex: Female,,2,3,43,yes
3654,3015435,Table 1.,BaselineCharacteristic,????Male, ; ,????Male, Sex: Female   ,3,0,2,no
3654,3015435,Table 1.,BaselineCharacteristic,xx,Ondansetron ; ,????Male, Sex: Female   ,3,1,3,yes
3654,3015435,Table 1.,BaselineCharacteristic,xx,Droperidol ; ,????Male, Sex: Female   ,3,2,3,yes
3654,3015435,Table 1.,BaselineCharacteristic,xx,Metoclopramide ; ,????Male, Sex: Female   ,3,3,3,yes
3654,3015435,Table 1.,BaselineCharacteristic,Weight: Female, ; ,Weight: Female,,4,0,24,no
3654,3015435,Table 1.,BaselineCharacteristic,xx.x +/? xx.x,Ondansetron ; ,Weight: Female,,4,1,43,no
3654,3015435,Table 1.,BaselineCharacteristic,xx.x +/? xx.x,Droperidol ; ,Weight: Female,,4,2,43,no
3654,3015435,Table 1.,BaselineCharacteristic,xx.x +/? xx.x,Metoclopramide ; ,Weight: Female,,4,3,43,no
3654,3015435,Table 1.,BaselineCharacteristic,????Male, ; ,????Male, Weight: Female   ,5,0,2,no
3654,3015435,Table 1.,BaselineCharacteristic,xx.x +/? xx.x,Ondansetron ; ,????Male, Weight: Female   ,5,1,3,no
3654,3015435,Table 1.,BaselineCharacteristic,xx.x +/? xx.x,Droperidol ; ,????Male, Weight: Female   ,5,2,3,no
3654,3015435,Table 1.,BaselineCharacteristic,xx.x +/? xx.x,Metoclopramide ; ,????Male, Weight: Female   ,5,3,3,no
3654,3015435,Table 1.,BaselineCharacteristic,Motion Sickness, ; ,Motion Sickness,,6,0,2,no
3654,3015435,Table 1.,BaselineCharacteristic,x,Ondansetron ; ,Motion Sickness,,6,1,3,no
3654,3015435,Table 1.,BaselineCharacteristic,x,Droperidol ; ,Motion Sickness,,6,2,3,no
3654,3015435,Table 1.,BaselineCharacteristic,x,Metoclopramide ; ,Motion Sickness,,6,3,3,no
3654,3015435,Table 1.,BaselineCharacteristic,PONV, ; ,PONV,,7,0,2,no
3654,3015435,Table 1.,BaselineCharacteristic,xx,Ondansetron ; ,PONV,,7,1,3,no
3654,3015435,Table 1.,BaselineCharacteristic,xx,Droperidol ; ,PONV,,7,2,3,no
3654,3015435,Table 1.,BaselineCharacteristic,xx,Metoclopramide ; ,PONV,,7,3,3,no
3654,3015435,Table 1.,BaselineCharacteristic,Diabetic, ; ,Diabetic,,8,0,2,no
3654,3015435,Table 1.,BaselineCharacteristic,x,Ondansetron ; ,Diabetic,,8,1,3,no
3654,3015435,Table 1.,BaselineCharacteristic,x,Droperidol ; ,Diabetic,,8,2,3,no
3654,3015435,Table 1.,BaselineCharacteristic,x,Metoclopramide ; ,Diabetic,,8,3,3,no
3654,3015435,Table 1.,BaselineCharacteristic,Age, ; ,Age,,9,0,2,no
3654,3015435,Table 1.,BaselineCharacteristic,xx +/? xx.x,Ondansetron ; ,Age,,9,1,3,no
3654,3015435,Table 1.,BaselineCharacteristic,xx +/? xx.x,Droperidol ; ,Age,,9,2,3,no
3654,3015435,Table 1.,BaselineCharacteristic,xx +/? xx.x,Metoclopramide ; ,Age,,9,3,3,no
3654,3015435,Table 1.,BaselineCharacteristic,Duration of Operation, ; ,Duration of Operation,,10,0,2,no
3654,3015435,Table 1.,BaselineCharacteristic,xx.x +/? xx.x,Ondansetron ; ,Duration of Operation,,10,1,3,no
3654,3015435,Table 1.,BaselineCharacteristic,xx.x +/? xx.x,Droperidol ; ,Duration of Operation,,10,2,3,no
3654,3015435,Table 1.,BaselineCharacteristic,xx +/? xx.x,Metoclopramide ; ,Duration of Operation,,10,3,3,no
3654,3015435,Table 1.,BaselineCharacteristic,Laparoscopic Cholecystectomy, ; ,Laparoscopic Cholecystectomy,,11,0,2,no
3654,3015435,Table 1.,BaselineCharacteristic,xx,Ondansetron ; ,Laparoscopic Cholecystectomy,,11,1,3,no
3654,3015435,Table 1.,BaselineCharacteristic,xx,Droperidol ; ,Laparoscopic Cholecystectomy,,11,2,3,no
3654,3015435,Table 1.,BaselineCharacteristic,xx,Metoclopramide ; ,Laparoscopic Cholecystectomy,,11,3,3,no
3654,3015435,Table 1.,BaselineCharacteristic,Laparoscopic Herniorrhaphy, ; ,Laparoscopic Herniorrhaphy,,12,0,2,no
3654,3015435,Table 1.,BaselineCharacteristic,x,Ondansetron ; ,Laparoscopic Herniorrhaphy,,12,1,3,no
3654,3015435,Table 1.,BaselineCharacteristic,x,Droperidol ; ,Laparoscopic Herniorrhaphy,,12,2,3,no
3654,3015435,Table 1.,BaselineCharacteristic,x,Metoclopramide ; ,Laparoscopic Herniorrhaphy,,12,3,3,no
3654,3015435,Table 1.,BaselineCharacteristic,Laparoscopic Appendectomy, ; ,Laparoscopic Appendectomy,,13,0,2,no
3654,3015435,Table 1.,BaselineCharacteristic,x,Ondansetron ; ,Laparoscopic Appendectomy,,13,1,3,no
3654,3015435,Table 1.,BaselineCharacteristic,x,Droperidol ; ,Laparoscopic Appendectomy,,13,2,3,no
3654,3015435,Table 1.,BaselineCharacteristic,x,Metoclopramide ; ,Laparoscopic Appendectomy,,13,3,3,no
3654,3015435,Table 1.,BaselineCharacteristic,Diagnostic Laparoscopy, ; ,Diagnostic Laparoscopy,,14,0,2,no
3654,3015435,Table 1.,BaselineCharacteristic,xx,Ondansetron ; ,Diagnostic Laparoscopy,,14,1,3,no
3654,3015435,Table 1.,BaselineCharacteristic,xx,Droperidol ; ,Diagnostic Laparoscopy,,14,2,3,no
3654,3015435,Table 1.,BaselineCharacteristic,xx,Metoclopramide ; ,Diagnostic Laparoscopy,,14,3,3,no
3713,3031899,Table 2,BaselineCharacteristic,Characteristics,,None,None,0,0,12,no
3713,3031899,Table 2,BaselineCharacteristic,Number (n=xx),,Characteristics,None,0,1,1,no
3713,3031899,Table 2,BaselineCharacteristic,%,,Characteristics,None,0,2,1,no
3713,3031899,Table 2,BaselineCharacteristic,Sex,Characteristics ; ,None,None,1,0,24,no
3713,3031899,Table 2,BaselineCharacteristic,Sex,Number (n=xx) ; ,Sex,None,1,1,43,no
3713,3031899,Table 2,BaselineCharacteristic,Sex,% ; ,Sex,None,1,2,43,no
3713,3031899,Table 2,BaselineCharacteristic,?Male: female,Characteristics ; ,?Male: female, Sex,2,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,xx?:?x,Number (n=xx) ; ,?Male: female, Sex,2,1,3,yes
3713,3031899,Table 2,BaselineCharacteristic,xx?:?x,% ; ,?Male: female, Sex,2,2,3,yes
3713,3031899,Table 2,BaselineCharacteristic,,Characteristics ; ,None,None,3,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,,Number (n=xx) ; ,None,None,3,1,3,no
3713,3031899,Table 2,BaselineCharacteristic,,% ; ,None,None,3,2,3,no
3713,3031899,Table 2,BaselineCharacteristic,Age (years),Characteristics ; ,None,None,4,0,24,no
3713,3031899,Table 2,BaselineCharacteristic,Age (years),Number (n=xx) ; ,Age (years),None,4,1,43,no
3713,3031899,Table 2,BaselineCharacteristic,Age (years),% ; ,Age (years),None,4,2,43,no
3713,3031899,Table 2,BaselineCharacteristic,?Median,Characteristics ; ,?Median, Age (years),5,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,xx,Number (n=xx) ; ,?Median, Age (years),5,1,3,no
3713,3031899,Table 2,BaselineCharacteristic,,% ; ,?Median, Age (years),5,2,3,no
3713,3031899,Table 2,BaselineCharacteristic,?Range,Characteristics ; ,?Range, Age (years),6,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,,% ; ,?Range, Age (years),6,2,3,no
3713,3031899,Table 2,BaselineCharacteristic,,Characteristics ; ,None,None,7,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,,Number (n=xx) ; ,None,None,7,1,3,no
3713,3031899,Table 2,BaselineCharacteristic,,% ; ,None,None,7,2,3,no
3713,3031899,Table 2,BaselineCharacteristic,ECOG performance status,Characteristics ; ,None,None,8,0,24,no
3713,3031899,Table 2,BaselineCharacteristic,ECOG performance status,Number (n=xx) ; ,ECOG performance status,None,8,1,43,no
3713,3031899,Table 2,BaselineCharacteristic,ECOG performance status,% ; ,ECOG performance status,None,8,2,43,no
3713,3031899,Table 2,BaselineCharacteristic,?x,Characteristics ; ,?x, ECOG performance status,9,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,x,Number (n=xx) ; ,?x, ECOG performance status,9,1,3,no
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?x, ECOG performance status,9,2,3,no
3713,3031899,Table 2,BaselineCharacteristic,?x,Characteristics ; ,?x, ECOG performance status,10,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,xx,Number (n=xx) ; ,?x, ECOG performance status,10,1,3,no
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?x, ECOG performance status,10,2,3,no
3713,3031899,Table 2,BaselineCharacteristic,,Characteristics ; ,None,None,11,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,,Number (n=xx) ; ,None,None,11,1,3,no
3713,3031899,Table 2,BaselineCharacteristic,,% ; ,None,None,11,2,3,no
3713,3031899,Table 2,BaselineCharacteristic,Histology,Characteristics ; ,None,None,12,0,24,no
3713,3031899,Table 2,BaselineCharacteristic,Histology,Number (n=xx) ; ,Histology,None,12,1,43,no
3713,3031899,Table 2,BaselineCharacteristic,Histology,% ; ,Histology,None,12,2,43,no
3713,3031899,Table 2,BaselineCharacteristic,?Squamous,Characteristics ; ,?Squamous, Histology,13,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,xx,Number (n=xx) ; ,?Squamous, Histology,13,1,3,no
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?Squamous, Histology,13,2,3,no
3713,3031899,Table 2,BaselineCharacteristic,?Adenocarcinoma,Characteristics ; ,?Adenocarcinoma, Histology,14,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,xx,Number (n=xx) ; ,?Adenocarcinoma, Histology,14,1,3,no
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?Adenocarcinoma, Histology,14,2,3,no
3713,3031899,Table 2,BaselineCharacteristic,,Characteristics ; ,None,None,15,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,,Number (n=xx) ; ,None,None,15,1,3,no
3713,3031899,Table 2,BaselineCharacteristic,,% ; ,None,None,15,2,3,no
3713,3031899,Table 2,BaselineCharacteristic,Tumour location,Characteristics ; ,None,None,16,0,24,no
3713,3031899,Table 2,BaselineCharacteristic,Tumour location,Number (n=xx) ; ,Tumour location,None,16,1,43,no
3713,3031899,Table 2,BaselineCharacteristic,Tumour location,% ; ,Tumour location,None,16,2,43,no
3713,3031899,Table 2,BaselineCharacteristic,?Upper third,Characteristics ; ,?Upper third, Tumour location,17,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,x,Number (n=xx) ; ,?Upper third, Tumour location,17,1,3,no
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?Upper third, Tumour location,17,2,3,no
3713,3031899,Table 2,BaselineCharacteristic,?Middle third,Characteristics ; ,?Middle third, Tumour location,18,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,x,Number (n=xx) ; ,?Middle third, Tumour location,18,1,3,no
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?Middle third, Tumour location,18,2,3,no
3713,3031899,Table 2,BaselineCharacteristic,?Lower third,Characteristics ; ,?Lower third, Tumour location,19,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,xx,Number (n=xx) ; ,?Lower third, Tumour location,19,1,3,no
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?Lower third, Tumour location,19,2,3,no
3713,3031899,Table 2,BaselineCharacteristic,,Characteristics ; ,None,None,20,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,,Number (n=xx) ; ,None,None,20,1,3,no
3713,3031899,Table 2,BaselineCharacteristic,,% ; ,None,None,20,2,3,no
3713,3031899,Table 2,BaselineCharacteristic,T stage,Characteristics ; ,None,None,21,0,24,no
3713,3031899,Table 2,BaselineCharacteristic,T stage,Number (n=xx) ; ,T stage,None,21,1,43,no
3713,3031899,Table 2,BaselineCharacteristic,T stage,% ; ,T stage,None,21,2,43,no
3713,3031899,Table 2,BaselineCharacteristic,?x,Characteristics ; ,?x, T stage,22,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,x,Number (n=xx) ; ,?x, T stage,22,1,3,no
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?x, T stage,22,2,3,no
3713,3031899,Table 2,BaselineCharacteristic,?x,Characteristics ; ,?x, T stage,23,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,x,Number (n=xx) ; ,?x, T stage,23,1,3,no
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?x, T stage,23,2,3,no
3713,3031899,Table 2,BaselineCharacteristic,?x,Characteristics ; ,?x, T stage,24,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,xx,Number (n=xx) ; ,?x, T stage,24,1,3,no
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?x, T stage,24,2,3,no
3713,3031899,Table 2,BaselineCharacteristic,?x,Characteristics ; ,?x, T stage,25,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,x,Number (n=xx) ; ,?x, T stage,25,1,3,no
3713,3031899,Table 2,BaselineCharacteristic,x.x,% ; ,?x, T stage,25,2,3,no
3713,3031899,Table 2,BaselineCharacteristic,,Characteristics ; ,None,None,26,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,,Number (n=xx) ; ,None,None,26,1,3,no
3713,3031899,Table 2,BaselineCharacteristic,,% ; ,None,None,26,2,3,no
3713,3031899,Table 2,BaselineCharacteristic,N stage,Characteristics ; ,None,None,27,0,24,no
3713,3031899,Table 2,BaselineCharacteristic,N stage,Number (n=xx) ; ,N stage,None,27,1,43,no
3713,3031899,Table 2,BaselineCharacteristic,N stage,% ; ,N stage,None,27,2,43,no
3713,3031899,Table 2,BaselineCharacteristic,?x,Characteristics ; ,?x, N stage,28,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,x,Number (n=xx) ; ,?x, N stage,28,1,3,no
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?x, N stage,28,2,3,no
3713,3031899,Table 2,BaselineCharacteristic,?x,Characteristics ; ,?x, N stage,29,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,xx,Number (n=xx) ; ,?x, N stage,29,1,3,no
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?x, N stage,29,2,3,no
3713,3031899,Table 2,BaselineCharacteristic,,Characteristics ; ,None,None,30,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,,Number (n=xx) ; ,None,None,30,1,3,no
3713,3031899,Table 2,BaselineCharacteristic,,% ; ,None,None,30,2,3,no
3713,3031899,Table 2,BaselineCharacteristic,Stage grouping,Characteristics ; ,None,None,31,0,24,no
3713,3031899,Table 2,BaselineCharacteristic,Stage grouping,Number (n=xx) ; ,Stage grouping,None,31,1,43,no
3713,3031899,Table 2,BaselineCharacteristic,Stage grouping,% ; ,Stage grouping,None,31,2,43,no
3713,3031899,Table 2,BaselineCharacteristic,?I,Characteristics ; ,?I, Stage grouping,32,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,x,Number (n=xx) ; ,?I, Stage grouping,32,1,3,no
3713,3031899,Table 2,BaselineCharacteristic,x.x,% ; ,?I, Stage grouping,32,2,3,no
3713,3031899,Table 2,BaselineCharacteristic,?IIa,Characteristics ; ,?IIa, Stage grouping,33,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,x,Number (n=xx) ; ,?IIa, Stage grouping,33,1,3,no
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?IIa, Stage grouping,33,2,3,no
3713,3031899,Table 2,BaselineCharacteristic,?IIb,Characteristics ; ,?IIb, Stage grouping,34,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,x,Number (n=xx) ; ,?IIb, Stage grouping,34,1,3,no
3713,3031899,Table 2,BaselineCharacteristic,x.x,% ; ,?IIb, Stage grouping,34,2,3,no
3713,3031899,Table 2,BaselineCharacteristic,?III,Characteristics ; ,?III, Stage grouping,35,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,xx,Number (n=xx) ; ,?III, Stage grouping,35,1,3,no
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?III, Stage grouping,35,2,3,no
3713,3031899,Table 2,BaselineCharacteristic,,Characteristics ; ,None,None,36,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,,Number (n=xx) ; ,None,None,36,1,3,no
3713,3031899,Table 2,BaselineCharacteristic,,% ; ,None,None,36,2,3,no
3713,3031899,Table 2,BaselineCharacteristic,Previous surgery,Characteristics ; ,None,None,37,0,24,no
3713,3031899,Table 2,BaselineCharacteristic,Previous surgery,Number (n=xx) ; ,Previous surgery,None,37,1,43,no
3713,3031899,Table 2,BaselineCharacteristic,Previous surgery,% ; ,Previous surgery,None,37,2,43,no
3713,3031899,Table 2,BaselineCharacteristic,?Yes,Characteristics ; ,?Yes, Previous surgery,38,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,x,Number (n=xx) ; ,?Yes, Previous surgery,38,1,3,no
3713,3031899,Table 2,BaselineCharacteristic,x.x,% ; ,?Yes, Previous surgery,38,2,3,no
3713,3031899,Table 2,BaselineCharacteristic,?No,Characteristics ; ,?No, Previous surgery,39,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,xx,Number (n=xx) ; ,?No, Previous surgery,39,1,3,no
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?No, Previous surgery,39,2,3,no
3713,3031899,Table 2,BaselineCharacteristic,,Characteristics ; ,None,None,40,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,,Number (n=xx) ; ,None,None,40,1,3,no
3713,3031899,Table 2,BaselineCharacteristic,,% ; ,None,None,40,2,3,no
3713,3031899,Table 2,BaselineCharacteristic,Weight loss over previous x months,Characteristics ; ,None,None,41,0,24,no
3713,3031899,Table 2,BaselineCharacteristic,Weight loss over previous x months,Number (n=xx) ; ,Weight loss over previous x months,None,41,1,43,no
3713,3031899,Table 2,BaselineCharacteristic,Weight loss over previous x months,% ; ,Weight loss over previous x months,None,41,2,43,no
3713,3031899,Table 2,BaselineCharacteristic,?None,Characteristics ; ,?None, Weight loss over previous x months,42,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,x,Number (n=xx) ; ,?None, Weight loss over previous x months,42,1,3,no
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?None, Weight loss over previous x months,42,2,3,no
3713,3031899,Table 2,BaselineCharacteristic,??xx%,Characteristics ; ,??xx%, Weight loss over previous x months,43,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,xx,Number (n=xx) ; ,??xx%, Weight loss over previous x months,43,1,3,no
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,??xx%, Weight loss over previous x months,43,2,3,no
3713,3031899,Table 2,BaselineCharacteristic,?>xx%,Characteristics ; ,?>xx%, Weight loss over previous x months,44,0,2,no
3713,3031899,Table 2,BaselineCharacteristic,x,Number (n=xx) ; ,?>xx%, Weight loss over previous x months,44,1,3,no
3713,3031899,Table 2,BaselineCharacteristic,xx.x,% ; ,?>xx%, Weight loss over previous x months,44,2,3,no
3716,3032760,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,0,12,no
3716,3032760,Table 1,BaselineCharacteristic,Everolimus x mg/day(n = xx),,Characteristic,None,0,1,1,no
3716,3032760,Table 1,BaselineCharacteristic,Everolimus xx mg/day(n = xx),,Characteristic,None,0,2,1,no
3716,3032760,Table 1,BaselineCharacteristic,"Median (range) age, y",Characteristic ; ,"Median (range) age, y",,1,0,2,no
3716,3032760,Table 1,BaselineCharacteristic,xx (xx-xx),Everolimus x mg/day(n = xx) ; ,"Median (range) age, y",,1,1,3,no
3716,3032760,Table 1,BaselineCharacteristic,xx (xx-xx),Everolimus xx mg/day(n = xx) ; ,"Median (range) age, y",,1,2,3,no
3716,3032760,Table 1,BaselineCharacteristic,"Sex, n (%)",Characteristic ; ,None,None,2,0,24,no
3716,3032760,Table 1,BaselineCharacteristic,,Everolimus x mg/day(n = xx) ; ,"Sex, n (%)",None,2,1,43,no
3716,3032760,Table 1,BaselineCharacteristic,,Everolimus xx mg/day(n = xx) ; ,"Sex, n (%)",None,2,2,43,no
3716,3032760,Table 1,BaselineCharacteristic,?Male,Characteristic ; ,?Male," Sex, n (%)",3,0,2,no
3716,3032760,Table 1,BaselineCharacteristic,x (xx.x),Everolimus x mg/day(n = xx) ; ,?Male," Sex, n (%)",3,1,3,yes
3716,3032760,Table 1,BaselineCharacteristic,x (xx.x),Everolimus xx mg/day(n = xx) ; ,?Male," Sex, n (%)",3,2,3,yes
3716,3032760,Table 1,BaselineCharacteristic,?Female,Characteristic ; ,?Female," Sex, n (%)",4,0,2,no
3716,3032760,Table 1,BaselineCharacteristic,x (xx.x),Everolimus x mg/day(n = xx) ; ,?Female," Sex, n (%)",4,1,3,yes
3716,3032760,Table 1,BaselineCharacteristic,x (xx.x),Everolimus xx mg/day(n = xx) ; ,?Female," Sex, n (%)",4,2,3,yes
3716,3032760,Table 1,BaselineCharacteristic,"WHO performance status, n (%)",Characteristic ; ,None,None,5,0,24,no
3716,3032760,Table 1,BaselineCharacteristic,,Everolimus x mg/day(n = xx) ; ,"WHO performance status, n (%)",None,5,1,43,no
3716,3032760,Table 1,BaselineCharacteristic,,Everolimus xx mg/day(n = xx) ; ,"WHO performance status, n (%)",None,5,2,43,no
3716,3032760,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x," WHO performance status, n (%)",6,0,2,no
3716,3032760,Table 1,BaselineCharacteristic,x (xx.x),Everolimus x mg/day(n = xx) ; ,?x," WHO performance status, n (%)",6,1,3,no
3716,3032760,Table 1,BaselineCharacteristic,x (x.x),Everolimus xx mg/day(n = xx) ; ,?x," WHO performance status, n (%)",6,2,3,no
3716,3032760,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x," WHO performance status, n (%)",7,0,2,no
3716,3032760,Table 1,BaselineCharacteristic,x (xx.x),Everolimus x mg/day(n = xx) ; ,?x," WHO performance status, n (%)",7,1,3,no
3716,3032760,Table 1,BaselineCharacteristic,x (xx.x),Everolimus xx mg/day(n = xx) ; ,?x," WHO performance status, n (%)",7,2,3,no
3716,3032760,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x," WHO performance status, n (%)",8,0,2,no
3716,3032760,Table 1,BaselineCharacteristic,x,Everolimus x mg/day(n = xx) ; ,?x," WHO performance status, n (%)",8,1,3,no
3716,3032760,Table 1,BaselineCharacteristic,x (xx.x),Everolimus xx mg/day(n = xx) ; ,?x," WHO performance status, n (%)",8,2,3,no
3716,3032760,Table 1,BaselineCharacteristic,"Prior antineoplastic therapy, n (%)",Characteristic ; ,None,None,9,0,24,no
3716,3032760,Table 1,BaselineCharacteristic,,Everolimus x mg/day(n = xx) ; ,"Prior antineoplastic therapy, n (%)",None,9,1,43,no
3716,3032760,Table 1,BaselineCharacteristic,,Everolimus xx mg/day(n = xx) ; ,"Prior antineoplastic therapy, n (%)",None,9,2,43,no
3716,3032760,Table 1,BaselineCharacteristic,?Surgery,Characteristic ; ,?Surgery," Prior antineoplastic therapy, n (%)",10,0,2,no
3716,3032760,Table 1,BaselineCharacteristic,xx (xx.x),Everolimus x mg/day(n = xx) ; ,?Surgery," Prior antineoplastic therapy, n (%)",10,1,3,no
3716,3032760,Table 1,BaselineCharacteristic,xx (xx.x),Everolimus xx mg/day(n = xx) ; ,?Surgery," Prior antineoplastic therapy, n (%)",10,2,3,no
3716,3032760,Table 1,BaselineCharacteristic,?Radiotherapy,Characteristic ; ,?Radiotherapy," Prior antineoplastic therapy, n (%)",11,0,2,no
3716,3032760,Table 1,BaselineCharacteristic,x (xx.x),Everolimus x mg/day(n = xx) ; ,?Radiotherapy," Prior antineoplastic therapy, n (%)",11,1,3,no
3716,3032760,Table 1,BaselineCharacteristic,x (xx.x),Everolimus xx mg/day(n = xx) ; ,?Radiotherapy," Prior antineoplastic therapy, n (%)",11,2,3,no
3716,3032760,Table 1,BaselineCharacteristic,?Chemotherapy,Characteristic ; ,?Chemotherapy," Prior antineoplastic therapy, n (%)",12,0,2,no
3716,3032760,Table 1,BaselineCharacteristic,xx (xx.x),Everolimus x mg/day(n = xx) ; ,?Chemotherapy," Prior antineoplastic therapy, n (%)",12,1,3,no
3716,3032760,Table 1,BaselineCharacteristic,xx (xx.x),Everolimus xx mg/day(n = xx) ; ,?Chemotherapy," Prior antineoplastic therapy, n (%)",12,2,3,no
3716,3032760,Table 1,BaselineCharacteristic,?Targeted therapy,Characteristic ; ,?Targeted therapy," Prior antineoplastic therapy, n (%)",13,0,2,no
3716,3032760,Table 1,BaselineCharacteristic,x (xx.x),Everolimus x mg/day(n = xx) ; ,?Targeted therapy," Prior antineoplastic therapy, n (%)",13,1,3,no
3716,3032760,Table 1,BaselineCharacteristic,x (xx.x),Everolimus xx mg/day(n = xx) ; ,?Targeted therapy," Prior antineoplastic therapy, n (%)",13,2,3,no
3716,3032760,Table 1,BaselineCharacteristic,?Immunotherapy,Characteristic ; ,?Immunotherapy," Prior antineoplastic therapy, n (%)",14,0,2,no
3716,3032760,Table 1,BaselineCharacteristic,x (xx.x),Everolimus x mg/day(n = xx) ; ,?Immunotherapy," Prior antineoplastic therapy, n (%)",14,1,3,no
3716,3032760,Table 1,BaselineCharacteristic,x (xx.x),Everolimus xx mg/day(n = xx) ; ,?Immunotherapy," Prior antineoplastic therapy, n (%)",14,2,3,no
3716,3032760,Table 1,BaselineCharacteristic,?Hormonal therapy,Characteristic ; ,?Hormonal therapy," Prior antineoplastic therapy, n (%)",15,0,2,no
3716,3032760,Table 1,BaselineCharacteristic,x (xx.x),Everolimus x mg/day(n = xx) ; ,?Hormonal therapy," Prior antineoplastic therapy, n (%)",15,1,3,no
3716,3032760,Table 1,BaselineCharacteristic,x,Everolimus xx mg/day(n = xx) ; ,?Hormonal therapy," Prior antineoplastic therapy, n (%)",15,2,3,no
3777,3048218,Table 1,BaselineCharacteristic,Number of patients,,None,None,0,0,12,no
3777,3048218,Table 1,BaselineCharacteristic,xx,,Number of patients,None,0,1,1,no
3777,3048218,Table 1,BaselineCharacteristic,"Mean age, years (range)",,None,None,1,0,12,no
3777,3048218,Table 1,BaselineCharacteristic,Gender (male/female),,None,None,2,0,12,no
3777,3048218,Table 1,BaselineCharacteristic,xx/xx,,Gender (male/female),None,2,1,1,yes
3777,3048218,Table 1,BaselineCharacteristic,Performance status (x/x/x),,None,None,3,0,12,no
3777,3048218,Table 1,BaselineCharacteristic,xx/xx/x,,Performance status (x/x/x),None,3,1,1,no
3777,3048218,Table 1,BaselineCharacteristic,,,None,None,4,0,2,no
3777,3048218,Table 1,BaselineCharacteristic,,,None,None,4,1,3,no
3777,3048218,Table 1,BaselineCharacteristic,Tumour type (n),,None,None,5,0,24,no
3777,3048218,Table 1,BaselineCharacteristic,Tumour type (n),,Tumour type (n),None,5,1,43,no
3777,3048218,Table 1,BaselineCharacteristic,?Melanoma,,?Melanoma, Tumour type (n),6,0,2,no
3777,3048218,Table 1,BaselineCharacteristic,xx,,?Melanoma, Tumour type (n),6,1,3,no
3777,3048218,Table 1,BaselineCharacteristic,?Colorectal,,?Colorectal, Tumour type (n),7,0,2,no
3777,3048218,Table 1,BaselineCharacteristic,x,,?Colorectal, Tumour type (n),7,1,3,no
3777,3048218,Table 1,BaselineCharacteristic,?Transitional cell carcinoma bladder,,?Transitional cell carcinoma bladder, Tumour type (n),8,0,2,no
3777,3048218,Table 1,BaselineCharacteristic,x,,?Transitional cell carcinoma bladder, Tumour type (n),8,1,3,no
3777,3048218,Table 1,BaselineCharacteristic,?Squamous cell carcinoma vulva,,?Squamous cell carcinoma vulva, Tumour type (n),9,0,2,no
3777,3048218,Table 1,BaselineCharacteristic,x,,?Squamous cell carcinoma vulva, Tumour type (n),9,1,3,no
3777,3048218,Table 1,BaselineCharacteristic,?Haemangioblastoma,,?Haemangioblastoma, Tumour type (n),10,0,2,no
3777,3048218,Table 1,BaselineCharacteristic,x,,?Haemangioblastoma, Tumour type (n),10,1,3,no
3777,3048218,Table 1,BaselineCharacteristic,?Merkel cell carcinoma,,?Merkel cell carcinoma, Tumour type (n),11,0,2,no
3777,3048218,Table 1,BaselineCharacteristic,x,,?Merkel cell carcinoma, Tumour type (n),11,1,3,no
3777,3048218,Table 1,BaselineCharacteristic,?Adenocarcinoma lung,,?Adenocarcinoma lung, Tumour type (n),12,0,2,no
3777,3048218,Table 1,BaselineCharacteristic,x,,?Adenocarcinoma lung, Tumour type (n),12,1,3,no
3777,3048218,Table 1,BaselineCharacteristic,,,None,None,13,0,2,no
3777,3048218,Table 1,BaselineCharacteristic,,,None,None,13,1,3,no
3777,3048218,Table 1,BaselineCharacteristic,Previous chemotherapy regimens (n),,None,None,14,0,24,no
3777,3048218,Table 1,BaselineCharacteristic,Previous chemotherapy regimens (n),,Previous chemotherapy regimens (n),None,14,1,43,no
3777,3048218,Table 1,BaselineCharacteristic,?x,,?x, Previous chemotherapy regimens (n),15,0,2,no
3777,3048218,Table 1,BaselineCharacteristic,xx,,?x, Previous chemotherapy regimens (n),15,1,3,no
3777,3048218,Table 1,BaselineCharacteristic,?x,,?x, Previous chemotherapy regimens (n),16,0,2,no
3777,3048218,Table 1,BaselineCharacteristic,x,,?x, Previous chemotherapy regimens (n),16,1,3,no
3777,3048218,Table 1,BaselineCharacteristic,?x,,?x, Previous chemotherapy regimens (n),17,0,2,no
3777,3048218,Table 1,BaselineCharacteristic,x,,?x, Previous chemotherapy regimens (n),17,1,3,no
3777,3048218,Table 1,BaselineCharacteristic,??x,,??x, Previous chemotherapy regimens (n),18,0,2,no
3777,3048218,Table 1,BaselineCharacteristic,x,,??x, Previous chemotherapy regimens (n),18,1,3,no
3781,3049578,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no
3781,3049578,Table 1,BaselineCharacteristic,No. of patients=xx (xxx%),,,None,0,1,1,no
3781,3049578,Table 1,BaselineCharacteristic,Age, ; ,None,None,1,0,24,no
3781,3049578,Table 1,BaselineCharacteristic,Age,No. of patients=xx (xxx%) ; ,Age,None,1,1,43,no
3781,3049578,Table 1,BaselineCharacteristic,?Median/range, ; ,?Median/range, Age,2,0,2,no
3781,3049578,Table 1,BaselineCharacteristic,, ; ,None,None,3,0,2,no
3781,3049578,Table 1,BaselineCharacteristic,,No. of patients=xx (xxx%) ; ,None,None,3,1,3,no
3781,3049578,Table 1,BaselineCharacteristic,Sex, ; ,None,None,4,0,24,no
3781,3049578,Table 1,BaselineCharacteristic,Sex,No. of patients=xx (xxx%) ; ,Sex,None,4,1,43,no
3781,3049578,Table 1,BaselineCharacteristic,?Male/female, ; ,?Male/female, Sex,5,0,2,no
3781,3049578,Table 1,BaselineCharacteristic,xx/xx (xx/xx),No. of patients=xx (xxx%) ; ,?Male/female, Sex,5,1,3,yes
3781,3049578,Table 1,BaselineCharacteristic,, ; ,None,None,6,0,2,no
3781,3049578,Table 1,BaselineCharacteristic,,No. of patients=xx (xxx%) ; ,None,None,6,1,3,no
3781,3049578,Table 1,BaselineCharacteristic,Performance status, ; ,None,None,7,0,24,no
3781,3049578,Table 1,BaselineCharacteristic,Performance status,No. of patients=xx (xxx%) ; ,Performance status,None,7,1,43,no
3781,3049578,Table 1,BaselineCharacteristic,?x/x, ; ,?x/x, Performance status,8,0,2,no
3781,3049578,Table 1,BaselineCharacteristic,xx/x (xx/xx),No. of patients=xx (xxx%) ; ,?x/x, Performance status,8,1,3,no
3781,3049578,Table 1,BaselineCharacteristic,, ; ,None,None,9,0,2,no
3781,3049578,Table 1,BaselineCharacteristic,,No. of patients=xx (xxx%) ; ,None,None,9,1,3,no
3781,3049578,Table 1,BaselineCharacteristic,Dysphagia, ; ,None,None,10,0,24,no
3781,3049578,Table 1,BaselineCharacteristic,Dysphagia,No. of patients=xx (xxx%) ; ,Dysphagia,None,10,1,43,no
3781,3049578,Table 1,BaselineCharacteristic,?Absent/moderate, ; ,?Absent/moderate, Dysphagia,11,0,2,no
3781,3049578,Table 1,BaselineCharacteristic,x/x (xx/xx),No. of patients=xx (xxx%) ; ,?Absent/moderate, Dysphagia,11,1,3,no
3781,3049578,Table 1,BaselineCharacteristic,?Severe, ; ,?Severe, Dysphagia,12,0,2,no
3781,3049578,Table 1,BaselineCharacteristic,xx (xx),No. of patients=xx (xxx%) ; ,?Severe, Dysphagia,12,1,3,no
3781,3049578,Table 1,BaselineCharacteristic,, ; ,None,None,13,0,2,no
3781,3049578,Table 1,BaselineCharacteristic,,No. of patients=xx (xxx%) ; ,None,None,13,1,3,no
3781,3049578,Table 1,BaselineCharacteristic,Tumor location, ; ,None,None,14,0,24,no
3781,3049578,Table 1,BaselineCharacteristic,Tumor location,No. of patients=xx (xxx%) ; ,Tumor location,None,14,1,43,no
3781,3049578,Table 1,BaselineCharacteristic,?Upper third, ; ,?Upper third, Tumor location,15,0,2,no
3781,3049578,Table 1,BaselineCharacteristic,x (xx),No. of patients=xx (xxx%) ; ,?Upper third, Tumor location,15,1,3,no
3781,3049578,Table 1,BaselineCharacteristic,?Middle third, ; ,?Middle third, Tumor location,16,0,2,no
3781,3049578,Table 1,BaselineCharacteristic,xx (xx),No. of patients=xx (xxx%) ; ,?Middle third, Tumor location,16,1,3,no
3781,3049578,Table 1,BaselineCharacteristic,?Lower third, ; ,?Lower third, Tumor location,17,0,2,no
3781,3049578,Table 1,BaselineCharacteristic,xx (xx),No. of patients=xx (xxx%) ; ,?Lower third, Tumor location,17,1,3,no
3781,3049578,Table 1,BaselineCharacteristic,, ; ,None,None,18,0,2,no
3781,3049578,Table 1,BaselineCharacteristic,,No. of patients=xx (xxx%) ; ,None,None,18,1,3,no
3781,3049578,Table 1,BaselineCharacteristic,Histology, ; ,None,None,19,0,24,no
3781,3049578,Table 1,BaselineCharacteristic,Histology,No. of patients=xx (xxx%) ; ,Histology,None,19,1,43,no
3781,3049578,Table 1,BaselineCharacteristic,?Adenocarcinoma, ; ,?Adenocarcinoma, Histology,20,0,2,no
3781,3049578,Table 1,BaselineCharacteristic,xx (xx),No. of patients=xx (xxx%) ; ,?Adenocarcinoma, Histology,20,1,3,no
3781,3049578,Table 1,BaselineCharacteristic,?Squamous cell carcinoma, ; ,?Squamous cell carcinoma, Histology,21,0,2,no
3781,3049578,Table 1,BaselineCharacteristic,xx (xx),No. of patients=xx (xxx%) ; ,?Squamous cell carcinoma, Histology,21,1,3,no
3781,3049578,Table 1,BaselineCharacteristic,, ; ,None,None,22,0,2,no
3781,3049578,Table 1,BaselineCharacteristic,,No. of patients=xx (xxx%) ; ,None,None,22,1,3,no
3781,3049578,Table 1,BaselineCharacteristic,EUS T stagea, ; ,None,None,23,0,24,no
3781,3049578,Table 1,BaselineCharacteristic,EUS T stagea,No. of patients=xx (xxx%) ; ,EUS T stagea,None,23,1,43,no
3781,3049578,Table 1,BaselineCharacteristic,?x, ; ,?x, EUS T stagea,24,0,2,no
3781,3049578,Table 1,BaselineCharacteristic,xx (xx),No. of patients=xx (xxx%) ; ,?x, EUS T stagea,24,1,3,no
3781,3049578,Table 1,BaselineCharacteristic,?x, ; ,?x, EUS T stagea,25,0,2,no
3781,3049578,Table 1,BaselineCharacteristic,xx (xx),No. of patients=xx (xxx%) ; ,?x, EUS T stagea,25,1,3,no
3781,3049578,Table 1,BaselineCharacteristic,?x, ; ,?x, EUS T stagea,26,0,2,no
3781,3049578,Table 1,BaselineCharacteristic,x (x),No. of patients=xx (xxx%) ; ,?x, EUS T stagea,26,1,3,no
3781,3049578,Table 1,BaselineCharacteristic,, ; ,None,None,27,0,2,no
3781,3049578,Table 1,BaselineCharacteristic,,No. of patients=xx (xxx%) ; ,None,None,27,1,3,no
3781,3049578,Table 1,BaselineCharacteristic,EUS N stagea, ; ,None,None,28,0,24,no
3781,3049578,Table 1,BaselineCharacteristic,EUS N stagea,No. of patients=xx (xxx%) ; ,EUS N stagea,None,28,1,43,no
3781,3049578,Table 1,BaselineCharacteristic,?x, ; ,?x, EUS N stagea,29,0,2,no
3781,3049578,Table 1,BaselineCharacteristic,x (xx),No. of patients=xx (xxx%) ; ,?x, EUS N stagea,29,1,3,no
3781,3049578,Table 1,BaselineCharacteristic,?x/Mxa, ; ,?x/Mxa, EUS N stagea,30,0,2,no
3781,3049578,Table 1,BaselineCharacteristic,xx/x (xx/xx),No. of patients=xx (xxx%) ; ,?x/Mxa, EUS N stagea,30,1,3,no
3787,3049870,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,0,12,no
3787,3049870,Table 1,BaselineCharacteristic,Number (%),,Characteristic,None,0,1,1,no
3787,3049870,Table 1,BaselineCharacteristic,"Age, years",Characteristic ; ,None,None,1,0,24,no
3787,3049870,Table 1,BaselineCharacteristic,"Age, years",Number (%) ; ,"Age, years",None,1,1,43,no
3787,3049870,Table 1,BaselineCharacteristic,"?Median, range",Characteristic ; ,"?Median, range"," Age, years",2,0,2,no
3787,3049870,Table 1,BaselineCharacteristic,"xx (xx, xx)",Number (%) ; ,"?Median, range"," Age, years",2,1,3,no
3787,3049870,Table 1,BaselineCharacteristic,"?Sex, male",Characteristic ; ,"?Sex, male"," Age, years",3,0,2,no
3787,3049870,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,"?Sex, male"," Age, years",3,1,3,no
3787,3049870,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,4,0,2,no
3787,3049870,Table 1,BaselineCharacteristic,,Number (%) ; ,None,None,4,1,3,no
3787,3049870,Table 1,BaselineCharacteristic,Performance status,Characteristic ; ,None,None,5,0,24,no
3787,3049870,Table 1,BaselineCharacteristic,Performance status,Number (%) ; ,Performance status,None,5,1,43,no
3787,3049870,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, Performance status,6,0,2,no
3787,3049870,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,?x, Performance status,6,1,3,no
3787,3049870,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, Performance status,7,0,2,no
3787,3049870,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,?x, Performance status,7,1,3,no
3787,3049870,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x, Performance status,8,0,2,no
3787,3049870,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,?x, Performance status,8,1,3,no
3787,3049870,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,9,0,2,no
3787,3049870,Table 1,BaselineCharacteristic,,Number (%) ; ,None,None,9,1,3,no
3787,3049870,Table 1,BaselineCharacteristic,Lymphoma stage at study entry,Characteristic ; ,None,None,10,0,24,no
3787,3049870,Table 1,BaselineCharacteristic,Lymphoma stage at study entry,Number (%) ; ,Lymphoma stage at study entry,None,10,1,43,no
3787,3049870,Table 1,BaselineCharacteristic,"?x, x",Characteristic ; ,"?x, x", Lymphoma stage at study entry,11,0,2,no
3787,3049870,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,"?x, x", Lymphoma stage at study entry,11,1,3,no
3787,3049870,Table 1,BaselineCharacteristic,"?x, x",Characteristic ; ,"?x, x", Lymphoma stage at study entry,12,0,2,no
3787,3049870,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,"?x, x", Lymphoma stage at study entry,12,1,3,no
3787,3049870,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,13,0,2,no
3787,3049870,Table 1,BaselineCharacteristic,,Number (%) ; ,None,None,13,1,3,no
3787,3049870,Table 1,BaselineCharacteristic,Disease type,Characteristic ; ,None,None,14,0,24,no
3787,3049870,Table 1,BaselineCharacteristic,Disease type,Number (%) ; ,Disease type,None,14,1,43,no
3787,3049870,Table 1,BaselineCharacteristic,?DLBCL,Characteristic ; ,?DLBCL, Disease type,15,0,2,no
3787,3049870,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,?DLBCL, Disease type,15,1,3,no
3787,3049870,Table 1,BaselineCharacteristic,?MCL,Characteristic ; ,?MCL, Disease type,16,0,2,no
3787,3049870,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,?MCL, Disease type,16,1,3,no
3787,3049870,Table 1,BaselineCharacteristic,?FL-III,Characteristic ; ,?FL-III, Disease type,17,0,2,no
3787,3049870,Table 1,BaselineCharacteristic,x (xx),Number (%) ; ,?FL-III, Disease type,17,1,3,no
3787,3049870,Table 1,BaselineCharacteristic,?TL,Characteristic ; ,?TL, Disease type,18,0,2,no
3787,3049870,Table 1,BaselineCharacteristic,x (x),Number (%) ; ,?TL, Disease type,18,1,3,no
3787,3049870,Table 1,BaselineCharacteristic,?Precursor T-lymphoblastic leukemia/lymphoma,Characteristic ; ,?Precursor T-lymphoblastic leukemia/lymphoma, Disease type,19,0,2,no
3787,3049870,Table 1,BaselineCharacteristic,x (x),Number (%) ; ,?Precursor T-lymphoblastic leukemia/lymphoma, Disease type,19,1,3,no
3787,3049870,Table 1,BaselineCharacteristic,?Unspecified high-grade B-cell lymphoma,Characteristic ; ,?Unspecified high-grade B-cell lymphoma, Disease type,20,0,2,no
3787,3049870,Table 1,BaselineCharacteristic,x (x),Number (%) ; ,?Unspecified high-grade B-cell lymphoma, Disease type,20,1,3,no
3787,3049870,Table 1,BaselineCharacteristic,Previous stem cell transplant,Characteristic ; ,Previous stem cell transplant,,21,0,2,no
3787,3049870,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,Previous stem cell transplant,,21,1,3,no
3787,3049870,Table 1,BaselineCharacteristic,Presence of B symptoms,Characteristic ; ,Presence of B symptoms,,22,0,2,no
3787,3049870,Table 1,BaselineCharacteristic,x (x),Number (%) ; ,Presence of B symptoms,,22,1,3,no
3787,3049870,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,23,0,2,no
3787,3049870,Table 1,BaselineCharacteristic,,Number (%) ; ,None,None,23,1,3,no
3787,3049870,Table 1,BaselineCharacteristic,Number of previous therapy treatments,Characteristic ; ,None,None,24,0,24,no
3787,3049870,Table 1,BaselineCharacteristic,Number of previous therapy treatments,Number (%) ; ,Number of previous therapy treatments,None,24,1,43,no
3787,3049870,Table 1,BaselineCharacteristic,"?Median, range",Characteristic ; ,"?Median, range", Number of previous therapy treatments,25,0,2,no
3787,3049870,Table 1,BaselineCharacteristic,"x (x, xx)",Number (%) ; ,"?Median, range", Number of previous therapy treatments,25,1,3,no
3787,3049870,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,26,0,2,no
3787,3049870,Table 1,BaselineCharacteristic,,Number (%) ; ,None,None,26,1,3,no
3787,3049870,Table 1,BaselineCharacteristic,Type of previous therapy,Characteristic ; ,None,None,27,0,24,no
3787,3049870,Table 1,BaselineCharacteristic,Type of previous therapy,Number (%) ; ,Type of previous therapy,None,27,1,43,no
3787,3049870,Table 1,BaselineCharacteristic,?Rituximab,Characteristic ; ,?Rituximab, Type of previous therapy,28,0,2,no
3787,3049870,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,?Rituximab, Type of previous therapy,28,1,3,no
3787,3049870,Table 1,BaselineCharacteristic,?Anthracycline,Characteristic ; ,?Anthracycline, Type of previous therapy,29,0,2,no
3787,3049870,Table 1,BaselineCharacteristic,xx (xx),Number (%) ; ,?Anthracycline, Type of previous therapy,29,1,3,no
3950,3080287,Table 1,BaselineCharacteristic,site,,None,None,0,0,12,no
3950,3080287,Table 1,BaselineCharacteristic,maxillary sinus,,site,None,0,1,1,no
3950,3080287,Table 1,BaselineCharacteristic,xx pts,,site,None,0,2,1,no
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,1,0,12,no
3950,3080287,Table 1,BaselineCharacteristic,nasal cavity,,,None,1,1,1,no
3950,3080287,Table 1,BaselineCharacteristic,x pts,,,None,1,2,1,no
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,2,0,12,no
3950,3080287,Table 1,BaselineCharacteristic,ethmoid sinus,,,None,2,1,1,no
3950,3080287,Table 1,BaselineCharacteristic,x pts,,,None,2,2,1,no
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,3,0,12,no
3950,3080287,Table 1,BaselineCharacteristic,sphenoid sinus,,,None,3,1,1,no
3950,3080287,Table 1,BaselineCharacteristic,x pt,,,None,3,2,1,no
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,4,0,12,no
3950,3080287,Table 1,BaselineCharacteristic,pansinus,,,None,4,1,1,no
3950,3080287,Table 1,BaselineCharacteristic,x pts,,,None,4,2,1,no
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,5,0,2,no
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,5,1,3,no
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,5,2,3,no
3950,3080287,Table 1,BaselineCharacteristic,histology,,histology,,6,0,24,no
3950,3080287,Table 1,BaselineCharacteristic,adenoidcystic carcinoma,,histology,,6,1,43,no
3950,3080287,Table 1,BaselineCharacteristic,xx pts,,histology,,6,2,43,no
3950,3080287,Table 1,BaselineCharacteristic,,,,,7,0,2,no
3950,3080287,Table 1,BaselineCharacteristic,malignant melanoma,,,,7,1,3,no
3950,3080287,Table 1,BaselineCharacteristic,x pts,,,,7,2,3,no
3950,3080287,Table 1,BaselineCharacteristic,,,,,8,0,2,no
3950,3080287,Table 1,BaselineCharacteristic,undifferentiated carcinoma,,,,8,1,3,no
3950,3080287,Table 1,BaselineCharacteristic,x pt,,,,8,2,3,no
3950,3080287,Table 1,BaselineCharacteristic,,,,,9,0,2,no
3950,3080287,Table 1,BaselineCharacteristic,chordoma,,,,9,1,3,no
3950,3080287,Table 1,BaselineCharacteristic,x pt,,,,9,2,3,no
3950,3080287,Table 1,BaselineCharacteristic,,,,,10,0,2,no
3950,3080287,Table 1,BaselineCharacteristic,chondrosarcoma,,,,10,1,3,no
3950,3080287,Table 1,BaselineCharacteristic,x pt,,,,10,2,3,no
3950,3080287,Table 1,BaselineCharacteristic,,,,,11,0,2,no
3950,3080287,Table 1,BaselineCharacteristic,osteosarcoma,,,,11,1,3,no
3950,3080287,Table 1,BaselineCharacteristic,x pt,,,,11,2,3,no
3950,3080287,Table 1,BaselineCharacteristic,,,,,12,0,2,no
3950,3080287,Table 1,BaselineCharacteristic,ameloblastic carcinoma,,,,12,1,3,no
3950,3080287,Table 1,BaselineCharacteristic,x pt,,,,12,2,3,no
3950,3080287,Table 1,BaselineCharacteristic,,,,,13,0,2,no
3950,3080287,Table 1,BaselineCharacteristic,malignant peripheral nerve sheath tumour,,,,13,1,3,no
3950,3080287,Table 1,BaselineCharacteristic,x pt,,,,13,2,3,no
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,14,0,2,no
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,14,1,3,no
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,14,2,3,no
3950,3080287,Table 1,BaselineCharacteristic,stage,,stage,,15,0,24,no
3950,3080287,Table 1,BaselineCharacteristic,Tx,,stage,,15,1,43,no
3950,3080287,Table 1,BaselineCharacteristic,xx pts,,stage,,15,2,43,no
3950,3080287,Table 1,BaselineCharacteristic,,,,,16,0,2,no
3950,3080287,Table 1,BaselineCharacteristic,Tx,,,,16,1,3,no
3950,3080287,Table 1,BaselineCharacteristic,x pts,,,,16,2,3,no
3950,3080287,Table 1,BaselineCharacteristic,,,,,17,0,2,no
3950,3080287,Table 1,BaselineCharacteristic,Tx,,,,17,1,3,no
3950,3080287,Table 1,BaselineCharacteristic,x pt,,,,17,2,3,no
3950,3080287,Table 1,BaselineCharacteristic,,,,,18,0,2,no
3950,3080287,Table 1,BaselineCharacteristic,N+,,,,18,1,3,no
3950,3080287,Table 1,BaselineCharacteristic,x pt,,,,18,2,3,no
3950,3080287,Table 1,BaselineCharacteristic,,,,,19,0,2,no
3950,3080287,Table 1,BaselineCharacteristic,not applicable,,,,19,1,3,no
3950,3080287,Table 1,BaselineCharacteristic,x pts,,,,19,2,3,no
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,20,0,2,no
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,20,1,3,no
3950,3080287,Table 1,BaselineCharacteristic,,,None,None,20,2,3,no
3950,3080287,Table 1,BaselineCharacteristic,therapy,,therapy,,21,0,24,no
3950,3080287,Table 1,BaselineCharacteristic,primary,,therapy,,21,1,43,no
3950,3080287,Table 1,BaselineCharacteristic,xx pts,,therapy,,21,2,43,no
3950,3080287,Table 1,BaselineCharacteristic,,,,,22,0,2,no
3950,3080287,Table 1,BaselineCharacteristic,local relapse,,,,22,1,3,no
3950,3080287,Table 1,BaselineCharacteristic,x pts,,,,22,2,3,no
3950,3080287,Table 1,BaselineCharacteristic,,,,,23,0,2,no
3950,3080287,Table 1,BaselineCharacteristic,reirradiation,,,,23,1,3,no
3950,3080287,Table 1,BaselineCharacteristic,x pts,,,,23,2,3,no
3950,3080287,Table 1,BaselineCharacteristic,,,,,24,0,2,no
3950,3080287,Table 1,BaselineCharacteristic,Rx-resected,,,,24,1,3,no
3950,3080287,Table 1,BaselineCharacteristic,xx pts,,,,24,2,3,no
3950,3080287,Table 1,BaselineCharacteristic,,,,,25,0,2,no
3950,3080287,Table 1,BaselineCharacteristic,Rx-resected/definitive RT,,,,25,1,3,no
3950,3080287,Table 1,BaselineCharacteristic,xx pts,,,,25,2,3,no
3950,3080287,Table 1,BaselineCharacteristic,,,,,26,0,2,no
3950,3080287,Table 1,BaselineCharacteristic,orbital exenteration,,,,26,1,3,no
3950,3080287,Table 1,BaselineCharacteristic,x pts,,,,26,2,3,no
3950,3080287,Table 1,BaselineCharacteristic,,,,,27,0,2,no
3950,3080287,Table 1,BaselineCharacteristic,post-induction,,,,27,1,3,no
3950,3080287,Table 1,BaselineCharacteristic,x pts,,,,27,2,3,no
3950,3080287,Table 1,BaselineCharacteristic,,,,,28,0,2,no
3950,3080287,Table 1,BaselineCharacteristic,comb. Radioimmunotherapy,,,,28,1,3,no
3950,3080287,Table 1,BaselineCharacteristic,x pt,,,,28,2,3,no
3950,3080287,Table 2,BaselineCharacteristic,,,None,None,0,0,12,no
3950,3080287,Table 2,BaselineCharacteristic,median dose/GyE or Gy,,,None,0,1,1,no
3950,3080287,Table 2,BaselineCharacteristic,range/GyE or Gy,,,None,0,2,1,no
3950,3080287,Table 2,BaselineCharacteristic,Cxx, ; ,Cxx,,1,0,2,no
3950,3080287,Table 2,BaselineCharacteristic,xx,median dose/GyE or Gy ; ,Cxx,,1,1,3,no
3950,3080287,Table 2,BaselineCharacteristic,xx - xx,range/GyE or Gy ; ,Cxx,,1,2,3,no
3950,3080287,Table 2,BaselineCharacteristic,IMRT, ; ,IMRT,,2,0,2,no
3950,3080287,Table 2,BaselineCharacteristic,xx,median dose/GyE or Gy ; ,IMRT,,2,1,3,no
3950,3080287,Table 2,BaselineCharacteristic,xx - xx,range/GyE or Gy ; ,IMRT,,2,2,3,no
3950,3080287,Table 2,BaselineCharacteristic,total, ; ,total,,3,0,24,no
3950,3080287,Table 2,BaselineCharacteristic,xx,median dose/GyE or Gy ; ,total,,3,1,43,no
3950,3080287,Table 2,BaselineCharacteristic,xx - xx,range/GyE or Gy ; ,total,,3,2,43,no
3950,3080287,Table 2,BaselineCharacteristic,, ; ,,,4,0,2,no
3950,3080287,Table 2,BaselineCharacteristic,median volume/cc,median dose/GyE or Gy ; ,,,4,1,3,no
3950,3080287,Table 2,BaselineCharacteristic,range/cc,range/GyE or Gy ; ,,,4,2,3,no
3950,3080287,Table 2,BaselineCharacteristic,CTVx, ; ,CTVx,,5,0,2,no
3950,3080287,Table 2,BaselineCharacteristic,xxx.x,median dose/GyE or Gy ; ,CTVx,,5,1,3,no
3950,3080287,Table 2,BaselineCharacteristic,xx.x - xxx.x,range/GyE or Gy ; ,CTVx,,5,2,3,no
3950,3080287,Table 2,BaselineCharacteristic,CTVx, ; ,CTVx,,6,0,2,no
3950,3080287,Table 2,BaselineCharacteristic,xxx.x,median dose/GyE or Gy ; ,CTVx,,6,1,3,no
3950,3080287,Table 2,BaselineCharacteristic,xxx.x - xxxx.x,range/GyE or Gy ; ,CTVx,,6,2,3,no
3950,3080287,Table 2,BaselineCharacteristic,, ; ,None,None,7,0,2,no
3950,3080287,Table 2,BaselineCharacteristic,,median dose/GyE or Gy ; ,None,None,7,1,3,no
3950,3080287,Table 2,BaselineCharacteristic,,range/GyE or Gy ; ,None,None,7,2,3,no
3950,3080287,Table 2,BaselineCharacteristic,combined treatment, ; ,combined treatment,,8,0,2,no
3950,3080287,Table 2,BaselineCharacteristic,xx pts,median dose/GyE or Gy ; ,combined treatment,,8,1,3,no
3950,3080287,Table 2,BaselineCharacteristic,(x fractions Cxx),range/GyE or Gy ; ,combined treatment,,8,2,3,no
3950,3080287,Table 2,BaselineCharacteristic,step& shoot IMRT, ; ,step& shoot IMRT,,9,0,2,no
3950,3080287,Table 2,BaselineCharacteristic,xx pts,median dose/GyE or Gy ; ,step& shoot IMRT,,9,1,3,no
3950,3080287,Table 2,BaselineCharacteristic,,range/GyE or Gy ; ,step& shoot IMRT,,9,2,3,no
3950,3080287,Table 2,BaselineCharacteristic,tomotherapy, ; ,tomotherapy,,10,0,2,no
3950,3080287,Table 2,BaselineCharacteristic,x pts,median dose/GyE or Gy ; ,tomotherapy,,10,1,3,no
3950,3080287,Table 2,BaselineCharacteristic,,range/GyE or Gy ; ,tomotherapy,,10,2,3,no
3950,3080287,Table 2,BaselineCharacteristic,Cxx only, ; ,Cxx only,,11,0,2,no
3950,3080287,Table 2,BaselineCharacteristic,x pts,median dose/GyE or Gy ; ,Cxx only,,11,1,3,no
3950,3080287,Table 2,BaselineCharacteristic,(xx-xx fractions),range/GyE or Gy ; ,Cxx only,,11,2,3,no
4000,3095543,Table 1,BaselineCharacteristic,Clinical characterisitics,,None,None,0,0,,no
4000,3095543,Table 1,BaselineCharacteristic,Mean (SD),,None,None,0,1,,no
4000,3095543,Table 1,BaselineCharacteristic,"Age, y",Clinical characterisitics ; ,None,None,1,0,,no
4000,3095543,Table 1,BaselineCharacteristic,x.xx (x.xx),Mean (SD) ; ,None,None,1,1,,no
4000,3095543,Table 1,BaselineCharacteristic,,"Clinical characterisitics ; Age, y ; ",None,None,2,0,,no
4000,3095543,Table 1,BaselineCharacteristic,,Mean (SD) ; x.xx (x.xx) ; ,None,None,2,1,,no
4000,3095543,Table 1,BaselineCharacteristic,IQ (WISC-III Full Scale),"Clinical characterisitics ; Age, y ;  ; ",None,None,3,0,,no
4000,3095543,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Mean (SD) ; x.xx (x.xx) ;  ; ,None,None,3,1,,no
4000,3095543,Table 1,BaselineCharacteristic,,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ; ",None,None,4,0,,no
4000,3095543,Table 1,BaselineCharacteristic,,Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ; ,None,None,4,1,,no
4000,3095543,Table 1,BaselineCharacteristic,"Mother's age, y","Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; ",None,None,5,0,,no
4000,3095543,Table 1,BaselineCharacteristic,xx.xx (x.xx),Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; ,None,None,5,1,,no
4000,3095543,Table 1,BaselineCharacteristic,,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ; ",None,None,6,0,,no
4000,3095543,Table 1,BaselineCharacteristic,,Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ; ,None,None,6,1,,no
4000,3095543,Table 1,BaselineCharacteristic,"Mother's education, y","Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; ",None,None,7,0,,no
4000,3095543,Table 1,BaselineCharacteristic,xx.xx (x.xx),Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; ,None,None,7,1,,no
4000,3095543,Table 1,BaselineCharacteristic,,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ; ",None,None,8,0,,no
4000,3095543,Table 1,BaselineCharacteristic,,Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ; ,None,None,8,1,,no
4000,3095543,Table 1,BaselineCharacteristic,CBCL scales,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",None,None,9,0,,no
4000,3095543,Table 1,BaselineCharacteristic,CBCL scales,Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,None,None,9,1,,no
4000,3095543,Table 1,BaselineCharacteristic,,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",None,None,10,0,,no
4000,3095543,Table 1,BaselineCharacteristic,,Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,None,None,10,1,,no
4000,3095543,Table 1,BaselineCharacteristic,Aggression,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",Aggression, CBCL scales,11,0,,no
4000,3095543,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,Aggression, CBCL scales,11,1,,no
4000,3095543,Table 1,BaselineCharacteristic,,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",None,None,12,0,,no
4000,3095543,Table 1,BaselineCharacteristic,,Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,None,None,12,1,,no
4000,3095543,Table 1,BaselineCharacteristic,Attention Problems,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",Attention Problems, CBCL scales,13,0,,no
4000,3095543,Table 1,BaselineCharacteristic,xx.xx (x.xx),Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,Attention Problems, CBCL scales,13,1,,no
4000,3095543,Table 1,BaselineCharacteristic,,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",None,None,14,0,,no
4000,3095543,Table 1,BaselineCharacteristic,,Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,None,None,14,1,,no
4000,3095543,Table 1,BaselineCharacteristic,CPRS scales,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",None,None,15,0,,no
4000,3095543,Table 1,BaselineCharacteristic,CPRS scales,Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,None,None,15,1,,no
4000,3095543,Table 1,BaselineCharacteristic,,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",None,None,16,0,,no
4000,3095543,Table 1,BaselineCharacteristic,,Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,None,None,16,1,,no
4000,3095543,Table 1,BaselineCharacteristic,Restless-Impulsive,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",Restless-Impulsive, CPRS scales,17,0,,no
4000,3095543,Table 1,BaselineCharacteristic,xx.xx (x.xx),Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,Restless-Impulsive, CPRS scales,17,1,,no
4000,3095543,Table 1,BaselineCharacteristic,,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",None,None,18,0,,no
4000,3095543,Table 1,BaselineCharacteristic,,Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,None,None,18,1,,no
4000,3095543,Table 1,BaselineCharacteristic,Emotional Lability,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",Emotional Lability, CPRS scales,19,0,,no
4000,3095543,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,Emotional Lability, CPRS scales,19,1,,no
4000,3095543,Table 1,BaselineCharacteristic,,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",None,None,20,0,,no
4000,3095543,Table 1,BaselineCharacteristic,,Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,None,None,20,1,,no
4000,3095543,Table 1,BaselineCharacteristic,CTRS scales,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",None,None,21,0,,no
4000,3095543,Table 1,BaselineCharacteristic,CTRS scales,Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,None,None,21,1,,no
4000,3095543,Table 1,BaselineCharacteristic,,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",None,None,22,0,,no
4000,3095543,Table 1,BaselineCharacteristic,,Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,None,None,22,1,,no
4000,3095543,Table 1,BaselineCharacteristic,Restless-Impulsive,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",Restless-Impulsive, CTRS scales,23,0,,no
4000,3095543,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,Restless-Impulsive, CTRS scales,23,1,,no
4000,3095543,Table 1,BaselineCharacteristic,,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",None,None,24,0,,no
4000,3095543,Table 1,BaselineCharacteristic,,Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,None,None,24,1,,no
4000,3095543,Table 1,BaselineCharacteristic,Emotional Lability,"Clinical characterisitics ; Age, y ;  ; IQ (WISC-III Full Scale) ;  ; Mother's age, y ;  ; Mother's education, y ;  ; ",Emotional Lability, CTRS scales,25,0,,no
4000,3095543,Table 1,BaselineCharacteristic,xx.xx (xx.xx),Mean (SD) ; x.xx (x.xx) ;  ; xx.xx (xx.xx) ;  ; xx.xx (x.xx) ;  ; xx.xx (x.xx) ;  ; ,Emotional Lability, CTRS scales,25,1,,no
4021,3101364,Table 1.,BaselineCharacteristic,Characteristic,,None,None,0,0,12,no
4021,3101364,Table 1.,BaselineCharacteristic,No. of patients,,Characteristic,None,0,1,1,no
4021,3101364,Table 1.,BaselineCharacteristic,No. of patients entered,Characteristic ; ,No. of patients entered,,1,0,2,no
4021,3101364,Table 1.,BaselineCharacteristic,xx,No. of patients ; ,No. of patients entered,,1,1,3,no
4021,3101364,Table 1.,BaselineCharacteristic,No. of patients eligible,Characteristic ; ,No. of patients eligible,,2,0,2,no
4021,3101364,Table 1.,BaselineCharacteristic,xx,No. of patients ; ,No. of patients eligible,,2,1,3,no
4021,3101364,Table 1.,BaselineCharacteristic,Age (years),Characteristic ; ,None,None,3,0,24,no
4021,3101364,Table 1.,BaselineCharacteristic,Age (years),No. of patients ; ,Age (years),None,3,1,43,no
4021,3101364,Table 1.,BaselineCharacteristic,????Median,Characteristic ; ,????Median, Age (years)   ,4,0,2,no
4021,3101364,Table 1.,BaselineCharacteristic,xx,No. of patients ; ,????Median, Age (years)   ,4,1,3,no
4021,3101364,Table 1.,BaselineCharacteristic,????Range,Characteristic ; ,????Range, Age (years)   ,5,0,2,no
4021,3101364,Table 1.,BaselineCharacteristic,Performance status,Characteristic ; ,None,None,6,0,24,no
4021,3101364,Table 1.,BaselineCharacteristic,Performance status,No. of patients ; ,Performance status,None,6,1,43,no
4021,3101364,Table 1.,BaselineCharacteristic,????x,Characteristic ; ,????x, Performance status   ,7,0,2,no
4021,3101364,Table 1.,BaselineCharacteristic,xx,No. of patients ; ,????x, Performance status   ,7,1,3,no
4021,3101364,Table 1.,BaselineCharacteristic,????x,Characteristic ; ,????x, Performance status   ,8,0,2,no
4021,3101364,Table 1.,BaselineCharacteristic,xx,No. of patients ; ,????x, Performance status   ,8,1,3,no
4021,3101364,Table 1.,BaselineCharacteristic,Histology,Characteristic ; ,None,None,9,0,24,no
4021,3101364,Table 1.,BaselineCharacteristic,Histology,No. of patients ; ,Histology,None,9,1,43,no
4021,3101364,Table 1.,BaselineCharacteristic,????Squamous cell carcinoma,Characteristic ; ,????Squamous cell carcinoma, Histology   ,10,0,2,no
4021,3101364,Table 1.,BaselineCharacteristic,xx,No. of patients ; ,????Squamous cell carcinoma, Histology   ,10,1,3,no
4021,3101364,Table 1.,BaselineCharacteristic,????Adenocarcinoma,Characteristic ; ,????Adenocarcinoma, Histology   ,11,0,2,no
4021,3101364,Table 1.,BaselineCharacteristic,x,No. of patients ; ,????Adenocarcinoma, Histology   ,11,1,3,no
4021,3101364,Table 1.,BaselineCharacteristic,????Adenosquamous,Characteristic ; ,????Adenosquamous, Histology   ,12,0,2,no
4021,3101364,Table 1.,BaselineCharacteristic,x,No. of patients ; ,????Adenosquamous, Histology   ,12,1,3,no
4021,3101364,Table 1.,BaselineCharacteristic,????Small cell carcinoma,Characteristic ; ,????Small cell carcinoma, Histology   ,13,0,2,no
4021,3101364,Table 1.,BaselineCharacteristic,x,No. of patients ; ,????Small cell carcinoma, Histology   ,13,1,3,no
4021,3101364,Table 1.,BaselineCharacteristic,Site of disease,Characteristic ; ,None,None,14,0,24,no
4021,3101364,Table 1.,BaselineCharacteristic,Site of disease,No. of patients ; ,Site of disease,None,14,1,43,no
4021,3101364,Table 1.,BaselineCharacteristic,????Pelvic,Characteristic ; ,????Pelvic, Site of disease   ,15,0,2,no
4021,3101364,Table 1.,BaselineCharacteristic,xx,No. of patients ; ,????Pelvic, Site of disease   ,15,1,3,no
4021,3101364,Table 1.,BaselineCharacteristic,????Distant,Characteristic ; ,????Distant, Site of disease   ,16,0,2,no
4021,3101364,Table 1.,BaselineCharacteristic,xx,No. of patients ; ,????Distant, Site of disease   ,16,1,3,no
4021,3101364,Table 1.,BaselineCharacteristic,????Both,Characteristic ; ,????Both, Site of disease   ,17,0,2,no
4021,3101364,Table 1.,BaselineCharacteristic,xx,No. of patients ; ,????Both, Site of disease   ,17,1,3,no
4021,3101364,Table 1.,BaselineCharacteristic,Prior therapy,Characteristic ; ,None,None,18,0,24,no
4021,3101364,Table 1.,BaselineCharacteristic,Prior therapy,No. of patients ; ,Prior therapy,None,18,1,43,no
4021,3101364,Table 1.,BaselineCharacteristic,????Prior radiotherapy,Characteristic ; ,????Prior radiotherapy, Prior therapy   ,19,0,2,no
4021,3101364,Table 1.,BaselineCharacteristic,xx,No. of patients ; ,????Prior radiotherapy, Prior therapy   ,19,1,3,no
4021,3101364,Table 1.,BaselineCharacteristic,?Prior chemotherapya,Characteristic ; ,?Prior chemotherapya, Prior therapy,20,0,24,no
4021,3101364,Table 1.,BaselineCharacteristic,xx,No. of patients ; ,?Prior chemotherapya, Prior therapy,20,1,43,no
4021,3101364,Table 1.,BaselineCharacteristic,????Prior chemoradiotherapy,Characteristic ; ,????Prior chemoradiotherapy, Prior therapy ?Prior chemotherapya  ,21,0,2,no
4021,3101364,Table 1.,BaselineCharacteristic,xx,No. of patients ; ,????Prior chemoradiotherapy, Prior therapy ?Prior chemotherapya  ,21,1,3,no
4021,3101364,Table 1.,BaselineCharacteristic,????Prior platinum therapy,Characteristic ; ,????Prior platinum therapy, Prior therapy ?Prior chemotherapya  ,22,0,2,no
4021,3101364,Table 1.,BaselineCharacteristic,xx,No. of patients ; ,????Prior platinum therapy, Prior therapy ?Prior chemotherapya  ,22,1,3,no
4021,3101364,Table 2.,BaselineCharacteristic,,,None,None,0,0,12,no
4021,3101364,Table 2.,BaselineCharacteristic,n,,,None,0,1,1,no
4021,3101364,Table 2.,BaselineCharacteristic,CR,,,None,0,2,1,no
4021,3101364,Table 2.,BaselineCharacteristic,PR,,,None,0,3,1,no
4021,3101364,Table 2.,BaselineCharacteristic,SD,,,None,0,4,1,no
4021,3101364,Table 2.,BaselineCharacteristic,PD,,,None,0,5,1,no
4021,3101364,Table 2.,BaselineCharacteristic,Response rate (xx% CI),,,None,0,6,1,no
4021,3101364,Table 2.,BaselineCharacteristic,Overall, ; ,Overall,,1,0,2,no
4021,3101364,Table 2.,BaselineCharacteristic,xx,n ; ,Overall,,1,1,3,no
4021,3101364,Table 2.,BaselineCharacteristic,x,CR ; ,Overall,,1,2,3,no
4021,3101364,Table 2.,BaselineCharacteristic,xx,PR ; ,Overall,,1,3,3,no
4021,3101364,Table 2.,BaselineCharacteristic,xx,SD ; ,Overall,,1,4,3,no
4021,3101364,Table 2.,BaselineCharacteristic,x,PD ; ,Overall,,1,5,3,no
4021,3101364,Table 2.,BaselineCharacteristic,Prior therapy, ; ,None,None,2,0,24,no
4021,3101364,Table 2.,BaselineCharacteristic,Prior therapy,n ; ,Prior therapy,None,2,1,43,no
4021,3101364,Table 2.,BaselineCharacteristic,Prior therapy,CR ; ,Prior therapy,None,2,2,43,no
4021,3101364,Table 2.,BaselineCharacteristic,Prior therapy,PR ; ,Prior therapy,None,2,3,43,no
4021,3101364,Table 2.,BaselineCharacteristic,Prior therapy,SD ; ,Prior therapy,None,2,4,43,no
4021,3101364,Table 2.,BaselineCharacteristic,Prior therapy,PD ; ,Prior therapy,None,2,5,43,no
4021,3101364,Table 2.,BaselineCharacteristic,Prior therapy,Response rate (xx% CI) ; ,Prior therapy,None,2,6,43,no
4021,3101364,Table 2.,BaselineCharacteristic,????Chemotherapy, ; ,????Chemotherapy, Prior therapy   ,3,0,2,no
4021,3101364,Table 2.,BaselineCharacteristic,xx,n ; ,????Chemotherapy, Prior therapy   ,3,1,3,no
4021,3101364,Table 2.,BaselineCharacteristic,x,CR ; ,????Chemotherapy, Prior therapy   ,3,2,3,no
4021,3101364,Table 2.,BaselineCharacteristic,x,PR ; ,????Chemotherapy, Prior therapy   ,3,3,3,no
4021,3101364,Table 2.,BaselineCharacteristic,x,SD ; ,????Chemotherapy, Prior therapy   ,3,4,3,no
4021,3101364,Table 2.,BaselineCharacteristic,x,PD ; ,????Chemotherapy, Prior therapy   ,3,5,3,no
4021,3101364,Table 2.,BaselineCharacteristic,????Chemoradiotherapy, ; ,????Chemoradiotherapy, Prior therapy   ,4,0,2,no
4021,3101364,Table 2.,BaselineCharacteristic,xx,n ; ,????Chemoradiotherapy, Prior therapy   ,4,1,3,no
4021,3101364,Table 2.,BaselineCharacteristic,x,CR ; ,????Chemoradiotherapy, Prior therapy   ,4,2,3,no
4021,3101364,Table 2.,BaselineCharacteristic,x,PR ; ,????Chemoradiotherapy, Prior therapy   ,4,3,3,no
4021,3101364,Table 2.,BaselineCharacteristic,x,SD ; ,????Chemoradiotherapy, Prior therapy   ,4,4,3,no
4021,3101364,Table 2.,BaselineCharacteristic,x,PD ; ,????Chemoradiotherapy, Prior therapy   ,4,5,3,no
4021,3101364,Table 2.,BaselineCharacteristic,????Platinum therapy, ; ,????Platinum therapy, Prior therapy   ,5,0,2,no
4021,3101364,Table 2.,BaselineCharacteristic,xx,n ; ,????Platinum therapy, Prior therapy   ,5,1,3,no
4021,3101364,Table 2.,BaselineCharacteristic,x,CR ; ,????Platinum therapy, Prior therapy   ,5,2,3,no
4021,3101364,Table 2.,BaselineCharacteristic,x,PR ; ,????Platinum therapy, Prior therapy   ,5,3,3,no
4021,3101364,Table 2.,BaselineCharacteristic,xx,SD ; ,????Platinum therapy, Prior therapy   ,5,4,3,no
4021,3101364,Table 2.,BaselineCharacteristic,x,PD ; ,????Platinum therapy, Prior therapy   ,5,5,3,no
4021,3101364,Table 2.,BaselineCharacteristic,????No platinum therapy, ; ,????No platinum therapy, Prior therapy   ,6,0,2,no
4021,3101364,Table 2.,BaselineCharacteristic,xx,n ; ,????No platinum therapy, Prior therapy   ,6,1,3,no
4021,3101364,Table 2.,BaselineCharacteristic,x,CR ; ,????No platinum therapy, Prior therapy   ,6,2,3,no
4021,3101364,Table 2.,BaselineCharacteristic,x,PR ; ,????No platinum therapy, Prior therapy   ,6,3,3,no
4021,3101364,Table 2.,BaselineCharacteristic,x,SD ; ,????No platinum therapy, Prior therapy   ,6,4,3,no
4021,3101364,Table 2.,BaselineCharacteristic,x,PD ; ,????No platinum therapy, Prior therapy   ,6,5,3,no
4275,3170974,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no
4275,3170974,Table 1,BaselineCharacteristic,Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d.,,,None,0,1,1,no
4275,3170974,Table 1,BaselineCharacteristic,Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d.,,,None,0,2,1,no
4275,3170974,Table 1,BaselineCharacteristic,"Median age (range), years", ; ,"Median age (range), years",,1,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,, ; ,None,None,2,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,,Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,None,None,2,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,,Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,None,None,2,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,"Sex, n (%)", ; ,None,None,3,0,24,no
4275,3170974,Table 1,BaselineCharacteristic,"Sex, n (%)",Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,"Sex, n (%)",None,3,1,43,no
4275,3170974,Table 1,BaselineCharacteristic,"Sex, n (%)",Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,"Sex, n (%)",None,3,2,43,no
4275,3170974,Table 1,BaselineCharacteristic,?Male, ; ,?Male," Sex, n (%)",4,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Male," Sex, n (%)",4,1,3,yes
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Male," Sex, n (%)",4,2,3,yes
4275,3170974,Table 1,BaselineCharacteristic,?Female, ; ,?Female," Sex, n (%)",5,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Female," Sex, n (%)",5,1,3,yes
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Female," Sex, n (%)",5,2,3,yes
4275,3170974,Table 1,BaselineCharacteristic,, ; ,None,None,6,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,,Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,None,None,6,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,,Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,None,None,6,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,"Tumor-related symptoms, n (%)", ; ,"Tumor-related symptoms, n (%)",,7,0,24,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,"Tumor-related symptoms, n (%)",,7,1,43,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,"Tumor-related symptoms, n (%)",,7,2,43,no
4275,3170974,Table 1,BaselineCharacteristic,?Appetite loss, ; ,?Appetite loss," Tumor-related symptoms, n (%)",8,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Appetite loss," Tumor-related symptoms, n (%)",8,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Appetite loss," Tumor-related symptoms, n (%)",8,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,?Nausea/vomiting, ; ,?Nausea/vomiting," Tumor-related symptoms, n (%)",9,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Nausea/vomiting," Tumor-related symptoms, n (%)",9,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Nausea/vomiting," Tumor-related symptoms, n (%)",9,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,?Weight loss, ; ,?Weight loss," Tumor-related symptoms, n (%)",10,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Weight loss," Tumor-related symptoms, n (%)",10,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Weight loss," Tumor-related symptoms, n (%)",10,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,?Pain, ; ,?Pain," Tumor-related symptoms, n (%)",11,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Pain," Tumor-related symptoms, n (%)",11,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Pain," Tumor-related symptoms, n (%)",11,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,?Dysphagia, ; ,?Dysphagia," Tumor-related symptoms, n (%)",12,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Dysphagia," Tumor-related symptoms, n (%)",12,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Dysphagia," Tumor-related symptoms, n (%)",12,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,?Other, ; ,?Other," Tumor-related symptoms, n (%)",13,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Other," Tumor-related symptoms, n (%)",13,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Other," Tumor-related symptoms, n (%)",13,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,, ; ,None,None,14,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,,Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,None,None,14,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,,Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,None,None,14,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,"ECOG performance status, n (%)", ; ,None,None,15,0,24,no
4275,3170974,Table 1,BaselineCharacteristic,"ECOG performance status, n (%)",Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,"ECOG performance status, n (%)",None,15,1,43,no
4275,3170974,Table 1,BaselineCharacteristic,"ECOG performance status, n (%)",Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,"ECOG performance status, n (%)",None,15,2,43,no
4275,3170974,Table 1,BaselineCharacteristic,?x, ; ,?x," ECOG performance status, n (%)",16,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,x (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?x," ECOG performance status, n (%)",16,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?x," ECOG performance status, n (%)",16,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,?x, ; ,?x," ECOG performance status, n (%)",17,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?x," ECOG performance status, n (%)",17,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?x," ECOG performance status, n (%)",17,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,?x, ; ,?x," ECOG performance status, n (%)",18,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,x (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?x," ECOG performance status, n (%)",18,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?x," ECOG performance status, n (%)",18,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,, ; ,None,None,19,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,,Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,None,None,19,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,,Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,None,None,19,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,"Primary tumor, n (%)", ; ,None,None,20,0,24,no
4275,3170974,Table 1,BaselineCharacteristic,"Primary tumor, n (%)",Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,"Primary tumor, n (%)",None,20,1,43,no
4275,3170974,Table 1,BaselineCharacteristic,"Primary tumor, n (%)",Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,"Primary tumor, n (%)",None,20,2,43,no
4275,3170974,Table 1,BaselineCharacteristic,?Gastro-esophageal junction, ; ,?Gastro-esophageal junction," Primary tumor, n (%)",21,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Gastro-esophageal junction," Primary tumor, n (%)",21,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Gastro-esophageal junction," Primary tumor, n (%)",21,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,?Gastric body, ; ,?Gastric body," Primary tumor, n (%)",22,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Gastric body," Primary tumor, n (%)",22,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Gastric body," Primary tumor, n (%)",22,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,?Not specified, ; ,?Not specified," Primary tumor, n (%)",23,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,x (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Not specified," Primary tumor, n (%)",23,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,x (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Not specified," Primary tumor, n (%)",23,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,, ; ,None,None,24,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,,Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,None,None,24,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,,Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,None,None,24,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,"Extent of disease, n (%)", ; ,None,None,25,0,24,no
4275,3170974,Table 1,BaselineCharacteristic,"Extent of disease, n (%)",Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,"Extent of disease, n (%)",None,25,1,43,no
4275,3170974,Table 1,BaselineCharacteristic,"Extent of disease, n (%)",Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,"Extent of disease, n (%)",None,25,2,43,no
4275,3170974,Table 1,BaselineCharacteristic,?Metastatic, ; ,?Metastatic," Extent of disease, n (%)",26,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xxx),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Metastatic," Extent of disease, n (%)",26,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xxx),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Metastatic," Extent of disease, n (%)",26,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,?Locally advanced, ; ,?Locally advanced," Extent of disease, n (%)",27,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,x (x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Locally advanced," Extent of disease, n (%)",27,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,x (x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Locally advanced," Extent of disease, n (%)",27,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,, ; ,None,None,28,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,,Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,None,None,28,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,,Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,None,None,28,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,Histological type, ; ,None,None,29,0,24,no
4275,3170974,Table 1,BaselineCharacteristic,Histological type,Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,Histological type,None,29,1,43,no
4275,3170974,Table 1,BaselineCharacteristic,Histological type,Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,Histological type,None,29,2,43,no
4275,3170974,Table 1,BaselineCharacteristic,?Intestinal, ; ,?Intestinal, Histological type,30,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Intestinal, Histological type,30,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Intestinal, Histological type,30,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,?Diffuse, ; ,?Diffuse, Histological type,31,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Diffuse, Histological type,31,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Diffuse, Histological type,31,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,?Not specified, ; ,?Not specified, Histological type,32,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Not specified, Histological type,32,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Not specified, Histological type,32,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,, ; ,None,None,33,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,,Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,None,None,33,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,,Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,None,None,33,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,"Metastatic sites, n (%)", ; ,None,None,34,0,24,no
4275,3170974,Table 1,BaselineCharacteristic,"Metastatic sites, n (%)",Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,"Metastatic sites, n (%)",None,34,1,43,no
4275,3170974,Table 1,BaselineCharacteristic,"Metastatic sites, n (%)",Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,"Metastatic sites, n (%)",None,34,2,43,no
4275,3170974,Table 1,BaselineCharacteristic,??x, ; ,??x," Metastatic sites, n (%)",35,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,??x," Metastatic sites, n (%)",35,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,??x," Metastatic sites, n (%)",35,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,?>x, ; ,?>x," Metastatic sites, n (%)",36,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?>x," Metastatic sites, n (%)",36,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?>x," Metastatic sites, n (%)",36,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,, ; ,None,None,37,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,,Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,None,None,37,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,,Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,None,None,37,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,"Organs involved by metastases, n (%)", ; ,None,None,38,0,24,no
4275,3170974,Table 1,BaselineCharacteristic,"Organs involved by metastases, n (%)",Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,"Organs involved by metastases, n (%)",None,38,1,43,no
4275,3170974,Table 1,BaselineCharacteristic,"Organs involved by metastases, n (%)",Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,"Organs involved by metastases, n (%)",None,38,2,43,no
4275,3170974,Table 1,BaselineCharacteristic,?Peritoneal carcinomatosis, ; ,?Peritoneal carcinomatosis," Organs involved by metastases, n (%)",39,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Peritoneal carcinomatosis," Organs involved by metastases, n (%)",39,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Peritoneal carcinomatosis," Organs involved by metastases, n (%)",39,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,?Lung, ; ,?Lung," Organs involved by metastases, n (%)",40,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,x (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Lung," Organs involved by metastases, n (%)",40,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,x (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Lung," Organs involved by metastases, n (%)",40,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,?Lymphnode, ; ,?Lymphnode," Organs involved by metastases, n (%)",41,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Lymphnode," Organs involved by metastases, n (%)",41,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Lymphnode," Organs involved by metastases, n (%)",41,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,?Liver, ; ,?Liver," Organs involved by metastases, n (%)",42,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Liver," Organs involved by metastases, n (%)",42,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Liver," Organs involved by metastases, n (%)",42,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,?Bone, ; ,?Bone," Organs involved by metastases, n (%)",43,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,x (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Bone," Organs involved by metastases, n (%)",43,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,x (x.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Bone," Organs involved by metastases, n (%)",43,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,?Intra-abdominal massa, ; ,?Intra-abdominal massa," Organs involved by metastases, n (%)",44,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,x (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Intra-abdominal massa," Organs involved by metastases, n (%)",44,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,x (x.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Intra-abdominal massa," Organs involved by metastases, n (%)",44,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,?Abdominal wall, ; ,?Abdominal wall," Organs involved by metastases, n (%)",45,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,x (x.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Abdominal wall," Organs involved by metastases, n (%)",45,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,x (x.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Abdominal wall," Organs involved by metastases, n (%)",45,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,?Otherb, ; ,?Otherb," Organs involved by metastases, n (%)",46,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,x (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Otherb," Organs involved by metastases, n (%)",46,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,x (x.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Otherb," Organs involved by metastases, n (%)",46,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,, ; ,None,None,47,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,,Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,None,None,47,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,,Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,None,None,47,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,"Surgery for primary tumor, n (%)", ; ,None,None,48,0,24,no
4275,3170974,Table 1,BaselineCharacteristic,"Surgery for primary tumor, n (%)",Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,"Surgery for primary tumor, n (%)",None,48,1,43,no
4275,3170974,Table 1,BaselineCharacteristic,"Surgery for primary tumor, n (%)",Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,"Surgery for primary tumor, n (%)",None,48,2,43,no
4275,3170974,Table 1,BaselineCharacteristic,?Yes, ; ,?Yes," Surgery for primary tumor, n (%)",49,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?Yes," Surgery for primary tumor, n (%)",49,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Yes," Surgery for primary tumor, n (%)",49,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,?No, ; ,?No," Surgery for primary tumor, n (%)",50,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,?No," Surgery for primary tumor, n (%)",50,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?No," Surgery for primary tumor, n (%)",50,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,?Not known, ; ,?Not known," Surgery for primary tumor, n (%)",51,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,x (x.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,?Not known," Surgery for primary tumor, n (%)",51,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,, ; ,None,None,52,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,,Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,None,None,52,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,,Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,None,None,52,2,3,no
4275,3170974,Table 1,BaselineCharacteristic,"Measurable disease, n (%)", ; ,"Measurable disease, n (%)",,53,0,2,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xxx),Cohort I (N=xx) Docetaxel xx?mg m?x plus capecitabine xxxx?mg m?x b.i.d. ; ,"Measurable disease, n (%)",,53,1,3,no
4275,3170974,Table 1,BaselineCharacteristic,xx (xx.x),Cohort II (N=xx) Docetaxel xx?mg m?x plus capecitabine xxx?mg m?x b.i.d. ; ,"Measurable disease, n (%)",,53,2,3,no
4321,3179720,Table 1,BaselineCharacteristic,Characteristics,,None,None,0,0,12,no
4321,3179720,Table 1,BaselineCharacteristic,Patients (n = xx),,Characteristics,None,0,1,1,no
4321,3179720,Table 1,BaselineCharacteristic,"Median age, years (range)",Characteristics ; ,"Median age, years (range)",,1,0,2,no
4321,3179720,Table 1,BaselineCharacteristic,xx (xx-xx),Patients (n = xx) ; ,"Median age, years (range)",,1,1,3,no
4321,3179720,Table 1,BaselineCharacteristic,"Gender, n (%):",Characteristics ; ,None,None,2,0,24,no
4321,3179720,Table 1,BaselineCharacteristic,,Patients (n = xx) ; ,"Gender, n (%):",None,2,1,43,no
4321,3179720,Table 1,BaselineCharacteristic,?Male,Characteristics ; ,?Male," Gender, n (%):",3,0,2,no
4321,3179720,Table 1,BaselineCharacteristic,xx (xx),Patients (n = xx) ; ,?Male," Gender, n (%):",3,1,3,yes
4321,3179720,Table 1,BaselineCharacteristic,?Female,Characteristics ; ,?Female," Gender, n (%):",4,0,2,no
4321,3179720,Table 1,BaselineCharacteristic,xx (xx),Patients (n = xx) ; ,?Female," Gender, n (%):",4,1,3,yes
4321,3179720,Table 1,BaselineCharacteristic,"WHO performance status, n (%)",Characteristics ; ,None,None,5,0,24,no
4321,3179720,Table 1,BaselineCharacteristic,,Patients (n = xx) ; ,"WHO performance status, n (%)",None,5,1,43,no
4321,3179720,Table 1,BaselineCharacteristic,?x,Characteristics ; ,?x," WHO performance status, n (%)",6,0,2,no
4321,3179720,Table 1,BaselineCharacteristic,xx (xx),Patients (n = xx) ; ,?x," WHO performance status, n (%)",6,1,3,no
4321,3179720,Table 1,BaselineCharacteristic,?x,Characteristics ; ,?x," WHO performance status, n (%)",7,0,2,no
4321,3179720,Table 1,BaselineCharacteristic,x (xx),Patients (n = xx) ; ,?x," WHO performance status, n (%)",7,1,3,no
4321,3179720,Table 1,BaselineCharacteristic,"TN clinical stage, n (%)",Characteristics ; ,None,None,8,0,24,no
4321,3179720,Table 1,BaselineCharacteristic,,Patients (n = xx) ; ,"TN clinical stage, n (%)",None,8,1,43,no
4321,3179720,Table 1,BaselineCharacteristic,?TxNx,Characteristics ; ,?TxNx," TN clinical stage, n (%)",9,0,2,no
4321,3179720,Table 1,BaselineCharacteristic,xx (xx.x),Patients (n = xx) ; ,?TxNx," TN clinical stage, n (%)",9,1,3,no
4321,3179720,Table 1,BaselineCharacteristic,?TxNx,Characteristics ; ,?TxNx," TN clinical stage, n (%)",10,0,2,no
4321,3179720,Table 1,BaselineCharacteristic,x (x.x),Patients (n = xx) ; ,?TxNx," TN clinical stage, n (%)",10,1,3,no
4321,3179720,Table 1,BaselineCharacteristic,?TxNx,Characteristics ; ,?TxNx," TN clinical stage, n (%)",11,0,2,no
4321,3179720,Table 1,BaselineCharacteristic,xx (xx.x),Patients (n = xx) ; ,?TxNx," TN clinical stage, n (%)",11,1,3,no
4321,3179720,Table 1,BaselineCharacteristic,?TxNx,Characteristics ; ,?TxNx," TN clinical stage, n (%)",12,0,2,no
4321,3179720,Table 1,BaselineCharacteristic,x (x.x),Patients (n = xx) ; ,?TxNx," TN clinical stage, n (%)",12,1,3,no
4321,3179720,Table 1,BaselineCharacteristic,?TxNx,Characteristics ; ,?TxNx," TN clinical stage, n (%)",13,0,2,no
4321,3179720,Table 1,BaselineCharacteristic,xx (xx.x),Patients (n = xx) ; ,?TxNx," TN clinical stage, n (%)",13,1,3,no
4321,3179720,Table 1,BaselineCharacteristic,?TxNx,Characteristics ; ,?TxNx," TN clinical stage, n (%)",14,0,2,no
4321,3179720,Table 1,BaselineCharacteristic,x (x.x),Patients (n = xx) ; ,?TxNx," TN clinical stage, n (%)",14,1,3,no
4321,3179720,Table 1,BaselineCharacteristic,"Median clinical tumour size per MRI, cm (range)",Characteristics ; ,"Median clinical tumour size per MRI, cm (range)",,15,0,2,no
4321,3179720,Table 1,BaselineCharacteristic,x (x-xx),Patients (n = xx) ; ,"Median clinical tumour size per MRI, cm (range)",,15,1,3,no
4321,3179720,Table 1,BaselineCharacteristic,"Median tumour distance from anal verge, cm (range)",Characteristics ; ,"Median tumour distance from anal verge, cm (range)",,16,0,2,no
4321,3179720,Table 1,BaselineCharacteristic,x (x-xx),Patients (n = xx) ; ,"Median tumour distance from anal verge, cm (range)",,16,1,3,no
4321,3179720,Table 1,BaselineCharacteristic,"Type of surgerya, n (%)",Characteristics ; ,None,None,17,0,24,no
4321,3179720,Table 1,BaselineCharacteristic,,Patients (n = xx) ; ,"Type of surgerya, n (%)",None,17,1,43,no
4321,3179720,Table 1,BaselineCharacteristic,?Low anterior resection,Characteristics ; ,?Low anterior resection," Type of surgerya, n (%)",18,0,2,no
4321,3179720,Table 1,BaselineCharacteristic,xx (xx.x),Patients (n = xx) ; ,?Low anterior resection," Type of surgerya, n (%)",18,1,3,no
4321,3179720,Table 1,BaselineCharacteristic,?Coloanal reconstruction,Characteristics ; ,?Coloanal reconstruction," Type of surgerya, n (%)",19,0,2,no
4321,3179720,Table 1,BaselineCharacteristic,xx (xx.x),Patients (n = xx) ; ,?Coloanal reconstruction," Type of surgerya, n (%)",19,1,3,no
4321,3179720,Table 1,BaselineCharacteristic,?Abdominoperineal resection,Characteristics ; ,?Abdominoperineal resection," Type of surgerya, n (%)",20,0,2,no
4321,3179720,Table 1,BaselineCharacteristic,xx (xx.x),Patients (n = xx) ; ,?Abdominoperineal resection," Type of surgerya, n (%)",20,1,3,no
4321,3179720,Table 1,BaselineCharacteristic,?Pelvic exenteration,Characteristics ; ,?Pelvic exenteration," Type of surgerya, n (%)",21,0,2,no
4321,3179720,Table 1,BaselineCharacteristic,x (x.x),Patients (n = xx) ; ,?Pelvic exenteration," Type of surgerya, n (%)",21,1,3,no
4604,3251866,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,0,12,no
4604,3251866,Table 1,BaselineCharacteristic,N=xx,,Characteristic,None,0,1,1,no
4604,3251866,Table 1,BaselineCharacteristic,Age (years),Characteristic ; ,None,None,1,0,24,no
4604,3251866,Table 1,BaselineCharacteristic,Age (years),N=xx ; ,Age (years),None,1,1,43,no
4604,3251866,Table 1,BaselineCharacteristic,?Age (range),Characteristic ; ,?Age (range), Age (years),3,0,2,no
4604,3251866,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,4,0,2,no
4604,3251866,Table 1,BaselineCharacteristic,,N=xx ; ,None,None,4,1,3,no
4604,3251866,Table 1,BaselineCharacteristic,Sex,Characteristic ; ,None,None,5,0,24,no
4604,3251866,Table 1,BaselineCharacteristic,Sex,N=xx ; ,Sex,None,5,1,43,no
4604,3251866,Table 1,BaselineCharacteristic,?Male (%),Characteristic ; ,?Male (%), Sex,6,0,2,no
4604,3251866,Table 1,BaselineCharacteristic,xx (xx.x),N=xx ; ,?Male (%), Sex,6,1,3,yes
4604,3251866,Table 1,BaselineCharacteristic,?Female (%),Characteristic ; ,?Female (%), Sex,7,0,2,no
4604,3251866,Table 1,BaselineCharacteristic,xx (xx.x),N=xx ; ,?Female (%), Sex,7,1,3,yes
4604,3251866,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,8,0,2,no
4604,3251866,Table 1,BaselineCharacteristic,,N=xx ; ,None,None,8,1,3,no
4604,3251866,Table 1,BaselineCharacteristic,ECOG performance status,Characteristic ; ,None,None,9,0,24,no
4604,3251866,Table 1,BaselineCharacteristic,ECOG performance status,N=xx ; ,ECOG performance status,None,9,1,43,no
4604,3251866,Table 1,BaselineCharacteristic,?x (%),Characteristic ; ,?x (%), ECOG performance status,10,0,2,no
4604,3251866,Table 1,BaselineCharacteristic,xx (xx.x),N=xx ; ,?x (%), ECOG performance status,10,1,3,no
4604,3251866,Table 1,BaselineCharacteristic,?x (%),Characteristic ; ,?x (%), ECOG performance status,11,0,2,no
4604,3251866,Table 1,BaselineCharacteristic,xx (xx.x),N=xx ; ,?x (%), ECOG performance status,11,1,3,no
4604,3251866,Table 1,BaselineCharacteristic,?x (%),Characteristic ; ,?x (%), ECOG performance status,12,0,2,no
4604,3251866,Table 1,BaselineCharacteristic,x (x.x),N=xx ; ,?x (%), ECOG performance status,12,1,3,no
4604,3251866,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,13,0,2,no
4604,3251866,Table 1,BaselineCharacteristic,,N=xx ; ,None,None,13,1,3,no
4604,3251866,Table 1,BaselineCharacteristic,Primary site,Characteristic ; ,None,None,14,0,24,no
4604,3251866,Table 1,BaselineCharacteristic,Primary site,N=xx ; ,Primary site,None,14,1,43,no
4604,3251866,Table 1,BaselineCharacteristic,?Head of pancreas (%),Characteristic ; ,?Head of pancreas (%), Primary site,15,0,2,no
4604,3251866,Table 1,BaselineCharacteristic,xx (xx.x),N=xx ; ,?Head of pancreas (%), Primary site,15,1,3,no
4604,3251866,Table 1,BaselineCharacteristic,?Body of pancreas (%),Characteristic ; ,?Body of pancreas (%), Primary site,16,0,2,no
4604,3251866,Table 1,BaselineCharacteristic,xx (xx.x),N=xx ; ,?Body of pancreas (%), Primary site,16,1,3,no
4604,3251866,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,17,0,2,no
4604,3251866,Table 1,BaselineCharacteristic,,N=xx ; ,None,None,17,1,3,no
4604,3251866,Table 1,BaselineCharacteristic,T stage,Characteristic ; ,None,None,18,0,24,no
4604,3251866,Table 1,BaselineCharacteristic,T stage,N=xx ; ,T stage,None,18,1,43,no
4604,3251866,Table 1,BaselineCharacteristic,?Tx (%),Characteristic ; ,?Tx (%), T stage,19,0,2,no
4604,3251866,Table 1,BaselineCharacteristic,x (x.x),N=xx ; ,?Tx (%), T stage,19,1,3,no
4604,3251866,Table 1,BaselineCharacteristic,?Tx (%),Characteristic ; ,?Tx (%), T stage,20,0,2,no
4604,3251866,Table 1,BaselineCharacteristic,xx (xx.x),N=xx ; ,?Tx (%), T stage,20,1,3,no
4604,3251866,Table 1,BaselineCharacteristic,?Tx (%),Characteristic ; ,?Tx (%), T stage,21,0,2,no
4604,3251866,Table 1,BaselineCharacteristic,x (xx.x),N=xx ; ,?Tx (%), T stage,21,1,3,no
4604,3251866,Table 1,BaselineCharacteristic,?Tx (%),Characteristic ; ,?Tx (%), T stage,22,0,2,no
4604,3251866,Table 1,BaselineCharacteristic,xx (xx.x),N=xx ; ,?Tx (%), T stage,22,1,3,no
4604,3251866,Table 1,BaselineCharacteristic,,Characteristic ; ,None,None,23,0,2,no
4604,3251866,Table 1,BaselineCharacteristic,,N=xx ; ,None,None,23,1,3,no
4604,3251866,Table 1,BaselineCharacteristic,N stage,Characteristic ; ,None,None,24,0,24,no
4604,3251866,Table 1,BaselineCharacteristic,N stage,N=xx ; ,N stage,None,24,1,43,no
4604,3251866,Table 1,BaselineCharacteristic,?Nx (%),Characteristic ; ,?Nx (%), N stage,25,0,2,no
4604,3251866,Table 1,BaselineCharacteristic,xx (xx.x),N=xx ; ,?Nx (%), N stage,25,1,3,no
4604,3251866,Table 1,BaselineCharacteristic,?Nx (%),Characteristic ; ,?Nx (%), N stage,26,0,2,no
4604,3251866,Table 1,BaselineCharacteristic,xx (xx.x),N=xx ; ,?Nx (%), N stage,26,1,3,no
4604,3251866,Table 4,BaselineCharacteristic,Component,,None,None,0,0,12,no
4604,3251866,Table 4,BaselineCharacteristic,Confounder,,Component,None,0,1,1,no
4604,3251866,Table 4,BaselineCharacteristic,Gem,,Component,None,0,2,1,no
4604,3251866,Table 4,BaselineCharacteristic,GemOx,,Component,None,0,3,1,no
4604,3251866,Table 4,BaselineCharacteristic,Favours,,Component,None,0,4,1,no
4604,3251866,Table 4,BaselineCharacteristic,Inclusion criteria,Component ; ,Inclusion criteria,,1,0,24,no
4604,3251866,Table 4,BaselineCharacteristic,Liver function tests,Confounder ; ,Inclusion criteria,,1,1,43,no
4604,3251866,Table 4,BaselineCharacteristic,No limit,Gem ; ,Inclusion criteria,,1,2,43,no
4604,3251866,Table 4,BaselineCharacteristic,GemOx,Favours ; ,Inclusion criteria,,1,4,43,no
4604,3251866,Table 4,BaselineCharacteristic,,Component ; ,,,2,0,2,no
4604,3251866,Table 4,BaselineCharacteristic,Operability,Confounder ; ,,,2,1,3,no
4604,3251866,Table 4,BaselineCharacteristic,Inoperable only,Gem ; ,,,2,2,3,no
4604,3251866,Table 4,BaselineCharacteristic,Included patients strongly declining surgery,GemOx ; ,,,2,3,3,no
4604,3251866,Table 4,BaselineCharacteristic,Gem,Favours ; ,,,2,4,3,no
4604,3251866,Table 4,BaselineCharacteristic,,Component ; ,None,None,3,0,2,no
4604,3251866,Table 4,BaselineCharacteristic,,Confounder ; ,None,None,3,1,3,no
4604,3251866,Table 4,BaselineCharacteristic,,Gem ; ,None,None,3,2,3,no
4604,3251866,Table 4,BaselineCharacteristic,,GemOx ; ,None,None,3,3,3,no
4604,3251866,Table 4,BaselineCharacteristic,,Favours ; ,None,None,3,4,3,no
4604,3251866,Table 4,BaselineCharacteristic,Baseline characteristics,Component ; ,Baseline characteristics,,4,0,24,no
4604,3251866,Table 4,BaselineCharacteristic,Male (%),Confounder ; ,Baseline characteristics,,4,1,43,no
4604,3251866,Table 4,BaselineCharacteristic,xx,Gem ; ,Baseline characteristics,,4,2,43,no
4604,3251866,Table 4,BaselineCharacteristic,xx,GemOx ; ,Baseline characteristics,,4,3,43,no
4604,3251866,Table 4,BaselineCharacteristic,Unknown,Favours ; ,Baseline characteristics,,4,4,43,no
4604,3251866,Table 4,BaselineCharacteristic,,Component ; ,,,5,0,2,no
4604,3251866,Table 4,BaselineCharacteristic,xx,Gem ; ,,,5,2,3,no
4604,3251866,Table 4,BaselineCharacteristic,xx,GemOx ; ,,,5,3,3,no
4604,3251866,Table 4,BaselineCharacteristic,Neither,Favours ; ,,,5,4,3,no
4604,3251866,Table 4,BaselineCharacteristic,,Component ; ,,,6,0,2,no
4604,3251866,Table 4,BaselineCharacteristic,Tx (%),Confounder ; ,,,6,1,3,no
4604,3251866,Table 4,BaselineCharacteristic,xx,Gem ; ,,,6,2,3,no
4604,3251866,Table 4,BaselineCharacteristic,xx,GemOx ; ,,,6,3,3,no
4604,3251866,Table 4,BaselineCharacteristic,Gem,Favours ; ,,,6,4,3,no
4604,3251866,Table 4,BaselineCharacteristic,,Component ; ,,,7,0,2,no
4604,3251866,Table 4,BaselineCharacteristic,Nx (%),Confounder ; ,,,7,1,3,no
4604,3251866,Table 4,BaselineCharacteristic,xx,Gem ; ,,,7,2,3,no
4604,3251866,Table 4,BaselineCharacteristic,xx,GemOx ; ,,,7,3,3,no
4604,3251866,Table 4,BaselineCharacteristic,Gem,Favours ; ,,,7,4,3,no
4604,3251866,Table 4,BaselineCharacteristic,,Component ; ,,,8,0,2,no
4604,3251866,Table 4,BaselineCharacteristic,Age (minimum),Confounder ; ,,,8,1,3,no
4604,3251866,Table 4,BaselineCharacteristic,xx,Gem ; ,,,8,2,3,no
4604,3251866,Table 4,BaselineCharacteristic,xx,GemOx ; ,,,8,3,3,no
4604,3251866,Table 4,BaselineCharacteristic,Gem,Favours ; ,,,8,4,3,no
4604,3251866,Table 4,BaselineCharacteristic,,Component ; ,None,None,9,0,2,no
4604,3251866,Table 4,BaselineCharacteristic,,Confounder ; ,None,None,9,1,3,no
4604,3251866,Table 4,BaselineCharacteristic,,Gem ; ,None,None,9,2,3,no
4604,3251866,Table 4,BaselineCharacteristic,,GemOx ; ,None,None,9,3,3,no
4604,3251866,Table 4,BaselineCharacteristic,,Favours ; ,None,None,9,4,3,no
4604,3251866,Table 4,BaselineCharacteristic,Treatment,Component ; ,Treatment,,10,0,2,no
4604,3251866,Table 4,BaselineCharacteristic,Schedule,Confounder ; ,Treatment,,10,1,3,no
4604,3251866,Table 4,BaselineCharacteristic,Gem dx dx dxx,Gem ; ,Treatment,,10,2,3,no
4604,3251866,Table 4,BaselineCharacteristic,GemOx dx dxx,GemOx ; ,Treatment,,10,3,3,no
4604,3251866,Table 4,BaselineCharacteristic,N/A,Favours ; ,Treatment,,10,4,3,no
4604,3251866,Table 4,BaselineCharacteristic,,Component ; ,None,None,11,0,2,no
4604,3251866,Table 4,BaselineCharacteristic,,Confounder ; ,None,None,11,1,3,no
4604,3251866,Table 4,BaselineCharacteristic,,Gem ; ,None,None,11,2,3,no
4604,3251866,Table 4,BaselineCharacteristic,,GemOx ; ,None,None,11,3,3,no
4604,3251866,Table 4,BaselineCharacteristic,,Favours ; ,None,None,11,4,3,no
4604,3251866,Table 4,BaselineCharacteristic,Assessment,Component ; ,Assessment,,12,0,24,no
4604,3251866,Table 4,BaselineCharacteristic,Tumour assessment,Confounder ; ,Assessment,,12,1,43,no
4604,3251866,Table 4,BaselineCharacteristic,WHO,Gem ; ,Assessment,,12,2,43,no
4604,3251866,Table 4,BaselineCharacteristic,RECIST,GemOx ; ,Assessment,,12,3,43,no
4604,3251866,Table 4,BaselineCharacteristic,Unknown,Favours ; ,Assessment,,12,4,43,no
4604,3251866,Table 4,BaselineCharacteristic,,Component ; ,,,13,0,2,no
4604,3251866,Table 4,BaselineCharacteristic,CT scans during Rx,Confounder ; ,,,13,1,3,no
4604,3251866,Table 4,BaselineCharacteristic,>x weeks apart,Gem ; ,,,13,2,3,no
4604,3251866,Table 4,BaselineCharacteristic,"Weeks x, xx, xx",GemOx ; ,,,13,3,3,no
4604,3251866,Table 4,BaselineCharacteristic,Unknown,Favours ; ,,,13,4,3,no
4680,3273358,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no
4680,3273358,Table 1,BaselineCharacteristic,Olaparib dose (mg b.i.d.),,,None,0,1,1,no
4680,3273358,Table 1,BaselineCharacteristic,Olaparib dose (mg b.i.d.),,,None,0,2,1,no
4680,3273358,Table 1,BaselineCharacteristic,Olaparib dose (mg b.i.d.),,,None,0,3,1,no
4680,3273358,Table 1,BaselineCharacteristic,Olaparib dose (mg b.i.d.),,,None,0,4,1,no
4680,3273358,Table 1,BaselineCharacteristic,, ; ,None,None,1,0,12,no
4680,3273358,Table 1,BaselineCharacteristic,xxx (n=x),Olaparib dose (mg b.i.d.) ; ,,None,1,1,1,no
4680,3273358,Table 1,BaselineCharacteristic,xxx (n=x),Olaparib dose (mg b.i.d.) ; ,,None,1,2,1,no
4680,3273358,Table 1,BaselineCharacteristic,xxx (n=x),Olaparib dose (mg b.i.d.) ; ,,None,1,3,1,no
4680,3273358,Table 1,BaselineCharacteristic,All patients (n=xx),Olaparib dose (mg b.i.d.) ; ,,None,1,4,1,no
4680,3273358,Table 1,BaselineCharacteristic,"Sex, n (%)", ;  ; ,None,None,2,0,24,no
4680,3273358,Table 1,BaselineCharacteristic,"Sex, n (%)",Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,"Sex, n (%)",None,2,1,43,no
4680,3273358,Table 1,BaselineCharacteristic,"Sex, n (%)",Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,"Sex, n (%)",None,2,2,43,no
4680,3273358,Table 1,BaselineCharacteristic,"Sex, n (%)",Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,"Sex, n (%)",None,2,3,43,no
4680,3273358,Table 1,BaselineCharacteristic,"Sex, n (%)",Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,"Sex, n (%)",None,2,4,43,no
4680,3273358,Table 1,BaselineCharacteristic,?Male, ;  ; ,?Male," Sex, n (%)",3,0,2,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Male," Sex, n (%)",3,1,3,yes
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Male," Sex, n (%)",3,2,3,yes
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Male," Sex, n (%)",3,3,3,yes
4680,3273358,Table 1,BaselineCharacteristic,x (xx),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?Male," Sex, n (%)",3,4,3,yes
4680,3273358,Table 1,BaselineCharacteristic,?Female, ;  ; ,?Female," Sex, n (%)",4,0,2,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Female," Sex, n (%)",4,1,3,yes
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Female," Sex, n (%)",4,2,3,yes
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Female," Sex, n (%)",4,3,3,yes
4680,3273358,Table 1,BaselineCharacteristic,xx (xx),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?Female," Sex, n (%)",4,4,3,yes
4680,3273358,Table 1,BaselineCharacteristic,?Median age (range), ;  ; ,?Median age (range)," Sex, n (%)",5,0,2,no
4680,3273358,Table 1,BaselineCharacteristic,, ;  ; ,None,None,6,0,2,no
4680,3273358,Table 1,BaselineCharacteristic,,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,None,None,6,1,3,no
4680,3273358,Table 1,BaselineCharacteristic,,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,None,None,6,2,3,no
4680,3273358,Table 1,BaselineCharacteristic,,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,None,None,6,3,3,no
4680,3273358,Table 1,BaselineCharacteristic,,Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,None,None,6,4,3,no
4680,3273358,Table 1,BaselineCharacteristic,"Race, n (%)", ;  ; ,None,None,7,0,24,no
4680,3273358,Table 1,BaselineCharacteristic,"Race, n (%)",Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,"Race, n (%)",None,7,1,43,no
4680,3273358,Table 1,BaselineCharacteristic,"Race, n (%)",Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,"Race, n (%)",None,7,2,43,no
4680,3273358,Table 1,BaselineCharacteristic,"Race, n (%)",Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,"Race, n (%)",None,7,3,43,no
4680,3273358,Table 1,BaselineCharacteristic,"Race, n (%)",Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,"Race, n (%)",None,7,4,43,no
4680,3273358,Table 1,BaselineCharacteristic,?Caucasian, ;  ; ,?Caucasian," Race, n (%)",8,0,2,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Caucasian," Race, n (%)",8,1,3,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Caucasian," Race, n (%)",8,2,3,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Caucasian," Race, n (%)",8,3,3,no
4680,3273358,Table 1,BaselineCharacteristic,xx (xx),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?Caucasian," Race, n (%)",8,4,3,no
4680,3273358,Table 1,BaselineCharacteristic,?Oriental, ;  ; ,?Oriental," Race, n (%)",9,0,2,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Oriental," Race, n (%)",9,1,3,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Oriental," Race, n (%)",9,2,3,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Oriental," Race, n (%)",9,3,3,no
4680,3273358,Table 1,BaselineCharacteristic,x (x),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?Oriental," Race, n (%)",9,4,3,no
4680,3273358,Table 1,BaselineCharacteristic,, ;  ; ,None,None,10,0,2,no
4680,3273358,Table 1,BaselineCharacteristic,,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,None,None,10,1,3,no
4680,3273358,Table 1,BaselineCharacteristic,,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,None,None,10,2,3,no
4680,3273358,Table 1,BaselineCharacteristic,,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,None,None,10,3,3,no
4680,3273358,Table 1,BaselineCharacteristic,,Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,None,None,10,4,3,no
4680,3273358,Table 1,BaselineCharacteristic,"ECOG PS at screening, n (%)", ;  ; ,None,None,11,0,24,no
4680,3273358,Table 1,BaselineCharacteristic,"ECOG PS at screening, n (%)",Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,"ECOG PS at screening, n (%)",None,11,1,43,no
4680,3273358,Table 1,BaselineCharacteristic,"ECOG PS at screening, n (%)",Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,"ECOG PS at screening, n (%)",None,11,2,43,no
4680,3273358,Table 1,BaselineCharacteristic,"ECOG PS at screening, n (%)",Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,"ECOG PS at screening, n (%)",None,11,3,43,no
4680,3273358,Table 1,BaselineCharacteristic,"ECOG PS at screening, n (%)",Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,"ECOG PS at screening, n (%)",None,11,4,43,no
4680,3273358,Table 1,BaselineCharacteristic,?x, ;  ; ,?x," ECOG PS at screening, n (%)",12,0,2,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?x," ECOG PS at screening, n (%)",12,1,3,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?x," ECOG PS at screening, n (%)",12,2,3,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?x," ECOG PS at screening, n (%)",12,3,3,no
4680,3273358,Table 1,BaselineCharacteristic,x (xx),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?x," ECOG PS at screening, n (%)",12,4,3,no
4680,3273358,Table 1,BaselineCharacteristic,?x, ;  ; ,?x," ECOG PS at screening, n (%)",13,0,2,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?x," ECOG PS at screening, n (%)",13,1,3,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?x," ECOG PS at screening, n (%)",13,2,3,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?x," ECOG PS at screening, n (%)",13,3,3,no
4680,3273358,Table 1,BaselineCharacteristic,x (xx),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?x," ECOG PS at screening, n (%)",13,4,3,no
4680,3273358,Table 1,BaselineCharacteristic,, ;  ; ,None,None,14,0,2,no
4680,3273358,Table 1,BaselineCharacteristic,,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,None,None,14,1,3,no
4680,3273358,Table 1,BaselineCharacteristic,,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,None,None,14,2,3,no
4680,3273358,Table 1,BaselineCharacteristic,,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,None,None,14,3,3,no
4680,3273358,Table 1,BaselineCharacteristic,,Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,None,None,14,4,3,no
4680,3273358,Table 1,BaselineCharacteristic,Previous therapy n (%)a, ;  ; ,None,None,15,0,24,no
4680,3273358,Table 1,BaselineCharacteristic,Previous therapy n (%)a,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,Previous therapy n (%)a,None,15,1,43,no
4680,3273358,Table 1,BaselineCharacteristic,Previous therapy n (%)a,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,Previous therapy n (%)a,None,15,2,43,no
4680,3273358,Table 1,BaselineCharacteristic,Previous therapy n (%)a,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,Previous therapy n (%)a,None,15,3,43,no
4680,3273358,Table 1,BaselineCharacteristic,Previous therapy n (%)a,Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,Previous therapy n (%)a,None,15,4,43,no
4680,3273358,Table 1,BaselineCharacteristic,?Radiotherapy, ;  ; ,?Radiotherapy, Previous therapy n (%)a,16,0,2,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Radiotherapy, Previous therapy n (%)a,16,1,3,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Radiotherapy, Previous therapy n (%)a,16,2,3,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Radiotherapy, Previous therapy n (%)a,16,3,3,no
4680,3273358,Table 1,BaselineCharacteristic,x (xx),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?Radiotherapy, Previous therapy n (%)a,16,4,3,no
4680,3273358,Table 1,BaselineCharacteristic,?Chemotherapy, ;  ; ,?Chemotherapy, Previous therapy n (%)a,17,0,2,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Chemotherapy, Previous therapy n (%)a,17,1,3,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Chemotherapy, Previous therapy n (%)a,17,2,3,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Chemotherapy, Previous therapy n (%)a,17,3,3,no
4680,3273358,Table 1,BaselineCharacteristic,xx (xxx),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?Chemotherapy, Previous therapy n (%)a,17,4,3,no
4680,3273358,Table 1,BaselineCharacteristic,?Immunotherapy/hormone therapy, ;  ; ,?Immunotherapy/hormone therapy, Previous therapy n (%)a,18,0,2,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Immunotherapy/hormone therapy, Previous therapy n (%)a,18,1,3,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Immunotherapy/hormone therapy, Previous therapy n (%)a,18,2,3,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Immunotherapy/hormone therapy, Previous therapy n (%)a,18,3,3,no
4680,3273358,Table 1,BaselineCharacteristic,x (xx),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?Immunotherapy/hormone therapy, Previous therapy n (%)a,18,4,3,no
4680,3273358,Table 1,BaselineCharacteristic,?Other systemic cancer therapyb, ;  ; ,?Other systemic cancer therapyb, Previous therapy n (%)a,19,0,2,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Other systemic cancer therapyb, Previous therapy n (%)a,19,1,3,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Other systemic cancer therapyb, Previous therapy n (%)a,19,2,3,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Other systemic cancer therapyb, Previous therapy n (%)a,19,3,3,no
4680,3273358,Table 1,BaselineCharacteristic,x (xx),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?Other systemic cancer therapyb, Previous therapy n (%)a,19,4,3,no
4680,3273358,Table 1,BaselineCharacteristic,?Surgeryc, ;  ; ,?Surgeryc, Previous therapy n (%)a,20,0,2,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Surgeryc, Previous therapy n (%)a,20,1,3,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Surgeryc, Previous therapy n (%)a,20,2,3,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Surgeryc, Previous therapy n (%)a,20,3,3,no
4680,3273358,Table 1,BaselineCharacteristic,xx (xx),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?Surgeryc, Previous therapy n (%)a,20,4,3,no
4680,3273358,Table 1,BaselineCharacteristic,, ;  ; ,None,None,21,0,2,no
4680,3273358,Table 1,BaselineCharacteristic,,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,None,None,21,1,3,no
4680,3273358,Table 1,BaselineCharacteristic,,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,None,None,21,2,3,no
4680,3273358,Table 1,BaselineCharacteristic,,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,None,None,21,3,3,no
4680,3273358,Table 1,BaselineCharacteristic,,Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,None,None,21,4,3,no
4680,3273358,Table 1,BaselineCharacteristic,"Primary tumour site, n (%)", ;  ; ,None,None,22,0,24,no
4680,3273358,Table 1,BaselineCharacteristic,"Primary tumour site, n (%)",Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,"Primary tumour site, n (%)",None,22,1,43,no
4680,3273358,Table 1,BaselineCharacteristic,"Primary tumour site, n (%)",Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,"Primary tumour site, n (%)",None,22,2,43,no
4680,3273358,Table 1,BaselineCharacteristic,"Primary tumour site, n (%)",Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,"Primary tumour site, n (%)",None,22,3,43,no
4680,3273358,Table 1,BaselineCharacteristic,"Primary tumour site, n (%)",Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,"Primary tumour site, n (%)",None,22,4,43,no
4680,3273358,Table 1,BaselineCharacteristic,?Colorectal, ;  ; ,?Colorectal," Primary tumour site, n (%)",23,0,2,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Colorectal," Primary tumour site, n (%)",23,1,3,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Colorectal," Primary tumour site, n (%)",23,2,3,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Colorectal," Primary tumour site, n (%)",23,3,3,no
4680,3273358,Table 1,BaselineCharacteristic,x (xx),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?Colorectal," Primary tumour site, n (%)",23,4,3,no
4680,3273358,Table 1,BaselineCharacteristic,?Breast, ;  ; ,?Breast," Primary tumour site, n (%)",24,0,2,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Breast," Primary tumour site, n (%)",24,1,3,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Breast," Primary tumour site, n (%)",24,2,3,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Breast," Primary tumour site, n (%)",24,3,3,no
4680,3273358,Table 1,BaselineCharacteristic,x (xx),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?Breast," Primary tumour site, n (%)",24,4,3,no
4680,3273358,Table 1,BaselineCharacteristic,?Pleura, ;  ; ,?Pleura," Primary tumour site, n (%)",25,0,2,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Pleura," Primary tumour site, n (%)",25,1,3,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Pleura," Primary tumour site, n (%)",25,2,3,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Pleura," Primary tumour site, n (%)",25,3,3,no
4680,3273358,Table 1,BaselineCharacteristic,x (x),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?Pleura," Primary tumour site, n (%)",25,4,3,no
4680,3273358,Table 1,BaselineCharacteristic,?Skin/soft tissue, ;  ; ,?Skin/soft tissue," Primary tumour site, n (%)",26,0,2,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Skin/soft tissue," Primary tumour site, n (%)",26,1,3,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Skin/soft tissue," Primary tumour site, n (%)",26,2,3,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Skin/soft tissue," Primary tumour site, n (%)",26,3,3,no
4680,3273358,Table 1,BaselineCharacteristic,x (x),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?Skin/soft tissue," Primary tumour site, n (%)",26,4,3,no
4680,3273358,Table 1,BaselineCharacteristic,?Cervix, ;  ; ,?Cervix," Primary tumour site, n (%)",27,0,2,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Cervix," Primary tumour site, n (%)",27,1,3,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Cervix," Primary tumour site, n (%)",27,2,3,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Cervix," Primary tumour site, n (%)",27,3,3,no
4680,3273358,Table 1,BaselineCharacteristic,x (x),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?Cervix," Primary tumour site, n (%)",27,4,3,no
4680,3273358,Table 1,BaselineCharacteristic,?Pseudomyxoma peritonei, ;  ; ,?Pseudomyxoma peritonei," Primary tumour site, n (%)",28,0,2,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Pseudomyxoma peritonei," Primary tumour site, n (%)",28,1,3,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Pseudomyxoma peritonei," Primary tumour site, n (%)",28,2,3,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Pseudomyxoma peritonei," Primary tumour site, n (%)",28,3,3,no
4680,3273358,Table 1,BaselineCharacteristic,x (x),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?Pseudomyxoma peritonei," Primary tumour site, n (%)",28,4,3,no
4680,3273358,Table 1,BaselineCharacteristic,?Upper GI, ;  ; ,?Upper GI," Primary tumour site, n (%)",29,0,2,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Upper GI," Primary tumour site, n (%)",29,1,3,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Upper GI," Primary tumour site, n (%)",29,2,3,no
4680,3273358,Table 1,BaselineCharacteristic,x,Olaparib dose (mg b.i.d.) ; xxx (n=x) ; ,?Upper GI," Primary tumour site, n (%)",29,3,3,no
4680,3273358,Table 1,BaselineCharacteristic,x (x),Olaparib dose (mg b.i.d.) ; All patients (n=xx) ; ,?Upper GI," Primary tumour site, n (%)",29,4,3,no
4688,3276256,Table 2,BaselineCharacteristic,Characteristics,,None,None,0,0,12,no
4688,3276256,Table 2,BaselineCharacteristic,MF/F xxx/xx ?g bid (n = xxx),,Characteristics,None,0,1,1,no
4688,3276256,Table 2,BaselineCharacteristic,MF/F xxx/xx ?g bid (n = xxx),,Characteristics,None,0,2,1,no
4688,3276256,Table 2,BaselineCharacteristic,MF xxx ?g bid (n = xxx),,Characteristics,None,0,3,1,no
4688,3276256,Table 2,BaselineCharacteristic,F xx ?g bid (n = xxx),,Characteristics,None,0,4,1,no
4688,3276256,Table 2,BaselineCharacteristic,Placebo (n = xxx),,Characteristics,None,0,5,1,no
4688,3276256,Table 2,BaselineCharacteristic,"Sex, n (%)",Characteristics ; ,None,None,1,0,24,no
4688,3276256,Table 2,BaselineCharacteristic,"Sex, n (%)",MF/F xxx/xx ?g bid (n = xxx) ; ,"Sex, n (%)",None,1,1,43,no
4688,3276256,Table 2,BaselineCharacteristic,"Sex, n (%)",MF/F xxx/xx ?g bid (n = xxx) ; ,"Sex, n (%)",None,1,2,43,no
4688,3276256,Table 2,BaselineCharacteristic,"Sex, n (%)",MF xxx ?g bid (n = xxx) ; ,"Sex, n (%)",None,1,3,43,no
4688,3276256,Table 2,BaselineCharacteristic,"Sex, n (%)",F xx ?g bid (n = xxx) ; ,"Sex, n (%)",None,1,4,43,no
4688,3276256,Table 2,BaselineCharacteristic,"Sex, n (%)",Placebo (n = xxx) ; ,"Sex, n (%)",None,1,5,43,no
4688,3276256,Table 2,BaselineCharacteristic,?Female,Characteristics ; ,?Female," Sex, n (%)",2,0,2,no
4688,3276256,Table 2,BaselineCharacteristic,xx (xx),MF/F xxx/xx ?g bid (n = xxx) ; ,?Female," Sex, n (%)",2,1,3,yes
4688,3276256,Table 2,BaselineCharacteristic,xx (xx),MF/F xxx/xx ?g bid (n = xxx) ; ,?Female," Sex, n (%)",2,2,3,yes
4688,3276256,Table 2,BaselineCharacteristic,xx (xx),MF xxx ?g bid (n = xxx) ; ,?Female," Sex, n (%)",2,3,3,yes
4688,3276256,Table 2,BaselineCharacteristic,xx (xx),F xx ?g bid (n = xxx) ; ,?Female," Sex, n (%)",2,4,3,yes
4688,3276256,Table 2,BaselineCharacteristic,xx (xx),Placebo (n = xxx) ; ,?Female," Sex, n (%)",2,5,3,yes
4688,3276256,Table 2,BaselineCharacteristic,?Male,Characteristics ; ,?Male," Sex, n (%)",3,0,2,no
4688,3276256,Table 2,BaselineCharacteristic,xxx (xx),MF/F xxx/xx ?g bid (n = xxx) ; ,?Male," Sex, n (%)",3,1,3,yes
4688,3276256,Table 2,BaselineCharacteristic,xxx (xx),MF/F xxx/xx ?g bid (n = xxx) ; ,?Male," Sex, n (%)",3,2,3,yes
4688,3276256,Table 2,BaselineCharacteristic,xxx (xx),MF xxx ?g bid (n = xxx) ; ,?Male," Sex, n (%)",3,3,3,yes
4688,3276256,Table 2,BaselineCharacteristic,xxx (xx),F xx ?g bid (n = xxx) ; ,?Male," Sex, n (%)",3,4,3,yes
4688,3276256,Table 2,BaselineCharacteristic,xxx (xx),Placebo (n = xxx) ; ,?Male," Sex, n (%)",3,5,3,yes
4688,3276256,Table 2,BaselineCharacteristic,"Age, mean, years (SD)",Characteristics ; ,"Age, mean, years (SD)",,4,0,2,no
4688,3276256,Table 2,BaselineCharacteristic,xx.x (x.x),MF/F xxx/xx ?g bid (n = xxx) ; ,"Age, mean, years (SD)",,4,1,3,no
4688,3276256,Table 2,BaselineCharacteristic,xx.x (x.x),MF/F xxx/xx ?g bid (n = xxx) ; ,"Age, mean, years (SD)",,4,2,3,no
4688,3276256,Table 2,BaselineCharacteristic,xx.x (x.x),MF xxx ?g bid (n = xxx) ; ,"Age, mean, years (SD)",,4,3,3,no
4688,3276256,Table 2,BaselineCharacteristic,xx.x (x.x),F xx ?g bid (n = xxx) ; ,"Age, mean, years (SD)",,4,4,3,no
4688,3276256,Table 2,BaselineCharacteristic,xx.x (x.x),Placebo (n = xxx) ; ,"Age, mean, years (SD)",,4,5,3,no
4688,3276256,Table 2,BaselineCharacteristic,"Weight, mean kg (SD)",Characteristics ; ,"Weight, mean kg (SD)",,5,0,2,no
4688,3276256,Table 2,BaselineCharacteristic,xx.xx (xx.xx),MF/F xxx/xx ?g bid (n = xxx) ; ,"Weight, mean kg (SD)",,5,1,3,no
4688,3276256,Table 2,BaselineCharacteristic,xx.xx (xx.xx),MF/F xxx/xx ?g bid (n = xxx) ; ,"Weight, mean kg (SD)",,5,2,3,no
4688,3276256,Table 2,BaselineCharacteristic,xx.xx (xx.xx),MF xxx ?g bid (n = xxx) ; ,"Weight, mean kg (SD)",,5,3,3,no
4688,3276256,Table 2,BaselineCharacteristic,xx.xx (xx.xx),F xx ?g bid (n = xxx) ; ,"Weight, mean kg (SD)",,5,4,3,no
4688,3276256,Table 2,BaselineCharacteristic,xx.xx (xx.xx),Placebo (n = xxx) ; ,"Weight, mean kg (SD)",,5,5,3,no
4688,3276256,Table 2,BaselineCharacteristic,"Race, n (%)",Characteristics ; ,None,None,6,0,24,no
4688,3276256,Table 2,BaselineCharacteristic,"Race, n (%)",MF/F xxx/xx ?g bid (n = xxx) ; ,"Race, n (%)",None,6,1,43,no
4688,3276256,Table 2,BaselineCharacteristic,"Race, n (%)",MF/F xxx/xx ?g bid (n = xxx) ; ,"Race, n (%)",None,6,2,43,no
4688,3276256,Table 2,BaselineCharacteristic,"Race, n (%)",MF xxx ?g bid (n = xxx) ; ,"Race, n (%)",None,6,3,43,no
4688,3276256,Table 2,BaselineCharacteristic,"Race, n (%)",F xx ?g bid (n = xxx) ; ,"Race, n (%)",None,6,4,43,no
4688,3276256,Table 2,BaselineCharacteristic,"Race, n (%)",Placebo (n = xxx) ; ,"Race, n (%)",None,6,5,43,no
4688,3276256,Table 2,BaselineCharacteristic,?White,Characteristics ; ,?White," Race, n (%)",7,0,2,no
4688,3276256,Table 2,BaselineCharacteristic,xxx (xx),MF/F xxx/xx ?g bid (n = xxx) ; ,?White," Race, n (%)",7,1,3,no
4688,3276256,Table 2,BaselineCharacteristic,xxx (xx),MF/F xxx/xx ?g bid (n = xxx) ; ,?White," Race, n (%)",7,2,3,no
4688,3276256,Table 2,BaselineCharacteristic,xxx (xx),MF xxx ?g bid (n = xxx) ; ,?White," Race, n (%)",7,3,3,no
4688,3276256,Table 2,BaselineCharacteristic,xxx (xx),F xx ?g bid (n = xxx) ; ,?White," Race, n (%)",7,4,3,no
4688,3276256,Table 2,BaselineCharacteristic,xxx (xx),Placebo (n = xxx) ; ,?White," Race, n (%)",7,5,3,no
4688,3276256,Table 2,BaselineCharacteristic,?Black or African American,Characteristics ; ,?Black or African American," Race, n (%)",8,0,2,no
4688,3276256,Table 2,BaselineCharacteristic,x (<x),MF/F xxx/xx ?g bid (n = xxx) ; ,?Black or African American," Race, n (%)",8,1,3,no
4688,3276256,Table 2,BaselineCharacteristic,x,MF/F xxx/xx ?g bid (n = xxx) ; ,?Black or African American," Race, n (%)",8,2,3,no
4688,3276256,Table 2,BaselineCharacteristic,x (x),MF xxx ?g bid (n = xxx) ; ,?Black or African American," Race, n (%)",8,3,3,no
4688,3276256,Table 2,BaselineCharacteristic,x (x),F xx ?g bid (n = xxx) ; ,?Black or African American," Race, n (%)",8,4,3,no
4688,3276256,Table 2,BaselineCharacteristic,x (x),Placebo (n = xxx) ; ,?Black or African American," Race, n (%)",8,5,3,no
4688,3276256,Table 2,BaselineCharacteristic,?Asian,Characteristics ; ,?Asian," Race, n (%)",9,0,2,no
4688,3276256,Table 2,BaselineCharacteristic,xx (xx),MF/F xxx/xx ?g bid (n = xxx) ; ,?Asian," Race, n (%)",9,1,3,no
4688,3276256,Table 2,BaselineCharacteristic,xx (xx),MF/F xxx/xx ?g bid (n = xxx) ; ,?Asian," Race, n (%)",9,2,3,no
4688,3276256,Table 2,BaselineCharacteristic,xx (xx),MF xxx ?g bid (n = xxx) ; ,?Asian," Race, n (%)",9,3,3,no
4688,3276256,Table 2,BaselineCharacteristic,xx (xx),F xx ?g bid (n = xxx) ; ,?Asian," Race, n (%)",9,4,3,no
4688,3276256,Table 2,BaselineCharacteristic,xx (xx),Placebo (n = xxx) ; ,?Asian," Race, n (%)",9,5,3,no
4688,3276256,Table 2,BaselineCharacteristic,?Multiracial,Characteristics ; ,?Multiracial," Race, n (%)",10,0,2,no
4688,3276256,Table 2,BaselineCharacteristic,x (x),MF/F xxx/xx ?g bid (n = xxx) ; ,?Multiracial," Race, n (%)",10,1,3,no
4688,3276256,Table 2,BaselineCharacteristic,x (x),MF/F xxx/xx ?g bid (n = xxx) ; ,?Multiracial," Race, n (%)",10,2,3,no
4688,3276256,Table 2,BaselineCharacteristic,x (x),MF xxx ?g bid (n = xxx) ; ,?Multiracial," Race, n (%)",10,3,3,no
4688,3276256,Table 2,BaselineCharacteristic,x (x),F xx ?g bid (n = xxx) ; ,?Multiracial," Race, n (%)",10,4,3,no
4688,3276256,Table 2,BaselineCharacteristic,x (x),Placebo (n = xxx) ; ,?Multiracial," Race, n (%)",10,5,3,no
4688,3276256,Table 2,BaselineCharacteristic,"Smoking status, n (%)",Characteristics ; ,None,None,11,0,24,no
4688,3276256,Table 2,BaselineCharacteristic,"Smoking status, n (%)",MF/F xxx/xx ?g bid (n = xxx) ; ,"Smoking status, n (%)",None,11,1,43,no
4688,3276256,Table 2,BaselineCharacteristic,"Smoking status, n (%)",MF/F xxx/xx ?g bid (n = xxx) ; ,"Smoking status, n (%)",None,11,2,43,no
4688,3276256,Table 2,BaselineCharacteristic,"Smoking status, n (%)",MF xxx ?g bid (n = xxx) ; ,"Smoking status, n (%)",None,11,3,43,no
4688,3276256,Table 2,BaselineCharacteristic,"Smoking status, n (%)",F xx ?g bid (n = xxx) ; ,"Smoking status, n (%)",None,11,4,43,no
4688,3276256,Table 2,BaselineCharacteristic,"Smoking status, n (%)",Placebo (n = xxx) ; ,"Smoking status, n (%)",None,11,5,43,no
4688,3276256,Table 2,BaselineCharacteristic,?Current smokers,Characteristics ; ,?Current smokers," Smoking status, n (%)",12,0,2,no
4688,3276256,Table 2,BaselineCharacteristic,xx (xx),MF/F xxx/xx ?g bid (n = xxx) ; ,?Current smokers," Smoking status, n (%)",12,1,3,no
4688,3276256,Table 2,BaselineCharacteristic,xx (xx),MF/F xxx/xx ?g bid (n = xxx) ; ,?Current smokers," Smoking status, n (%)",12,2,3,no
4688,3276256,Table 2,BaselineCharacteristic,xx (xx),MF xxx ?g bid (n = xxx) ; ,?Current smokers," Smoking status, n (%)",12,3,3,no
4688,3276256,Table 2,BaselineCharacteristic,xx (xx),F xx ?g bid (n = xxx) ; ,?Current smokers," Smoking status, n (%)",12,4,3,no
4688,3276256,Table 2,BaselineCharacteristic,xx (xx),Placebo (n = xxx) ; ,?Current smokers," Smoking status, n (%)",12,5,3,no
4688,3276256,Table 2,BaselineCharacteristic,?Ex-smokers,Characteristics ; ,?Ex-smokers," Smoking status, n (%)",13,0,2,no
4688,3276256,Table 2,BaselineCharacteristic,xxx (xx),MF/F xxx/xx ?g bid (n = xxx) ; ,?Ex-smokers," Smoking status, n (%)",13,1,3,no
4688,3276256,Table 2,BaselineCharacteristic,xxx (xx),MF/F xxx/xx ?g bid (n = xxx) ; ,?Ex-smokers," Smoking status, n (%)",13,2,3,no
4688,3276256,Table 2,BaselineCharacteristic,xxx (xx),MF xxx ?g bid (n = xxx) ; ,?Ex-smokers," Smoking status, n (%)",13,3,3,no
4688,3276256,Table 2,BaselineCharacteristic,xxx (xx),F xx ?g bid (n = xxx) ; ,?Ex-smokers," Smoking status, n (%)",13,4,3,no
4688,3276256,Table 2,BaselineCharacteristic,xxx (xx),Placebo (n = xxx) ; ,?Ex-smokers," Smoking status, n (%)",13,5,3,no
4688,3276256,Table 2,BaselineCharacteristic,"Smoking history, mean pack-years (SD)",Characteristics ; ,"Smoking history, mean pack-years (SD)",,14,0,2,no
4688,3276256,Table 2,BaselineCharacteristic,xx.xx (xx.xx),MF/F xxx/xx ?g bid (n = xxx) ; ,"Smoking history, mean pack-years (SD)",,14,1,3,no
4688,3276256,Table 2,BaselineCharacteristic,xx.xx (xx.xx),MF/F xxx/xx ?g bid (n = xxx) ; ,"Smoking history, mean pack-years (SD)",,14,2,3,no
4688,3276256,Table 2,BaselineCharacteristic,xx.xx (xx.xx),MF xxx ?g bid (n = xxx) ; ,"Smoking history, mean pack-years (SD)",,14,3,3,no
4688,3276256,Table 2,BaselineCharacteristic,xx.xx (xx.xx),F xx ?g bid (n = xxx) ; ,"Smoking history, mean pack-years (SD)",,14,4,3,no
4688,3276256,Table 2,BaselineCharacteristic,xx.xx (xx.xx),Placebo (n = xxx) ; ,"Smoking history, mean pack-years (SD)",,14,5,3,no
4689,3276257,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no
4689,3276257,Table 1,BaselineCharacteristic,MF/F xxx/xx ?g BID (n = xxx),,,None,0,1,1,no
4689,3276257,Table 1,BaselineCharacteristic,MF/F xxx/xx ?g BID (n = xxx),,,None,0,2,1,no
4689,3276257,Table 1,BaselineCharacteristic,MF xxx ?g BID (n = xxx),,,None,0,3,1,no
4689,3276257,Table 1,BaselineCharacteristic,F xx ?g BID (n = xxx),,,None,0,4,1,no
4689,3276257,Table 1,BaselineCharacteristic,Placebo (n = xxx),,,None,0,5,1,no
4689,3276257,Table 1,BaselineCharacteristic,"Males, n (%)", ; ,"Males, n (%)",None,1,0,2,no
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),MF/F xxx/xx ?g BID (n = xxx) ; ,"Males, n (%)",None,1,1,3,yes
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),MF/F xxx/xx ?g BID (n = xxx) ; ,"Males, n (%)",None,1,2,3,yes
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),MF xxx ?g BID (n = xxx) ; ,"Males, n (%)",None,1,3,3,yes
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),F xx ?g BID (n = xxx) ; ,"Males, n (%)",None,1,4,3,yes
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),Placebo (n = xxx) ; ,"Males, n (%)",None,1,5,3,yes
4689,3276257,Table 1,BaselineCharacteristic,"White, n (%)", ; ,"White, n (%)",None,4,0,2,no
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),MF/F xxx/xx ?g BID (n = xxx) ; ,"White, n (%)",None,4,1,3,no
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),MF/F xxx/xx ?g BID (n = xxx) ; ,"White, n (%)",None,4,2,3,no
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),MF xxx ?g BID (n = xxx) ; ,"White, n (%)",None,4,3,3,no
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),F xx ?g BID (n = xxx) ; ,"White, n (%)",None,4,4,3,no
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),Placebo (n = xxx) ; ,"White, n (%)",None,4,5,3,no
4689,3276257,Table 1,BaselineCharacteristic,"Black or African American, n (%)", ; ,"Black or African American, n (%)",None,5,0,2,no
4689,3276257,Table 1,BaselineCharacteristic,x (x),MF/F xxx/xx ?g BID (n = xxx) ; ,"Black or African American, n (%)",None,5,1,3,no
4689,3276257,Table 1,BaselineCharacteristic,xx (x),MF/F xxx/xx ?g BID (n = xxx) ; ,"Black or African American, n (%)",None,5,2,3,no
4689,3276257,Table 1,BaselineCharacteristic,x (x),MF xxx ?g BID (n = xxx) ; ,"Black or African American, n (%)",None,5,3,3,no
4689,3276257,Table 1,BaselineCharacteristic,x (x),F xx ?g BID (n = xxx) ; ,"Black or African American, n (%)",None,5,4,3,no
4689,3276257,Table 1,BaselineCharacteristic,x (x),Placebo (n = xxx) ; ,"Black or African American, n (%)",None,5,5,3,no
4689,3276257,Table 1,BaselineCharacteristic,"Asian, n (%)", ; ,"Asian, n (%)",None,6,0,2,no
4689,3276257,Table 1,BaselineCharacteristic,xx (xx),MF/F xxx/xx ?g BID (n = xxx) ; ,"Asian, n (%)",None,6,1,3,no
4689,3276257,Table 1,BaselineCharacteristic,xx (xx),MF/F xxx/xx ?g BID (n = xxx) ; ,"Asian, n (%)",None,6,2,3,no
4689,3276257,Table 1,BaselineCharacteristic,xx (xx),MF xxx ?g BID (n = xxx) ; ,"Asian, n (%)",None,6,3,3,no
4689,3276257,Table 1,BaselineCharacteristic,xx (xx),F xx ?g BID (n = xxx) ; ,"Asian, n (%)",None,6,4,3,no
4689,3276257,Table 1,BaselineCharacteristic,xx (xx),Placebo (n = xxx) ; ,"Asian, n (%)",None,6,5,3,no
4689,3276257,Table 1,BaselineCharacteristic,"Current smokers, n (%)", ; ,"Current smokers, n (%)",None,7,0,2,no
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),MF/F xxx/xx ?g BID (n = xxx) ; ,"Current smokers, n (%)",None,7,1,3,no
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),MF/F xxx/xx ?g BID (n = xxx) ; ,"Current smokers, n (%)",None,7,2,3,no
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),MF xxx ?g BID (n = xxx) ; ,"Current smokers, n (%)",None,7,3,3,no
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),F xx ?g BID (n = xxx) ; ,"Current smokers, n (%)",None,7,4,3,no
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),Placebo (n = xxx) ; ,"Current smokers, n (%)",None,7,5,3,no
4689,3276257,Table 1,BaselineCharacteristic,"Ex-smokers, n (%)", ; ,"Ex-smokers, n (%)",None,8,0,2,no
4689,3276257,Table 1,BaselineCharacteristic,xx (xx),MF/F xxx/xx ?g BID (n = xxx) ; ,"Ex-smokers, n (%)",None,8,1,3,no
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),MF/F xxx/xx ?g BID (n = xxx) ; ,"Ex-smokers, n (%)",None,8,2,3,no
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),MF xxx ?g BID (n = xxx) ; ,"Ex-smokers, n (%)",None,8,3,3,no
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),F xx ?g BID (n = xxx) ; ,"Ex-smokers, n (%)",None,8,4,3,no
4689,3276257,Table 1,BaselineCharacteristic,xxx (xx),Placebo (n = xxx) ; ,"Ex-smokers, n (%)",None,8,5,3,no
4928,3342898,Table 1,BaselineCharacteristic,characteristic,,None,None,0,0,,no
4928,3342898,Table 1,BaselineCharacteristic,,,None,None,0,1,,no
4928,3342898,Table 1,BaselineCharacteristic,range,,None,None,0,2,,no
4928,3342898,Table 1,BaselineCharacteristic,"median age (years), n = xx",characteristic ; ,None,None,1,0,,no
4928,3342898,Table 1,BaselineCharacteristic,xx, ; ,None,None,1,1,,no
4928,3342898,Table 1,BaselineCharacteristic,xx - xx,range ; ,None,None,1,2,,no
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ; ",None,None,2,0,,no
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ; ,None,None,2,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ; ,None,None,2,2,,no
4928,3342898,Table 1,BaselineCharacteristic,"median follow-up (months), n = xx excluding pts under treatment","characteristic ; median age (years), n = xx ;  ; ",None,None,3,0,,no
4928,3342898,Table 1,BaselineCharacteristic,xx.x, ; xx ;  ; ,None,None,3,1,,no
4928,3342898,Table 1,BaselineCharacteristic,x.x - xx,range ; xx - xx ;  ; ,None,None,3,2,,no
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ; ",None,None,4,0,,no
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ; ,None,None,4,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ; ,None,None,4,2,,no
4928,3342898,Table 1,BaselineCharacteristic,deceased (pts),"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; ",None,None,5,0,,no
4928,3342898,Table 1,BaselineCharacteristic,x, ; xx ;  ; xx.x ;  ; ,None,None,5,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ; ,None,None,5,2,,no
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ; ",None,None,6,0,,no
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ; ,None,None,6,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ; ,None,None,6,2,,no
4928,3342898,Table 1,BaselineCharacteristic,male (pts),"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; ",None,None,7,0,,no
4928,3342898,Table 1,BaselineCharacteristic,xx, ; xx ;  ; xx.x ;  ; x ;  ; ,None,None,7,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ; ,None,None,7,2,,no
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ; ",None,None,8,0,,no
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ; ,None,None,8,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ; ,None,None,8,2,,no
4928,3342898,Table 1,BaselineCharacteristic,female (pts),"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; ",None,None,9,0,,no
4928,3342898,Table 1,BaselineCharacteristic,x, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; ,None,None,9,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ; ,None,None,9,2,,no
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ; ",None,None,10,0,,no
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ; ,None,None,10,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ; ,None,None,10,2,,no
4928,3342898,Table 1,BaselineCharacteristic,Site (n = xx),"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,11,0,,no
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,11,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,11,2,,no
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,12,0,,no
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,12,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,12,2,,no
4928,3342898,Table 1,BaselineCharacteristic,palate (pts),"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",palate (pts),,13,0,,no
4928,3342898,Table 1,BaselineCharacteristic,x, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,palate (pts),,13,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,palate (pts),,13,2,,no
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,14,0,,no
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,14,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,14,2,,no
4928,3342898,Table 1,BaselineCharacteristic,oropharynx,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",oropharynx,,15,0,,no
4928,3342898,Table 1,BaselineCharacteristic,x, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,oropharynx,,15,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,oropharynx,,15,2,,no
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,16,0,,no
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,16,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,16,2,,no
4928,3342898,Table 1,BaselineCharacteristic,hypopharynx,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",hypopharynx,,17,0,,no
4928,3342898,Table 1,BaselineCharacteristic,x, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,hypopharynx,,17,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,hypopharynx,,17,2,,no
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,18,0,,no
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,18,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,18,2,,no
4928,3342898,Table 1,BaselineCharacteristic,larynx,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",larynx,,19,0,,no
4928,3342898,Table 1,BaselineCharacteristic,x, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,larynx,,19,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,larynx,,19,2,,no
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,20,0,,no
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,20,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,20,2,,no
4928,3342898,Table 1,BaselineCharacteristic,Stage (n = xx),"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,21,0,,no
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,21,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,21,2,,no
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,22,0,,no
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,22,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,22,2,,no
4928,3342898,Table 1,BaselineCharacteristic,Tx,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",Tx,,23,0,,no
4928,3342898,Table 1,BaselineCharacteristic,x, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,Tx,,23,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,Tx,,23,2,,no
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,24,0,,no
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,24,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,24,2,,no
4928,3342898,Table 1,BaselineCharacteristic,Tx,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",Tx,,25,0,,no
4928,3342898,Table 1,BaselineCharacteristic,x, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,Tx,,25,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,Tx,,25,2,,no
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,26,0,,no
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,26,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,26,2,,no
4928,3342898,Table 1,BaselineCharacteristic,Tx,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",Tx,,27,0,,no
4928,3342898,Table 1,BaselineCharacteristic,x, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,Tx,,27,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,Tx,,27,2,,no
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,28,0,,no
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,28,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,28,2,,no
4928,3342898,Table 1,BaselineCharacteristic,Nx,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",Nx,,29,0,,no
4928,3342898,Table 1,BaselineCharacteristic,x, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,Nx,,29,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,Nx,,29,2,,no
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,30,0,,no
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,30,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,30,2,,no
4928,3342898,Table 1,BaselineCharacteristic,Nxb,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",Nxb,,31,0,,no
4928,3342898,Table 1,BaselineCharacteristic,x, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,Nxb,,31,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,Nxb,,31,2,,no
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,32,0,,no
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,32,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,32,2,,no
4928,3342898,Table 1,BaselineCharacteristic,Nxc,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",Nxc,,33,0,,no
4928,3342898,Table 1,BaselineCharacteristic,xx, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,Nxc,,33,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,Nxc,,33,2,,no
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,34,0,,no
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,34,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,34,2,,no
4928,3342898,Table 1,BaselineCharacteristic,Nx,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",Nx,,35,0,,no
4928,3342898,Table 1,BaselineCharacteristic,x, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,Nx,,35,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,Nx,,35,2,,no
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,36,0,,no
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,36,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,36,2,,no
4928,3342898,Table 1,BaselineCharacteristic,therapy (n = xx),"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,37,0,,no
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,37,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,37,2,,no
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,38,0,,no
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,38,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,38,2,,no
4928,3342898,Table 1,BaselineCharacteristic,median dose (cervical lymph nodes)/Gy,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",median dose (cervical lymph nodes)/Gy,,39,0,,no
4928,3342898,Table 1,BaselineCharacteristic,xx, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,median dose (cervical lymph nodes)/Gy,,39,1,,no
4928,3342898,Table 1,BaselineCharacteristic,xx - xx,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,median dose (cervical lymph nodes)/Gy,,39,2,,no
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,40,0,,no
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,40,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,40,2,,no
4928,3342898,Table 1,BaselineCharacteristic,median dose (primary and involved nodes)/Gy,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",median dose (primary and involved nodes)/Gy,,41,0,,no
4928,3342898,Table 1,BaselineCharacteristic,xx, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,median dose (primary and involved nodes)/Gy,,41,1,,no
4928,3342898,Table 1,BaselineCharacteristic,xx - xx,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,median dose (primary and involved nodes)/Gy,,41,2,,no
4928,3342898,Table 1,BaselineCharacteristic,,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",None,None,42,0,,no
4928,3342898,Table 1,BaselineCharacteristic,, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,None,None,42,1,,no
4928,3342898,Table 1,BaselineCharacteristic,,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,None,None,42,2,,no
4928,3342898,Table 1,BaselineCharacteristic,median total dose/Gy,"characteristic ; median age (years), n = xx ;  ; median follow-up (months), n = xx excluding pts under treatment ;  ; deceased (pts) ;  ; male (pts) ;  ; female (pts) ;  ; ",median total dose/Gy,,43,0,,no
4928,3342898,Table 1,BaselineCharacteristic,xx, ; xx ;  ; xx.x ;  ; x ;  ; xx ;  ; x ;  ; ,median total dose/Gy,,43,1,,no
4928,3342898,Table 1,BaselineCharacteristic,xx - xx,range ; xx - xx ;  ; x.x - xx ;  ;  ;  ;  ;  ;  ;  ; ,median total dose/Gy,,43,2,,no
5127,3389237,Table I,BaselineCharacteristic,Parameter,,None,None,0,0,12,no
5127,3389237,Table I,BaselineCharacteristic,Total (N?=?xx),,Parameter,None,0,1,1,no
5127,3389237,Table I,BaselineCharacteristic,Gender,Parameter ; ,None,None,1,0,24,no
5127,3389237,Table I,BaselineCharacteristic,Gender,Total (N?=?xx) ; ,Gender,None,1,1,43,no
5127,3389237,Table I,BaselineCharacteristic,,Parameter ; ,, Gender,2,0,2,no
5127,3389237,Table I,BaselineCharacteristic,xx (xx.x%),Total (N?=?xx) ; ,, Gender,2,1,3,yes
5127,3389237,Table I,BaselineCharacteristic,,Parameter ; ,, Gender,3,0,2,no
5127,3389237,Table I,BaselineCharacteristic,xx (xx.x%),Total (N?=?xx) ; ,, Gender,3,1,3,yes
5127,3389237,Table I,BaselineCharacteristic,Age (yr),Parameter ; ,None,None,4,0,24,no
5127,3389237,Table I,BaselineCharacteristic,Age (yr),Total (N?=?xx) ; ,Age (yr),None,4,1,43,no
5127,3389237,Table I,BaselineCharacteristic,,Parameter ; ,, Age (yr),5,0,2,no
5127,3389237,Table I,BaselineCharacteristic,xx.x (xx.xx),Total (N?=?xx) ; ,, Age (yr),5,1,3,no
5127,3389237,Table I,BaselineCharacteristic,,Parameter ; ,, Age (yr),6,0,2,no
5127,3389237,Table I,BaselineCharacteristic,xx.x,Total (N?=?xx) ; ,, Age (yr),6,1,3,no
5127,3389237,Table I,BaselineCharacteristic,,Parameter ; ,, Age (yr),7,0,2,no
5127,3389237,Table I,BaselineCharacteristic,"x, xx",Total (N?=?xx) ; ,, Age (yr),7,1,3,no
5127,3389237,Table I,BaselineCharacteristic,Age group,Parameter ; ,None,None,8,0,24,no
5127,3389237,Table I,BaselineCharacteristic,Age group,Total (N?=?xx) ; ,Age group,None,8,1,43,no
5127,3389237,Table I,BaselineCharacteristic,,Parameter ; ,, Age group,9,0,2,no
5127,3389237,Table I,BaselineCharacteristic,x (x.x%),Total (N?=?xx) ; ,, Age group,9,1,3,no
5127,3389237,Table I,BaselineCharacteristic,,Parameter ; ,, Age group,10,0,2,no
5127,3389237,Table I,BaselineCharacteristic,x (x.x%),Total (N?=?xx) ; ,, Age group,10,1,3,no
5127,3389237,Table I,BaselineCharacteristic,,Parameter ; ,, Age group,11,0,2,no
5127,3389237,Table I,BaselineCharacteristic,xx (xx.x%),Total (N?=?xx) ; ,, Age group,11,1,3,no
5127,3389237,Table I,BaselineCharacteristic,,Parameter ; ,, Age group,12,0,2,no
5127,3389237,Table I,BaselineCharacteristic,x (xx.x%),Total (N?=?xx) ; ,, Age group,12,1,3,no
5127,3389237,Table I,BaselineCharacteristic,Race,Parameter ; ,None,None,13,0,24,no
5127,3389237,Table I,BaselineCharacteristic,Race,Total (N?=?xx) ; ,Race,None,13,1,43,no
5127,3389237,Table I,BaselineCharacteristic,,Parameter ; ,, Race,14,0,2,no
5127,3389237,Table I,BaselineCharacteristic,xx (xx.x%),Total (N?=?xx) ; ,, Race,14,1,3,no
5127,3389237,Table I,BaselineCharacteristic,,Parameter ; ,, Race,15,0,2,no
5127,3389237,Table I,BaselineCharacteristic,x (x.x%),Total (N?=?xx) ; ,, Race,15,1,3,no
5127,3389237,Table I,BaselineCharacteristic,Primary diagnosis,Parameter ; ,None,None,16,0,24,no
5127,3389237,Table I,BaselineCharacteristic,Primary diagnosis,Total (N?=?xx) ; ,Primary diagnosis,None,16,1,43,no
5127,3389237,Table I,BaselineCharacteristic,,Parameter ; ,, Primary diagnosis,17,0,2,no
5127,3389237,Table I,BaselineCharacteristic,x (x.x%),Total (N?=?xx) ; ,, Primary diagnosis,17,1,3,no
5127,3389237,Table I,BaselineCharacteristic,,Parameter ; ,, Primary diagnosis,18,0,2,no
5127,3389237,Table I,BaselineCharacteristic,xx (xx.x%),Total (N?=?xx) ; ,, Primary diagnosis,18,1,3,no
5127,3389237,Table I,BaselineCharacteristic,,Parameter ; ,, Primary diagnosis,19,0,2,no
5127,3389237,Table I,BaselineCharacteristic,x (x.x%),Total (N?=?xx) ; ,, Primary diagnosis,19,1,3,no
5127,3389237,Table I,BaselineCharacteristic,SBI history,Parameter ; ,SBI history, Primary diagnosis,20,0,2,no
5127,3389237,Table I,BaselineCharacteristic,x (xx.x%),Total (N?=?xx) ; ,SBI history, Primary diagnosis,20,1,3,no
5127,3389237,Table I,BaselineCharacteristic,,Parameter ; ,, Primary diagnosis,21,0,2,no
5127,3389237,Table I,BaselineCharacteristic,x (xx.x%),Total (N?=?xx) ; ,, Primary diagnosis,21,1,3,no
5127,3389237,Table I,BaselineCharacteristic,,Parameter ; ,, Primary diagnosis,22,0,2,no
5127,3389237,Table I,BaselineCharacteristic,x (x.x%),Total (N?=?xx) ; ,, Primary diagnosis,22,1,3,no
5153,3396277,Table 2,BaselineCharacteristic,,,None,None,0,0,12,no
5153,3396277,Table 2,BaselineCharacteristic,AZDxxxx cohort x(xx U/kg)(n = x),,,None,0,1,1,no
5153,3396277,Table 2,BaselineCharacteristic,AZDxxxx cohort x(xxx U/kg)(n = x),,,None,0,2,1,no
5153,3396277,Table 2,BaselineCharacteristic,AZDxxxx cohort x(xxx/xx U/kg) (n = xx),,,None,0,3,1,no
5153,3396277,Table 2,BaselineCharacteristic,AZDxxxx cohort x(xxx/xxx U/kg) (n = xx),,,None,0,4,1,no
5153,3396277,Table 2,BaselineCharacteristic,AZDxxxx cohort x(xxx/xxx U/kg)(n = x),,,None,0,5,1,no
5153,3396277,Table 2,BaselineCharacteristic,Placebo (n = xx),,,None,0,6,1,no
5153,3396277,Table 2,BaselineCharacteristic,Total(n = xx),,,None,0,7,1,no
5153,3396277,Table 2,BaselineCharacteristic,"Male:female, n", ; ,"Male:female, n",,2,0,2,no
5153,3396277,Table 2,BaselineCharacteristic,x:x,AZDxxxx cohort x(xx U/kg)(n = x) ; ,"Male:female, n",,2,1,3,yes
5153,3396277,Table 2,BaselineCharacteristic,x:x,AZDxxxx cohort x(xxx U/kg)(n = x) ; ,"Male:female, n",,2,2,3,yes
5153,3396277,Table 2,BaselineCharacteristic,x:x,AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,"Male:female, n",,2,3,3,yes
5153,3396277,Table 2,BaselineCharacteristic,x:x,AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,"Male:female, n",,2,4,3,yes
5153,3396277,Table 2,BaselineCharacteristic,x:x,AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,"Male:female, n",,2,5,3,yes
5153,3396277,Table 2,BaselineCharacteristic,xx:xx,Placebo (n = xx) ; ,"Male:female, n",,2,6,3,yes
5153,3396277,Table 2,BaselineCharacteristic,xx:xx,Total(n = xx) ; ,"Male:female, n",,2,7,3,yes
5153,3396277,Table 2,BaselineCharacteristic,"Race, n (%)", ; ,None,None,3,0,24,no
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xx U/kg)(n = x) ; ,"Race, n (%)",None,3,1,43,no
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xxx U/kg)(n = x) ; ,"Race, n (%)",None,3,2,43,no
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,"Race, n (%)",None,3,3,43,no
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,"Race, n (%)",None,3,4,43,no
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,"Race, n (%)",None,3,5,43,no
5153,3396277,Table 2,BaselineCharacteristic,,Placebo (n = xx) ; ,"Race, n (%)",None,3,6,43,no
5153,3396277,Table 2,BaselineCharacteristic,,Total(n = xx) ; ,"Race, n (%)",None,3,7,43,no
5153,3396277,Table 2,BaselineCharacteristic,?Caucasian/white, ; ,?Caucasian/white," Race, n (%)",4,0,2,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,?Caucasian/white," Race, n (%)",4,1,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?Caucasian/white," Race, n (%)",4,2,3,no
5153,3396277,Table 2,BaselineCharacteristic,xx (xx.x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?Caucasian/white," Race, n (%)",4,3,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?Caucasian/white," Race, n (%)",4,4,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?Caucasian/white," Race, n (%)",4,5,3,no
5153,3396277,Table 2,BaselineCharacteristic,xx (xx.x),Placebo (n = xx) ; ,?Caucasian/white," Race, n (%)",4,6,3,no
5153,3396277,Table 2,BaselineCharacteristic,xx (xx.x),Total(n = xx) ; ,?Caucasian/white," Race, n (%)",4,7,3,no
5153,3396277,Table 2,BaselineCharacteristic,?Black/African American, ; ,?Black/African American," Race, n (%)",5,0,2,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,?Black/African American," Race, n (%)",5,1,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?Black/African American," Race, n (%)",5,2,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (x.x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?Black/African American," Race, n (%)",5,3,3,no
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?Black/African American," Race, n (%)",5,4,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?Black/African American," Race, n (%)",5,5,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (x.x),Placebo (n = xx) ; ,?Black/African American," Race, n (%)",5,6,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (x.x),Total(n = xx) ; ,?Black/African American," Race, n (%)",5,7,3,no
5153,3396277,Table 2,BaselineCharacteristic,?Other, ; ,?Other," Race, n (%)",6,0,2,no
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xx U/kg)(n = x) ; ,?Other," Race, n (%)",6,1,3,no
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?Other," Race, n (%)",6,2,3,no
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?Other," Race, n (%)",6,3,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?Other," Race, n (%)",6,4,3,no
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?Other," Race, n (%)",6,5,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (x.x),Placebo (n = xx) ; ,?Other," Race, n (%)",6,6,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (x.x),Total(n = xx) ; ,?Other," Race, n (%)",6,7,3,no
5153,3396277,Table 2,BaselineCharacteristic,"Shock, n (%)", ; ,None,None,7,0,24,no
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xx U/kg)(n = x) ; ,"Shock, n (%)",None,7,1,43,no
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xxx U/kg)(n = x) ; ,"Shock, n (%)",None,7,2,43,no
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,"Shock, n (%)",None,7,3,43,no
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,"Shock, n (%)",None,7,4,43,no
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,"Shock, n (%)",None,7,5,43,no
5153,3396277,Table 2,BaselineCharacteristic,,Placebo (n = xx) ; ,"Shock, n (%)",None,7,6,43,no
5153,3396277,Table 2,BaselineCharacteristic,,Total(n = xx) ; ,"Shock, n (%)",None,7,7,43,no
5153,3396277,Table 2,BaselineCharacteristic,?Yes, ; ,?Yes," Shock, n (%)",8,0,2,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,?Yes," Shock, n (%)",8,1,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?Yes," Shock, n (%)",8,2,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?Yes," Shock, n (%)",8,3,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?Yes," Shock, n (%)",8,4,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?Yes," Shock, n (%)",8,5,3,no
5153,3396277,Table 2,BaselineCharacteristic,xx (xx.x),Placebo (n = xx) ; ,?Yes," Shock, n (%)",8,6,3,no
5153,3396277,Table 2,BaselineCharacteristic,xx (xx.x),Total(n = xx) ; ,?Yes," Shock, n (%)",8,7,3,no
5153,3396277,Table 2,BaselineCharacteristic,?No, ; ,?No," Shock, n (%)",9,0,2,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,?No," Shock, n (%)",9,1,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?No," Shock, n (%)",9,2,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?No," Shock, n (%)",9,3,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?No," Shock, n (%)",9,4,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?No," Shock, n (%)",9,5,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),Placebo (n = xx) ; ,?No," Shock, n (%)",9,6,3,no
5153,3396277,Table 2,BaselineCharacteristic,xx (xx.x),Total(n = xx) ; ,?No," Shock, n (%)",9,7,3,no
5153,3396277,Table 2,BaselineCharacteristic,"On ventilator, n (%)*", ; ,None,None,10,0,24,no
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xx U/kg)(n = x) ; ,"On ventilator, n (%)*",None,10,1,43,no
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xxx U/kg)(n = x) ; ,"On ventilator, n (%)*",None,10,2,43,no
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,"On ventilator, n (%)*",None,10,3,43,no
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,"On ventilator, n (%)*",None,10,4,43,no
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,"On ventilator, n (%)*",None,10,5,43,no
5153,3396277,Table 2,BaselineCharacteristic,,Placebo (n = xx) ; ,"On ventilator, n (%)*",None,10,6,43,no
5153,3396277,Table 2,BaselineCharacteristic,,Total(n = xx) ; ,"On ventilator, n (%)*",None,10,7,43,no
5153,3396277,Table 2,BaselineCharacteristic,?Yes, ; ,?Yes," On ventilator, n (%)*",11,0,2,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,?Yes," On ventilator, n (%)*",11,1,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xxx.x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?Yes," On ventilator, n (%)*",11,2,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?Yes," On ventilator, n (%)*",11,3,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?Yes," On ventilator, n (%)*",11,4,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xxx.x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?Yes," On ventilator, n (%)*",11,5,3,no
5153,3396277,Table 2,BaselineCharacteristic,xx (xx.x),Placebo (n = xx) ; ,?Yes," On ventilator, n (%)*",11,6,3,no
5153,3396277,Table 2,BaselineCharacteristic,xx (xx.x),Total(n = xx) ; ,?Yes," On ventilator, n (%)*",11,7,3,no
5153,3396277,Table 2,BaselineCharacteristic,?No, ; ,?No," On ventilator, n (%)*",12,0,2,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,?No," On ventilator, n (%)*",12,1,3,no
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?No," On ventilator, n (%)*",12,2,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?No," On ventilator, n (%)*",12,3,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?No," On ventilator, n (%)*",12,4,3,no
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?No," On ventilator, n (%)*",12,5,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),Placebo (n = xx) ; ,?No," On ventilator, n (%)*",12,6,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),Total(n = xx) ; ,?No," On ventilator, n (%)*",12,7,3,no
5153,3396277,Table 2,BaselineCharacteristic,?Missing, ; ,?Missing," On ventilator, n (%)*",13,0,2,no
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xx U/kg)(n = x) ; ,?Missing," On ventilator, n (%)*",13,1,3,no
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?Missing," On ventilator, n (%)*",13,2,3,no
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?Missing," On ventilator, n (%)*",13,3,3,no
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?Missing," On ventilator, n (%)*",13,4,3,no
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?Missing," On ventilator, n (%)*",13,5,3,no
5153,3396277,Table 2,BaselineCharacteristic,x,Placebo (n = xx) ; ,?Missing," On ventilator, n (%)*",13,6,3,no
5153,3396277,Table 2,BaselineCharacteristic,x,Total(n = xx) ; ,?Missing," On ventilator, n (%)*",13,7,3,no
5153,3396277,Table 2,BaselineCharacteristic,"Shock + ventilator, n (%)*", ; ,"Shock + ventilator, n (%)*",,14,0,2,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,"Shock + ventilator, n (%)*",,14,1,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,"Shock + ventilator, n (%)*",,14,2,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,"Shock + ventilator, n (%)*",,14,3,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,"Shock + ventilator, n (%)*",,14,4,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,"Shock + ventilator, n (%)*",,14,5,3,no
5153,3396277,Table 2,BaselineCharacteristic,xx (xx.x),Placebo (n = xx) ; ,"Shock + ventilator, n (%)*",,14,6,3,no
5153,3396277,Table 2,BaselineCharacteristic,xx (xx.x),Total(n = xx) ; ,"Shock + ventilator, n (%)*",,14,7,3,no
5153,3396277,Table 2,BaselineCharacteristic,"Organ failures, n (%)**", ; ,None,None,15,0,24,no
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xx U/kg)(n = x) ; ,"Organ failures, n (%)**",None,15,1,43,no
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xxx U/kg)(n = x) ; ,"Organ failures, n (%)**",None,15,2,43,no
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,"Organ failures, n (%)**",None,15,3,43,no
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,"Organ failures, n (%)**",None,15,4,43,no
5153,3396277,Table 2,BaselineCharacteristic,,AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,"Organ failures, n (%)**",None,15,5,43,no
5153,3396277,Table 2,BaselineCharacteristic,,Placebo (n = xx) ; ,"Organ failures, n (%)**",None,15,6,43,no
5153,3396277,Table 2,BaselineCharacteristic,,Total(n = xx) ; ,"Organ failures, n (%)**",None,15,7,43,no
5153,3396277,Table 2,BaselineCharacteristic,?x, ; ,?x," Organ failures, n (%)**",16,0,2,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,?x," Organ failures, n (%)**",16,1,3,no
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?x," Organ failures, n (%)**",16,2,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (x.x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?x," Organ failures, n (%)**",16,3,3,no
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?x," Organ failures, n (%)**",16,4,3,no
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?x," Organ failures, n (%)**",16,5,3,no
5153,3396277,Table 2,BaselineCharacteristic,x,Placebo (n = xx) ; ,?x," Organ failures, n (%)**",16,6,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (x.x),Total(n = xx) ; ,?x," Organ failures, n (%)**",16,7,3,no
5153,3396277,Table 2,BaselineCharacteristic,?x, ; ,?x," Organ failures, n (%)**",17,0,2,no
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xx U/kg)(n = x) ; ,?x," Organ failures, n (%)**",17,1,3,no
5153,3396277,Table 2,BaselineCharacteristic,x,AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?x," Organ failures, n (%)**",17,2,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?x," Organ failures, n (%)**",17,3,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?x," Organ failures, n (%)**",17,4,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?x," Organ failures, n (%)**",17,5,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (x.x),Placebo (n = xx) ; ,?x," Organ failures, n (%)**",17,6,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),Total(n = xx) ; ,?x," Organ failures, n (%)**",17,7,3,no
5153,3396277,Table 2,BaselineCharacteristic,?x, ; ,?x," Organ failures, n (%)**",18,0,2,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,?x," Organ failures, n (%)**",18,1,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?x," Organ failures, n (%)**",18,2,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?x," Organ failures, n (%)**",18,3,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?x," Organ failures, n (%)**",18,4,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?x," Organ failures, n (%)**",18,5,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),Placebo (n = xx) ; ,?x," Organ failures, n (%)**",18,6,3,no
5153,3396277,Table 2,BaselineCharacteristic,xx (xx.x),Total(n = xx) ; ,?x," Organ failures, n (%)**",18,7,3,no
5153,3396277,Table 2,BaselineCharacteristic,?x, ; ,?x," Organ failures, n (%)**",19,0,2,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,?x," Organ failures, n (%)**",19,1,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?x," Organ failures, n (%)**",19,2,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?x," Organ failures, n (%)**",19,3,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?x," Organ failures, n (%)**",19,4,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?x," Organ failures, n (%)**",19,5,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),Placebo (n = xx) ; ,?x," Organ failures, n (%)**",19,6,3,no
5153,3396277,Table 2,BaselineCharacteristic,xx (xx.x),Total(n = xx) ; ,?x," Organ failures, n (%)**",19,7,3,no
5153,3396277,Table 2,BaselineCharacteristic,?? x, ; ,?? x," Organ failures, n (%)**",20,0,2,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,?? x," Organ failures, n (%)**",20,1,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?? x," Organ failures, n (%)**",20,2,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?? x," Organ failures, n (%)**",20,3,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?? x," Organ failures, n (%)**",20,4,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?? x," Organ failures, n (%)**",20,5,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),Placebo (n = xx) ; ,?? x," Organ failures, n (%)**",20,6,3,no
5153,3396277,Table 2,BaselineCharacteristic,xx (xx.x),Total(n = xx) ; ,?? x," Organ failures, n (%)**",20,7,3,no
5153,3396277,Table 2,BaselineCharacteristic,APACHE II score, ; ,APACHE II score,,21,0,24,no
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,APACHE II score,,21,1,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,APACHE II score,,21,2,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,APACHE II score,,21,3,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,APACHE II score,,21,4,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,APACHE II score,,21,5,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),Placebo (n = xx) ; ,APACHE II score,,21,6,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),Total(n = xx) ; ,APACHE II score,,21,7,43,no
5153,3396277,Table 2,BaselineCharacteristic,SOFA score, ; ,SOFA score,,23,0,24,no
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,SOFA score,,23,1,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,SOFA score,,23,2,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,SOFA score,,23,3,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,SOFA score,,23,4,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,SOFA score,,23,5,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),Placebo (n = xx) ; ,SOFA score,,23,6,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),Total(n = xx) ; ,SOFA score,,23,7,43,no
5153,3396277,Table 2,BaselineCharacteristic,"TNF-? concentration, pg/mL", ; ,"TNF-? concentration, pg/mL",,25,0,24,no
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,"TNF-? concentration, pg/mL",,25,1,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,"TNF-? concentration, pg/mL",,25,2,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,"TNF-? concentration, pg/mL",,25,3,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,"TNF-? concentration, pg/mL",,25,4,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,"TNF-? concentration, pg/mL",,25,5,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),Placebo (n = xx) ; ,"TNF-? concentration, pg/mL",,25,6,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),Total(n = xx) ; ,"TNF-? concentration, pg/mL",,25,7,43,no
5153,3396277,Table 2,BaselineCharacteristic,?Median (range), ; ,?Median (range)," TNF-? concentration, pg/mL",26,0,2,no
5153,3396277,Table 2,BaselineCharacteristic,x.x(x.x to xx.x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,?Median (range)," TNF-? concentration, pg/mL",26,1,3,no
5153,3396277,Table 2,BaselineCharacteristic,x.x(x.x to xx.x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?Median (range)," TNF-? concentration, pg/mL",26,2,3,no
5153,3396277,Table 2,BaselineCharacteristic,x.x(x.x to xx.x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?Median (range)," TNF-? concentration, pg/mL",26,3,3,no
5153,3396277,Table 2,BaselineCharacteristic,x.x(x.x to x.x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?Median (range)," TNF-? concentration, pg/mL",26,4,3,no
5153,3396277,Table 2,BaselineCharacteristic,x.x(x.x to xx.x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?Median (range)," TNF-? concentration, pg/mL",26,5,3,no
5153,3396277,Table 2,BaselineCharacteristic,x.x(x.x to xx.x),Placebo (n = xx) ; ,?Median (range)," TNF-? concentration, pg/mL",26,6,3,no
5153,3396277,Table 2,BaselineCharacteristic,x.x(x.x to xx.x),Total(n = xx) ; ,?Median (range)," TNF-? concentration, pg/mL",26,7,3,no
5153,3396277,Table 2,BaselineCharacteristic,"IL-x concentration, pg/mL", ; ,"IL-x concentration, pg/mL",,27,0,24,no
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,"IL-x concentration, pg/mL",,27,1,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,"IL-x concentration, pg/mL",,27,2,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,"IL-x concentration, pg/mL",,27,3,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,"IL-x concentration, pg/mL",,27,4,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,"IL-x concentration, pg/mL",,27,5,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),Placebo (n = xx) ; ,"IL-x concentration, pg/mL",,27,6,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),Total(n = xx) ; ,"IL-x concentration, pg/mL",,27,7,43,no
5153,3396277,Table 2,BaselineCharacteristic,?Median (range), ; ,?Median (range)," IL-x concentration, pg/mL",28,0,2,no
5153,3396277,Table 2,BaselineCharacteristic,"xxx(xx to xx,xxx)",AZDxxxx cohort x(xx U/kg)(n = x) ; ,?Median (range)," IL-x concentration, pg/mL",28,1,3,no
5153,3396277,Table 2,BaselineCharacteristic,"xxx(xx to xx,xxx)",AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?Median (range)," IL-x concentration, pg/mL",28,2,3,no
5153,3396277,Table 2,BaselineCharacteristic,"xxx(xx to xx,xxx)",AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?Median (range)," IL-x concentration, pg/mL",28,3,3,no
5153,3396277,Table 2,BaselineCharacteristic,"xxxx(xxx to xx,xxx)",AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?Median (range)," IL-x concentration, pg/mL",28,4,3,no
5153,3396277,Table 2,BaselineCharacteristic,"xxx(xxx to xx,xxx)",AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?Median (range)," IL-x concentration, pg/mL",28,5,3,no
5153,3396277,Table 2,BaselineCharacteristic,"xxx(xx to xxx,xxx)",Placebo (n = xx) ; ,?Median (range)," IL-x concentration, pg/mL",28,6,3,no
5153,3396277,Table 2,BaselineCharacteristic,"xxx(xx to xxx,xxx)",Total(n = xx) ; ,?Median (range)," IL-x concentration, pg/mL",28,7,3,no
5153,3396277,Table 2,BaselineCharacteristic,"Procalcitonin level, ng/mL", ; ,"Procalcitonin level, ng/mL",,29,0,24,no
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,"Procalcitonin level, ng/mL",,29,1,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,"Procalcitonin level, ng/mL",,29,2,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,"Procalcitonin level, ng/mL",,29,3,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,"Procalcitonin level, ng/mL",,29,4,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,"Procalcitonin level, ng/mL",,29,5,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),Placebo (n = xx) ; ,"Procalcitonin level, ng/mL",,29,6,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),Total(n = xx) ; ,"Procalcitonin level, ng/mL",,29,7,43,no
5153,3396277,Table 2,BaselineCharacteristic,?Median (range), ; ,?Median (range)," Procalcitonin level, ng/mL",30,0,2,no
5153,3396277,Table 2,BaselineCharacteristic,xx.x (x.x to xxx.x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,?Median (range)," Procalcitonin level, ng/mL",30,1,3,no
5153,3396277,Table 2,BaselineCharacteristic,x.x(x.x to xxx.x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?Median (range)," Procalcitonin level, ng/mL",30,2,3,no
5153,3396277,Table 2,BaselineCharacteristic,x.x(x.x to xxx.x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?Median (range)," Procalcitonin level, ng/mL",30,3,3,no
5153,3396277,Table 2,BaselineCharacteristic,xx.x(x.x to xx.x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?Median (range)," Procalcitonin level, ng/mL",30,4,3,no
5153,3396277,Table 2,BaselineCharacteristic,xx.x(x.x to xx.x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?Median (range)," Procalcitonin level, ng/mL",30,5,3,no
5153,3396277,Table 2,BaselineCharacteristic,xx.x(x.x to xxx.x),Placebo (n = xx) ; ,?Median (range)," Procalcitonin level, ng/mL",30,6,3,no
5153,3396277,Table 2,BaselineCharacteristic,xx.x(x.x to xxx.x),Total(n = xx) ; ,?Median (range)," Procalcitonin level, ng/mL",30,7,3,no
5153,3396277,Table 2,BaselineCharacteristic,"?> x.x ng/mL, n (%)", ; ,"?> x.x ng/mL, n (%)"," Procalcitonin level, ng/mL",31,0,2,no
5153,3396277,Table 2,BaselineCharacteristic,x (xxx),AZDxxxx cohort x(xx U/kg)(n = x) ; ,"?> x.x ng/mL, n (%)"," Procalcitonin level, ng/mL",31,1,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,"?> x.x ng/mL, n (%)"," Procalcitonin level, ng/mL",31,2,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xx.x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,"?> x.x ng/mL, n (%)"," Procalcitonin level, ng/mL",31,3,3,no
5153,3396277,Table 2,BaselineCharacteristic,xx (xxx),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,"?> x.x ng/mL, n (%)"," Procalcitonin level, ng/mL",31,4,3,no
5153,3396277,Table 2,BaselineCharacteristic,x (xxx),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,"?> x.x ng/mL, n (%)"," Procalcitonin level, ng/mL",31,5,3,no
5153,3396277,Table 2,BaselineCharacteristic,xx (xx.x),Placebo (n = xx) ; ,"?> x.x ng/mL, n (%)"," Procalcitonin level, ng/mL",31,6,3,no
5153,3396277,Table 2,BaselineCharacteristic,xx (xx.x),Total(n = xx) ; ,"?> x.x ng/mL, n (%)"," Procalcitonin level, ng/mL",31,7,3,no
5153,3396277,Table 2,BaselineCharacteristic,"Total fluid volume in xx h prior to randomization, mL/kg", ; ,"Total fluid volume in xx h prior to randomization, mL/kg",,32,0,24,no
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,"Total fluid volume in xx h prior to randomization, mL/kg",,32,1,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,"Total fluid volume in xx h prior to randomization, mL/kg",,32,2,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,"Total fluid volume in xx h prior to randomization, mL/kg",,32,3,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,"Total fluid volume in xx h prior to randomization, mL/kg",,32,4,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,"Total fluid volume in xx h prior to randomization, mL/kg",,32,5,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),Placebo (n = xx) ; ,"Total fluid volume in xx h prior to randomization, mL/kg",,32,6,43,no
5153,3396277,Table 2,BaselineCharacteristic,(n = xx),Total(n = xx) ; ,"Total fluid volume in xx h prior to randomization, mL/kg",,32,7,43,no
5153,3396277,Table 2,BaselineCharacteristic,?Median (range), ; ,?Median (range)," Total fluid volume in xx h prior to randomization, mL/kg",33,0,2,no
5153,3396277,Table 2,BaselineCharacteristic,xx.x(xx.x to xxx.x),AZDxxxx cohort x(xx U/kg)(n = x) ; ,?Median (range)," Total fluid volume in xx h prior to randomization, mL/kg",33,1,3,no
5153,3396277,Table 2,BaselineCharacteristic,xx.x(x.x to xxx.x),AZDxxxx cohort x(xxx U/kg)(n = x) ; ,?Median (range)," Total fluid volume in xx h prior to randomization, mL/kg",33,2,3,no
5153,3396277,Table 2,BaselineCharacteristic,xx.x(xx.x to xxx.x),AZDxxxx cohort x(xxx/xx U/kg) (n = xx) ; ,?Median (range)," Total fluid volume in xx h prior to randomization, mL/kg",33,3,3,no
5153,3396277,Table 2,BaselineCharacteristic,xx.x(xx.x to xxx.x),AZDxxxx cohort x(xxx/xxx U/kg) (n = xx) ; ,?Median (range)," Total fluid volume in xx h prior to randomization, mL/kg",33,4,3,no
5153,3396277,Table 2,BaselineCharacteristic,xx.x(xx.x to xxx.x),AZDxxxx cohort x(xxx/xxx U/kg)(n = x) ; ,?Median (range)," Total fluid volume in xx h prior to randomization, mL/kg",33,5,3,no
5153,3396277,Table 2,BaselineCharacteristic,xx.x(x.x to xxx.x),Placebo (n = xx) ; ,?Median (range)," Total fluid volume in xx h prior to randomization, mL/kg",33,6,3,no
5153,3396277,Table 2,BaselineCharacteristic,xx.x(x.x to xxx.x),Total(n = xx) ; ,?Median (range)," Total fluid volume in xx h prior to randomization, mL/kg",33,7,3,no
5225,3405220,Table 1,BaselineCharacteristic,Operating characteristic,,None,None,0,0,12,no
5225,3405220,Table 1,BaselineCharacteristic,Standard treatment alone,,Operating characteristic,None,0,1,1,no
5225,3405220,Table 1,BaselineCharacteristic,Standard treatment + huachansu,,Operating characteristic,None,0,2,1,no
5225,3405220,Table 1,BaselineCharacteristic,True overall response rate,Operating characteristic ; ,True overall response rate,None,1,0,2,no
5225,3405220,Table 1,BaselineCharacteristic,xx%,Standard treatment alone ; ,True overall response rate,None,1,1,3,no
5225,3405220,Table 1,BaselineCharacteristic,xx%,Standard treatment + huachansu ; ,True overall response rate,None,1,2,3,no
5225,3405220,Table 1,BaselineCharacteristic,Average number of patients,Operating characteristic ; ,Average number of patients,None,2,0,2,no
5225,3405220,Table 1,BaselineCharacteristic,xx.x,Standard treatment alone ; ,Average number of patients,None,2,1,3,no
5225,3405220,Table 1,BaselineCharacteristic,xx.x,Standard treatment + huachansu ; ,Average number of patients,None,2,2,3,no
5225,3405220,Table 1,BaselineCharacteristic,Probability of selection as best,Operating characteristic ; ,Probability of selection as best,None,3,0,2,no
5225,3405220,Table 1,BaselineCharacteristic,x.xxx,Standard treatment alone ; ,Probability of selection as best,None,3,1,3,no
5225,3405220,Table 1,BaselineCharacteristic,x.xxx,Standard treatment + huachansu ; ,Probability of selection as best,None,3,2,3,no
5225,3405220,Table 1,BaselineCharacteristic,Probability of early selection,Operating characteristic ; ,Probability of early selection,None,4,0,2,no
5225,3405220,Table 1,BaselineCharacteristic,x.xxx,Standard treatment alone ; ,Probability of early selection,None,4,1,3,no
5225,3405220,Table 1,BaselineCharacteristic,x.xxx,Standard treatment + huachansu ; ,Probability of early selection,None,4,2,3,no
5225,3405220,Table 1,BaselineCharacteristic,,Operating characteristic ; ,None,None,5,0,2,no
5225,3405220,Table 1,BaselineCharacteristic,,Standard treatment alone ; ,None,None,5,1,3,no
5225,3405220,Table 1,BaselineCharacteristic,,Standard treatment + huachansu ; ,None,None,5,2,3,no
5225,3405220,Table 1,BaselineCharacteristic,True overall response rate,Operating characteristic ; ,True overall response rate,None,6,0,2,no
5225,3405220,Table 1,BaselineCharacteristic,xx%,Standard treatment alone ; ,True overall response rate,None,6,1,3,no
5225,3405220,Table 1,BaselineCharacteristic,xx%,Standard treatment + huachansu ; ,True overall response rate,None,6,2,3,no
5225,3405220,Table 1,BaselineCharacteristic,Average number of patients,Operating characteristic ; ,Average number of patients,None,7,0,2,no
5225,3405220,Table 1,BaselineCharacteristic,xx.x,Standard treatment alone ; ,Average number of patients,None,7,1,3,no
5225,3405220,Table 1,BaselineCharacteristic,xx.x,Standard treatment + huachansu ; ,Average number of patients,None,7,2,3,no
5225,3405220,Table 1,BaselineCharacteristic,Probability of selection as best,Operating characteristic ; ,Probability of selection as best,None,8,0,2,no
5225,3405220,Table 1,BaselineCharacteristic,x.xxx,Standard treatment alone ; ,Probability of selection as best,None,8,1,3,no
5225,3405220,Table 1,BaselineCharacteristic,x.xxx,Standard treatment + huachansu ; ,Probability of selection as best,None,8,2,3,no
5225,3405220,Table 1,BaselineCharacteristic,Probability of early selection,Operating characteristic ; ,Probability of early selection,None,9,0,2,no
5225,3405220,Table 1,BaselineCharacteristic,x.xxx,Standard treatment alone ; ,Probability of early selection,None,9,1,3,no
5225,3405220,Table 1,BaselineCharacteristic,x.xxx,Standard treatment + huachansu ; ,Probability of early selection,None,9,2,3,no
5225,3405220,Table 1,BaselineCharacteristic,,Operating characteristic ; ,None,None,10,0,2,no
5225,3405220,Table 1,BaselineCharacteristic,,Standard treatment alone ; ,None,None,10,1,3,no
5225,3405220,Table 1,BaselineCharacteristic,,Standard treatment + huachansu ; ,None,None,10,2,3,no
5225,3405220,Table 1,BaselineCharacteristic,True overall response rate,Operating characteristic ; ,True overall response rate,None,11,0,2,no
5225,3405220,Table 1,BaselineCharacteristic,xx%,Standard treatment alone ; ,True overall response rate,None,11,1,3,no
5225,3405220,Table 1,BaselineCharacteristic,xx%,Standard treatment + huachansu ; ,True overall response rate,None,11,2,3,no
5225,3405220,Table 1,BaselineCharacteristic,Average number of patients,Operating characteristic ; ,Average number of patients,None,12,0,2,no
5225,3405220,Table 1,BaselineCharacteristic,xx.x,Standard treatment alone ; ,Average number of patients,None,12,1,3,no
5225,3405220,Table 1,BaselineCharacteristic,xx.x,Standard treatment + huachansu ; ,Average number of patients,None,12,2,3,no
5225,3405220,Table 1,BaselineCharacteristic,Probability of selection as best,Operating characteristic ; ,Probability of selection as best,None,13,0,2,no
5225,3405220,Table 1,BaselineCharacteristic,x.xxx,Standard treatment alone ; ,Probability of selection as best,None,13,1,3,no
5225,3405220,Table 1,BaselineCharacteristic,x.xxx,Standard treatment + huachansu ; ,Probability of selection as best,None,13,2,3,no
5225,3405220,Table 1,BaselineCharacteristic,Probability of early selection,Operating characteristic ; ,Probability of early selection,None,14,0,2,no
5225,3405220,Table 1,BaselineCharacteristic,x.xxx,Standard treatment alone ; ,Probability of early selection,None,14,1,3,no
5225,3405220,Table 1,BaselineCharacteristic,x.xxx,Standard treatment + huachansu ; ,Probability of early selection,None,14,2,3,no
5225,3405220,Table 1,BaselineCharacteristic,,Operating characteristic ; ,None,None,15,0,2,no
5225,3405220,Table 1,BaselineCharacteristic,,Standard treatment alone ; ,None,None,15,1,3,no
5225,3405220,Table 1,BaselineCharacteristic,,Standard treatment + huachansu ; ,None,None,15,2,3,no
5225,3405220,Table 1,BaselineCharacteristic,True overall response rate,Operating characteristic ; ,True overall response rate,None,16,0,2,no
5225,3405220,Table 1,BaselineCharacteristic,xx%,Standard treatment alone ; ,True overall response rate,None,16,1,3,no
5225,3405220,Table 1,BaselineCharacteristic,xx%,Standard treatment + huachansu ; ,True overall response rate,None,16,2,3,no
5225,3405220,Table 1,BaselineCharacteristic,Average number of patients,Operating characteristic ; ,Average number of patients,None,17,0,2,no
5225,3405220,Table 1,BaselineCharacteristic,xx.x,Standard treatment alone ; ,Average number of patients,None,17,1,3,no
5225,3405220,Table 1,BaselineCharacteristic,xx.x,Standard treatment + huachansu ; ,Average number of patients,None,17,2,3,no
5225,3405220,Table 1,BaselineCharacteristic,Probability of selection as best,Operating characteristic ; ,Probability of selection as best,None,18,0,2,no
5225,3405220,Table 1,BaselineCharacteristic,x.xxx,Standard treatment alone ; ,Probability of selection as best,None,18,1,3,no
5225,3405220,Table 1,BaselineCharacteristic,x.xxx,Standard treatment + huachansu ; ,Probability of selection as best,None,18,2,3,no
5225,3405220,Table 1,BaselineCharacteristic,Probability of early selection,Operating characteristic ; ,Probability of early selection,None,19,0,2,no
5225,3405220,Table 1,BaselineCharacteristic,x.xxx,Standard treatment alone ; ,Probability of early selection,None,19,1,3,no
5225,3405220,Table 1,BaselineCharacteristic,x.xxx,Standard treatment + huachansu ; ,Probability of early selection,None,19,2,3,no
5225,3405220,Table 2,BaselineCharacteristic,,,None,None,0,0,12,no
5225,3405220,Table 2,BaselineCharacteristic,Treatment arm,,,None,0,1,1,no
5225,3405220,Table 2,BaselineCharacteristic,Treatment arm,,,None,0,2,1,no
5225,3405220,Table 2,BaselineCharacteristic,Treatment arm,,,None,0,3,1,no
5225,3405220,Table 2,BaselineCharacteristic,Treatment arm,,,None,0,4,1,no
5225,3405220,Table 2,BaselineCharacteristic,,,,None,0,5,1,no
5225,3405220,Table 2,BaselineCharacteristic,,,,None,0,6,1,no
5225,3405220,Table 2,BaselineCharacteristic,,,,None,0,7,1,no
5225,3405220,Table 2,BaselineCharacteristic,, ; ,None,None,1,0,12,no
5225,3405220,Table 2,BaselineCharacteristic,Gemcitabine + huachansu,Treatment arm ; ,,None,1,1,1,no
5225,3405220,Table 2,BaselineCharacteristic,Gemcitabine + huachansu,Treatment arm ; ,,None,1,2,1,no
5225,3405220,Table 2,BaselineCharacteristic,Gemcitabine + placebo,Treatment arm ; ,,None,1,3,1,no
5225,3405220,Table 2,BaselineCharacteristic,Gemcitabine + placebo,Treatment arm ; ,,None,1,4,1,no
5225,3405220,Table 2,BaselineCharacteristic,Total, ; ,,None,1,5,1,no
5225,3405220,Table 2,BaselineCharacteristic,Total, ; ,,None,1,6,1,no
5225,3405220,Table 2,BaselineCharacteristic,, ; ,,None,1,7,1,no
5225,3405220,Table 2,BaselineCharacteristic,Characteristic, ;  ; ,None,None,2,0,12,no
5225,3405220,Table 2,BaselineCharacteristic,No. of patients,Treatment arm ; Gemcitabine + huachansu ; ,Characteristic,None,2,1,1,no
5225,3405220,Table 2,BaselineCharacteristic,%,Treatment arm ; Gemcitabine + huachansu ; ,Characteristic,None,2,2,1,no
5225,3405220,Table 2,BaselineCharacteristic,No. of patients,Treatment arm ; Gemcitabine + placebo ; ,Characteristic,None,2,3,1,no
5225,3405220,Table 2,BaselineCharacteristic,%,Treatment arm ; Gemcitabine + placebo ; ,Characteristic,None,2,4,1,no
5225,3405220,Table 2,BaselineCharacteristic,No. of patients, ; Total ; ,Characteristic,None,2,5,1,no
5225,3405220,Table 2,BaselineCharacteristic,%, ; Total ; ,Characteristic,None,2,6,1,no
5225,3405220,Table 2,BaselineCharacteristic,Pa, ;  ; ,Characteristic,None,2,7,1,no
5225,3405220,Table 2,BaselineCharacteristic,Gender, ;  ; Characteristic ; ,None,None,3,0,24,no
5225,3405220,Table 2,BaselineCharacteristic,Gender,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,Gender,None,3,1,43,no
5225,3405220,Table 2,BaselineCharacteristic,Gender,Treatment arm ; Gemcitabine + huachansu ; % ; ,Gender,None,3,2,43,no
5225,3405220,Table 2,BaselineCharacteristic,Gender,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,Gender,None,3,3,43,no
5225,3405220,Table 2,BaselineCharacteristic,Gender,Treatment arm ; Gemcitabine + placebo ; % ; ,Gender,None,3,4,43,no
5225,3405220,Table 2,BaselineCharacteristic,Gender, ; Total ; No. of patients ; ,Gender,None,3,5,43,no
5225,3405220,Table 2,BaselineCharacteristic,Gender, ; Total ; % ; ,Gender,None,3,6,43,no
5225,3405220,Table 2,BaselineCharacteristic,Gender, ;  ; Pa ; ,Gender,None,3,7,43,no
5225,3405220,Table 2,BaselineCharacteristic,?Male, ;  ; Characteristic ; ,?Male, Gender,4,0,2,no
5225,3405220,Table 2,BaselineCharacteristic,xx,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,?Male, Gender,4,1,3,yes
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + huachansu ; % ; ,?Male, Gender,4,2,3,yes
5225,3405220,Table 2,BaselineCharacteristic,xx,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,?Male, Gender,4,3,3,yes
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + placebo ; % ; ,?Male, Gender,4,4,3,yes
5225,3405220,Table 2,BaselineCharacteristic,xx, ; Total ; No. of patients ; ,?Male, Gender,4,5,3,yes
5225,3405220,Table 2,BaselineCharacteristic,xx.xx, ; Total ; % ; ,?Male, Gender,4,6,3,yes
5225,3405220,Table 2,BaselineCharacteristic,x.xxx, ;  ; Pa ; ,?Male, Gender,4,7,3,yes
5225,3405220,Table 2,BaselineCharacteristic,?Female, ;  ; Characteristic ; ,?Female, Gender,5,0,2,no
5225,3405220,Table 2,BaselineCharacteristic,xx,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,?Female, Gender,5,1,3,yes
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + huachansu ; % ; ,?Female, Gender,5,2,3,yes
5225,3405220,Table 2,BaselineCharacteristic,xx,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,?Female, Gender,5,3,3,yes
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + placebo ; % ; ,?Female, Gender,5,4,3,yes
5225,3405220,Table 2,BaselineCharacteristic,xx, ; Total ; No. of patients ; ,?Female, Gender,5,5,3,yes
5225,3405220,Table 2,BaselineCharacteristic,xx.xx, ; Total ; % ; ,?Female, Gender,5,6,3,yes
5225,3405220,Table 2,BaselineCharacteristic,, ;  ; Pa ; ,?Female, Gender,5,7,3,no
5225,3405220,Table 2,BaselineCharacteristic,, ;  ; Characteristic ; ,None,None,6,0,2,no
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,None,None,6,1,3,no
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + huachansu ; % ; ,None,None,6,2,3,no
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,None,None,6,3,3,no
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + placebo ; % ; ,None,None,6,4,3,no
5225,3405220,Table 2,BaselineCharacteristic,, ; Total ; No. of patients ; ,None,None,6,5,3,no
5225,3405220,Table 2,BaselineCharacteristic,, ; Total ; % ; ,None,None,6,6,3,no
5225,3405220,Table 2,BaselineCharacteristic,, ;  ; Pa ; ,None,None,6,7,3,no
5225,3405220,Table 2,BaselineCharacteristic,Stage, ;  ; Characteristic ; ,None,None,7,0,24,no
5225,3405220,Table 2,BaselineCharacteristic,Stage,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,Stage,None,7,1,43,no
5225,3405220,Table 2,BaselineCharacteristic,Stage,Treatment arm ; Gemcitabine + huachansu ; % ; ,Stage,None,7,2,43,no
5225,3405220,Table 2,BaselineCharacteristic,Stage,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,Stage,None,7,3,43,no
5225,3405220,Table 2,BaselineCharacteristic,Stage,Treatment arm ; Gemcitabine + placebo ; % ; ,Stage,None,7,4,43,no
5225,3405220,Table 2,BaselineCharacteristic,Stage, ; Total ; No. of patients ; ,Stage,None,7,5,43,no
5225,3405220,Table 2,BaselineCharacteristic,Stage, ; Total ; % ; ,Stage,None,7,6,43,no
5225,3405220,Table 2,BaselineCharacteristic,Stage, ;  ; Pa ; ,Stage,None,7,7,43,no
5225,3405220,Table 2,BaselineCharacteristic,?Metastatic, ;  ; Characteristic ; ,?Metastatic, Stage,8,0,2,no
5225,3405220,Table 2,BaselineCharacteristic,xx,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,?Metastatic, Stage,8,1,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + huachansu ; % ; ,?Metastatic, Stage,8,2,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,?Metastatic, Stage,8,3,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + placebo ; % ; ,?Metastatic, Stage,8,4,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx, ; Total ; No. of patients ; ,?Metastatic, Stage,8,5,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx.xx, ; Total ; % ; ,?Metastatic, Stage,8,6,3,no
5225,3405220,Table 2,BaselineCharacteristic,x.xxx, ;  ; Pa ; ,?Metastatic, Stage,8,7,3,no
5225,3405220,Table 2,BaselineCharacteristic,?Locally advanced, ;  ; Characteristic ; ,?Locally advanced, Stage,9,0,2,no
5225,3405220,Table 2,BaselineCharacteristic,xx,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,?Locally advanced, Stage,9,1,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + huachansu ; % ; ,?Locally advanced, Stage,9,2,3,no
5225,3405220,Table 2,BaselineCharacteristic,x,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,?Locally advanced, Stage,9,3,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + placebo ; % ; ,?Locally advanced, Stage,9,4,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx, ; Total ; No. of patients ; ,?Locally advanced, Stage,9,5,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx.xx, ; Total ; % ; ,?Locally advanced, Stage,9,6,3,no
5225,3405220,Table 2,BaselineCharacteristic,, ;  ; Pa ; ,?Locally advanced, Stage,9,7,3,no
5225,3405220,Table 2,BaselineCharacteristic,, ;  ; Characteristic ; ,None,None,10,0,2,no
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,None,None,10,1,3,no
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + huachansu ; % ; ,None,None,10,2,3,no
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,None,None,10,3,3,no
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + placebo ; % ; ,None,None,10,4,3,no
5225,3405220,Table 2,BaselineCharacteristic,, ; Total ; No. of patients ; ,None,None,10,5,3,no
5225,3405220,Table 2,BaselineCharacteristic,, ; Total ; % ; ,None,None,10,6,3,no
5225,3405220,Table 2,BaselineCharacteristic,, ;  ; Pa ; ,None,None,10,7,3,no
5225,3405220,Table 2,BaselineCharacteristic,Location of the tumour in the pancreas, ;  ; Characteristic ; ,None,None,11,0,24,no
5225,3405220,Table 2,BaselineCharacteristic,Location of the tumour in the pancreas,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,Location of the tumour in the pancreas,None,11,1,43,no
5225,3405220,Table 2,BaselineCharacteristic,Location of the tumour in the pancreas,Treatment arm ; Gemcitabine + huachansu ; % ; ,Location of the tumour in the pancreas,None,11,2,43,no
5225,3405220,Table 2,BaselineCharacteristic,Location of the tumour in the pancreas,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,Location of the tumour in the pancreas,None,11,3,43,no
5225,3405220,Table 2,BaselineCharacteristic,Location of the tumour in the pancreas,Treatment arm ; Gemcitabine + placebo ; % ; ,Location of the tumour in the pancreas,None,11,4,43,no
5225,3405220,Table 2,BaselineCharacteristic,Location of the tumour in the pancreas, ; Total ; No. of patients ; ,Location of the tumour in the pancreas,None,11,5,43,no
5225,3405220,Table 2,BaselineCharacteristic,Location of the tumour in the pancreas, ; Total ; % ; ,Location of the tumour in the pancreas,None,11,6,43,no
5225,3405220,Table 2,BaselineCharacteristic,Location of the tumour in the pancreas, ;  ; Pa ; ,Location of the tumour in the pancreas,None,11,7,43,no
5225,3405220,Table 2,BaselineCharacteristic,?Head, ;  ; Characteristic ; ,?Head, Location of the tumour in the pancreas,12,0,2,no
5225,3405220,Table 2,BaselineCharacteristic,xx,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,?Head, Location of the tumour in the pancreas,12,1,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + huachansu ; % ; ,?Head, Location of the tumour in the pancreas,12,2,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,?Head, Location of the tumour in the pancreas,12,3,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + placebo ; % ; ,?Head, Location of the tumour in the pancreas,12,4,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx, ; Total ; No. of patients ; ,?Head, Location of the tumour in the pancreas,12,5,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx.xx, ; Total ; % ; ,?Head, Location of the tumour in the pancreas,12,6,3,no
5225,3405220,Table 2,BaselineCharacteristic,x.xxx, ;  ; Pa ; ,?Head, Location of the tumour in the pancreas,12,7,3,no
5225,3405220,Table 2,BaselineCharacteristic,?Body, ;  ; Characteristic ; ,?Body, Location of the tumour in the pancreas,13,0,2,no
5225,3405220,Table 2,BaselineCharacteristic,x,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,?Body, Location of the tumour in the pancreas,13,1,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + huachansu ; % ; ,?Body, Location of the tumour in the pancreas,13,2,3,no
5225,3405220,Table 2,BaselineCharacteristic,x,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,?Body, Location of the tumour in the pancreas,13,3,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + placebo ; % ; ,?Body, Location of the tumour in the pancreas,13,4,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx, ; Total ; No. of patients ; ,?Body, Location of the tumour in the pancreas,13,5,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx.xx, ; Total ; % ; ,?Body, Location of the tumour in the pancreas,13,6,3,no
5225,3405220,Table 2,BaselineCharacteristic,, ;  ; Pa ; ,?Body, Location of the tumour in the pancreas,13,7,3,no
5225,3405220,Table 2,BaselineCharacteristic,?Tail, ;  ; Characteristic ; ,?Tail, Location of the tumour in the pancreas,14,0,2,no
5225,3405220,Table 2,BaselineCharacteristic,xx,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,?Tail, Location of the tumour in the pancreas,14,1,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + huachansu ; % ; ,?Tail, Location of the tumour in the pancreas,14,2,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,?Tail, Location of the tumour in the pancreas,14,3,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + placebo ; % ; ,?Tail, Location of the tumour in the pancreas,14,4,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx, ; Total ; No. of patients ; ,?Tail, Location of the tumour in the pancreas,14,5,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx.xx, ; Total ; % ; ,?Tail, Location of the tumour in the pancreas,14,6,3,no
5225,3405220,Table 2,BaselineCharacteristic,, ;  ; Pa ; ,?Tail, Location of the tumour in the pancreas,14,7,3,no
5225,3405220,Table 2,BaselineCharacteristic,, ;  ; Characteristic ; ,None,None,15,0,2,no
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,None,None,15,1,3,no
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + huachansu ; % ; ,None,None,15,2,3,no
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,None,None,15,3,3,no
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + placebo ; % ; ,None,None,15,4,3,no
5225,3405220,Table 2,BaselineCharacteristic,, ; Total ; No. of patients ; ,None,None,15,5,3,no
5225,3405220,Table 2,BaselineCharacteristic,, ; Total ; % ; ,None,None,15,6,3,no
5225,3405220,Table 2,BaselineCharacteristic,, ;  ; Pa ; ,None,None,15,7,3,no
5225,3405220,Table 2,BaselineCharacteristic,Prior surgery, ;  ; Characteristic ; ,None,None,16,0,24,no
5225,3405220,Table 2,BaselineCharacteristic,Prior surgery,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,Prior surgery,None,16,1,43,no
5225,3405220,Table 2,BaselineCharacteristic,Prior surgery,Treatment arm ; Gemcitabine + huachansu ; % ; ,Prior surgery,None,16,2,43,no
5225,3405220,Table 2,BaselineCharacteristic,Prior surgery,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,Prior surgery,None,16,3,43,no
5225,3405220,Table 2,BaselineCharacteristic,Prior surgery,Treatment arm ; Gemcitabine + placebo ; % ; ,Prior surgery,None,16,4,43,no
5225,3405220,Table 2,BaselineCharacteristic,Prior surgery, ; Total ; No. of patients ; ,Prior surgery,None,16,5,43,no
5225,3405220,Table 2,BaselineCharacteristic,Prior surgery, ; Total ; % ; ,Prior surgery,None,16,6,43,no
5225,3405220,Table 2,BaselineCharacteristic,Prior surgery, ;  ; Pa ; ,Prior surgery,None,16,7,43,no
5225,3405220,Table 2,BaselineCharacteristic,?Yes, ;  ; Characteristic ; ,?Yes, Prior surgery,17,0,2,no
5225,3405220,Table 2,BaselineCharacteristic,x,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,?Yes, Prior surgery,17,1,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + huachansu ; % ; ,?Yes, Prior surgery,17,2,3,no
5225,3405220,Table 2,BaselineCharacteristic,x,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,?Yes, Prior surgery,17,3,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + placebo ; % ; ,?Yes, Prior surgery,17,4,3,no
5225,3405220,Table 2,BaselineCharacteristic,x, ; Total ; No. of patients ; ,?Yes, Prior surgery,17,5,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx.xx, ; Total ; % ; ,?Yes, Prior surgery,17,6,3,no
5225,3405220,Table 2,BaselineCharacteristic,x.xxxb, ;  ; Pa ; ,?Yes, Prior surgery,17,7,3,no
5225,3405220,Table 2,BaselineCharacteristic,?No, ;  ; Characteristic ; ,?No, Prior surgery,18,0,2,no
5225,3405220,Table 2,BaselineCharacteristic,xx,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,?No, Prior surgery,18,1,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + huachansu ; % ; ,?No, Prior surgery,18,2,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,?No, Prior surgery,18,3,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + placebo ; % ; ,?No, Prior surgery,18,4,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx, ; Total ; No. of patients ; ,?No, Prior surgery,18,5,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx.xx, ; Total ; % ; ,?No, Prior surgery,18,6,3,no
5225,3405220,Table 2,BaselineCharacteristic,, ;  ; Pa ; ,?No, Prior surgery,18,7,3,no
5225,3405220,Table 2,BaselineCharacteristic,, ;  ; Characteristic ; ,None,None,19,0,2,no
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,None,None,19,1,3,no
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + huachansu ; % ; ,None,None,19,2,3,no
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,None,None,19,3,3,no
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + placebo ; % ; ,None,None,19,4,3,no
5225,3405220,Table 2,BaselineCharacteristic,, ; Total ; No. of patients ; ,None,None,19,5,3,no
5225,3405220,Table 2,BaselineCharacteristic,, ; Total ; % ; ,None,None,19,6,3,no
5225,3405220,Table 2,BaselineCharacteristic,, ;  ; Pa ; ,None,None,19,7,3,no
5225,3405220,Table 2,BaselineCharacteristic,Prior chemotherapy, ;  ; Characteristic ; ,None,None,20,0,24,no
5225,3405220,Table 2,BaselineCharacteristic,Prior chemotherapy,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,Prior chemotherapy,None,20,1,43,no
5225,3405220,Table 2,BaselineCharacteristic,Prior chemotherapy,Treatment arm ; Gemcitabine + huachansu ; % ; ,Prior chemotherapy,None,20,2,43,no
5225,3405220,Table 2,BaselineCharacteristic,Prior chemotherapy,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,Prior chemotherapy,None,20,3,43,no
5225,3405220,Table 2,BaselineCharacteristic,Prior chemotherapy,Treatment arm ; Gemcitabine + placebo ; % ; ,Prior chemotherapy,None,20,4,43,no
5225,3405220,Table 2,BaselineCharacteristic,Prior chemotherapy, ; Total ; No. of patients ; ,Prior chemotherapy,None,20,5,43,no
5225,3405220,Table 2,BaselineCharacteristic,Prior chemotherapy, ; Total ; % ; ,Prior chemotherapy,None,20,6,43,no
5225,3405220,Table 2,BaselineCharacteristic,Prior chemotherapy, ;  ; Pa ; ,Prior chemotherapy,None,20,7,43,no
5225,3405220,Table 2,BaselineCharacteristic,?Yes, ;  ; Characteristic ; ,?Yes, Prior chemotherapy,21,0,2,no
5225,3405220,Table 2,BaselineCharacteristic,x,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,?Yes, Prior chemotherapy,21,1,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + huachansu ; % ; ,?Yes, Prior chemotherapy,21,2,3,no
5225,3405220,Table 2,BaselineCharacteristic,x,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,?Yes, Prior chemotherapy,21,3,3,no
5225,3405220,Table 2,BaselineCharacteristic,x.xx,Treatment arm ; Gemcitabine + placebo ; % ; ,?Yes, Prior chemotherapy,21,4,3,no
5225,3405220,Table 2,BaselineCharacteristic,x, ; Total ; No. of patients ; ,?Yes, Prior chemotherapy,21,5,3,no
5225,3405220,Table 2,BaselineCharacteristic,x.xx, ; Total ; % ; ,?Yes, Prior chemotherapy,21,6,3,no
5225,3405220,Table 2,BaselineCharacteristic,x.xxxb, ;  ; Pa ; ,?Yes, Prior chemotherapy,21,7,3,no
5225,3405220,Table 2,BaselineCharacteristic,?No, ;  ; Characteristic ; ,?No, Prior chemotherapy,22,0,2,no
5225,3405220,Table 2,BaselineCharacteristic,xx,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,?No, Prior chemotherapy,22,1,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx.xx,Treatment arm ; Gemcitabine + huachansu ; % ; ,?No, Prior chemotherapy,22,2,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,?No, Prior chemotherapy,22,3,3,no
5225,3405220,Table 2,BaselineCharacteristic,xxx.xx,Treatment arm ; Gemcitabine + placebo ; % ; ,?No, Prior chemotherapy,22,4,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx, ; Total ; No. of patients ; ,?No, Prior chemotherapy,22,5,3,no
5225,3405220,Table 2,BaselineCharacteristic,xx.xx, ; Total ; % ; ,?No, Prior chemotherapy,22,6,3,no
5225,3405220,Table 2,BaselineCharacteristic,, ;  ; Pa ; ,?No, Prior chemotherapy,22,7,3,no
5225,3405220,Table 2,BaselineCharacteristic,, ;  ; Characteristic ; ,None,None,23,0,2,no
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + huachansu ; No. of patients ; ,None,None,23,1,3,no
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + huachansu ; % ; ,None,None,23,2,3,no
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + placebo ; No. of patients ; ,None,None,23,3,3,no
5225,3405220,Table 2,BaselineCharacteristic,,Treatment arm ; Gemcitabine + placebo ; % ; ,None,None,23,4,3,no
5225,3405220,Table 2,BaselineCharacteristic,, ; Total ; No. of patients ; ,None,None,23,5,3,no
5225,3405220,Table 2,BaselineCharacteristic,, ; Total ; % ; ,None,None,23,6,3,no
5225,3405220,Table 2,BaselineCharacteristic,, ;  ; Pa ; ,None,None,23,7,3,no
5225,3405220,Table 2,BaselineCharacteristic,Age (years), ;  ; Characteristic ; ,Age (years),,24,0,2,no
5225,3405220,Table 2,BaselineCharacteristic,x.xxxc, ;  ; Pa ; ,Age (years),,24,7,3,no
5225,3405220,Table 2,BaselineCharacteristic,Karnofsky performance status, ;  ; Characteristic ; ,Karnofsky performance status,,25,0,2,no
5225,3405220,Table 2,BaselineCharacteristic,x.xxxd, ;  ; Pa ; ,Karnofsky performance status,,25,7,3,no
5228,3405224,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no
5228,3405224,Table 1,BaselineCharacteristic,n,,,None,0,1,1,no
5228,3405224,Table 1,BaselineCharacteristic,%,,,None,0,2,1,no
5228,3405224,Table 1,BaselineCharacteristic,Gender: male/female, ; ,Gender: male/female,,1,0,2,no
5228,3405224,Table 1,BaselineCharacteristic,xx/xx,n ; ,Gender: male/female,,1,1,3,yes
5228,3405224,Table 1,BaselineCharacteristic,xx/xx,% ; ,Gender: male/female,,1,2,3,yes
5228,3405224,Table 1,BaselineCharacteristic,"Median age (range, in years)", ; ,"Median age (range, in years)",,2,0,2,no
5228,3405224,Table 1,BaselineCharacteristic,,% ; ,"Median age (range, in years)",,2,2,3,no
5228,3405224,Table 1,BaselineCharacteristic,, ; ,None,None,3,0,2,no
5228,3405224,Table 1,BaselineCharacteristic,,n ; ,None,None,3,1,3,no
5228,3405224,Table 1,BaselineCharacteristic,,% ; ,None,None,3,2,3,no
5228,3405224,Table 1,BaselineCharacteristic,Primary melanoma, ; ,None,None,4,0,24,no
5228,3405224,Table 1,BaselineCharacteristic,Primary melanoma,n ; ,Primary melanoma,None,4,1,43,no
5228,3405224,Table 1,BaselineCharacteristic,Primary melanoma,% ; ,Primary melanoma,None,4,2,43,no
5228,3405224,Table 1,BaselineCharacteristic,?SSM, ; ,?SSM, Primary melanoma,5,0,2,no
5228,3405224,Table 1,BaselineCharacteristic,xx,n ; ,?SSM, Primary melanoma,5,1,3,no
5228,3405224,Table 1,BaselineCharacteristic,xx,% ; ,?SSM, Primary melanoma,5,2,3,no
5228,3405224,Table 1,BaselineCharacteristic,?Nodular, ; ,?Nodular, Primary melanoma,6,0,2,no
5228,3405224,Table 1,BaselineCharacteristic,x,n ; ,?Nodular, Primary melanoma,6,1,3,no
5228,3405224,Table 1,BaselineCharacteristic,xx,% ; ,?Nodular, Primary melanoma,6,2,3,no
5228,3405224,Table 1,BaselineCharacteristic,?Uveal, ; ,?Uveal, Primary melanoma,7,0,2,no
5228,3405224,Table 1,BaselineCharacteristic,x,n ; ,?Uveal, Primary melanoma,7,1,3,no
5228,3405224,Table 1,BaselineCharacteristic,xx,% ; ,?Uveal, Primary melanoma,7,2,3,no
5228,3405224,Table 1,BaselineCharacteristic,?Unknown primary, ; ,?Unknown primary, Primary melanoma,8,0,2,no
5228,3405224,Table 1,BaselineCharacteristic,x,n ; ,?Unknown primary, Primary melanoma,8,1,3,no
5228,3405224,Table 1,BaselineCharacteristic,xx,% ; ,?Unknown primary, Primary melanoma,8,2,3,no
5228,3405224,Table 1,BaselineCharacteristic,?Others, ; ,?Others, Primary melanoma,9,0,2,no
5228,3405224,Table 1,BaselineCharacteristic,x,n ; ,?Others, Primary melanoma,9,1,3,no
5228,3405224,Table 1,BaselineCharacteristic,x,% ; ,?Others, Primary melanoma,9,2,3,no
5228,3405224,Table 1,BaselineCharacteristic,, ; ,None,None,10,0,2,no
5228,3405224,Table 1,BaselineCharacteristic,,n ; ,None,None,10,1,3,no
5228,3405224,Table 1,BaselineCharacteristic,,% ; ,None,None,10,2,3,no
5228,3405224,Table 1,BaselineCharacteristic,AJCC stage IV, ; ,None,None,11,0,24,no
5228,3405224,Table 1,BaselineCharacteristic,AJCC stage IV,n ; ,AJCC stage IV,None,11,1,43,no
5228,3405224,Table 1,BaselineCharacteristic,AJCC stage IV,% ; ,AJCC stage IV,None,11,2,43,no
5228,3405224,Table 1,BaselineCharacteristic,?Mxa, ; ,?Mxa, AJCC stage IV,12,0,2,no
5228,3405224,Table 1,BaselineCharacteristic,x,n ; ,?Mxa, AJCC stage IV,12,1,3,no
5228,3405224,Table 1,BaselineCharacteristic,x,% ; ,?Mxa, AJCC stage IV,12,2,3,no
5228,3405224,Table 1,BaselineCharacteristic,?Mxb, ; ,?Mxb, AJCC stage IV,13,0,2,no
5228,3405224,Table 1,BaselineCharacteristic,x,n ; ,?Mxb, AJCC stage IV,13,1,3,no
5228,3405224,Table 1,BaselineCharacteristic,x,% ; ,?Mxb, AJCC stage IV,13,2,3,no
5228,3405224,Table 1,BaselineCharacteristic,?Mxc, ; ,?Mxc, AJCC stage IV,14,0,2,no
5228,3405224,Table 1,BaselineCharacteristic,xx,n ; ,?Mxc, AJCC stage IV,14,1,3,no
5228,3405224,Table 1,BaselineCharacteristic,xx,% ; ,?Mxc, AJCC stage IV,14,2,3,no
5228,3405224,Table 1,BaselineCharacteristic,, ; ,None,None,15,0,2,no
5228,3405224,Table 1,BaselineCharacteristic,,n ; ,None,None,15,1,3,no
5228,3405224,Table 1,BaselineCharacteristic,,% ; ,None,None,15,2,3,no
5228,3405224,Table 1,BaselineCharacteristic,>x Metastatic sites, ; ,>x Metastatic sites,,16,0,24,no
5228,3405224,Table 1,BaselineCharacteristic,xx,n ; ,>x Metastatic sites,,16,1,43,no
5228,3405224,Table 1,BaselineCharacteristic,xx,% ; ,>x Metastatic sites,,16,2,43,no
5228,3405224,Table 1,BaselineCharacteristic,?Lung metastases, ; ,?Lung metastases, >x Metastatic sites,17,0,2,no
5228,3405224,Table 1,BaselineCharacteristic,xx,n ; ,?Lung metastases, >x Metastatic sites,17,1,3,no
5228,3405224,Table 1,BaselineCharacteristic,xx,% ; ,?Lung metastases, >x Metastatic sites,17,2,3,no
5228,3405224,Table 1,BaselineCharacteristic,?Liver metastases, ; ,?Liver metastases, >x Metastatic sites,18,0,2,no
5228,3405224,Table 1,BaselineCharacteristic,xx,n ; ,?Liver metastases, >x Metastatic sites,18,1,3,no
5228,3405224,Table 1,BaselineCharacteristic,xx,% ; ,?Liver metastases, >x Metastatic sites,18,2,3,no
5228,3405224,Table 1,BaselineCharacteristic,?Brain metastases, ; ,?Brain metastases, >x Metastatic sites,19,0,2,no
5228,3405224,Table 1,BaselineCharacteristic,xx,n ; ,?Brain metastases, >x Metastatic sites,19,1,3,no
5228,3405224,Table 1,BaselineCharacteristic,xx,% ; ,?Brain metastases, >x Metastatic sites,19,2,3,no
5228,3405224,Table 1,BaselineCharacteristic,, ; ,None,None,20,0,2,no
5228,3405224,Table 1,BaselineCharacteristic,,n ; ,None,None,20,1,3,no
5228,3405224,Table 1,BaselineCharacteristic,,% ; ,None,None,20,2,3,no
5228,3405224,Table 1,BaselineCharacteristic,LDH>N, ; ,LDH>N,,21,0,2,no
5228,3405224,Table 1,BaselineCharacteristic,xx,n ; ,LDH>N,,21,1,3,no
5228,3405224,Table 1,BaselineCharacteristic,xx,% ; ,LDH>N,,21,2,3,no
5228,3405224,Table 1,BaselineCharacteristic,, ; ,None,None,22,0,2,no
5228,3405224,Table 1,BaselineCharacteristic,,n ; ,None,None,22,1,3,no
5228,3405224,Table 1,BaselineCharacteristic,,% ; ,None,None,22,2,3,no
5228,3405224,Table 1,BaselineCharacteristic,Previous chemotherapy, ; ,Previous chemotherapy,,23,0,24,no
5228,3405224,Table 1,BaselineCharacteristic,xx,n ; ,Previous chemotherapy,,23,1,43,no
5228,3405224,Table 1,BaselineCharacteristic,xx,% ; ,Previous chemotherapy,,23,2,43,no
5228,3405224,Table 1,BaselineCharacteristic,??x Lines of chemotherapy, ; ,??x Lines of chemotherapy, Previous chemotherapy,24,0,2,no
5228,3405224,Table 1,BaselineCharacteristic,xx,n ; ,??x Lines of chemotherapy, Previous chemotherapy,24,1,3,no
5228,3405224,Table 1,BaselineCharacteristic,xx,% ; ,??x Lines of chemotherapy, Previous chemotherapy,24,2,3,no
5228,3405224,Table 1,BaselineCharacteristic,, ; ,None,None,25,0,2,no
5228,3405224,Table 1,BaselineCharacteristic,,n ; ,None,None,25,1,3,no
5228,3405224,Table 1,BaselineCharacteristic,,% ; ,None,None,25,2,3,no
5228,3405224,Table 1,BaselineCharacteristic,Performance Status (WHO), ; ,None,None,26,0,24,no
5228,3405224,Table 1,BaselineCharacteristic,Performance Status (WHO),n ; ,Performance Status (WHO),None,26,1,43,no
5228,3405224,Table 1,BaselineCharacteristic,Performance Status (WHO),% ; ,Performance Status (WHO),None,26,2,43,no
5228,3405224,Table 1,BaselineCharacteristic,, ; ,None,None,29,0,2,no
5228,3405224,Table 1,BaselineCharacteristic,,n ; ,None,None,29,1,3,no
5228,3405224,Table 1,BaselineCharacteristic,,% ; ,None,None,29,2,3,no
5228,3405224,Table 1,BaselineCharacteristic,"Median time from first metastasis (range, in months)", ; ,"Median time from first metastasis (range, in months)",,30,0,2,no
5228,3405224,Table 1,BaselineCharacteristic,,% ; ,"Median time from first metastasis (range, in months)",,30,2,3,no
5354,3419963,Table 1,BaselineCharacteristic,,,None,None,0,0,12,no
5354,3419963,Table 1,BaselineCharacteristic,"Patients (n=xx), n (%)",,,None,0,1,1,no
5354,3419963,Table 1,BaselineCharacteristic,"Age, years", ; ,None,None,1,0,24,no
5354,3419963,Table 1,BaselineCharacteristic,,"Patients (n=xx), n (%) ; ","Age, years",None,1,1,43,no
5354,3419963,Table 1,BaselineCharacteristic,?Median, ; ,?Median," Age, years",2,0,2,no
5354,3419963,Table 1,BaselineCharacteristic,xx,"Patients (n=xx), n (%) ; ",?Median," Age, years",2,1,3,no
5354,3419963,Table 1,BaselineCharacteristic,?Range, ; ,?Range," Age, years",3,0,2,no
5354,3419963,Table 1,BaselineCharacteristic,, ; ,None,None,4,0,2,no
5354,3419963,Table 1,BaselineCharacteristic,,"Patients (n=xx), n (%) ; ",None,None,4,1,3,no
5354,3419963,Table 1,BaselineCharacteristic,Gender, ; ,None,None,5,0,24,no
5354,3419963,Table 1,BaselineCharacteristic,Gender,"Patients (n=xx), n (%) ; ",Gender,None,5,1,43,no
5354,3419963,Table 1,BaselineCharacteristic,?Male, ; ,?Male, Gender,6,0,2,no
5354,3419963,Table 1,BaselineCharacteristic,x (xx),"Patients (n=xx), n (%) ; ",?Male, Gender,6,1,3,yes
5354,3419963,Table 1,BaselineCharacteristic,?Female, ; ,?Female, Gender,7,0,2,no
5354,3419963,Table 1,BaselineCharacteristic,x (xx),"Patients (n=xx), n (%) ; ",?Female, Gender,7,1,3,yes
5354,3419963,Table 1,BaselineCharacteristic,, ; ,None,None,8,0,2,no
5354,3419963,Table 1,BaselineCharacteristic,,"Patients (n=xx), n (%) ; ",None,None,8,1,3,no
5354,3419963,Table 1,BaselineCharacteristic,ECOG PS, ; ,None,None,9,0,24,no
5354,3419963,Table 1,BaselineCharacteristic,ECOG PS,"Patients (n=xx), n (%) ; ",ECOG PS,None,9,1,43,no
5354,3419963,Table 1,BaselineCharacteristic,?x, ; ,?x, ECOG PS,10,0,2,no
5354,3419963,Table 1,BaselineCharacteristic,x (xx),"Patients (n=xx), n (%) ; ",?x, ECOG PS,10,1,3,no
5354,3419963,Table 1,BaselineCharacteristic,?x, ; ,?x, ECOG PS,11,0,2,no
5354,3419963,Table 1,BaselineCharacteristic,xx (xx),"Patients (n=xx), n (%) ; ",?x, ECOG PS,11,1,3,no
5354,3419963,Table 1,BaselineCharacteristic,, ; ,None,None,12,0,2,no
5354,3419963,Table 1,BaselineCharacteristic,,"Patients (n=xx), n (%) ; ",None,None,12,1,3,no
5354,3419963,Table 1,BaselineCharacteristic,Type of tumour, ; ,None,None,13,0,24,no
5354,3419963,Table 1,BaselineCharacteristic,Type of tumour,"Patients (n=xx), n (%) ; ",Type of tumour,None,13,1,43,no
5354,3419963,Table 1,BaselineCharacteristic,?Mesothelioma, ; ,?Mesothelioma, Type of tumour,14,0,2,no
5354,3419963,Table 1,BaselineCharacteristic,x (xx),"Patients (n=xx), n (%) ; ",?Mesothelioma, Type of tumour,14,1,3,no
5354,3419963,Table 1,BaselineCharacteristic,?Non-small-cell lung cancer, ; ,?Non-small-cell lung cancer, Type of tumour,15,0,2,no
5354,3419963,Table 1,BaselineCharacteristic,x (xx),"Patients (n=xx), n (%) ; ",?Non-small-cell lung cancer, Type of tumour,15,1,3,no
5354,3419963,Table 1,BaselineCharacteristic,?Angiosarcoma, ; ,?Angiosarcoma, Type of tumour,16,0,2,no
5354,3419963,Table 1,BaselineCharacteristic,x (x),"Patients (n=xx), n (%) ; ",?Angiosarcoma, Type of tumour,16,1,3,no
5354,3419963,Table 1,BaselineCharacteristic,?Breast cancer, ; ,?Breast cancer, Type of tumour,17,0,2,no
5354,3419963,Table 1,BaselineCharacteristic,x (x),"Patients (n=xx), n (%) ; ",?Breast cancer, Type of tumour,17,1,3,no
5354,3419963,Table 1,BaselineCharacteristic,?Cholangiocarcinoma, ; ,?Cholangiocarcinoma, Type of tumour,18,0,2,no
5354,3419963,Table 1,BaselineCharacteristic,x (x),"Patients (n=xx), n (%) ; ",?Cholangiocarcinoma, Type of tumour,18,1,3,no
5354,3419963,Table 1,BaselineCharacteristic,?Endometrial stromal sarcoma, ; ,?Endometrial stromal sarcoma, Type of tumour,19,0,2,no
5354,3419963,Table 1,BaselineCharacteristic,x (x),"Patients (n=xx), n (%) ; ",?Endometrial stromal sarcoma, Type of tumour,19,1,3,no
5354,3419963,Table 1,BaselineCharacteristic,?Appendiceal adenocarcinoma, ; ,?Appendiceal adenocarcinoma, Type of tumour,20,0,2,no
5354,3419963,Table 1,BaselineCharacteristic,x (x),"Patients (n=xx), n (%) ; ",?Appendiceal adenocarcinoma, Type of tumour,20,1,3,no
5354,3419963,Table 1,BaselineCharacteristic,?Carcinoma of unknown origin, ; ,?Carcinoma of unknown origin, Type of tumour,21,0,2,no
5354,3419963,Table 1,BaselineCharacteristic,x (x),"Patients (n=xx), n (%) ; ",?Carcinoma of unknown origin, Type of tumour,21,1,3,no
5354,3419963,Table 1,BaselineCharacteristic,?Rectal cancer, ; ,?Rectal cancer, Type of tumour,22,0,2,no
5354,3419963,Table 1,BaselineCharacteristic,x (x),"Patients (n=xx), n (%) ; ",?Rectal cancer, Type of tumour,22,1,3,no
5354,3419963,Table 1,BaselineCharacteristic,?Thyroid poorly differentiated carcinoma, ; ,?Thyroid poorly differentiated carcinoma, Type of tumour,23,0,2,no
5354,3419963,Table 1,BaselineCharacteristic,x (x),"Patients (n=xx), n (%) ; ",?Thyroid poorly differentiated carcinoma, Type of tumour,23,1,3,no
5354,3419963,Table 1,BaselineCharacteristic,, ; ,None,None,24,0,2,no
5354,3419963,Table 1,BaselineCharacteristic,,"Patients (n=xx), n (%) ; ",None,None,24,1,3,no
5354,3419963,Table 1,BaselineCharacteristic,Prior treatment, ; ,None,None,25,0,24,no
5354,3419963,Table 1,BaselineCharacteristic,Prior treatment,"Patients (n=xx), n (%) ; ",Prior treatment,None,25,1,43,no
5354,3419963,Table 1,BaselineCharacteristic,?Surgery, ; ,?Surgery, Prior treatment,26,0,2,no
5354,3419963,Table 1,BaselineCharacteristic,xx (xx),"Patients (n=xx), n (%) ; ",?Surgery, Prior treatment,26,1,3,no
5354,3419963,Table 1,BaselineCharacteristic,?Chemotherapy, ; ,?Chemotherapy, Prior treatment,27,0,2,no
5354,3419963,Table 1,BaselineCharacteristic,x (xx),"Patients (n=xx), n (%) ; ",?Chemotherapy, Prior treatment,27,1,3,no
5354,3419963,Table 1,BaselineCharacteristic,?Radiotherapy, ; ,?Radiotherapy, Prior treatment,28,0,2,no
5354,3419963,Table 1,BaselineCharacteristic,x (xx),"Patients (n=xx), n (%) ; ",?Radiotherapy, Prior treatment,28,1,3,no
5354,3419963,Table 1,BaselineCharacteristic,, ; ,None,None,29,0,2,no
5354,3419963,Table 1,BaselineCharacteristic,,"Patients (n=xx), n (%) ; ",None,None,29,1,3,no
5354,3419963,Table 1,BaselineCharacteristic,No. of prior chemotherapy regimens, ; ,None,None,30,0,24,no
5354,3419963,Table 1,BaselineCharacteristic,No. of prior chemotherapy regimens,"Patients (n=xx), n (%) ; ",No. of prior chemotherapy regimens,None,30,1,43,no
5354,3419963,Table 1,BaselineCharacteristic,?x, ; ,?x, No. of prior chemotherapy regimens,31,0,2,no
5354,3419963,Table 1,BaselineCharacteristic,xx,"Patients (n=xx), n (%) ; ",?x, No. of prior chemotherapy regimens,31,1,3,no
5354,3419963,Table 1,BaselineCharacteristic,?x, ; ,?x, No. of prior chemotherapy regimens,32,0,2,no
5354,3419963,Table 1,BaselineCharacteristic,x,"Patients (n=xx), n (%) ; ",?x, No. of prior chemotherapy regimens,32,1,3,no
5354,3419963,Table 1,BaselineCharacteristic,?x, ; ,?x, No. of prior chemotherapy regimens,33,0,2,no
5354,3419963,Table 1,BaselineCharacteristic,x,"Patients (n=xx), n (%) ; ",?x, No. of prior chemotherapy regimens,33,1,3,no
5354,3419963,Table 1,BaselineCharacteristic,?x, ; ,?x, No. of prior chemotherapy regimens,34,0,2,no
5354,3419963,Table 1,BaselineCharacteristic,x,"Patients (n=xx), n (%) ; ",?x, No. of prior chemotherapy regimens,34,1,3,no
5354,3419963,Table 1,BaselineCharacteristic,?x, ; ,?x, No. of prior chemotherapy regimens,35,0,2,no
5354,3419963,Table 1,BaselineCharacteristic,x,"Patients (n=xx), n (%) ; ",?x, No. of prior chemotherapy regimens,35,1,3,no
5767,3504074,Table 1,BaselineCharacteristic,Characteristic,,None,None,0,0,12,no
5767,3504074,Table 1,BaselineCharacteristic,Etanercept + placebo (n = xxx),,Characteristic,None,0,1,1,no
5767,3504074,Table 1,BaselineCharacteristic,Etanercept + methotrexate (n = xxx),,Characteristic,None,0,2,1,no
5767,3504074,Table 1,BaselineCharacteristic,"Male sex, n (%)",Characteristic ; ,"Male sex, n (%)",,1,0,2,no
5767,3504074,Table 1,BaselineCharacteristic,"Race, n (%)",Characteristic ; ,None,None,2,0,24,no
5767,3504074,Table 1,BaselineCharacteristic,"Race, n (%)",Etanercept + placebo (n = xxx) ; ,"Race, n (%)",None,2,1,43,no
5767,3504074,Table 1,BaselineCharacteristic,"Race, n (%)",Etanercept + methotrexate (n = xxx) ; ,"Race, n (%)",None,2,2,43,no
5767,3504074,Table 1,BaselineCharacteristic,?White,Characteristic ; ,?White," Race, n (%)",3,0,2,no
5767,3504074,Table 1,BaselineCharacteristic,?Black,Characteristic ; ,?Black," Race, n (%)",4,0,2,no
5767,3504074,Table 1,BaselineCharacteristic,?Hispanic,Characteristic ; ,?Hispanic," Race, n (%)",5,0,2,no
5767,3504074,Table 1,BaselineCharacteristic,?Asian,Characteristic ; ,?Asian," Race, n (%)",6,0,2,no
5767,3504074,Table 1,BaselineCharacteristic,?Other,Characteristic ; ,?Other," Race, n (%)",7,0,2,no
5767,3504074,Table 1,BaselineCharacteristic,"Age (years), mean (SD)",Characteristic ; ,"Age (years), mean (SD)",,8,0,24,no
5767,3504074,Table 1,BaselineCharacteristic,"?Median (Qx, Qx)",Characteristic ; ,"?Median (Qx, Qx)"," Age (years), mean (SD)",9,0,2,no
5767,3504074,Table 1,BaselineCharacteristic,"Weight (kg), mean (SD)",Characteristic ; ,"Weight (kg), mean (SD)",,10,0,24,no
5767,3504074,Table 1,BaselineCharacteristic,"?Median (Qx, Qx)",Characteristic ; ,"?Median (Qx, Qx)"," Weight (kg), mean (SD)",11,0,2,no
5767,3504074,Table 1,BaselineCharacteristic,"Height (cm), mean (SD)",Characteristic ; ,"Height (cm), mean (SD)",,12,0,24,no
5767,3504074,Table 1,BaselineCharacteristic,"?Median (Qx, Qx)",Characteristic ; ,"?Median (Qx, Qx)"," Height (cm), mean (SD)",13,0,2,no
5767,3504074,Table 1,BaselineCharacteristic,"BMI (kg m?x), mean (SD)",Characteristic ; ,"BMI (kg m?x), mean (SD)",,14,0,24,no
5767,3504074,Table 1,BaselineCharacteristic,"?Median (Qx, Qx)",Characteristic ; ,"?Median (Qx, Qx)"," BMI (kg m?x), mean (SD)",15,0,2,no
5767,3504074,Table 1,BaselineCharacteristic,"?? xx kg m?x, n (%)",Characteristic ; ,"?? xx kg m?x, n (%)"," BMI (kg m?x), mean (SD)",16,0,2,no
5767,3504074,Table 1,BaselineCharacteristic,"?> xx kg m?x, n (%)",Characteristic ; ,"?> xx kg m?x, n (%)"," BMI (kg m?x), mean (SD)",17,0,2,no
5767,3504074,Table 1,BaselineCharacteristic,"Psoriasis BSA affected, %, mean (SD)",Characteristic ; ,"Psoriasis BSA affected, %, mean (SD)",,18,0,24,no
5767,3504074,Table 1,BaselineCharacteristic,"?Median (Qx, Qx)",Characteristic ; ,"?Median (Qx, Qx)"," Psoriasis BSA affected, %, mean (SD)",19,0,2,no
5767,3504074,Table 1,BaselineCharacteristic,"PASI, mean (SD)",Characteristic ; ,"PASI, mean (SD)",,20,0,24,no
5767,3504074,Table 1,BaselineCharacteristic,"?Median (Qx, Qx)",Characteristic ; ,"?Median (Qx, Qx)"," PASI, mean (SD)",21,0,2,no
5767,3504074,Table 1,BaselineCharacteristic,"sPGA, n (%)",Characteristic ; ,None,None,22,0,24,no
5767,3504074,Table 1,BaselineCharacteristic,"sPGA, n (%)",Etanercept + placebo (n = xxx) ; ,"sPGA, n (%)",None,22,1,43,no
5767,3504074,Table 1,BaselineCharacteristic,"sPGA, n (%)",Etanercept + methotrexate (n = xxx) ; ,"sPGA, n (%)",None,22,2,43,no
5767,3504074,Table 1,BaselineCharacteristic,?Unknown,Characteristic ; ,?Unknown," sPGA, n (%)",23,0,2,no
5767,3504074,Table 1,BaselineCharacteristic,x (x),Etanercept + methotrexate (n = xxx) ; ,?Unknown," sPGA, n (%)",23,2,3,no
5767,3504074,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x," sPGA, n (%)",24,0,2,no
5767,3504074,Table 1,BaselineCharacteristic,x (x),Etanercept + placebo (n = xxx) ; ,?x," sPGA, n (%)",24,1,3,no
5767,3504074,Table 1,BaselineCharacteristic,x (x),Etanercept + methotrexate (n = xxx) ; ,?x," sPGA, n (%)",24,2,3,no
5767,3504074,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x," sPGA, n (%)",25,0,2,no
5767,3504074,Table 1,BaselineCharacteristic,x (x),Etanercept + methotrexate (n = xxx) ; ,?x," sPGA, n (%)",25,2,3,no
5767,3504074,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x," sPGA, n (%)",26,0,2,no
5767,3504074,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x," sPGA, n (%)",27,0,2,no
5767,3504074,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x," sPGA, n (%)",28,0,2,no
5767,3504074,Table 1,BaselineCharacteristic,?x,Characteristic ; ,?x," sPGA, n (%)",29,0,2,no
5767,3504074,Table 1,BaselineCharacteristic,"Duration of psoriasis, years, mean (SD)",Characteristic ; ,"Duration of psoriasis, years, mean (SD)",,30,0,24,no
5767,3504074,Table 1,BaselineCharacteristic,"?Median (Qx, Qx)",Characteristic ; ,"?Median (Qx, Qx)"," Duration of psoriasis, years, mean (SD)",31,0,2,no
5767,3504074,Table 1,BaselineCharacteristic,"History of psoriatic arthritis, n (%)",Characteristic ; ,"History of psoriatic arthritis, n (%)",,32,0,2,no
5767,3504074,Table 1,BaselineCharacteristic,"Prior psoriasis therapy, n (%)",Characteristic ; ,"Prior psoriasis therapy, n (%)",,33,0,2,no
5767,3504074,Table 1,BaselineCharacteristic,"Prior systemic therapy, n (%)",Characteristic ; ,"Prior systemic therapy, n (%)",,34,0,24,no
5767,3504074,Table 1,BaselineCharacteristic,?Methotrexate,Characteristic ; ,?Methotrexate," Prior systemic therapy, n (%)",35,0,2,no
5767,3504074,Table 1,BaselineCharacteristic,?Oral retinoids,Characteristic ; ,?Oral retinoids," Prior systemic therapy, n (%)",36,0,2,no
5767,3504074,Table 1,BaselineCharacteristic,?Steroids,Characteristic ; ,?Steroids," Prior systemic therapy, n (%)",37,0,2,no
5767,3504074,Table 1,BaselineCharacteristic,"Prior TNF-blocker therapy, n (%)",Characteristic ; ,"Prior TNF-blocker therapy, n (%)",,38,0,24,no
5767,3504074,Table 1,BaselineCharacteristic,?Etanercept,Characteristic ; ,?Etanercept," Prior TNF-blocker therapy, n (%)",39,0,2,no
5767,3504074,Table 1,BaselineCharacteristic,?Adalimumab,Characteristic ; ,?Adalimumab," Prior TNF-blocker therapy, n (%)",40,0,2,no
5767,3504074,Table 1,BaselineCharacteristic,"Prior phototherapy, n (%)",Characteristic ; ,"Prior phototherapy, n (%)",,41,0,24,no
5767,3504074,Table 1,BaselineCharacteristic,?UVB,Characteristic ; ,?UVB," Prior phototherapy, n (%)",42,0,2,no
5767,3504074,Table 1,BaselineCharacteristic,?PUVA,Characteristic ; ,?PUVA," Prior phototherapy, n (%)",43,0,2,no
5767,3504074,Table 1,BaselineCharacteristic,"Prior topical nonsteroid use, n (%)",Characteristic ; ,"Prior topical nonsteroid use, n (%)",,44,0,24,no
5767,3504074,Table 1,BaselineCharacteristic,?Vitamin D analogues,Characteristic ; ,?Vitamin D analogues," Prior topical nonsteroid use, n (%)",45,0,2,no
5767,3504074,Table 1,BaselineCharacteristic,?Tar compounds,Characteristic ; ,?Tar compounds," Prior topical nonsteroid use, n (%)",46,0,2,no
5767,3504074,Table 1,BaselineCharacteristic,"Prior topical steroid use, n (%)",Characteristic ; ,"Prior topical steroid use, n (%)",,47,0,24,no
5767,3504074,Table 1,BaselineCharacteristic,?Other,Characteristic ; ,?Other," Prior topical steroid use, n (%)",48,0,2,no
6312,3600662,Table 1,BaselineCharacteristic,Patient characteristic,,None,None,0,0,12,no
6312,3600662,Table 1,BaselineCharacteristic,"huKS-ILx dosing cohort, mg/mx",,Patient characteristic,None,0,1,1,no
6312,3600662,Table 1,BaselineCharacteristic,"huKS-ILx dosing cohort, mg/mx",,Patient characteristic,None,0,2,1,no
6312,3600662,Table 1,BaselineCharacteristic,"huKS-ILx dosing cohort, mg/mx",,Patient characteristic,None,0,3,1,no
6312,3600662,Table 1,BaselineCharacteristic,"huKS-ILx dosing cohort, mg/mx",,Patient characteristic,None,0,4,1,no
6312,3600662,Table 1,BaselineCharacteristic,"huKS-ILx dosing cohort, mg/mx",,Patient characteristic,None,0,5,1,no
6312,3600662,Table 1,BaselineCharacteristic,Total (N = xx),,Patient characteristic,None,0,6,1,no
6312,3600662,Table 1,BaselineCharacteristic,Patient characteristic,Patient characteristic ; ,None,None,1,0,12,no
6312,3600662,Table 1,BaselineCharacteristic,x.x,"huKS-ILx dosing cohort, mg/mx ; ",Patient characteristic,None,1,1,1,no
6312,3600662,Table 1,BaselineCharacteristic,x.x,"huKS-ILx dosing cohort, mg/mx ; ",Patient characteristic,None,1,2,1,no
6312,3600662,Table 1,BaselineCharacteristic,x.x,"huKS-ILx dosing cohort, mg/mx ; ",Patient characteristic,None,1,3,1,no
6312,3600662,Table 1,BaselineCharacteristic,x.x,"huKS-ILx dosing cohort, mg/mx ; ",Patient characteristic,None,1,4,1,no
6312,3600662,Table 1,BaselineCharacteristic,x.x,"huKS-ILx dosing cohort, mg/mx ; ",Patient characteristic,None,1,5,1,no
6312,3600662,Table 1,BaselineCharacteristic,Total (N = xx),Total (N = xx) ; ,Patient characteristic,None,1,6,1,no
6312,3600662,Table 1,BaselineCharacteristic,Patient characteristic,Patient characteristic ; Patient characteristic ; ,None,None,2,0,12,no
6312,3600662,Table 1,BaselineCharacteristic,(n = x),"huKS-ILx dosing cohort, mg/mx ; x.x ; ",Patient characteristic,None,2,1,1,no
6312,3600662,Table 1,BaselineCharacteristic,(n = x),"huKS-ILx dosing cohort, mg/mx ; x.x ; ",Patient characteristic,None,2,2,1,no
6312,3600662,Table 1,BaselineCharacteristic,(n = x),"huKS-ILx dosing cohort, mg/mx ; x.x ; ",Patient characteristic,None,2,3,1,no
6312,3600662,Table 1,BaselineCharacteristic,(n = x),"huKS-ILx dosing cohort, mg/mx ; x.x ; ",Patient characteristic,None,2,4,1,no
6312,3600662,Table 1,BaselineCharacteristic,(n = x),"huKS-ILx dosing cohort, mg/mx ; x.x ; ",Patient characteristic,None,2,5,1,no
6312,3600662,Table 1,BaselineCharacteristic,Total (N = xx),Total (N = xx) ; Total (N = xx) ; ,Patient characteristic,None,2,6,1,no
6312,3600662,Table 1,BaselineCharacteristic,"Age, years",Patient characteristic ; Patient characteristic ; Patient characteristic ; ,None,None,3,0,24,no
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Age, years",None,3,1,43,no
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Age, years",None,3,2,43,no
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Age, years",None,3,3,43,no
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Age, years",None,3,4,43,no
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Age, years",None,3,5,43,no
6312,3600662,Table 1,BaselineCharacteristic,,Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,"Age, years",None,3,6,43,no
6312,3600662,Table 1,BaselineCharacteristic,?Median,Patient characteristic ; Patient characteristic ; Patient characteristic ; ,?Median," Age, years",4,0,2,no
6312,3600662,Table 1,BaselineCharacteristic,xx,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?Median," Age, years",4,1,3,no
6312,3600662,Table 1,BaselineCharacteristic,xx,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?Median," Age, years",4,2,3,no
6312,3600662,Table 1,BaselineCharacteristic,xx,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?Median," Age, years",4,3,3,no
6312,3600662,Table 1,BaselineCharacteristic,xx,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?Median," Age, years",4,4,3,no
6312,3600662,Table 1,BaselineCharacteristic,xx,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?Median," Age, years",4,5,3,no
6312,3600662,Table 1,BaselineCharacteristic,xx,Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,?Median," Age, years",4,6,3,no
6312,3600662,Table 1,BaselineCharacteristic,?Range,Patient characteristic ; Patient characteristic ; Patient characteristic ; ,?Range," Age, years",5,0,2,no
6312,3600662,Table 1,BaselineCharacteristic,"Sex, n (%)",Patient characteristic ; Patient characteristic ; Patient characteristic ; ,None,None,6,0,24,no
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Sex, n (%)",None,6,1,43,no
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Sex, n (%)",None,6,2,43,no
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Sex, n (%)",None,6,3,43,no
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Sex, n (%)",None,6,4,43,no
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Sex, n (%)",None,6,5,43,no
6312,3600662,Table 1,BaselineCharacteristic,,Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,"Sex, n (%)",None,6,6,43,no
6312,3600662,Table 1,BaselineCharacteristic,?Men,Patient characteristic ; Patient characteristic ; Patient characteristic ; ,?Men," Sex, n (%)",7,0,2,no
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?Men," Sex, n (%)",7,1,3,yes
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?Men," Sex, n (%)",7,2,3,yes
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?Men," Sex, n (%)",7,3,3,yes
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?Men," Sex, n (%)",7,4,3,yes
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?Men," Sex, n (%)",7,5,3,yes
6312,3600662,Table 1,BaselineCharacteristic,xx (xx),Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,?Men," Sex, n (%)",7,6,3,yes
6312,3600662,Table 1,BaselineCharacteristic,?Women,Patient characteristic ; Patient characteristic ; Patient characteristic ; ,?Women," Sex, n (%)",8,0,24,no
6312,3600662,Table 1,BaselineCharacteristic,x (xxx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?Women," Sex, n (%)",8,1,43,yes
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?Women," Sex, n (%)",8,2,43,yes
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?Women," Sex, n (%)",8,3,43,yes
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?Women," Sex, n (%)",8,4,43,yes
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?Women," Sex, n (%)",8,5,43,yes
6312,3600662,Table 1,BaselineCharacteristic,xx (xx),Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,?Women," Sex, n (%)",8,6,43,yes
6312,3600662,Table 1,BaselineCharacteristic,"Tumor type, n (%)",Patient characteristic ; Patient characteristic ; Patient characteristic ; ,None,None,9,0,2,no
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",None,None,9,1,3,no
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",None,None,9,2,3,no
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",None,None,9,3,3,no
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",None,None,9,4,3,no
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",None,None,9,5,3,no
6312,3600662,Table 1,BaselineCharacteristic,,Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,None,None,9,6,3,no
6312,3600662,Table 1,BaselineCharacteristic,??Ovarian carcinoma,Patient characteristic ; Patient characteristic ; Patient characteristic ; ,??Ovarian carcinoma," Tumor type, n (%) ?Women",10,0,2,no
6312,3600662,Table 1,BaselineCharacteristic,x (xxx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Ovarian carcinoma," Tumor type, n (%) ?Women",10,1,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Ovarian carcinoma," Tumor type, n (%) ?Women",10,2,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Ovarian carcinoma," Tumor type, n (%) ?Women",10,3,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Ovarian carcinoma," Tumor type, n (%) ?Women",10,4,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Ovarian carcinoma," Tumor type, n (%) ?Women",10,5,3,no
6312,3600662,Table 1,BaselineCharacteristic,xx (xx),Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,??Ovarian carcinoma," Tumor type, n (%) ?Women",10,6,3,no
6312,3600662,Table 1,BaselineCharacteristic,??Lung carcinoma,Patient characteristic ; Patient characteristic ; Patient characteristic ; ,??Lung carcinoma," Tumor type, n (%) ?Women",11,0,2,no
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Lung carcinoma," Tumor type, n (%) ?Women",11,1,3,no
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Lung carcinoma," Tumor type, n (%) ?Women",11,2,3,no
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Lung carcinoma," Tumor type, n (%) ?Women",11,3,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Lung carcinoma," Tumor type, n (%) ?Women",11,4,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Lung carcinoma," Tumor type, n (%) ?Women",11,5,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (xx),Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,??Lung carcinoma," Tumor type, n (%) ?Women",11,6,3,no
6312,3600662,Table 1,BaselineCharacteristic,??Colon,Patient characteristic ; Patient characteristic ; Patient characteristic ; ,??Colon," Tumor type, n (%) ?Women",12,0,2,no
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Colon," Tumor type, n (%) ?Women",12,1,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Colon," Tumor type, n (%) ?Women",12,2,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Colon," Tumor type, n (%) ?Women",12,3,3,no
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Colon," Tumor type, n (%) ?Women",12,4,3,no
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Colon," Tumor type, n (%) ?Women",12,5,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (xx),Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,??Colon," Tumor type, n (%) ?Women",12,6,3,no
6312,3600662,Table 1,BaselineCharacteristic,??Prostate,Patient characteristic ; Patient characteristic ; Patient characteristic ; ,??Prostate," Tumor type, n (%) ?Women",13,0,2,no
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Prostate," Tumor type, n (%) ?Women",13,1,3,no
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Prostate," Tumor type, n (%) ?Women",13,2,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Prostate," Tumor type, n (%) ?Women",13,3,3,no
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Prostate," Tumor type, n (%) ?Women",13,4,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Prostate," Tumor type, n (%) ?Women",13,5,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (x),Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,??Prostate," Tumor type, n (%) ?Women",13,6,3,no
6312,3600662,Table 1,BaselineCharacteristic,??Othera,Patient characteristic ; Patient characteristic ; Patient characteristic ; ,??Othera," Tumor type, n (%) ?Women",14,0,2,no
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Othera," Tumor type, n (%) ?Women",14,1,3,no
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Othera," Tumor type, n (%) ?Women",14,2,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Othera," Tumor type, n (%) ?Women",14,3,3,no
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Othera," Tumor type, n (%) ?Women",14,4,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??Othera," Tumor type, n (%) ?Women",14,5,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (xx),Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,??Othera," Tumor type, n (%) ?Women",14,6,3,no
6312,3600662,Table 1,BaselineCharacteristic,"Tumor stage, n (%)",Patient characteristic ; Patient characteristic ; Patient characteristic ; ,None,None,15,0,24,no
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Tumor stage, n (%)",None,15,1,43,no
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Tumor stage, n (%)",None,15,2,43,no
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Tumor stage, n (%)",None,15,3,43,no
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Tumor stage, n (%)",None,15,4,43,no
6312,3600662,Table 1,BaselineCharacteristic,,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Tumor stage, n (%)",None,15,5,43,no
6312,3600662,Table 1,BaselineCharacteristic,,Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,"Tumor stage, n (%)",None,15,6,43,no
6312,3600662,Table 1,BaselineCharacteristic,??I,Patient characteristic ; Patient characteristic ; Patient characteristic ; ,??I," Tumor stage, n (%) ?Women",16,0,2,no
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??I," Tumor stage, n (%) ?Women",16,1,3,no
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??I," Tumor stage, n (%) ?Women",16,2,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??I," Tumor stage, n (%) ?Women",16,3,3,no
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??I," Tumor stage, n (%) ?Women",16,4,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",??I," Tumor stage, n (%) ?Women",16,5,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (x),Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,??I," Tumor stage, n (%) ?Women",16,6,3,no
6312,3600662,Table 1,BaselineCharacteristic,?II,Patient characteristic ; Patient characteristic ; Patient characteristic ; ,?II," Tumor stage, n (%)",17,0,2,no
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?II," Tumor stage, n (%)",17,1,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?II," Tumor stage, n (%)",17,2,3,no
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?II," Tumor stage, n (%)",17,3,3,no
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?II," Tumor stage, n (%)",17,4,3,no
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?II," Tumor stage, n (%)",17,5,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (x),Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,?II," Tumor stage, n (%)",17,6,3,no
6312,3600662,Table 1,BaselineCharacteristic,?III,Patient characteristic ; Patient characteristic ; Patient characteristic ; ,?III," Tumor stage, n (%)",18,0,2,no
6312,3600662,Table 1,BaselineCharacteristic,x (xxx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?III," Tumor stage, n (%)",18,1,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?III," Tumor stage, n (%)",18,2,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?III," Tumor stage, n (%)",18,3,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?III," Tumor stage, n (%)",18,4,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?III," Tumor stage, n (%)",18,5,3,no
6312,3600662,Table 1,BaselineCharacteristic,xx (xx),Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,?III," Tumor stage, n (%)",18,6,3,no
6312,3600662,Table 1,BaselineCharacteristic,?IV,Patient characteristic ; Patient characteristic ; Patient characteristic ; ,?IV," Tumor stage, n (%)",19,0,2,no
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?IV," Tumor stage, n (%)",19,1,3,no
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?IV," Tumor stage, n (%)",19,2,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?IV," Tumor stage, n (%)",19,3,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?IV," Tumor stage, n (%)",19,4,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ",?IV," Tumor stage, n (%)",19,5,3,no
6312,3600662,Table 1,BaselineCharacteristic,xx (xx),Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,?IV," Tumor stage, n (%)",19,6,3,no
6312,3600662,Table 1,BaselineCharacteristic,"Prior chemotherapy, n (%)",Patient characteristic ; Patient characteristic ; Patient characteristic ; ,"Prior chemotherapy, n (%)",,20,0,2,no
6312,3600662,Table 1,BaselineCharacteristic,x (xxx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Prior chemotherapy, n (%)",,20,1,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (xxx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Prior chemotherapy, n (%)",,20,2,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Prior chemotherapy, n (%)",,20,3,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Prior chemotherapy, n (%)",,20,4,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Prior chemotherapy, n (%)",,20,5,3,no
6312,3600662,Table 1,BaselineCharacteristic,xx (xx),Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,"Prior chemotherapy, n (%)",,20,6,3,no
6312,3600662,Table 1,BaselineCharacteristic,"Prior radiotherapy, n (%)",Patient characteristic ; Patient characteristic ; Patient characteristic ; ,"Prior radiotherapy, n (%)",,21,0,2,no
6312,3600662,Table 1,BaselineCharacteristic,x,"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Prior radiotherapy, n (%)",,21,1,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Prior radiotherapy, n (%)",,21,2,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Prior radiotherapy, n (%)",,21,3,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Prior radiotherapy, n (%)",,21,4,3,no
6312,3600662,Table 1,BaselineCharacteristic,x (xx),"huKS-ILx dosing cohort, mg/mx ; x.x ; (n = x) ; ","Prior radiotherapy, n (%)",,21,5,3,no
6312,3600662,Table 1,BaselineCharacteristic,xx (xx),Total (N = xx) ; Total (N = xx) ; Total (N = xx) ; ,"Prior radiotherapy, n (%)",,21,6,3,no
6425,493270,Table 1,BaselineCharacteristic,Characteristics*,,None,None,0,0,12,no
6425,493270,Table 1,BaselineCharacteristic,Phase I (n = xx),,Characteristics*,None,0,1,1,no
6425,493270,Table 1,BaselineCharacteristic,Phase II (n = xx),,Characteristics*,None,0,2,1,no
6425,493270,Table 1,BaselineCharacteristic,Eligible,Characteristics* ; ,Eligible,,1,0,2,no
6425,493270,Table 1,BaselineCharacteristic,xx (xxx%),Phase I (n = xx) ; ,Eligible,,1,1,3,no
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,Eligible,,1,2,3,no
6425,493270,Table 1,BaselineCharacteristic,Evaluable,Characteristics* ; ,Evaluable,,2,0,2,no
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase I (n = xx) ; ,Evaluable,,2,1,3,no
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,Evaluable,,2,2,3,no
6425,493270,Table 1,BaselineCharacteristic,Median age (range) years,Characteristics* ; ,Median age (range) years,,3,0,2,no
6425,493270,Table 1,BaselineCharacteristic,Sex,Characteristics* ; ,None,None,4,0,24,no
6425,493270,Table 1,BaselineCharacteristic,Sex,Phase I (n = xx) ; ,Sex,None,4,1,43,no
6425,493270,Table 1,BaselineCharacteristic,Sex,Phase II (n = xx) ; ,Sex,None,4,2,43,no
6425,493270,Table 1,BaselineCharacteristic,?Male,Characteristics* ; ,?Male, Sex,5,0,2,no
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase I (n = xx) ; ,?Male, Sex,5,1,3,yes
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,?Male, Sex,5,2,3,yes
6425,493270,Table 1,BaselineCharacteristic,?Female,Characteristics* ; ,?Female, Sex,6,0,2,no
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase I (n = xx) ; ,?Female, Sex,6,1,3,yes
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,?Female, Sex,6,2,3,yes
6425,493270,Table 1,BaselineCharacteristic,WHO performance status,Characteristics* ; ,None,None,7,0,24,no
6425,493270,Table 1,BaselineCharacteristic,WHO performance status,Phase I (n = xx) ; ,WHO performance status,None,7,1,43,no
6425,493270,Table 1,BaselineCharacteristic,WHO performance status,Phase II (n = xx) ; ,WHO performance status,None,7,2,43,no
6425,493270,Table 1,BaselineCharacteristic,?x,Characteristics* ; ,?x, WHO performance status,8,0,2,no
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase I (n = xx) ; ,?x, WHO performance status,8,1,3,no
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,?x, WHO performance status,8,2,3,no
6425,493270,Table 1,BaselineCharacteristic,?x,Characteristics* ; ,?x, WHO performance status,9,0,2,no
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase I (n = xx) ; ,?x, WHO performance status,9,1,3,no
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,?x, WHO performance status,9,2,3,no
6425,493270,Table 1,BaselineCharacteristic,?x,Characteristics* ; ,?x, WHO performance status,10,0,2,no
6425,493270,Table 1,BaselineCharacteristic,x,Phase I (n = xx) ; ,?x, WHO performance status,10,1,3,no
6425,493270,Table 1,BaselineCharacteristic,x (x%),Phase II (n = xx) ; ,?x, WHO performance status,10,2,3,no
6425,493270,Table 1,BaselineCharacteristic,Primary tumour site,Characteristics* ; ,None,None,11,0,24,no
6425,493270,Table 1,BaselineCharacteristic,Primary tumour site,Phase I (n = xx) ; ,Primary tumour site,None,11,1,43,no
6425,493270,Table 1,BaselineCharacteristic,Primary tumour site,Phase II (n = xx) ; ,Primary tumour site,None,11,2,43,no
6425,493270,Table 1,BaselineCharacteristic,?Colon,Characteristics* ; ,?Colon, Primary tumour site,12,0,2,no
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase I (n = xx) ; ,?Colon, Primary tumour site,12,1,3,no
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,?Colon, Primary tumour site,12,2,3,no
6425,493270,Table 1,BaselineCharacteristic,?Rectum,Characteristics* ; ,?Rectum, Primary tumour site,13,0,2,no
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase I (n = xx) ; ,?Rectum, Primary tumour site,13,1,3,no
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,?Rectum, Primary tumour site,13,2,3,no
6425,493270,Table 1,BaselineCharacteristic,?Colon rectosigmoid,Characteristics* ; ,?Colon rectosigmoid, Primary tumour site,14,0,2,no
6425,493270,Table 1,BaselineCharacteristic,x (x%),Phase I (n = xx) ; ,?Colon rectosigmoid, Primary tumour site,14,1,3,no
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,?Colon rectosigmoid, Primary tumour site,14,2,3,no
6425,493270,Table 1,BaselineCharacteristic,Organ involved,Characteristics* ; ,None,None,15,0,24,no
6425,493270,Table 1,BaselineCharacteristic,Organ involved,Phase I (n = xx) ; ,Organ involved,None,15,1,43,no
6425,493270,Table 1,BaselineCharacteristic,Organ involved,Phase II (n = xx) ; ,Organ involved,None,15,2,43,no
6425,493270,Table 1,BaselineCharacteristic,?Median number,Characteristics* ; ,?Median number, Organ involved,16,0,2,no
6425,493270,Table 1,BaselineCharacteristic,?Liver,Characteristics* ; ,?Liver, Organ involved,17,0,2,no
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase I (n = xx) ; ,?Liver, Organ involved,17,1,3,no
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,?Liver, Organ involved,17,2,3,no
6425,493270,Table 1,BaselineCharacteristic,?Lung,Characteristics* ; ,?Lung, Organ involved,18,0,2,no
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase I (n = xx) ; ,?Lung, Organ involved,18,1,3,no
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,?Lung, Organ involved,18,2,3,no
6425,493270,Table 1,BaselineCharacteristic,?Lymph node,Characteristics* ; ,?Lymph node, Organ involved,19,0,2,no
6425,493270,Table 1,BaselineCharacteristic,x (x%),Phase I (n = xx) ; ,?Lymph node, Organ involved,19,1,3,no
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,?Lymph node, Organ involved,19,2,3,no
6425,493270,Table 1,BaselineCharacteristic,?Other soft tissue,Characteristics* ; ,?Other soft tissue, Organ involved,20,0,2,no
6425,493270,Table 1,BaselineCharacteristic,x,Phase I (n = xx) ; ,?Other soft tissue, Organ involved,20,1,3,no
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,?Other soft tissue, Organ involved,20,2,3,no
6425,493270,Table 1,BaselineCharacteristic,?Abdominal cavity,Characteristics* ; ,?Abdominal cavity, Organ involved,21,0,2,no
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase I (n = xx) ; ,?Abdominal cavity, Organ involved,21,1,3,no
6425,493270,Table 1,BaselineCharacteristic,x (x%),Phase II (n = xx) ; ,?Abdominal cavity, Organ involved,21,2,3,no
6425,493270,Table 1,BaselineCharacteristic,?Peritoneum,Characteristics* ; ,?Peritoneum, Organ involved,22,0,2,no
6425,493270,Table 1,BaselineCharacteristic,x (x%),Phase I (n = xx) ; ,?Peritoneum, Organ involved,22,1,3,no
6425,493270,Table 1,BaselineCharacteristic,x,Phase II (n = xx) ; ,?Peritoneum, Organ involved,22,2,3,no
6425,493270,Table 1,BaselineCharacteristic,?Bone,Characteristics* ; ,?Bone, Organ involved,23,0,2,no
6425,493270,Table 1,BaselineCharacteristic,x (x%),Phase I (n = xx) ; ,?Bone, Organ involved,23,1,3,no
6425,493270,Table 1,BaselineCharacteristic,x,Phase II (n = xx) ; ,?Bone, Organ involved,23,2,3,no
6425,493270,Table 1,BaselineCharacteristic,?Skin,Characteristics* ; ,?Skin, Organ involved,24,0,2,no
6425,493270,Table 1,BaselineCharacteristic,x,Phase I (n = xx) ; ,?Skin, Organ involved,24,1,3,no
6425,493270,Table 1,BaselineCharacteristic,x (x%),Phase II (n = xx) ; ,?Skin, Organ involved,24,2,3,no
6425,493270,Table 1,BaselineCharacteristic,?Other,Characteristics* ; ,?Other, Organ involved,25,0,2,no
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase I (n = xx) ; ,?Other, Organ involved,25,1,3,no
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase II (n = xx) ; ,?Other, Organ involved,25,2,3,no
6425,493270,Table 1,BaselineCharacteristic,Prior therapy,Characteristics* ; ,None,None,26,0,24,no
6425,493270,Table 1,BaselineCharacteristic,Prior therapy,Phase I (n = xx) ; ,Prior therapy,None,26,1,43,no
6425,493270,Table 1,BaselineCharacteristic,Prior therapy,Phase II (n = xx) ; ,Prior therapy,None,26,2,43,no
6425,493270,Table 1,BaselineCharacteristic,?Surgery,Characteristics* ; ,?Surgery, Prior therapy,27,0,2,no
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase I (n = xx) ; ,?Surgery, Prior therapy,27,1,3,no
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,?Surgery, Prior therapy,27,2,3,no
6425,493270,Table 1,BaselineCharacteristic,?Radiotherapy,Characteristics* ; ,?Radiotherapy, Prior therapy,28,0,2,no
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase I (n = xx) ; ,?Radiotherapy, Prior therapy,28,1,3,no
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,?Radiotherapy, Prior therapy,28,2,3,no
6425,493270,Table 1,BaselineCharacteristic,?Adjuvant chemotherapy,Characteristics* ; ,?Adjuvant chemotherapy, Prior therapy,29,0,2,no
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase I (n = xx) ; ,?Adjuvant chemotherapy, Prior therapy,29,1,3,no
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,?Adjuvant chemotherapy, Prior therapy,29,2,3,no
6425,493270,Table 1,BaselineCharacteristic,?Surgery + radiotherapy,Characteristics* ; ,?Surgery + radiotherapy, Prior therapy,30,0,2,no
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase I (n = xx) ; ,?Surgery + radiotherapy, Prior therapy,30,1,3,no
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,?Surgery + radiotherapy, Prior therapy,30,2,3,no
6425,493270,Table 1,BaselineCharacteristic,?Surgery + chemotherapy,Characteristics* ; ,?Surgery + chemotherapy, Prior therapy,31,0,2,no
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase I (n = xx) ; ,?Surgery + chemotherapy, Prior therapy,31,1,3,no
6425,493270,Table 1,BaselineCharacteristic,xx (xx%),Phase II (n = xx) ; ,?Surgery + chemotherapy, Prior therapy,31,2,3,no
6425,493270,Table 1,BaselineCharacteristic,?Radiotherapy + chemotherapy,Characteristics* ; ,?Radiotherapy + chemotherapy, Prior therapy,32,0,2,no
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase I (n = xx) ; ,?Radiotherapy + chemotherapy, Prior therapy,32,1,3,no
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase II (n = xx) ; ,?Radiotherapy + chemotherapy, Prior therapy,32,2,3,no
6425,493270,Table 1,BaselineCharacteristic,?Surgery + radiotherapy + chemotherapy,Characteristics* ; ,?Surgery + radiotherapy + chemotherapy, Prior therapy,33,0,2,no
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase I (n = xx) ; ,?Surgery + radiotherapy + chemotherapy, Prior therapy,33,1,3,no
6425,493270,Table 1,BaselineCharacteristic,x (xx%),Phase II (n = xx) ; ,?Surgery + radiotherapy + chemotherapy, Prior therapy,33,2,3,no
